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Abstract 
The last decade has seen significant development in understanding the genetic basis of 
myeloproliferative neoplasms (MPN), with the underlying somatic mutational landscape 
revealed by genome and targeted exome sequencing. The aim of this research was to 
conduct a series of original investigations to develop insight into the utility and clinical 
application of these disease markers. 
Initially, three recently identified disease-specific molecular markers (mutations 
in JAK2, CALR and CSF3R) were utilised to measure the burden of disease post-
allogeneic transplantation using methods based on quantitative PCR, capillary 
electrophoresis and Sanger sequencing. The measured variant allelic frequency of the 
disease was compared against percentage donor chimerism – a short tandem repeat PCR 
based method with high discriminatory power that enables a semi-quantitative measure 
of engraftment based on the calculation of donor and recipient DNA in the blood. All 
three mutation markers were shown to be stable and robust for monitoring purposes 
throughout the disease course, inversely correlating with percentage donor chimerism. 
The increased sensitivity of the JAK2 V617F qPCR used in the JAK2 study highlighted 
the potential of these disease specific markers to detect molecular and haematological 
relapse in patients several weeks before clinical manifestation and proved an 
advantageous adjunct in the clinical assessment of transplantation efficacy.  
 In a second series of studies, the incidence and significance of recurrent MPN mutations 
in specific clinical scenarios and MPN disease cohorts was investigated. A baseline for 
the incidence of JAK2, CALR and MPL mutations in Irish patients referred for suspected 
MPN was established and shown to be comparable with that of other Western European 
cohorts. To extend this finding, the incidence and significance of these mutations was 
investigated in specific clinically relevant disease cohorts, revealing a distinct molecular 
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pathogenesis in paediatric patients with essential thrombocythaemia (ET) when compared 
to adults, a low incidence of CALR mutations in splanchnic vein thrombosis patients that 
correlated with the aetiology of the disease and the presence of CALR driver mutations in 
familial MPN cases. Additionally, the presence of a JAK2 V617F mutation in utero in ET 
was established for the first time and the dynamic nature of MPN disease clones over the 
course of disease was revealed, thus informing insight into the clonal evolution and 
molecular heterogeneity of MPN patients. This information was collated with results from 
a number of audits based on clinical referral patterns to a routine molecular diagnostic 
facility to inform the development of a molecular diagnostic testing algorithm for patients 
with suspected MPN.  
In the third series of studies novel next generation sequencing (NGS) technology 
was applied to investigate somatic mutations in acute myeloid leukaemia (AML) related 
patient cohorts. A proprietary NGS panel for recurrently mutated genes possessing 
diagnostic and prognostic significance in AML was evaluated on the Ion Torrent 
(ThermoFisher) NGS platform across three molecular diagnostic centres in Ireland, 
Northern Ireland and Scotland. This verified the technique to be robust and reproducible 
for mutation detection in AML patients. The technology was subsequently deployed to 
profile mutation status in a clinically high-risk AML patient cohort undergoing 
transplantation therapy and in a familial AML disease setting to clarify the genotype, 
reveal the diverse clonal architecture of patients and identify additional driver mutations 
relevant for existing and emerging therapeutic interventions. 
Taken together, the studies in this thesis inform clinical understanding and 
decision making in MPN and AML related settings, provide novel insight into underlying 
mutational status and clonal behaviour in myeloid malignancies and have the potential to 
translate into optimised and improved treatment for these patient cohorts. 
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1.0 Introduction 
 
1.1 Development of the haematopoietic system 
 
Haematopoiesis, from the Greek term for “blood making”, is the adaptive process by 
which mature and functional blood cells are continuously replaced over the entire lifetime 
of an individual. Erythrocytes, platelets, and the various subsets of leucocytes all have 
finite although different life spans. As a consequence, the daily production of red blood 
cells, platelets, and neutrophils in homeostatic conditions amount to more than 300 billion 
cells (Aiuti et al., 2019). 
Definitive haematopoietic stem cells (HSCs) lie at the foundation of the adult 
hematopoietic system and provide an organism throughout its life with all blood cell 
types. Several tissues demonstrate haematopoietic activity at early stages of embryonic 
development, The ontogeny of the vertebrate haematopoietic system is characterised by 
two waves: embryonic haematopoiesis, which generates transitory haematopoietic cell 
populations, such as primitive erythrocytes and some myeloid cells; and permanent, 
definitive haematopoiesis, which originates later in development from definitive HSCs 
and which gives rise to all the mature blood (erythroid, myeloid and lymphoid) lineages 
in the adult organism. It was Francoise Dieterlen-Lievre in 1975 (Dieterlen-Lievre, 1975) 
who showed, using quail chick chimeric embryos, that the adult haematopoietic system 
originates inside the embryo proper.  
During human embryogenesis, three weeks after the formation of the zygote 
caused as a result of fusion of a sperm and an egg, gastrulation occurs. Gastrulation is the 
development of a single layered blastula into the three germ layers; ectoderm (developing 
into the brain, spinal cord, hair nails, epidermis) endoderm (developing into epithelial 
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lining of the digestive tract, stomach, liver pancreas, lung, bladder) and mesoderm 
(developing into muscle, bone, connective tissue, kidney, gonads, circulatory system) 
(Pansky, 1982). 
The formation of HSCs during development occurs by a multistep process that 
begins with the induction of ventral mesoderm. Following gastrulation, a subset of ventral 
mesoderm is specified to become HSCs (Gao et al., 2018). Haematopoiesis, the process 
by which blood cells are formed initially occurs first in the yolk sac outside the embryo 
and later within the embryo within the paraaortic splanchnopleura. After approximately 
5 weeks gestation, haematopoiesis transitions temporarily to the liver, with the long bones 
developing sufficient marrow capacity after 12 weeks to begin definitive haematopoiesis 
and the thymus maturing by 15 weeks gestation (Golub and Cumano, 2013) (Figure 1.1).   
                 
Figure 1.1: Ontogeny of haematopoiesis in humans. Changes in the anatomical location 
of haematopoiesis during human development are shown on a circular timeline (Muench 
and Bárcena, 2004). 
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1.2 Normal differentiation in Haematopoiesis 
 
In 1909 A.A. Maximow proposed the unitarian theory of haematopoiesis; that a common 
stem cell was responsible for all blood elements (Maximow, 1909). During postnatal life, 
a steady state is established in which HSC pool size is maintained by the regulation of the 
multipotent HSC self-renewal and differentiation (Boulais and Frenette, 2015). 
Haematopoiesis is understood to be organised as a cellular hierarchy derived from 
multipotent HSCs that progress to terminally differentiated cells. As they differentiate, 
HSCs give rise to a series of progenitor cell intermediates that undergo a gradual fate 
restriction to assume the identity of a mature blood cell which is subsequently released 
into the circulation. The common myeloid progenitor gives rise to platelets, erythrocytes, 
granulocytes and monocytes, whereas the common myeloid progenitor gives rise to B, T 
and NK lymphocytes (Figure 1.2). The end result is the continuous production of 
sufficient, but not excessive, numbers of cells of all lineages (Boulais and Frenette, 2015). 
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Figure 1.2. Overview of myeloid haematopoiesis and cell lineage differentiation. Stem 
cells originate in the bone marrow before committing to particular lineages and 
migrating to the peripheral blood or destination tissue upon maturity. B, Basophil; N, 
Neutrophil; E, Eosinophil. Source: 
https://commons.wikimedia.org/wiki/File:Hematopoiesis_(human)_ diagram .png A. 
Rad [CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0/)]. 
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1.3 Regulation of Haematopoiesis 
 
The bone marrow contains specialised niches in which the multipotency of HSCs is 
conserved through cell divisions, while their progeny are directed towards lineage 
differentiation (Tweedell, 2017). Accumulating evidence reveals that various cell types 
in and around the bone marrow participate in HSC function and its niche regulation 
(Schofield, 1978; Morrison and Scadden, 2014; Flynn and Kaufman, 2015). A complex 
and diverse group of cells have been implicated including stromal cells, osteoblasts, 
neurons and glial cells, all of which produce growth factors and cytokines that impact 
HSC regulation and maintenance (Anthony and Link, 2014) (Figure 1.3, Figure 1.4). 
Some factors like stem cell factor (also known as kit ligand), FMS like tyrosine receptor 
3 ligand (FLT- 3 ligand), Granulocyte-Macrophage colony stimulating factor (GM-CSF) 
and interleukin 3 (IL-3) act upon stem cells or primitive committed progenitor cells early 
on in haematopoiesis. Other cytokines are lineage-specific and only exert their activities 
late in haematopoiesis on a single pathway, for example granulocyte colony stimulating 
factor (G-CSF), Erythropoietin (EPO) and Thrombopoietin (TPO). Like all homeostatic 
systems, haematopoiesis is regulated by a balance of positive and negative influences. 
Direct inhibitory cytokines include macrophage inflammatory protein 1 alpha (MIP-1α) 
and transforming growth factor beta (TGF-β). Action of these negative regulators ensure 
that the number of cells produced do not exceed the body’s needs. 
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Figure 1.3. Stromal populations in the bone marrow affect maintenance of HSCs. 
Osteoblasts, spindle-shaped N-cadherin+ osteoblasts (SNO cells), endothelial cells, 
mesenchymal stem cells (MSCs), and CXCL12- expressing mesenchymal progenitors 
(CEMP cells) produce a number of factors that support HSCs, including CXCL12, 
angiopoietin, and stem cell factor (SCF). Glial cells, through production of active 
transforming growth factor-β (TGF-β) and adipocytes also regulate HSCs (Anthony and 
Link, 2014). 
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Figure 1.4 Overview of hematopoietic cytokines and the cell lineages they stimulate to 
cause differentiation into the principle types of blood cells. IL, interleukin; SCF, stem cell 
factor; TPO, thrombopoietin; EPO, erythropoietin; GM-CSF, granulocyte macrophage 
colony stimulating factor; M-CSF, macrophage colony stimulating factor. Source: 
https://www.sigmaaldrich.com/technical-documents/articles/biofiles/hematopoietic-
cytokines.html 
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1.4 Regulation of haematopoiesis by transcription factors. 
 
Several transcription factors play critical roles in HSC formation and function and in 
lineage specific differentiation.  Both temporal and lineage restricted expression of these 
transcription factors is required to determine phenotype. These factors include stem cell 
leukaemia haematopoietic transcription factors (SCL/tal1), PU.1, GATA Binding Protein 
2 (GATA-2), and LIM Domain Only 2 (LMO-2), which are essential for primitive and 
definitive haematopoiesis, in addition to AML-1 which is required for definitive 
haematopoiesis (Orkin and Zon, 2008) (Figure 1.5). Other transcription factors such as 
Lysine Methyltransferase 2A  (KMT2A/MLL), Runt Related Transcription Factor 1  
(RUNX1), ETS Variant 6  (ETV6), CCAAT Enhancer Binding Protein Alpha (CEBPα) 
and GATA Binding Protein 1 (GATA-1) also play an important role in haematopoiesis, 
with translocations and somatic mutations often occurring within the genes for these 
factors in haematopoietic malignancies, intertwining cell fate and leukaemic origins. 
Disturbance of the homeostatic balance of the critical transcriptional regulators is a 
defining feature of leukaemia. Once HSCs divide and generate more differentiated 
daughter cells, within 10 ± 15 divisions the genetic programs of the descendent cells 
become fixed toward a single lineage (Doulatov et al., 2012).  
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Figure 1.5 Critical transcription factors in blood development. The stages at which 
haematopoietic development is blocked in the absence of a given transcription factor, as 
determined through conventional gene knockouts, are indicated by red bars. The factors 
depicted in grey have been associated with oncogenesis. LT-HSC, long-term 
hematopoietic stem cell; ST-HSC, short-term hematopoietic stem cell; CMP, common 
myeloid progenitor; CLP, common lymphoid progenitor; MEP, megakaryocyte/erythroid 
progenitor; GMP, granulocyte/macrophage progenitor; RBCs, red blood cells (Orkin and 
Zon, 2008). 
 
1.5 The haematological malignant process 
 
Physicians in the early 19th century had observed that some of their patients had 
abnormally high levels of white blood cells, leading them to call the associated condition 
weisses blut, or “white blood.” The first definitive descriptions of this phenomenon as 
leukaemia came in the 1840’s from Rudolph Virchow, in Germany, John Hughes Bennett 
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in Edinburgh and Alfred Donne in France. The first type of lymphoma was described in 
a paper published in 1832 by Thomas Hodgkin (Hodgkin, 1832). Introduction of 
histochemical staining methods by Paul Ehrlich in 1877 allowed discrimination among 
leucocyte subsets, with Ehrlich first identifying a primitive cell, which he described as 
the ancestor of the various hematopoietic lineages (Ehrlich, 1877). By 1913, leukaemia 
was classified as acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), 
chronic lymphocytic leukaemia (CLL), and chronic myeloid leukaemia (CML) (Gaynon, 
Zomorodian and Pinkel, 2012). 
In 1914 Theodor Boveri observed that cancer cells acquire chromosomal 
abnormalities, hinting at a genetic driver of tumour growth (Wright, 2014).  The seminal 
identification of a characteristic short chromosome in the neoplastic cells of patients with 
CML, the so-called Philadelphia chromosome (Ph1) by Peter Nowell and David 
Hungerford, was a landmark discovery in the understanding of leukaemia development 
(Nowell and Hungerford, 1960).  Evidence for the stem cell origins of cancer derived 
from the studies of Philip Fialkow and colleagues in the 1970’s using X‑ linked 
glucose‑ 6‑ phosphate dehydrogenase (G6PD) as a marker of monoclonality in female 
patients, indicating that the cancer clone in CML, despite its relatively mature 
granulocytic phenotype, originated from a lympho-myeloid stem cell (Fialkow, 1974).  
In 1976 Nowell proposed that tumorigenesis in humans is a multistep process that 
drives the transformation of normal cells into malignant derivatives and is analogous to 
Darwinian evolution in which a succession of genetic changes, each conferring one or 
another type of growth advantage, leads to the progressive conversion of normal human 
cells into cancer cells (Nowell, 1976). However it took until the 1990s before formal 
demonstration that a subpopulation of self-renewing cells can propagate cancer was first 
achieved by John Dick and colleagues (Lopez-Bertoni, Li and Laterra, 2015). 
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Defects in the molecular controls of haematopoiesis that perturb normal development lie 
at the root of haematological malignancies and are best exemplified by somatic mutations 
in factors responsible for stem cell control and differentiation such as GATA-1 in Down 
Syndrome-associated megakaryocytic leukaemia, CEBPα in myeloid leukaemia and 
Paired Box 5 (PAX5) in B-cell derived leukaemia (Pabst et al., 2001; Wechsler et al., 
2002; Mullighan et al., 2007). Leukaemic Stem cells (LSC) appear to retain many 
characteristics of normal HSCs as evidenced by a hierarchical developmental pattern, a 
mostly quiescent cell cycle profile, and an immunophenotype very similar to HSC (Jordan 
and Guzman, 2004). With regard to myeloid lineage leukaemogenesis, the LSC may 
result from mutations in cells in different stages of the haematopoietic hierarchy (Figure 
1.6).  
         
Figure 1.6. The leukaemic stem cell model. Normal haematopoiesis is outlined in the 
green highlighted area, with a leukaemic cell of origin acquiring a first hit mutation at 
various possible stages of maturation (yellow highlighted area) with the susceptible stem 
cell then acquiring a specific second hit to drive creation of the leukaemic clonal stem 
cell (peach highlight), which further develops into an expanded leukaemia clone with 
potential to acquire further mutations and a specific phenotype. HSC, haematopoietic 
stem cell; MPP, multipotent progenitor; LMPP, lymphoid multipotent progenitor; CMP, 
common myeloid progenitors; CLP, common lymphoid progenitor; MEP, 
megakaryocyte-erythrocyte progenitor; GMP, granulocyte macrophage progenitor; LSC, 
leukaemic stem cell. (Riether, Schürch and Ochsenbein, 2015). 
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1.6 Myeloid malignancies 
 
Myeloid malignancies are clonal diseases of hematopoietic stem or progenitor cells, that 
result from genetic and epigenetic alterations in HSCs and functional changes in bone 
marrow niche cells that perturb key processes such as self-renewal, proliferation and 
differentiation. They comprise a heterogenous group of diseases that includes chronic 
stages such as CML, myeloproliferative neoplasms (MPN) and myelodysplastic 
syndromes (MDS), with acute stages being represented by the various AML subtypes. 
While there is considerable overlap of the underlying molecular mechanisms responsible 
for driving these malignancies, each disease has its own genotypic and phenotypic 
characteristics. A diagrammatic representation of the spectrum of myeloid disorders is 
outlined in Figure 1.7.   
 
Figure 1.7. Spectrum of myeloid disorders. Those diseases with lower proliferative 
expansion and increased dysplastic features are located toward the bottom left of the 
diagram, whereas the more proliferative clonally driven disorders are located toward the 
top right of the diagram. ITP; immune thrombocytopenic purpura, PRCS; pure red cell 
aplasia, PNH; paroxysmal nocturnal haemoglobinuria, LGL; Large granular lymphocyte 
leukaemia, MDS; myelodysplastic syndrome, CMML; chronic myelomonocytic 
leukaemia, MPN; myeloproliferative neoplasm, CML; chronic myeloid leukaemia, AML; 
acute myeloid leukaemia (Tiu and Sekeres, 2014). 
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Myeloid neoplasms continue to be organised into AML and chronic myeloid 
neoplasms, based primarily on the percentage of peripheral blood or bone marrow blasts. 
Chronic myeloid neoplasms are in turn classified into five operational categories: MDS, 
MPNs, MDS/MPN overlap, mastocytosis and myeloid/lymphoid neoplasms with 
eosinophilia and recurrent rearrangements of platelet derived growth factor alpha/beta 
(PDGFRA/PDGFRB), Fibroblast Growth Factor Receptor 1 (FGFR1) or Pericentriolar 
Material 1-Janus Kinase 2 (PCM1-JAK2); the latter mutations correspond to 5q33, 4q12, 
8p11.2 or t(8;9)(p22;p24.1) cytogenetic abnormalities respectively. MPNs are generally 
distinguished from both MDS and MDS/MPN, by the absence of morphologic dysplasia, 
which includes dyserythropoiesis and dysgranulopoiesis and monocytosis (Barbui et al., 
2018). 
1.6.1 Chronic Myeloid Leukaemia  
The history of discovery, biological understanding and treatment of chronic myeloid 
leukaemia (CML) is the paradigm for haematological malignancies and worthy of 
discussion to frame an understanding of more recent developments in this field. The 
identification of the Philadelphia chromosome (Ph Chromosome) led to identification of 
the reciprocal chromosome translocation involving chromosomes 22 and 9 (Rowley, 
1973) and subsequently the identification of the chimeric fusion gene breakpoint cluster 
region- ABL Proto-Oncogene 1, (BCR-ABL1) (Heisterkamp et al., 1983) (Figure 1.8).  
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Figure 1.8 A: Partial karyogram showing chromosomes 9 and 22 and a translocation 
t(9;22)(q34;q11.2). The normal chromosome 9 and 22 are on the left side of each pair and 
the abnormal or "derivative" chromosomes are on the right side. B: Schematic of BCR-
ABL1 reciprocal translocation. Source:https://en.m.wikipedia.org/wiki/File: 
T922_CML.jpg 
 
CML has an incidence of 1–2 cases per 100,000 adults in the USA, and accounts for 15% 
of newly diagnosed cases of leukaemia in adults (Jabbour and Kantarjian, 2018). 
Diagnosis is confirmed in a setting of persistent unexplained leucocytosis by the presence 
of the Ph chromosome and the associated t(9;22)(q34;q11) translocation and BCR-ABL1 
fusion gene, by routine cytogenetics, fluorescent in situ hybridisation (FISH) or by 
molecular studies such a polymerase chain reaction (PCR). A 210 kilodalton BCR-ABL1 
transcript (p210) transcribed from the most common rearrangements between exons 13 
or 14 of BCR and exon 2 of ABL1 (known as e13a2 and e14a2 respectively) is most 
common, but rare cases will have alternative BCR-ABL1 breakpoints, leading to a p190 
transcript, from the e1a2 rearrangement most typically seen in Ph-positive ALL or p230 
transcript. The disease is classically staged into chronic phase (most patients at 
presentation), accelerated phase (>15% blasts in BM and PB, >20% basophils in PB and 
A B 
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<100,000/µl platelet count) and blast phase (>30% blasts in BM or PB), clusters of blasts 
in the marrow or presence of extramedullary disease  (Arber et al., 2016).  
Clinically, up to 50% of patients are asymptomatic and diagnosed incidentally 
after routine laboratory evaluation with clinical features when present, generally 
nonspecific. Splenomegaly is present in the majority while fatigue, night sweats and 
symptoms of anaemia and bleeding due to platelet dysfunction may occur (Thompson, 
Kantarjian and Cortes, 2015). Effective treatment of CML began with the use of 
radiotherapy directed at the spleen before being replaced with oral alkylating agents 
developed after the second world war such as busulfan. Antimetabolites such as 
hydroxyurea and immune modulators such as recombinant interferon alpha were next 
introduced, which extend overall survival but are associated with severe toxicities 
(Rushing et al., 1982; Silver et al., 1999). The development of bone marrow 
transplantation in CML began with the treatment of four chronic phase (CP) patients by 
high-dose chemoradiotherapy followed by transfusion of normal stem cells from their 
genetically identical twins and resulted in disappearance of the Ph+ cells from the bone 
marrow and development of a normal haematological picture up to 31 months post 
transplantation. This raised the possibility that CML, until then regarded as a fatal disease 
may be successfully treated and cured by transplantation (Fefer et al., 1979). Subsequent 
development of this technique throughout the 1980’s  and 1990’s to incorporate the use 
of sibling and unrelated donors and the use of post-transplant infused donor lymphocytes 
to induce a graft-versus-leukaemia (GVL) effect ultimately led to transplantation as the 
treatment of choice for CML in those patients capable of tolerating the intensity of the 
regimen (Hansen et al., 1998; Kolb et al., 2005). 
Studies in the 1990’s with compounds that inhibited the BCR-ABL1 tyrosine 
kinase fusion protein resulted in the development of Imatinib Mesylate, a small tyrosine 
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kinase inhibitor (TKI) by Brian Druker, an oncologist at the Dana-Farber Institute, in 
collaboration with Ciba-Geigy (now Novartis). This compound interfered with the 
interaction of BCR-ABL1 protein and adenosine tri-phosphate (ATP) and resulted in 
blocking proliferation of the malignant clone which dramatically altered the natural 
course of the disease, improving 10-year overall survival from 20% to over 80% and 
effectively turning a fatal disease into one capable of being managed proactively. The 
majority of patients presenting with CP CML now achieve long-term disease control with 
stem cell transplantation needed only in a small minority (Druker et al., 2001; Hochhaus 
et al., 2017).  Following the success achieved with imatinib, second generation tyrosine 
kinase inhibitors such as dasatinib (Bristol-Myers Squibb) and nilotinib (Novartis) 
(Figure 1.9), which have significantly increased potency for CML cells and the BCR-
ABL1 fusion protein, were developed and approved, initially in patients that developed 
resistance to prior imatinib therapy  (Kantarjian et al., 2006; Talpaz et al., 2006).  
       
Figure 1.9 Structure of ABL1 in complex with Imatinib, Nilotinib and Dasatinib 
(Weisberg et al., 2007). 
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Clonal chromosomal evolution, BCR-ABL1 amplification and pharmacogenomic 
variations have been implicated in the development of imatinib drug resistance (Majlis et 
al., 1996; Gadzicki et al., 2005; Polillo et al., 2015), however recognition that the 
development of a clone carrying mutations in the BCR-ABL1 kinase domain was the 
leading cause for development of resistance led to the mapping of mutations (Figure 1.10) 
and understanding the associated levels of conferred resistance to therapy and resulted in 
recommendations to rationalise mutation testing and  help translate the results into clinical 
decision making (Hochhaus et al., 2011; Soverini et al., 2011). 
 
 
 
Figure 1.10. Map of amino acid substitutions in the BCR-ABL1 kinase domain with 
highlighted structural motifs. P-loop; phosphate binding loop; A-loop, activation loop; 
SH2/SH3, contact regions for SH2/SH3 domain containing proteins (Soverini et al., 
2011). 
 
Response to TKI therapy is determined by measures at the haematological, cytogenetic 
and molecular levels. Quantitative molecular testing for BCR-ABL1 transcripts using RQ-
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PCR is more sensitive for low-level residual disease than cytogenetics or FISH 
(sensitivity of 10−4 to 10−5).  Levels of response to TKI therapy by RQ-PCR are clinically 
relevant and are usually reported as a percentage relative to the transcript levels of ABL1 
or BCR. There have been successful international efforts to standardise the testing and 
reporting of BCR-ABL1 transcript levels to ensure harmonised reporting across 
jurisdictions using an International Standard (IS) to develop individual reporting 
laboratory specific conversion factors.  
At present a major molecular response (MMR or MR3.0) corresponds to <0.1% 
BCR-ABL1 on the IS, which represents a 3-log reduction from the standardised baseline, 
rather than a three-log reduction from the individual patient’s baseline BCR-ABL1 
transcript level (which can vary significantly). MR4.0 is <0.01% BCR-ABL1 on the IS 
and MR4.5 is ≤0.0032% on the IS (equivalent to a ≥4.5 log reduction) (Hughes et al., 
2006; Branford et al., 2008; Müller et al., 2009; White et al., 2015; Cross et al., 2016). 
These efforts have led to the development of criteria that have helped guide treatment and 
dosage with TKI therapies (Jain et al., 2013). More recently, several studies have focused 
on stopping treatment based on a prolonged complete molecular remission (CMR),  
undetectable BCR-ABL1 transcripts for 24 months by standardised techniques with 
approximately 40% of patients remaining in molecular remission for 2 years after 
cessation of imatinib therapy (Mahon et al., 2010; Ross et al., 2013; Benjamini et al., 
2014). 
The paradigm of CML and the BCR-ABL1 fusion gene established the modern 
development of targeted therapies and the move towards personalised medicine. As 
studies in related diseases such as MPNs, MDS and AML developed, it became apparent 
that CML was novel for its singular causal molecular event and that greater understanding 
of the molecular nature of these diseases was required to enable progress. 
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1.6.2 Philadelphia negative Myeloproliferative Neoplasms 
MPNs originate from a common ancestral clone that arises from a polyclonal, but disease 
susceptible stem cell pool and have a propensity at late stage for transformation to AML 
(Spivak, 2017). The concept of myeloproliferative disorders was first proposed by 
William Dameshek in a 1951 editorial in the Blood journal, where he described the 
conditions as being characterised by excessive proliferation of haematopoietic precursors 
in the bone marrow and excessive production of mature blood cells. Dameshek’s augural 
view grouped several diseases in the MPD category including CML, polycythaemia vera 
(PV), essential thrombocythaemia (ET), primary myelofibrosis (PMF) and 
erythroleukaemia (Dameshek, 1951).  
PV, ET and PMF present with overlapping clinical features and are kept as distinct 
entities under the umbrella of classical Ph- MPN. Such disorders are rare, with prevalence 
in the EU per 100,000 head of population estimated for PV at 0.4 to 2.8, ET from 0.38 to 
1.7, and PMF from 0.1 to 1.0 per year. They generally occur in middle- or advanced-age 
adults, with a median age of 65 years for PV, 68 years for ET, and 70 years for PMF 
(Moulard et al., 2014). Unlike PV, which is the only MPN which causes an increased red 
blood cell mass, ET and PMF do not display a unique clinical or biologic characteristic 
allowing their unequivocal identification. 
Thrombocytosis, a key feature of ET, can also be present in some PV or PMF 
patients. Bone marrow biopsy morphology can discriminate between ET and PMF 
however its universal reproducibility has been questioned (Wilkins et al., 2008). Fibrosis 
and splenomegaly are often associated with PMF however they may also present in ET 
and PV. Thrombosis and haemorrhage can occur across the Ph- MPNs (Figure 1.11) 
(Kiladjian, 2012). Transformation to AML occurs at a rate of 5-15% per 10 years for PV, 
8-23% per 10 years for PMF and 1.4% per 10 years for ET (Lee et al., 2013).  
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Figure 1.11.  Overlapping clinical features observed in each of the main Ph- MPN entities 
(Kiladjian, 2012). Red blocks approximate prevalence in disease entity. Schematic 
representation of the proportion of patients presenting with a specific feature. The top 
panel shows clinical characteristics and the bottom panel, complications. 
 
The occurrence of thrombotic events is the major risk for patients with PV or ET and the 
main goal of therapy is to prevent these complications. Accurate diagnosis is important 
in terms of both prognostication and treatment. The World Health Organisation (WHO) 
classification system for haematopoietic tumours provides clear and concise guidelines 
in distinguishing MPN from both reactive thrombocytosis and other myeloid neoplasms, 
(Swerdlow et al., 2008; Arber et al., 2016) with differential diagnosis being essential to 
determine survival and prognosis (Barbui et al., 2011; Barbui et al., 2018). Increasing 
age, a history of vascular events and driver mutation status have consistently proven to 
be independent predictors of thrombosis in patients with PV and ET classifying patients 
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into low- and high-risk groups (Tefferi and Barbui, 2017).  A number of national 
consensus guidelines for the diagnosis, stratification and treatment of MPN patients have 
been developed (Barbui et al., 2004; McMullin et al., 2005; Barbui et al., 2011; Reilly et 
al., 2012; Lindgren and Larsen, 2013; Vannucchi, et al., 2015) with the gathered 
consensus reflected in the recent issue of the WHO 2016 guidelines which also 
incorporated the discovery of new molecular diagnostic and prognostic markers, allowing 
novel insight into the understanding of the pathobiology of these disorders.  (Arber et al., 
2016).  
In representative cases, bone marrow morphology shows disease specific features, 
for example in ET the presence of increased numbers of hyperlobulated megakaryocytes, 
in PV a hypercellular marrow with erythroid proliferation, in overt PMF megakaryocytic 
proliferation and atypia combined with reticulin/collagen fibrosis (Figure 1.11) (Rumi 
and Cazzola, 2017).   
                 
Figure 1.12. Representative bone marrow biopsies from patients with MPNs. A: Normal 
Bone Marrow biopsy: heterogenous cell population; B: ET marrow: Proliferation of giant 
megakaryocytes with hyperlobulated nuclei (black arrows); C: PV marrow: Hypercellular 
marrow with erythroid proliferation and scattered pleomorphic megakaryocytes; D: PMF 
marrow: Hypercellular marrow with granulocytic proliferation and collagen fibrosis 
(black arrow) Rumi & Cazzola 2017.  
A B 
C D 
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1.6.2.1 Diagnosis of Philadelphia negative Myeloproliferative Neoplasms 
Diagnosis of MPN is according to the WHO 2016 guidelines, which have had four 
important improvements for diagnosis made based on clinicopathological and molecular 
genetic studies since the WHO 2008 edition:  
(i) Discovery of novel molecular findings that provide understanding of the pathobiology 
of MPNs and exert an impact on diagnosis and outcome. 
(ii) Lowering of the diagnostic haemoglobin (Hb)/ haematocrit (Hct) threshold values 
with introduction of masked PV (mPV) revealing that PV has been underdiagnosed in the 
past.  
(iii) Emphasising the need to discriminate “true” ET from pre-PMF by an accurate 
evaluation of BM biopsy features, including the lack of reticulin fibrosis at onset in <5% 
of cases which is of significant prognostic and therapeutic relevance. 
(iv) Advancements regarding the characterisation and standardisation of morphological 
BM features yielded an improvement in the differentiation of MPN subtypes, improving 
pathologist agreement rates and decreasing the number of unclassifiable cases (Barbui et 
al., 2018). 
The current criteria for diagnosis of the Ph- MPN are outlined in tables 1.1-1.4 below. 
Diagnosis of PV, according to WHO guidelines requires meeting either all 3 major 
criteria, or the first 2 major criteria and the minor criterion. Diagnosis of ET requires 
meeting all 4 major criteria or the first 3 major criteria and the minor criterion. Diagnosis 
of pre-PMF requires meeting all 3 major criteria, and at least 1 minor criterion. Diagnosis 
of overt PMF requires meeting all 3 major criteria, and at least 1 minor criterion. 
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Table 1.1. Criteria for PV according to WHO 2016 guidelines 
Major criteria 
Haemoglobin >16.5 g/dL in men, Haemoglobin >16.0 g/dL in women 
Or 
Haematocrit >49% in men, Haematocrit >48% in women 
Or 
increased red cell mass (RCM) 
2. BM biopsy showing hypercellularity for age with trilineage growth (panmyelosis) including 
prominent erythroid, granulocytic, and megakaryocytic proliferation with pleomorphic, mature 
megakaryocytes (differences in size). 
3. Presence of JAK2V617F or JAK2 exon 12 mutation 
Minor criterion 
Subnormal serum erythropoietin level 
 
Table 1.2: Criteria for ET according to WHO 2016 guidelines 
Major criteria 
 1. Platelet count ≥450 × 109/L 
 2. BM biopsy showing proliferation mainly of the megakaryocyte lineage with increased 
numbers of enlarged, mature megakaryocytes with hyperlobulated nuclei. No significant 
increase or left shift in neutrophil granulopoiesis or erythropoiesis and very rarely minor (grade 
1) increase in reticulin fibres 
3. Not meeting WHO criteria for BCR-ABL1+ CML, PV, PMF, myelodysplastic syndromes, or 
other myeloid neoplasms 
4. Presence of JAK2, CALR, or MPL mutation 
Minor criterion 
Presence of a clonal marker or absence of evidence for reactive thrombocytosis. 
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Table 1.3: Criteria for pre-PMF 
Major criteria 
 1. Megakaryocytic proliferation and atypia, without reticulin fibrosis >grade 1, accompanied 
by increased age-adjusted BM cellularity, granulocytic proliferation, and often decreased 
erythropoiesis. 
 2. Not meeting the WHO criteria for BCR-ABL1+ CML, PV, ET, myelodysplastic 
syndromes, or other myeloid neoplasms 
 3. Presence of JAK2, CALR, or MPL mutation or in the absence of these mutations, presence 
of another clonal marker, or absence of minor reactive BM reticulin fibrosis. 
Minor criteria 
Presence of at least 1 of the following, confirmed in 2 consecutive determinations: 
 a. Anaemia not attributed to a comorbid condition 
 b. Leukocytosis ≥11 × 109/L 
 c. Palpable splenomegaly 
 d. LDH increased to above upper normal limit of institutional reference range 
 
 
Table 1.4: WHO overt PMF criteria 
Major criteria 
1. Presence of megakaryocytic proliferation and atypia, accompanied by either reticulin and/or 
collagen fibrosis grades 2 or 3. 
 2. Not meeting WHO criteria for ET, PV, BCR-ABL1+ CML, myelodysplastic syndromes, 
or other myeloid neoplasms.  
3. Presence of JAK2, CALR, or MPL mutation or in the absence of these mutations, presence 
of another clonal marker, or absence of reactive myelofibrosis. 
Minor criteria 
Presence of at least 1 of the following, confirmed in 2 consecutive determinations: 
 a. Anaemia not attributed to a comorbid condition 
 b. Leukocytosis ≥11 × 109/L 
 c. Palpable splenomegaly 
 d. LDH increased to above upper normal limit of institutional reference range 
 e. Leukoerythroblastosis 
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1.6.2.2 Treatment of Philadelphia Myeloproliferative Neoplasms 
Treatment in PV requires a daily aspirin dose supplemented with phlebotomy to maintain 
the haematocrit <45% in men and <45% in women with the addition of cytoreductive 
therapy such as hydroxyurea in high risk patients. Very low risk ET patients might not 
require any form of therapy while low-risk patients require at least once-daily aspirin and 
cytoreductive therapy is recommended for high-risk ET patients (Barbui et al., 2011; 
Spivak, 2017; Barbui et al., 2018). In patients with secondary myelofibrosis (MF) due to 
either ET or PV, as well as in patients with PMF, longevity is compromised by 
extramedullary haematopoiesis, marrow failure, and leukaemic transformation (Spivak, 
2017). Myelofibrosis is associated with greatest symptom burden and largest effect on 
quality of life among the MPNs, and has the worst prognosis with an overall median 
survival of 5.7 years as measured by the International Prognostic Score System (IPSS) 
(Cervantes et al., 2009). In this system patients are scored based on the severity of 
cytopenia, bone marrow blast percentage and cytogenetic findings (Greenberg et al., 
2012). 
The inclusion of spleen volume, which has been associated with an increased risk 
of death and molecular markers such as ASXL Transcriptional Regulator 1 (ASXL1) and 
Isocitrate Dehydrogenase 1 or 2 (IDH1/2) associated with high risk disease into the IPSS 
is likely, however the only potentially curative approach is haematopoietic stem cell 
transplantation which is associated with a high rate of mortality (20-40%) (Vannucchi 
and Harrison, 2017). An orally administered inhibitor of Janus kinases (JAK) 1 and 2 
(ruxolitinib) has been licenced for use in the management of patients with myelofibrosis. 
Clinical trials have demonstrated marked and durable clinical benefits in terms of 
reductions in splenomegaly and disease-related symptoms in patients with intermediate-
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2 or high-risk myelofibrosis and with improvements in health-related quality of life and 
functioning (Vannucchi et al., 2015).  
 
1.7 Paroxysmal Nocturnal Haemoglobinuria 
In 1969, William Dameshek proposed that paroxysmal nocturnal haemoglobinuria (PNH) 
should be considered a candidate MPN based on the evidence of red blood cell 
abnormalities in the context of bone marrow pancytopenia, low leucocyte alkaline 
phosphatase and the potential for leukaemic transformation (Dameshek, 1969). Further 
similarities between MPN and PNH include expansion of subsequent or simultaneous 
myeloid clones and an increased frequency of abdominal vein thrombosis. PNH is an 
acquired stem cell disorder associated with mutations of the Phosphatidyl Inositol 
Glycan-class A (PIG-A) gene that encodes a protein required for the synthesis of 
glycosylphosphatidylinositol-inositol anchored proteins (GPI-AP). PNH blood cells are 
therefore deficient in cell surface proteins that use the GPI anchor and may be detected 
immunophenotypically by absent or reduced expression of CD55 and CD59 on red blood 
cells (RBC) and CD16, CD24, CD66b and FLAER (fluorescence labelled aerolysin) on 
granulocytes (Figure 1.13). PNH clones are also present in a significant number of 
patients with the related marrow failure syndromes aplastic anaemia (AA) and 
hypoplastic MDS. Although PNH originates from a multipotent haematopoietic stem cell, 
PIG-A mutations are insufficient to drive clonal expansion and several models have 
attempted to explain this phenomenon: GPI-AP may be immunogenic and their 
deficiency enables evasion from immunological surveillance or the possibility that PIG-
A mutations themselves confer an intrinsic resistance to apoptosis (Brodsky, 2008).  
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Another theory postulates the acquisition of a second genetic event that enables 
clonal expansion in co-operation with the PIG-A mutation, some evidence for which 
comes from the deregulated expression of High Mobility Group AT-Hook 2 (HMGA2) 
in a minority of PNH patients (Inoue et al, 2006). 
 
 
Figure 1.13 Pathogenesis of PNH. A somatic acquired mutation in the gene encoding 
PIG-A is the pathobiological mechanism underlying the development of PNH. Affected 
stem cells are deficient in all GPI-APs that serve as erythrocyte membrane-bound 
regulators of complement. Deficiency of CD55 and CD59 proteins accounts for the 
complement-mediated intravascular haemolysis and other clinical manifestations (Sahin 
et al., 2015). 
 
 
1.8 Chronic Neutrophilic Leukaemia related mutations 
 
Chronic neutrophilic leukaemia (CNL) and atypical chronic myeloid leukaemia (aCML) 
are rare haematologic neoplasms that are characterised by leucocytosis and 
hypercellularity of the bone marrow consisting predominantly of granulocytic cells, the 
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absence of the Ph chromosome with translocation t(9;22) (BCR-ABL1), and the absence 
of rearrangements in genes encoding PDGFRA/B and FGFR1. CNL is diagnosed on the 
basis of the expansion of neutrophils in both bone marrow and blood (segmented 
neutrophils and band forms, >80% of white cells) and is classified as a MPN, according 
to WHO diagnostic criteria (Maxson et al., 2013). Disease acceleration often manifests 
with the development of progressive neutrophilia with resistance to previously effective 
therapy and CNL can progress to AML with a mean time to blast transformation of only 
21 months (Elliott et al., 2005).  
Until recently, diagnosis of CNL was essentially a process of exclusion, by ruling out 
basophilia, monocytosis, or a BCR-ABL1 fusion it could be distinguished from CML, 
aCML, and chronic myelomonocytic leukaemia (CMML). Similarly, by eliminating 
potentially confounding underlying clinical conditions such as infections or malignancy 
it could, sometimes with difficulty, be differentiated from a leukaemic reaction (Szuber 
and Tefferi, 2018). The fact that some patients with CNL have nonspecific cytogenetic 
abnormalities such as 11q23 monosomy in granulocytes but not lymphocytes, reveals the 
clonal nature of this disease (Froberg et al., 1998). 
 
1.9 Bone Marrow Transplantation 
 
Investigations into radiation induced bone marrow injury after the detonation of nuclear 
weapons in Japan during World War II led in 1949 to Jacobson and colleagues 
discovering protection of mice from total body irradiation (TBI) by shielding their spleens 
with lead. A couple of years later, Lorenz and colleagues reported radiation protection of 
mice and guinea pigs by infusion of marrow cells. Although the initial thought was that 
the radiation protection was from a humoral factor in the spleen or marrow, this 
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hypothesis was rejected after several laboratories demonstrated that the radiation 
protection was due to seeding of the marrow by donor cells (Champlin, 1990). The 
observation of dose-dependent toxicity of radiation on bone marrow supported the idea 
of using high doses of radiation to kill leukaemia cells and then using donor marrow cells 
to replenish the host marrow. In 1956, Barnes and colleagues successfully treated murine 
leukaemia with a supra-lethal dose of radiation (1500-rad) followed by intravenous bone 
marrow infusion and grafting (Barnes et al., 1956). One year later, Thomas and colleagues 
reported treatment of acute leukaemia in six human subjects using supra-lethal radiation 
followed by bone marrow infusion from fetal or adult cadavers (Thomas et al., 1957). 
Only two of the six patients demonstrated hematopoietic recovery and all patients died 
within the first 100 days. A review of 200 human marrow grafts reported between 1957 
and 1967 showed all 200 patients died of either graft failure, graft versus host disease 
(GVHD), infections, or recurrence of disease (Aiuti, Scala and Chabannon, 2019).  
Continued research in animal models led to refinement of the process with 
discoveries on the influence of histocompatibility antigens on graft tolerance, the use of 
cyclophosphamide instead of radiation, the evidence of a leucocyte antigen system in 
dogs (DLA) that determined risk of graft failure, with long term engraftment observed in 
DLA-matched dogs, prevention of GVHD with methotrexate (Epstein et al., 1968; Storb 
et al., 1969, 1970; Snell, 1992). After a return to human transplants in the 1970’s and 
armed with an improved understanding of the underlying biology, in 1977, Thomas and 
colleagues published their results of allogeneic transplantation for 100 consecutive 
patients with acute myeloid or lymphoblastic leukaemia and demonstrated that a small 
percentage of patients could be cured, establishing the important observation that patients 
transplanted earlier in their disease course had better outcomes than those with advanced 
disease (Thomas et al., 1977) . The observation that CD34+ stem cells were present in the 
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peripheral blood at low levels led to the development of therapies that mobilised these 
cells from the marrow into the blood using recombinant human granulocyte colony-
stimulating factor (rG-CSF) and provided a more convenient way to harvest stem cells 
for transplantation. (Duhrsen et al., 1988). An schematic outlining the process of stem 
cell transplantation is shown in Figure 1.36 below. 
 
Figure 1.14 Overview of stem cell transplantation process. Encyclopedia brittanica: 
https://www.britannica.com/science/graft-versus-host-disease/media/240689/123191. 
 
An increased understanding of GVHD also led to an appreciation of the graft versus 
leukaemia effect (GVL) effect, a donor T-cell mediated response to the recipient 
leukaemic cells and the use of donor lymphocyte infusions (DLI) to enable remission and 
prevent GVHD (Kolb et al., 1990). This development has led to transplant regimen with 
reduced intensity conditioning that is less ablative than standard conditioning, can be 
applied to older patients (>60 years) and results in the presence of both donor and 
recipient cells post-transplant (known as mixed chimerism). Subsequent DLI as part of 
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these regimen are used to encourage full engraftment of donor cells, however relapse is a 
continuing challenge with this approach (Pasquini et al., 2015).    
Understanding the effect of the dog leucocyte antigen system in canine 
transplantation allowed for the extension of this idea to humans and the human leucocyte 
antigen system (HLA) which are the genes and proteins that make up the major 
histocompatibility complex (MHC) and define a person’s immunological profile. MHC 
class I and class II molecules are similar in function: they present peptides at the cell 
surface to CD8+ and CD4+ T cells, respectively. In allogeneic transplant, the most 
important HLA molecules include class I molecules HLA-A, HLA-B, and HLA-C and 
class II molecules HLA-DP, HLA-DQ, and HLA-DR (Neefjes et al., 2011). Every HLA 
antigen mismatch between donor and recipient has been shown to adversely affect the 
success of allogeneic transplant (Lee et al., 2007). 
Recent developments in genetically engineering T-cells to target leukaemic cells 
has resulted in engineered chimeric antigen receptors on the T cells (CAR-T). These 
receptors, with the incorporation of costimulatory molecules or cytokines has enabled the 
elimination of tumour cells, initially proven with CD19 on B-cells in the treatment of  
chronic lymphocytic leukaemia (Porter et al., 2011).  Following in the footsteps of 
allogeneic transplant development, this approach could be powerful in developing safe 
and effective cancer therapeutics and may be incorporated into future transplantation 
regimen (Dai et al., 2016).  
 For patients with high-risk refractory or relapsed myeloid neoplasms, the 
prognosis is poor and outcome after standard chemotherapy alone rarely results in cure. 
Although ASCT offers a potential cure, relapse rates are high and patients can be 
precluded from standard protocols on the basis of older age, refractory or relapsed disease, 
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and presence of comorbidities. Reduced intensity conditioning (RIC) transplantation 
regimens offer lower rates of non-relapse mortality (NRM) in aggressive disease although 
they may not be sufficient to control disease until a graft versus leukaemia (GvL) effect 
occurs. In an attempt to overcome this, intermediate sequential conditioning regimen 
incorporating a short course of chemotherapy combining fludarabine, cytosine, 
arabinoside, amsacrine, cyclophosphamide, and either total body irradiation or busulfan 
(FLAMSA) to reduce disease burden prior to reduced intensity conditioning has been 
designed and implemented in high-risk myeloid neoplasms (Schmid et al., 2005; Saure et 
al., 2012; Malard et al., 2017) (Figure 1.15). 
 
 
Figure 1.15 FLAMSA-BU regimen for high risk myeloid malignancies. Short course 
chemotherapy is administered Day-12 to Day-9 followed by three days rest before 
transplantation conditioning from Day-6 to Day 0. Immunosuppression is administered 
with mycophenolate (MMF) for 30 days and cyclosporin for up to 90 days after infusion 
of peripheral blood stem cells (PBSC), with donor lymphocyte infusions administered to 
enhance engraftment if there is no evidence of graft versus host disease (GVHD). 
 
 
33 
 
1.10 Molecular Pathogenesis of Myeloproliferative Neoplasms 
The discovery of recently identified molecular features has yielded new perspectives 
regarding diagnostic and prognostic markers that provide novel insights for the 
understanding of the pathobiology of these disorders and has increased the reliability and 
reproducibility of diagnoses  (Wang et al., 2015; Arber et al., 2016). Recurrent mutations 
in the JAK2 gene at exon 14 (JAK2 V617F), mutations in CALR exon 9 and MPL in exon 
10 has focussed attention on the JAK-STAT pathway as a source of disruption in these 
disorders. 
1.10.1 JAK-STAT pathway  
The JAK-STAT pathway is a common signalling pathway used by many cytokines. The 
binding of a cytokine to its cell-surface receptor results in receptor dimerization and the 
subsequent activation of JAK tyrosine kinases. There are four members of the JAK 
tyrosine kinase family; JAK1-JAK3 and tyrosine kinase 2 (TYK) which are constitutively 
associated with cytokine receptors. Specific tyrosine residues on the receptor are then 
phosphorylated by activated JAKs and serve as docking sites for a family of latent 
cytoplasmic transcription factors known as STATs. There are seven mammalian STATs: 
STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6, which are highly 
homologous in several regions. STATs are phosphorylated by JAKs, causing dimerisation 
and subsequently leave the receptor and translocate to the nucleus, where they activate 
gene transcription (Shuai and Liu, 2003) (Figure 1.17).   
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Figure 1.16 The JAK-STAT signalling pathway. Regulation of this pathway occurs at the 
post-translational level by suppressor of cytokine signalling (SOC) proteins, protein 
tyrosine phosphatases (PTP) and ubiquitin mediated protein degradation (Shuai and Liu, 
2003). 
1.10.2 JAK2 Gene Mutations 
1.10.2.1 JAK2 V617F 
The landmark discovery of a recurrent somatic mutation in exon 14 of JAK2 at nucleotide 
1849 that leads to a substitution of a valine to phenylalanine at codon 617; the JAK2 
V617F (c.1849G>T) in 2005 (Baxter et al., 2005; James et al., 2005; Kralovics et al., 
2005; Levine et al., 2005) not only revolutionised the area of MPN molecular diagnostics 
but also prompted disease re-classification, investigation into many new aspects of MPN 
genetics and biology, and has led to the clinical introduction of novel therapeutic agents 
(Pasquier et al., 2014; Arber et al., 2016). This mutation is found in ~70% of MPNs: 
>95% of PV and 50% to 60% of ET and PMF patients.  
The JAK2 V617F mutation arises in a multipotent haematopoietic progenitor as it 
is present in all myeloid lineages and can also be detected in B and T lineage cells (Larsen 
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et al., 2007). The variant allelic frequency (VAF) of the JAK2 V617F ranges from 1-
100% with a rising VAF across the diseases with ET the lowest (25%), PV (>50%) rising 
to close to 100% in post-PV/ET myelofibrosis. In PMF the VAF is variable but generally 
high (Rumi et al., 2014).  
The JAK2 V617F abrogates the negative regulatory activity of the pseudokinase 
domain JH2 of the encoded JAK2 tyrosine kinase, leading to a constitutively active JAK2 
signalling, independent of cytokine stimuli when homodimeric type 1 cytokine receptors 
such as erythropoietin receptor (EPOR) or granulocyte colony-stimulating factor receptor 
(GCSF-R) are co-expressed  indicating that JAK2 V617F requires a cytokine receptor 
scaffold for its transforming and signalling activities (Lu et al., 2005). This state is 
different from normal conditions where JAK2 is activated after dimerisation or 
oligomerisation of cytokine receptors bound to their respective ligands (Baker, Rane and 
Reddy, 2007). 
 
1.10.2.2 JAK2 Exon 12 mutations 
JAK2 mutations also occur in exon 12 and are predominantly associated with JAK2 
V617F negative PV (Scott et al., 2007), isolated erythrocytosis, reduced serum EPO 
levels at clinical onset and a clinical course similar to JAK2 V617F positive PV 
(Passamonti et al., 2011). The functional consequences of these mutations are thought to 
be equivalent to the V617F mutation (Them and Kralovics, 2013). Over 30 different point 
mutations, small deletions, or insertions in JH2 of JAK2 have been shown to cause or be 
linked to haematologic diseases (Silvennoinen and Hubbard, 2015). A schematic of JAK2 
domain organisation is shown in Figure 1.17. 
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Figure 1.17. The JAK2 protein. A: Domain Organisation of JAK2 highlighting positive 
(green) and negative (red) regulatory phosphorylation sites. B: Structural schematic of 
JAK2 protein with location of selected mutations. JH2 domain is coloured orange, JH1 is 
blue (Silvennoinen and Hubbard, 2015). 
 
1.10.2.3 JAK2 V617F Biological Characteristics 
Transgenic mouse models have shown that expression of JAK2 V617F plays an important 
role in determining MPN phenotype, with increasing mutant JAK2 expression changing 
the phenotype from ET-like to PV-like and onward to MF-like (Tiedt et al., 2008). Ex-
vivo studies using exogenous erythroid colonies from patients with ET or PV have shown 
that JAK2 V617F homozygosity occurs in both PV and ET, however expansion of a single 
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dominant homozygous clone occurred only in PV and was likely due to the acquisition 
of additional genetic or epigenetic changes (Godfrey et al., 2012). JAK2 V617F is 
predominantly found in classical MPN but is also found in myelodysplastic subtype 
refractory anaemia with ringed sideroblasts and thrombocytosis (RARS-T) and rarely in 
other haematological malignancies (Figure 1.18). The fact that the JAK2 V617F mutation 
can be associated with different phenotypes has led to the idea of a continuum between 
disease subtypes as documented by the increase JAK2 V617F VAF between ET and PV, 
with the degree of erythrocytosis determined by physiological and genetic modifiers and 
by the progression of ET and PV to secondary myelofibrosis (Campbell et al., 2005). The 
JAK2 V617F has been detected at low levels in the general population and associated 
with increased morbidity and mortality (Nielsen et al., 2011) reflecting previous reports 
of the presence of leukaemia associated genes such as the BCR-ABL1 transcript in normal 
leukocytes (Bose et al., 1998). 
In ET, JAK2 V617F positive patients present with older age at diagnosis, higher 
haemoglobin level and leucocyte count, more venous thrombosis, but lower platelet count 
(Campbell et al., 2005). In a study evaluating JAK2 V617F mutation and phenotypic 
variation in PMF, the mutation independently predicted the evolution toward large 
splenomegaly, need of splenectomy, and leukaemic transformation and contributed to 
haemoglobin and platelet count variability (Barosi et al., 2007).  
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Figure 1.18. Frequency and distribution of acquired gene mutations in haematologic 
malignancies. (Skoda, Duek and Grisouard, 2015) 
 
In patients presenting with Budd-Chiari syndrome, a disorder causing primary 
extrahepatic portal vein obstruction resulting in a swollen liver and ascites, the underlying 
cause may be a MPN in up to 40% of cases. Testing for JAK2 V617F in this context can 
help define the diagnosis and identify a latent MPN, with over 50% of well-defined 
clinical cases testing positive (Patel et al., 2006; Primignani et al., 2006). As outlined in 
the WHO classification, identification of the JAK2 mutation provides clear evidence for 
malignant, clonal haematopoiesis, and provides pivotal evidence for PV in the case of the 
JAK2 V617F, but further clinical and biological features are required to allow a final 
diagnosis.  
1.10.2.4 JAK2 V617F Detection 
A wide variety of molecular techniques to detect and quantify JAK2 V617F have been 
developed to meet clinical demand for this marker. However, decisions made in the pre-
analytical phase of testing are critical to success, with choice of blood anti-coagulant 
types used affecting outcome (Yokota et al., 1999). Variability in sensitivity and 
39 
 
specificity in the methods used to detect the JAK2 V617F mutation led to a 
comprehensive evaluation of several prominent methods across Europe by the European 
LeukemiaNet and MPN&MPNr-EuroNet study groups, identifying robust assays suitable 
for quantifying JAK2 V617F (Jovanovic et al., 2011) and subsequently informing the 
development of national guidelines for the molecular diagnosis of MPN (Bench et al., 
2013).   
The detection rate of JAK2 V617F in patients does not differ significantly between 
bone marrow and peripheral blood samples if a sufficiently sensitive assay is used for 
detection (~1%), however as a myeloid disorder, the quantitative level in purified 
granulocytes is approximately 15% higher than in whole blood (Hermouet et al., 2007; 
Larsen et al., 2008). The capacity to detect a low JAK2 V617F allele burden of  ≥0.1% is 
important as it is of pathogenetic and clinical  importance (Wang et al., 2008; Mason, 
Akiki and Griffiths, 2011).  In a study of JAK2 V617F positive PMF patients who 
received allogeneic stem cell transplantation (ASCT) therapy, those patients with a JAK2 
V617F allelic burden >1% at day 28 post-ASCT had a higher risk of relapse and poorer 
overall survival, indicating a predictive role of JAK2 V617F burden in this setting (Lange 
et al., 2013). 
1.10.2.5 Myeloproliferative Leukaemia Virus Oncogene exon 10 mutations 
Subsequent to the discovery of JAK2 V617F mutations, in 2006 heterozygous mutations 
in exon 10 of the thrombopoietin receptor gene the myeloproliferative leukaemia virus 
oncogene (MPL) were discovered in a subset of JAK2 V617F negative MF patients and 
shown to result in constitutive activation of the Janus Kinase/signal transducer and 
activator of transcription (JAK-STAT) signalling pathway, thus providing a common 
convergent mechanism for activation of signal transduction in haematopoietic 
malignancies (Pikman et al., 2006). Located  on chromosome 1p34, the most frequent 
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mutations in MPL are located at tryptophan W515 at the boundary of the transmembrane 
and the cytosolic domains of MPL, with W515L and K being the most frequent, however 
others substitutions W515R, W515A, and W515G have been described (Defour et al., 
2016). MPL mutations require the haematopoietic growth factor thrombopoietin (TPO) 
for complete kinase activation in the heterozygous state (Spivak, 2017). MPLW515 
mutations have a low incidence in ET and PMF (3-5% respectively) and can also be found 
in RARS-T (Figure 1.19). The S505N mutation was first described in familial 
thrombocythemia and was also identified as a somatic mutation in ET and PMF (Ding et 
al., 2004; Beer et al., 2008) (Figure 1.14).  Alternative mutations have been reported in 
rare cases including V501A, S505C, A506T, V507I, G509C, L510P, R514K and R519T, 
although the pathogenic significance of some of these mutations is not clear (Williams et 
al., 2007; Schnittger et al., 2009). Mutations in MPL are usually heterozygous, but can 
be homozygous during disease progression (Rumi et al., 2013). 
 
Figure 1.19. Transmembrane structure of MPL protein. Gold balls represent the 
membrane bilayer, MPL protein is in green with three key residues, W491, S505, and 
W515, coloured red and indicated by the black arrows. The upper part of the figures is 
the extracellular region while the lower part the intracellular region (Lee et al., 2011). 
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1.10.2.6 Calreticulin exon 9 mutations 
In late 2013, a second seminal breakthrough in the molecular pathogenesis of MPN 
occurred with the application of whole exome sequencing to well characterised MPN 
patients, leading to the discovery of somatic mutations in CALR, the gene encoding 
calreticulin, a calcium binding chaperone associated with the endoplasmic reticulum 
(Klampfl et al., 2013; Nangalia et al., 2013).  
MPN-associated CALR mutations are insertions, deletions or insertions and 
deletions (indels) and occur in exon 9 resulting in a +1 base pair frame-shift of the coding 
sequence and generation of a translated protein with a novel C-terminus that lacks a 
retrieval sequence (KDEL) typical of normal CALR and other endoplasmic reticulum 
resident proteins. CALR exon 9 mutations are predominantly heterozygous with the 
majority of cases (80–90%) carrying a 52-bp deletion: (CALRdel52/type I; 
c.1092_1143del; L367 fs*46) or a 5-bp insertion CALRins5/type II; c1154_1155ins-
TTGTC; K385 fs*47). Of the remaining cases, more than 50 different variations have 
been identified to date (Figure 1.20).  
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Figure 1.20.  Alignment of C-domain in wild-type and predominant mutant CALR 
proteins. Mutation type is indicated on the left , the amino acid sequence starts from codon 
A352: acidic, basic and neutral residues are in red, blue and green, respectively. All the 
variants involve three different stretches of negatively charged amino acids, highlighted 
in red. Type 1-like mutations predict deletion of stretches II and III (as happens with the 
L367fs*46 or type 1 mutation), while type 2-like mutations predict conservation of all the 
three stretches (as happens with the K385fs*47 or type 2 mutation); other types involve 
deletion of stretches III exclusively (Pietra et al., 2016). 
 
Extended screening in large cohorts has confirmed the presence of CALR mutations in 
60–80% of patients with ET and PMF that are JAK2 and MPL mutation negative (Figure 
1.21) (Klampfl et al., 2013; Nangalia et al., 2013; Andrikovics et al., 2014; Rotunno et 
al., 2014; Rumi, et al., 2014). CALR mutations are occasionally present in RARS-T 
(Broséus et al., 2014a), rarely observed in PV (Broséus et al., 2014b) and very rarely may 
coexist with the JAK2 V617F or BCR-ABL1 (McGaffin et al., 2014; Cabagnols, Cayuela 
and Vainchenker, 2015). 
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Figure 1.21. Distribution of JAK2, MPL, and CALR mutations in Ph- MPN. Reproduced 
with permission from (Klampfl et al., 2013), Copyright Massachusetts Medical Society. 
 
1.10.2.7 CALR mutation; Biological Characteristics 
CALR mutation status may also provide information on the clinical phenotype and 
prognosis. In retrospective analyses of ET and PMF, CALR-mutated patients were found 
to present with higher platelet count, lower haemoglobin and improved overall survival 
when compared to JAK2 mutated, MPL mutated or triple negative patients (Klampfl et 
al., 2013).  In ET, CALR mutated cases are associated with a reduced cumulative 
incidence of thrombosis, reduced major cardiovascular events and a higher incidence of 
myelofibrotic transformation versus JAK2 mutated patients (Klampfl et al., 2013; 
Andrikovics et al., 2014; Rotunno et al., 2014; Rumi, et al., 2014b).  
PMF patients with CALR mutations have a reduced rate of red-cell transfusion 
dependency with an improved survival as compared to JAK2 mutated patients (Tefferi et 
al., 2014).  The high prevalence of type 1 and type 2 CALR mutations in ET and PMF has 
prompted investigators to assess the impact of mutation type on prognosis and phenotype, 
with a higher frequency of type 1 CALR mutations noted in PMF compared to ET, an 
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association in PMF of type 2 CALR mutations with higher circulating blast count, 
leucocyte count and inferior survival compared to type 1, and a potential link between 
CALR mutation type and megakaryocyte function (Tefferi et al., 2014b; Tefferi et al., 
2014c; Rumi et al., 2014c). CALR mutations are thought to arise in multipotent 
progenitors, often as initiating events (Klampfl et al., 2013; Nangalia et al., 2013) with 
mutational load increasing with myelofibrotic transformation (Lundberg et al., 2014).  
 
1.10.2.8 CALR mutation Detection 
The incidence and specificity of CALR mutations in ET and PMF require analytical 
methods which can determine CALR mutation status accurately and rapidly to aid the 
diagnostic workup of MPN. Given the multitude and complexity of CALR exon 9 
mutations, methodologies that can accommodate this variability will provide most utility 
in a diagnostic setting.  
Whilst initial reports employed PCR of CALR exon 9 followed by fragment 
analysis or Sanger sequencing to determine CALR mutation status (Klampfl et al., 2013; 
Nangalia et al., 2013), subsequent studies have explored the utility of alternative High 
Resolution Melting (HRM) techniques (Bilbao-Sieyro et al., 2014). A comparison of the 
limits of detection for HRM, next-generation sequencing (NGS), and fragment analysis 
techniques to detect CALR mutations found a bespoke NGS approach capable of detecting 
mutations when present at a level of 1.25%, an improvement in sensitivity over HRM and 
fragment analysis (Jones et al., 2015). The majority of CALR positive samples tested by 
NGS had greater than 15% mutant alleles suggesting the more readily deployed fragment 
analysis may be sufficient for routine molecular diagnosis in the majority of clinical 
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laboratories. Further investigation by Sanger sequencing would be required to determine 
the exact nature of the CALR mutation detected by screening approaches.  
The value of quantitative assessment of CALR mutations remains to be fully 
elucidated, yet preliminary data have shown a reduction in CALR allele burden in patients 
treated with interferon-alpha therapy and a potential role for monitoring disease burden 
post-ASCT (Cassinat, Verger and Kiladjian, 2014; Haslam et al., 2014). 
 
1.10.3 Double driver mutations 
Mutations in JAK2, CALR and MPL are generally found to be mutually exclusive and are 
considered ‘driver’ mutations of MPN as they can recapitulate the MPN phenotype when 
introduced into mouse models. However, in some rare cases a second driver mutation has 
been found. Concurrent mutations found include JAK2 and CALR in ET or PMF  (Tefferi, 
et al., 2014; Lundberg et al., 2014) or JAK2 and MPL (Boyd et al., 2010). A recent large 
study of 47 double mutant MPN patients found JAK2 V617F and CALR double mutations 
most frequent, with the majority harbouring a low JAK2 V617F allelic burden (<5%) 
(Mansier et al., 2018). JAK V617F and MPL, CALR and MPL, JAK2 V617F and JAK2 
exon 12, and CALR double mutations were also found. In ET double mutation patients 
the predominant clone appeared to determine the phenotype (Mansier et al., 2018). The 
clinical impact of double driver mutations in MPN remains to be fully elucidated. 
1.10.4 Triple negative Myeloproliferative Neoplasms 
The 10-15% of MPN patients negative for mutations in JAK2 V617F, CALR exon 9 or 
MPL exon 10 by conventional methods are often referred to as “triple negative” and have 
been associated with a prognostically detrimental effect in PMF (Tefferi et al., 2015). 
Recent studies comparing whole exome data from granulocyte (tumour) cells with T cell 
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exome data in triple negative ET and PMF patients have revealed additional JAK2 and 
MPL noncanonical mutations, (Cabagnols et al., 2016; Feenstra et al., 2016) highlighting 
the limitations of standard clinical molecular diagnostic methods for this cohort of 
patients and supporting the hypothesis of JAK-STAT pathway disruption in MPN. 
 
1.10.5 JAK-STAT pathway disruption in Myeloproliferative Neoplasms 
A functional consequence of recurrent somatic mutations in MPNs such as JAK2 V617F, 
CALR exon 9 and MPL exon 10 includes disruption of the JAK-STAT signalling pathway. 
JAK2 V617F is associated with ligand-independent activation of cytokine signalling 
pathways, with tyrosine phosphorylation and activation of STAT5 and STAT3 playing a 
central role in MPN pathogenesis (Chen, Staudt and Green, 2012). Gene expression 
signatures from peripheral blood granulocytes suggests that mutations that lead to 
constitutive JAK-STAT signalling are a common genetic event in MPN regardless of 
clinical phenotype or somatic genotype (Rampal et al., 2014), however further studies in 
megakaryocytes suggest that whilst a JAK2 activation signal may be present in CALR-
mutant ET granulocytes, downstream signalling mechanisms other than STAT3 and 
STAT5 are likely involved in the pathogenesis of CALR-mutant MPNs (Lau et al., 2015).  
A schematic of JAK-STAT signalling in MPNs is shown in Figure 1.22. 
Constitutive activation of EPOR, MPL and G-CSFR by JAK2 V617F can cause 
phosphorylation of Signal Transducer And Activator Of Transcription 3 or 5 (STAT3/5) 
(dimerisation), Phosphoinositide 3-kinases/AKT Serine/Threonine Kinase 1 
(PI3K/AKT), RAS Related/ Mitogen-Activated Protein Kinase (RAS/MAPK) with 
subsequent upregulation of gene transcription. Mutated CALR binds MPL directly with 
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JAK-STAT upregulation. MPL exon 10 mutations transform MPL receptor to remain 
constitutively active with uninhibited JAK-STAT signalling. 
 
Figure 1.22. Schematic diagram of JAK-STAT pathways involved in MPN pathogenesis. 
JAK2 V617F constitutively activates EPOR (erythropoietin receptor), MPL 
(thrombopoietin receptor), G-CSF-R (granulocyte colony-stimulating factor receptor) 
leading to proliferation of all three cell lines and may lead to PV, ET or PMF. It 
phosphorylates STAT3/5 (dimerisation), PI3K/AKT, RAS/MAPK with subsequent 
upregulation of gene transcription. Mutant CALR binds MPL directly with JAK-STAT 
upregulation leading to ET or PMF. MPL exon 10 mutations transform MPL receptor to 
remain constitutively active with uninhibited JAK-STAT signalling (O’Sullivan and 
Harrison, 2017a).. 
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1.11 Gene Mutations in Inherited Haematological Malignancies 
 
The inclusion of germ line predisposition to myeloid malignancies for the first time within 
the recent WHO classification (Arber et al., 2016) has designated familial haematopoietic 
malignancies as an essential component of leukaemia diagnosis (Table 1.5). 
Table 1.5 WHO 2016 classification of myeloid neoplasms with germ line 
predisposition.  Adapted from (Arber et al., 2016). 
Myeloid neoplasm 
classification 
Subtypes 
Myeloid neoplasms with 
germ line predisposition 
without a pre-existing 
disorder or organ dysfunction 
AML with germ line CEBPA mutation; myeloid 
neoplasms with germ line DDX41 mutation 
Myeloid neoplasms with 
germ line predisposition and 
pre-existing platelet disorders 
Myeloid neoplasms with germ line RUNX1 mutation; 
myeloid neoplasms with germ line ANKRD26 
mutation; myeloid neoplasms with germ line ETV6 
mutation 
Myeloid neoplasms with 
germ line predisposition and 
other organ dysfunction 
Myeloid neoplasms with germ line GATA2 mutation; 
myeloid neoplasms associated with bone marrow 
failure syndromes; myeloid neoplasms associated 
with telomere biology disorders; JMML associated 
with neurofibromatosis, Noonan syndrome, or Noon 
syndrome–like disorders; myeloid neoplasms 
associated with Down syndrome 
 
The role of germline mutations in children and adults with haematologic malignancies 
(HM) has been underappreciated to date. Diagnosing an inherited predisposition to HM 
can be used by clinicians to inform choice of therapy, risk of treatment-related 
complications, evaluation of comorbidities, and surveillance strategies to improve clinical 
outcomes (Furutani and Shimamura, 2017). 
49 
 
To date leukaemia predisposition syndromes have been grouped into three types with 
associated germline gene mutations, those with HM alone and mutations in CEBPA, 
Autophagy Related 2B/GSK3B Interacting Protein  (ATG2B/GSKIP) or DEAD-Box 
Helicase 41 (DDX41), those with an associated bone marrow failure syndrome and 
mutations in Telomerase RNA Component (TERC), Telomerase Reverse Transcriptase  
TERT, Signal Recognition Particle 72 subunit (SRP72) or Shelterin Complex Subunit And 
Telomerase Recruitment Factor (ACD7), and those with preceding cytopenia and/or 
platelet dysfunction and mutations in RUNX1, GATA2, ANKRD26 or ETV6) (Tawana and 
Fitzgibbon, 2016) (Figure 1.23). 
 
Figure 1.23 The genetic landscape of inherited HM ordered by discovery and showing 
prevalence in lymphoid and myeloid malignancies. Those with HMs alone (blue), 
associated bone marrow failure syndromes (red), cytopenia and/or platelet dysfunction 
(yellow) (Tawana and Fitzgibbon, 2016). 
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1.11.1 Familial predisposition to Myeloproliferative Neoplasms 
The majority of MPN are somatically acquired stem cell mutations that cause clonal 
expansion of myeloid precursors. In adults, MPNs due to somatic JAK2, MPL, or CALR 
mutations are usually sporadic. However, 7% of cases involve a familial predisposition, 
with first-degree relatives of an affected patient at increased risk by a factor of 5-7, for 
the same MPN (in some families) or for different MPNs (in other families), involving 
JAK2, MPL, and CALR mutations or no identifiable mutation. These results support the 
hypothesis that common shared susceptibility genes predispose to PV, ET, MF, and 
possibly CML (Landgren et al., 2008; Spivak, 2017) however the causative germline 
mutations underlying familial MPN remain largely unknown and are of low penetrance. 
Other lines of evidence also support this hypothesis, such as the observation of 
biclonality in MPN patients (Beer et al., 2009) and that some first-degree relatives of 
JAK2 V617F mutation positive MPN patients are healthy with no MPN phenotype can 
grow in vitro erythroid colonies that are hypersensitive to exogenous erythropoietin 
compared to normal individuals (Tashi, Swierczek and Prchal, 2017). Consistent with the 
existence of MPN predisposition loci, the recent finding that JAK2 V617F is not acquired 
randomly but instead arises preferentially on a specific constitutional JAK2 haplotype 
supports this. JAK2 V617F associated disease was strongly associated with a specific 
constitutional JAK2 haplotype, in PV, ET and PMF compared to healthy controls. The 
JAK2 V617F was found to be non-randomly distributed between two parental alleles of 
the JAK2 gene and was preferentially acquired in cis with the predisposition allele 
rs10974944 on a haplotype designated 46/1. This haplotype is found in approximately 
50% of normal persons and thus is a common, very low penetrance predisposition allele 
of the type that is typically detected by genome-wide association studies. This data 
suggests a certain combination of single nucleotide polymorphisms (SNPs) renders 
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haplotypes differentially susceptible to somatic mutagenesis or that a functional 
difference of JAK2 on 46/1 positively interacts with V617F and thus provides “fertile 
ground” for development of an MPN (Jones et al., 2009; Kilpivaara et al., 2009; Olcaydu 
et al., 2009).  Another example is a single-nucleotide variant located in the second intron 
of the TERT gene: rs2736100_C, which is linked to activated myeloid haematopoiesis 
and is associated with all three classical MPNs and significantly with their familial forms. 
This variant, in combination with 46/1 and other single-nucleotide variants, has an 
additive effect on susceptibility to MPNs (Jäger et al., 2014; Spivak, 2017). 
 
1.12 Additional mutations in Myeloproliferative Neoplasms 
 
As people age, changes in the haematopoietic stem cell compartment lead to an elevated 
risk of myeloid malignancies and are attributes of the aging haematopoietic system 
(Beerman et al., 2010). Aging is characterised by clonal expansion of myeloid-biased 
haematopoietic stem cells and by increased risk of myeloid malignancies. Although some 
of these mutated individuals may develop or possess an underlying MPN, many have 
blood counts within the normal range and thus represent examples of what is now termed 
age-related clonal haematopoiesis (ARCH) or clonal haematopoiesis of indeterminate 
potential (CHIP). In this regard, mutations in DNA methyltransferase 3 alpha (DNMT3A) 
and Tet methylcytosine dioxygenase 2 (TET2) were found to predominate in individuals 
with clonal haematopoiesis without HM (Busque et al., 2012; Jaiswal et al., 2014; 
McKerrell et al., 2015). Persons with CHIP have a markedly increased rate of 
cardiovascular mortality regardless of their cancer risk, demonstrating that CHIP is of 
clinical significance (Busque et al., 2012; Jaiswal et al., 2014). 
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All MPN subtypes can progress into blast-phase disease (MPN-BP). Whereas no strong 
predictors of MPN transformation to AML have been identified, some clinically useful 
prognostic factors have been identified, in particular for patients with MF. For ET, 
reported risk factors for leukaemic transformation include advanced age, extreme 
thrombocytosis, anaemia, leucocytosis, and sequence variants/mutations involving 
Tumor Protein P53 (TP53) and Enhancer of zeste homolog 2 (EZH2); for polycythaemia 
vera, advanced age, leucocytosis, abnormal karyotype, mutations involving Serine And 
Arginine Rich Splicing Factor 2 (SRSF2) and Isocitrate Dehydrogenase 2 (IDH2), and for 
PMF, increased blast percentage, thrombocytopenia, abnormal karyotype, triple-negative 
driver mutational status, and sequence variants/mutations involving SRSF2, RUNX1, 
CEBPA, and SH2B Adaptor Protein 3 (SH2B3) (Yogarajah and Tefferi, 2017). Five 
mutated genes (ASXL1, EZH2, SRSF2 and IDH1/2) have been identified in PMF patients 
who are at risk for premature death or leukemic transformation, with the number of 
detrimental mutations detected in a patient associated with worsening survival 
(Vannucchi et al., 2013; Guglielmelli et al., 2014). 
 
1.13 Paroxysmal Nocturnal Haemoglobinuria related mutations 
 
Recent work in PNH has discovered that it is in fact a complex genetic disorder 
orchestrated by many genetic alterations in addition to PIG-A mutations for example 
mutations in TET2, Polycomb Repressive Complex 2 Subunit (SUZ12), JAK2, and U2 
Small Nuclear RNA Auxiliary Factor 1 (U2AF1), many of which have been observed in 
other myeloid disorders such as AML or MDS and indicate that PNH has a clonal 
evolution and architecture strikingly similar to that of other myeloid neoplasms, 
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highlighting a potentially broader mechanism of disease pathogenesis in this disorder 
(Lee and Abdel-Wahab, 2014). 
 
1.14 Chronic Neutrophilic Leukaemia related mutations 
 
 The recent seminal discovery of activating mutations in the granulocyte colony-
stimulating factor receptor (CSF3R) in sporadic CNL has clarified diagnosis in these 
patients and provided a useful tool for diagnoses (Maxson et al., 2013).  In this study 89% 
and 40% of CNL and aCML cases respectively, were found to harbour CSF3R mutations. 
Two main types of mutational variants of CSF3R were identified: the more common 
membrane proximal mutations consisting primarily of T618I and T615A point mutations, 
and frameshift or non-sense mutations leading to premature truncation of the cytoplasmic 
tail of CSF3R (D771fs, S783fs, Y752X, and W791Z) which typically coexisted with 
membrane proximal or transmembrane CSF3R mutations as compound mutations (Figure  
1.24). 
Figure 1.24. Location and recurrence of CSF3R mutations found in CNL aCML (Maxson 
 et al., 2013). 
54 
 
The proximal mutations prevent O-glycosylation of CSF3R, increase receptor 
dimerisation and result in increased ligand independent receptor activation, whereas the 
truncation mutations result in decreased receptor degradation, increased CSF3R 
expression on the cell surface and STAT5 activity leading to cell transformation (Maxson 
et al., 2014; Zhang et al., 2017). A follow up study by Pardanani et al. who divided WHO 
defined CNL and aCML found that CSF3R mutations were found in WHO CNL only, 
and endorsed the incorporation of the T618I mutation as a sensitive and specific marker 
of WHO defined CNL (Pardanani et al., 2013).  
The granulocyte-macrophage colony-stimulating factors are well-characterised 
glycoproteins that interact to control the production, differentiation, and function of 
granulocytes and monocyte-macrophages, with proliferation of myeloid leukaemia cells  
dependent on stimulation by colony-stimulating factors (Metcalf, 1985). Specifically, 
CSF3R-deficient mice have been found to be severely neutropenic which reinforces the 
role of these cytokines in neutrophil production (Lieschke et al., 1994). Upon binding to 
its receptor, G-CSF exerts its effects via classical downstream pathways that include 
JAK-STAT, SRC family kinases, Ras/Raf/MAP kinases, and PI3K/Akt pathways, 
inducing neutrophilic differentiation, proliferation, and survival as well as stimulating 
neutrophil function (Beekman and Touw, 2010).  In the Maxon et al. landmark study, 
proximal and distal CSF3R mutations showed differential susceptibilities to different 
TKIs with proximal mutations responding to the JAK inhibitor ruxolitinib whereas 
truncation mutations displayed sensitivity to the SRC kinase inhibitor dasatinib thus 
providing a rationale for molecularly directed therapeutic targeting of CNL (Figure 1.25).  
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Figure 1.25. Model for Activation and Signalling of CSF3R Mutations (Maxson, et al., 
2013).  
 
Truncation mutations in CSF3R (the receptor for G-CSF) result in increased expression 
levels. Downstream signalling mediators - SRC family kinases and TNK2 are 
preferentially activated by these truncation mutations. Consequently, leukaemic cells 
harbouring the mutations are highly sensitive to dasatinib. Truncation mutations in 
CSF3R may also show sensitivity to JAK kinase inhibitors in the context of JAK kinase 
stimulation downstream of high ligand concentrations. In contrast, membrane proximal 
mutations in CSF3R show completely ligand-independent function. In this capacity, the 
dominant mode of signalling appears to operate through the JAK–STAT pathway. Thus, 
patients with membrane proximal mutations may be candidates for treatment with JAK 
kinase inhibitors, such as ruxolitinib (Maxson et al., 2013). 
CNL is not a disease solely driven by CSF3R mutation, with subsequent studies 
highlighting additional commonalities with other chronic myeloid malignancies at the 
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genetic level, including mutations in  SET Binding Protein 1 (SETBP1), spliceosome 
proteins (SRSF2, U2AF1), and epigenetic modifiers (TET2, ASXL1) (Piazza et al., 2013; 
Maxson and Tyner, 2017). In the case of SETBP1 mutations, exome sequencing of eight 
aCMLs identified somatic alterations with extended analysis identifying SETBP1 
mutations in 17 of 70 aCML’s (24.3%). Most mutations (92%) were located between 
codons 858 and 871 and were identical to changes seen in individuals with Schinzel-
Giedion syndrome (Figure 1.26). Although enriched and recurrently mutated in aCML 
SETBP1 mutations were also found in CMML, a disease considered to be very similar to 
aCML that has overlapping diagnostic criteria, but with a prevalence almost seven times 
greater, demonstrating for the first time a biological difference between these two entities 
(Piazza et al., 2013). At present the functional significance of SETBP1 mutations in 
aCML and CNL are not yet fully understood. 
 
Figure 1.26. Distribution of alterations on the SETBP1 protein. Black circles represent 
alterations found in aCML samples, green circles represent alterations found in other 
diseases. Variants confirmed as somatic are indicated in bold (Piazza et al., 2013). 
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1.15 Myelodysplastic Syndrome 
 
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal myeloid diseases 
characterised by inefficient haematopoiesis, peripheral cytopenias and risk of progression 
to AML. MDS is primarily a disease of the elderly with an estimated incidence of up to 
75/100,000 people over 65 years and is the leading cause of acquired bone marrow failure 
in adults (Swerdlow et al., 2008; Bejar, Levine and Ebert, 2011; Cogle et al., 2011). The 
outcome of MDS patients is extremely variable with median survival ranging from over 
5 years to less than 6 months (Greenberg et al., 2012). Approximately 150 people in 
Ireland receive a diagnosis of MDS every year, however, there are many more patients 
for whom treatment decisions are withheld until the clinical picture clarifies or worsens 
before that decision can be made. 
MDS is usually suspected by the presence of cytopenia on a routine analysis of 
peripheral blood. This prompts evaluation of bone marrow cell morphology (aspirate) and 
cellularity (biopsy). A manual count of bone marrow blasts is fundamental for risk 
assessment. Cytogenetic analysis helps in predicting risk and in selecting therapy. Once 
this information is collected, the risk of the patient can be calculated (Montalban-Bravo 
and Garcia-Manero, 2018). Diagnosis of MDS is largely determined by clinical and 
morphologic parameters yet often remains a challenge, particularly in cases of cytopenias 
with equivocal bone marrow morphology and normal cytogenetics (Gondek and DeZern, 
2014). 
MDS are classified into five subtypes of varying severity in the recent 2016 update 
to the WHO classification of myeloid haematological malignancies (Arber et al., 2016), 
which utilises clinical features, peripheral blood counts, bone marrow morphology and 
cytogenetic analysis to distinguish sub-types. Recurrent chromosomal abnormalities are 
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detected in half of MDS patients, with the most common aberrations being deletions of 
chromosomes 5 and 7, monosomy of chromosomes 5 and 7, trisomy 8, and del(20q) (List 
et al., 2006; Ebert et al., 2008; Giagounidis and Haase, 2013). Currently, the diagnosis of 
MDS is established based on the presence of persistent and significant cytopenia, a 
haemoglobin count < 10 mg/dL, absolute neutrophil count <1.8 x109/L, a platelet count 
< 100 x 109/L, >10% bone marrow dysplasia in 1 or more lineages, <20% myeloblasts in 
the bone marrow and/or abnormal karyotype (Bennett and Orazi, 2009). An iron stain is 
performed on marrow aspirates to identify the presence and quantity of ring sideroblasts, 
which should be at least 15% of the total erythroblasts to be diagnostic of MDS with 
ringed sideroblasts. Cytogenetic patterns are heterogeneous and unstable in MDS with a 
significant fraction of patients acquiring additional cytogenetic changes which can 
increase the risk of transformation to AML. The most recent cytogenetic risk 
classification in MDS includes 5 different subgroups and includes 20 different alterations 
(Montalban-Bravo and Garcia-Manero, 2018) (Figure 1.27). Around 50% of de novo 
MDS patients will be found to have a chromosomal abnormality. The only subtype of 
MDS to be defined by a genetic abnormality is the group with isolated deletion of 
chromosome 5q [del(5q)]. In the 10% of cases with the del(5q) as a sole abnormality, this 
lesion is associated with a more favourable prognosis (Haase et al., 2007). In another 5–
10% of cases, del(5q) is found as part of a complex karyotype (3 or more cytogenetic 
abnormalities): the prognosis in these cases is poorer (Adema and Bejar, 2013). 
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Figure 1.27 Cytogenetic classification of MDS (Montalban-Bravo and Garcia-Manero, 
2018). 
 
The current myelodysplastic syndromes 2016 WHO classification is outlined below: 
 MDS with single lineage dysplasia  
 MDS with multilineage dysplasia  
 MDS with ring sideroblasts (MDS-RS) 
o MDS-RS with single lineage dysplasia  
o MDS-RS with multilineage dysplasia  
 MDS with isolated del(5q) 
 MDS with excess blasts (MDS-EB) 
o MDS-EB I (5-9% Blasts) 
o MDS-EB II (10-19% Blasts) 
 MDS, unclassifiable (MDS-U) 
o with 1% blood blasts 
o with single lineage dysplasia and pancytopenia 
o based on defining cytogenetic abnormality 
o Refractory cytopenia of childhood 
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When a clear diagnosis of MDS is achieved, an accurate prediction of prognosis is 
important to determine the clinical outcome as this can vary greatly between subtypes. 
This is accomplished using the Revised International Prognostic Scoring System (IPSS-
R) to determine survival and risk of progression to AML. To achieve this a large number 
of patients were evaluated from multiple coalesced databases (n = 7012) and integrated 
with various independent clinical factors for MDS to produce a comprehensive model to 
assess relative prognostic impact. This model can be used to predict an age-adjusted risk 
category for individual patients (Figure 1.28). 
 
 
Figure 1.28: Age-adjusted IPSS-R risk categories. The nomogram describes predicted 
survival based on patient age and IPSS-R risk status (IPSS-RA) (Greenberg et al., 2012). 
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An overview of the pathobiology observed across the MDS continuum is outlined below, 
where IPSS low patients show a high level of bone marrow function, differentiation of 
myeloid cells and functional apoptosis, whereas higher risk MDS patients show loss of 
these normal functions and a propensity for myeloid cell proliferation and the presence 
of blast cells (Figure 1.29). 
 
 
Figure 1.29. Overview of pathobiology across MDS disease spectrum. 
 
Diagnosis of MDS can be hampered by a lack of clear diagnostic information to 
distinguish the disease from benign or reactive conditions that present with similar 
clinical features such as ARCH or CHIP as discussed earlier. The clinical phenotype of 
MDS patients is diverse, with this heterogeneity due to the variety of underlying genetic 
lesions that contribute to disease pathogenesis. Some patients have persistent blood 
cytopenias for which no explanation is apparent, so-called idiopathic cytopenias of 
undetermined significance (ICUS), yet have unremarkable marrow morphology and lack 
a known MDS-associated somatic mutation karyotypic abnormality (Steensma et al., 
2015). 
62 
 
Recent large-scale sequencing studies have revealed acquisition of clonally restricted 
somatic mutations in MDS-associated genes in blood cells of individuals with normal 
blood counts and without any apparent disease and that they confer an increased risk of 
subsequent haematological malignancy diagnosis, as well as higher all-cause mortality 
(Busque et al., 2012; Genovese et al., 2014; Jaiswal et al., 2014; Xie et al., 2014). 
Whereas, in some of these individuals, a myeloid neoplasm develops in the follow-up, 
others will never develop an overt myeloid disorder during their lifetime. The risk of 
developing a myeloid neoplasm depends on the type of mutations and other factors. The 
recognition of the potential for clonal haematopoiesis to manifest as disease has led to 
further splitting of this potential into clonal haematopoiesis with indeterminate potential 
(CHIP) and clonal haematopoiesis with oncogenic potential (harbouring a driver 
mutation) (CHOP) (Valent et al., 2019). Whereas some of these drivers may directly 
induce the proliferation of neoplastic stem and progenitor cells, others induce 
differentiation in distinct haematopoietic lineages and are therefore disease-specific and 
lineage-related and often detected in premalignant chronic neoplasms. In the context of 
multimutated sub-clones, oncogenic drivers contribute to the transformation to secondary 
AML (Valent et al., 2019).  
Efforts to understand the underlying genetic mutations in MDS has led to the 
discovery of recurrently mutated genes involved in epigenetic regulation, chromatin 
modification, spliceosomal machinery, signalling and DNA repair pathways, (M. J. 
Walter et al., 2011; Yoshida et al., 2011). Recent application of high throughput genomic 
techniques such as NGS has allowed the discovery of recurrent somatic mutations in over 
40 genes in patients with MDS. These techniques allow for analysis of multiple genes, 
often requiring coverage of several amplicons, to be sequenced in parallel on a single 
operating platform. Genes mutated in MDS include those involved in transcriptional 
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regulation (RUNX1, GATA2, EVI1), chromatin modification (EZH2, ASXL1), DNA 
methylation (DNMT3A, IDH1, IDH2, TET2) RNA splicing (SF3B1, U2AF1, SRSF2, 
ZRSR2), and signal transduction (JAK2, KRAS, CBL) (Bejar and Steensma, 2014). Large 
studies have demonstrated at least one oncogenic mutation is present in up to 90% of 
patients. The mutational profile in MDS shows that there is a large number of gene 
mutations detected, producing a long tail of low-frequency mutations (Walter et al., 2013; 
Haferlach et al., 2014; Papaemmanuil et al., 2015) (Figure 1.30, 1.31). Some of these 
mutations impact on patient prognosis, e.g. mutations in TP53, ETV6, ASXL1, DNMT3A, 
RUNX1 and EZH2 are associated with poor overall survival or more rapid progression to 
AML (Bejar and Steensma, 2014). Mutations in the spliceosome gene Splicing Factor 3b 
Subunit 1 (SF3B1) has been strongly associated with ring sideroblasts and these MDS 
patients are unlikely to develop detrimental sub-clonal mutations and have an indolent 
clinical course and favourable outcome (Papaemmanuil et al., 2011; Bacher et al., 2012; 
Malcovati et al., 2015). Leukaemia free survival between clonal and sub-clonal mutations 
for these genes has shown no significant difference and emphasises the importance of 
detecting sub-clones to identify high risk patients (Papaemmanuil et al., 2013). In 
addition, TET2 mutations have been shown to predict response in patients treated with 
azacytidine (Bejar, et al., 2014).  
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Figure 1.30 Landscape of MDS I (Papaemmanuil et al., 2013) 
 
 
Figure 1.31 Landscape of MDS II (Haferlach et al., 2014) 
 
Management of patients with MDS depends on whether they are defined as high or low 
risk. Patients defined as high risk MDS have a 33-45% chance of progression to AML 
and a median survival of around 12 months without intervention. Treatment options are 
observation, red cell and platelet transfusions, erythropoiesis stimulating agents, and 
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hypomethylating agents or ASCT depending on eligibility (Killick et al., 2014). Not all 
patients with MDS require therapy, some can be safely observed with intermittent blood 
count monitoring.  When therapy is justified by the development of indices such as severe 
cytopenia or increasing blasts, IPSS-R can aid in selection of therapy (Figure 1.32).  
 
 
Figure 1.32. Treatment options for spectrum of MDS patients from low (observation) to 
high risk disease (transplantation). 
 
The ability to conclusively diagnose and treat MDS will be greatly enhanced with the 
availability of new molecular information and forthcoming targeted therapies. Advances 
in the molecular understanding of MDS are set to become part of routine clinical care for 
patients with incorporation of molecular data into the prognostic algorithm (IPSS-RM) 
already underway (Bejar and Steensma, 2014).  
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1.16 Acute Myeloid Leukaemia 
 
AML is the most common acute leukaemia in adults, accounting for ~80% of cases in 
this group. Incidence of AML in the United States ranges from 3-5 cases per 100,000 
population, and increases with age, from ~1.3/100,000 in patients less than 65 years old, 
to 12.2/100 000 in those over 65 years (De Kouchkovsky and Abdul-Hay, 2016).  In the 
majority of cases AML arises as a de novo malignancy from a transformed multipotential 
haematopoietic stem cell that has acquired successive genomic alterations, ultimately 
evolving into clinically overt disease, however it can arise in patients with an underlying 
haematological disorder such as MPN or MDS, or as a consequence of prior therapy such 
as exposure to alkylating agents or radiation (Sill et al., 2011; Lowenberg and Rowe, 
2016). Advances in the treatment of AML have led to significant improvements in 
outcomes for younger patients, with 5-year survival rates in the United Kingdom between 
1976-2016 dramatically increasing in those aged 15-24 years, from 7% to 53%. However 
prognosis in the elderly who account for the majority of new cases remains poor (Shah et 
al., 2013). Within defined cytogenetic risk groups, elderly AML patients still have a 
higher relapse rate and show an inferior outcome compared to younger patients of the 
same risk group (Büchner et al., 2009; Lazarevic et al., 2014; Tsai et al., 2016). In 
addition to her pioneering work in CML in the 1970’s, Janet Rowley also established that 
AML is a genetic disease, with the discovery of somatic chromosomal abnormalities 
including the balanced translocations t(8;21) and t(15;17) in the leukaemic cells of some 
patients (Rowley, Golomb and Dougherty, 1977). These studies paved the way for 
identification of the genes disrupted at the chromosomal breakpoints of leukaemia-
associated translocations and inversions. The balanced chromosomal rearrangements 
were found to give rise to in-frame chimeric fusion genes and recurrently target genes 
encoding hematopoietic transcription factors (retinoic acid receptor alpha (RARA), 
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RUNX1, or CBFβ subunits of the core binding factor [CBF] complex), epigenetic 
regulators (MLL, CREB Binding Protein (CREBBP)), and components of the nuclear pore 
complex (NUP98, NUP214), providing major insights into normal haematopoiesis and 
uncovering common mechanistic themes in the pathogenesis of AML (Grimwade, Ivey 
and Huntly, 2016). Molecular and cytogenetic abnormalities in AML involve mutations 
in critical genes of normal cell development, cellular survival, proliferation, and 
maturation. 
1.16.1 Classification of Acute Myeloid Leukaemia 
The first attempt to classify different types of AML was achieved with the French-
Amercian-British (FAB) classification system established in 1976, that defined eight 
subtypes (M0-M7) based on the morphological and cytochemical characteristics of the 
leukemic cells (Bennett et al., 1976) (Table 1.6). 
 
Table 1.6: FAB classification of Acute Myeloid Leukaemia. 
M0 Undifferentiated acute myeloblastic leukaemia 
M1 Acute myeloblastic leukaemia with minimal maturation 
M2 Acute myeloblastic leukaemia with maturation 
M3 Acute promyelocytic leukaemia (APL) 
M4 Acute myelomonocytic leukaemia 
M4eos Acute myelomonocytic leukaemia with eosinophilia 
M5 Acute monocytic leukaemia 
M6 Acute erythroid leukaemia 
M7 Acute megakaryocytic leukaemia 
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This classification of AML was superseded in 2008 and subsequently in 2016 by the 
WHO classification system. The WHO classification of AML distinguishes itself by 
incorporating genetic information with morphology, immunophenotype and clinical 
presentation to define six major disease entities with further delineation where applicable: 
AML with recurrent genetic abnormalities; AML with myelodysplasia-related features; 
therapy-related AML; AML not otherwise specified; myeloid sarcoma; and myeloid 
proliferation related to Down syndrome (Table 1.7).  
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Table 1.7: WHO classification of AML and related neoplasms. 
AML with 
recurrent genetic 
abnormalities  
 AML with t(8:21)(q22;q22); RUNX1-RUNX1T1 
 AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
 APL with PML-RARA 
 AML with t(9;11)(p21.3;q23.3); MLLT3-KMT2A 
 ML with t(6;9)(p23;q34.1); DEK-NUP214 
 AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM 
 AML (megakaryoblastic) with t(1;22)(p13.3;q13.3); RBM15-MKL1 
 AML with BCR-ABL1 (provisional entity) 
 AML with mutated NPM1 
 AML with biallelic mutations of CEBPA 
 AML with mutated RUNX1 (provisional entity) 
AML with 
myelodysplasia-
related changes 
A history of MDS or morphological evidence of dysplasia in two or more 
myeloid cell lineages, the presence of myelodysplasia-related cytogenetic 
abnormalities such as monosomy 5 or 7, and deletion 5q or 7q  help identify 
these cases.  
   
Therapy-related 
myeloid neoplasms 
 AML with minimal differentiation 
 AML without maturation 
 AML with maturation 
 Acute myelomonocytic leukaemia 
 Acute monoblastic/monocytic leukaemia 
 Acute erythroid leukaemia 
 Pure erythroid leukaemia 
 Acute megakaryoblastic leukaemia 
 Acute basophilic leukaemia 
 Acute panmyelosis with myelofibrosis 
AML not otherwise 
specified 
 
Myeloid sarcoma  
Myeloid 
proliferations 
related to Down 
syndrome 
 Transient abnormal myelopoiesis 
 ML associated with Down syndrome 
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1.16.2 Prognosis of Acute Myeloid Leukaemia 
Stratification of AML patients according to their risk of resistance to treatment or 
treatment related mortality helps define treatment approaches. Clinical factors such as 
age, the performance status of the patient, whether the AML is a secondary malignancy 
or therapy related affect treatment related mortality (Walter et al., 2011b; Hulegårdh et 
al., 2015). Cytogenetic changes provide the strongest prognostic factor for overall 
survival and are used to risk stratify patients into three main groups of favourable, 
intermediate and adverse risk groups. Further incorporation of molecular changes has 
helped to refine the risk stratification of patients with cytogenetically normal AML (CN-
AML), which represents nearly half of de novo AML cases. An outline of the impact of 
cytogenetic and molecular lesions is outlined in Table 1.8 and Figure 1.33. This data is 
used as a framework for risk stratification to predict risk of relapse in those with normal 
karyotype and to further dissect out groups of patients with differing prognoses who share 
particular cytogenetic abnormalities, or fall within the same cytogenetic-risk group 
(Grimwade et al., 2010) 
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Table 1.8 Prognostic risk grouping in AML based on cytogenetic and molecular 
profile. 
Prognostic risk group Cytogenetic profile alone Cytogenetic profile and 
molecular abnormalities 
Favourable 
  
  
  
  
t(8:21)(q22;q22) t(8:21)(q22;q22) with no c-KIT 
mutation 
inv(16)(p13;1q22) inv(16)(p13;1q22) 
t(15;17)(q22;q12) 
  
  
t(15;17)(q22;q12) 
Mutated NPM1 without FLT3-
ITD (CN-AML) 
Mutated biallelic CEBPA (CN-
AML) 
Intermediate 
  
CN-AML t(8:21)(q22;q22) with mutated c-
KIT 
t(9;11)(p22;q23) CN-AML other than those 
included in the favourable or 
adverse prognostic group 
Cytogenetic abnormalities not 
included in the favourable or 
adverse prognostic risk groups 
 
Adverse 
  
  
  
  
  
  
  
  
inv(3)(q21q26.2) TP53 mutation, regardless of 
cytogenetic profile 
t(6;9)(p23;q34) CN with FLT3-ITD 
11q abnormalities other than 
t(9;11) 
CN with DNMT3A 
−5 or del(5q) CN with KMT2A-PTD 
−7 inv(3)(q21q26.2) 
Complex karyotype 
  
  
  
t(6;9)(p23;q34) 
11q abnormalities other than 
t(9;11) 
−5 or del(5q) 
−7 
Complex karyotype 
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Figure 1.33. Impact of cytogenetic entities recognized in 2008 WHO classification on 
survival from the UK MRC trials (Grimwade et al., 2010). 
 
1.16.3 Recurrent mutations in Acute Myeloid Leukaemia 
Studies of animal models at the turn of the century led to the development of a two-hit 
model of leukemogenesis, which offers a conceptual framework for classifying the 
various mutations associated with AML. According to this model, class I mutations which 
result in the activation of pro-proliferative pathways must occur in conjunction with class 
II mutations which impair normal hematopoietic differentiation in order for leukaemia to 
develop (Gilliland and Griffin, 2002). Common class I mutations, such as FLT3 internal 
tandem duplications (FLT3-ITD), K/NRAS, TP53 and c-KIT are found in 28%, 12%, 8% 
and 4% of cases, respectively. Class II mutations include NPM1 and CEBPA, which are 
found in 27% and 6% of cases respectively, and confer a better prognosis (Cancer 
Genome Atlas Research Network et al., 2013). Alterations in genes involved in epigenetic 
regulation have recently emerged as a third class of mutations, with downstream effects 
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on both cellular differentiation and proliferation. These include mutations in  DNMT3A, 
TET2, IDH-1 and IDH-2, which are found in more than 40% of AML cases (De 
Kouchkovsky and Abdul-Hay, 2016).  
During initial diagnostic workup, the European Leukaemia Net (ELN) 
recommendations suggest screening for mutations in NPM1, CEBPA, RUNX1, ASXL1 
and FLT3 at diagnosis (Döhner et al., 2017). In addition mutations in isocitrate 
dehydrogenase two (IDH2) are also often tested for initially, due to their newly actionable 
status in the relapsed or refractory setting (Döhner, Weisdorf and Bloomfield, 2015). In 
younger adults, cytogenetic analyses of large cohorts of AML patients have shown that 
translocations/inversions underlie disease pathogenesis in ∼50% and 30% of AML 
arising in children and younger adults, respectively, whereas only a minority of AMLs 
presenting in older adults have balanced rearrangements. The distribution of the defined 
subsets in younger adults and the frequently associated cooperating mutations are shown 
in Figure 1.34.  
 
Figure 1.34 Distribution of cytogenetically and molecularly defined subsets of AML 
presenting in younger adults and associated cooperating mutations (boxes) (Grimwade, 
Ivey and Huntly, 2016). 
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1.16.4 Genomic landscape of Acute Myeloid Leukaemia 
The past two decades have seen major advances in the understanding of the mutational 
landscape of AML providing an unprecedented view of the spectrum and frequency of 
mutations, patterns of cooperativity and mutual exclusivity, subclonal architecture, clonal 
evolution during the disease course, and the epigenetic landscape of the disease. 
Beginning with the comprehensive analysis of The Cancer Genome Atlas Research 
Network (TCGA) , who analysed the genomes of 200 clinically annotated adult cases of 
AML using matched primary tumour and normal skin samples (50 patients by whole 
genome sequencing and 150 with the use of whole-exome sequencing, RNA and 
microRNA sequencing and DNA-methylation analysis) and revealed adult AML to have 
the fewest mutations of adult cancer types sequenced (Figure 1.35). AML are clonally 
heterogenous, show a pattern of mutual exclusivity for mutations in genes within certain 
biologic classes, a high correlation between expression signature and state of 
differentiation and corroborated methylation signatures in CpG islands for transcription 
factor fusions and IDH mutations (Cancer Genome Atlas Research Network et al., 2013). 
Subsequent work has shown the distribution of mutations across risk groups in AML and 
that relapsed AML is associated with the addition of new mutations and dynamic clonal 
evolution and may contribute therapy resistance (Papaemmanuil et al., 2013) (Ding et al., 
2012) (Figures 1.36, 1.37). 
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Figure 1.35 Organisation of mutations into categories of related genes, (Cancer Genome 
Atlas Research Network et al., 2013). 
 
Figure 1.36 Identification of 5234 driver mutations involving 76 genes or regions in 1540 
AML patients (Papaemmanuil et al., 2013). 
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Figure 1.37. Representation of clonal evolution from a primary tumour to relapse in a 
single case of AML (Ding et al., 2012). 
 
Building on the understanding of the genomic landscape of AML, efforts have been made 
to understand how the genetic diversity defines the pathophysiology of AML. Combining 
driver mutation data with cytogenetic and clinical data has revealed distinct molecular 
subgroups that reflect discrete paths in the evolution of AML and allow for a genomic 
classification of AML. Mutations in epigenetic modification genes DNMT3A, ASXL1, 
IDH1/2, and TET2, are often observed to be acquired early in the disease and are not 
sufficient for overt disease as they are also found mutated in elderly populations with 
clonal haematopoiesis (Busque et al., 2012; Genovese et al., 2014; Xie et al., 2014) 
  
1.16.5 Familial Platelet Disorder with propensity to AML 
Familial platelet disorder with propensity to AML (FPD-AML) is a rare, autosomal 
dominant disorder characterised by quantitative and qualitative platelet abnormalities 
with a propensity to develop an MDS or AML. FPD-AML kindred are defined by germ-
line mutations of RUNX1 (Song et al., 1999), commonly dysregulated by translocations, 
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mutations or amplification in de novo and secondary MDS and acute leukaemia. Most 
germ line RUNX1 mutations are unique to the individual FPD-AML pedigree with 
variability observed in the MDS or AML phenotype and the incidence of leukaemic 
transformation of affected individuals (Nickels et al., 2013).  
The spectrum of somatic genetic events associated with progression to MDS or 
AML have not been fully appreciated but acquisition of cytogenetic abnormalities, single 
gene defects that occur in de novo MDS and AML, and bi-allelic RUNX1 mutations have 
all been demonstrated (Minelli et al., 2004; Preudhomme et al., 2009; Shiba et al., 2012). 
More recently, mutations of CDC25C have been identified in approximately half of 
affected FPD-AML patients. CDC25C mutations appear to disrupt a critical cell cycle 
check point in pre-leukaemic clones, allowing subsequent acquisition of further sub-
clonal mutations (Yoshimi et al., 2014). 
 
1.16.6 Treatment of Acute Myeloid Leukaemia 
The general therapeutic strategy in patients with AML has not changed substantially in 
more than 30 years with initial assessment determining whether a patient is eligible for 
intensive induction chemotherapy (Döhner, Weisdorf and Bloomfield, 2015). Patients 
eligible for intensive treatment are considered for remission-induction chemotherapy and 
depending on response and the risk profile of the disease, an allogeneic HSCT as 
consolidation therapy can be considered. In eligible adults with newly diagnosed AML, 
the traditional standard therapy is ‘7+3’ induction chemotherapy with infusional 
cytarabine for 7 days with 3 days of anthracycline chemotherapy (daunorubicin or 
idarubicin) (Roboz, 2012). A complete remission (CR) is achieved in 60%–85% of 
patients younger than the age of 60, and in 40%–60% of patients greater than the age of 
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60 (Davis, Benjamin and Jonas, 2018). For patients with an unfavourable-risk AML, 
intensive chemotherapy is mainly considered when a donor for an ASCT is available and 
a subsequent transplant can be foreseen. Otherwise, these unfavourable-risk patients and 
patients ineligible for intensive chemotherapy will more likely be considered for less-
intensive treatment approaches, or for a clinical trial with an investigational agent 
(Ossenkoppele and Lowenberg, 2015) (Figure 1.38).  
 
 
Figure 1.38 General Algorithm for the treatment of older patients with AML 
(Ossenkoppele and Lowenberg, 2015). 
 
1.16.7 New therapies in Acute Myeloid Leukaemia 
With a growing understanding of the underlying genomic landscape of AML, several new 
therapeutics have been put into development to target particular sub-populations and in 
2017, four new therapies were approved.  
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1.16.8 Midostaurin 
Midostaurin was FDA approved after a phase 3 trial comparing the addition of 
midostaurin, an oral multitargeted kinase inhibitor active in patients with a FLT3 mutation 
to standard chemotherapy was shown to significantly prolong overall and event-free 
survival among patients with AML and a FLT3 mutation. A median overall survival of 
74.7 months in the midostaurin group versus 25.6 months with placebo was observed 
(Stone et al., 2017).  
1.16.9 Gemtuzumab Ozogamicin 
Fractioned doses of gemtuzumab ozogamicin (GO) was approved for use with standard 
first line chemotherapy in newly diagnosed CD33+AML and also relapsed or refractory 
CD33+ AML. GO, a humanised immunoglobulin antibody directed against CD33 and 
conjugated with calicheamicin, a cytotoxic antibiotic had been withdrawn almost 20 years 
ago after a phase III study in patients with untreated AML comparing standard 
7+3 induction chemotherapy plus GO versus 7+3 alone found a higher mortality rate in 
the GO arm (5.5% vs 1.4%), without any improvement in complete remission, disease-
free or overall survival (Petersdorf et al., 2013). 
1.16.10 CPX-351 
CPX-351 a liposomal formulation of cytarabine and daunorubicin in a fixed 5:1 molar 
ratio was compared in a phase III trial to standard 7+3 chemotherapy in patients aged 60-
75 years with high risk secondary AML and showed superior overall survival 9.56 vs 5.95 
months (p=0.005) in the CPX-351 arm with similar adverse events in both arms, leading 
to FDA approval for newly diagnosed therapy-related AML or AML with MDS-related 
changes (Lancet et al., 2016). 
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1.16.11 Enasidenib 
Enasidenib  a selective inhibitor of mutated IDH2 received FDA approval for IDH2-
mutant relapsed or refractory AML at a dosing of 100 mg orally once per day, after 
showing a median overall survival among relapsed/refractory patients of 9.3 months, and 
was 19.7 months for the 34 patients (19.3%) who attained complete remission  in  a phase 
I/II study (Stein et al., 2017). 
Cancer medicine continues to move toward immunotherapeutic strategies and the idea of 
personalised medicine. To achieve this, a refined diagnosis and molecular profile of the 
individual’s tumour will be required at presentation and throughout the disease course as 
a patient responds to therapy. Developments in our understanding of the molecular drivers 
of disease is fragmenting the traditional disease classifications and the application of 
molecular diagnostics in relevant clinical scenarios, can enhance our ability to deliver on 
the promise of personalised medicine.  
The aim of the research in this thesis was to determine if mutation status in myeloid 
malignancies can be used inform clinical insight. This was investigated using the 
following objectives: 
1: Validate the utility of specific mutations to monitor MPN disease burden post 
transplantation 
2: Investigate the incidence and significance of MPN mutations in various clinical 
contexts. 
3: Validate the introduction of next generation sequencing techniques for detection of 
somatic mutations in AML clinical cohorts. 
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2.0 Materials and Methods 
 
2.1 Ethical Statement 
 
All studies were performed in accordance with the 1964 Helsinki declaration and its later 
amendments and with the ethical standards of the institutional research committee. The 
publications in this thesis are based on patient testing that was conducted within an 
ISO15189 accredited department as part of routine clinical patient care. The studies were 
retrospective in nature and consent for the testing performed was acquired by the referring 
clinical consultant at the point of care. Samples for all studies were anonymised in 
subsequent aggregate analysis. For case studies where identifiable information was 
documented, individual consent for publication was acquired from the patient or 
parent/legal guardian in a paediatric case by the physician in charge of care. Records and 
pathological material were retained in accordance with Royal College of Pathology 
guidelines 5th Edition. All records were kept on a secure PC under password protection 
available to supervisor. 
 
2.2 Sample selection and processing 
For all studies, samples were processed in a routine molecular diagnostic facility that 
adheres to international accreditation standards (ISO 15189). Samples were processed 
using validated methods for DNA and RNA extraction as outlined below in section 2.3 
and 2.5. Prior to arrival at the laboratory, peripheral blood samples were drawn into 6ml 
purple topped BD Vacutainer® tubes containing EDTA anti-coagulant. For bone marrow 
samples, 2ml of bone marrow aspirate was diluted into 12ml of Roswell Park Memorial 
Institute (RPMI) 1640 Medium in a 30ml sterile universal container.  
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2.3 DNA extraction from whole blood and bone marrow samples 
DNA was extracted from 200µl of blood or bone marrow using the DNA Blood mini kit 
(QIAGEN, Hilden, Germany), as per manufacturer instructions. Briefly, protease solution 
was added to a 1.5 ml microcentrifuge tube to which 200μl of whole blood or bone 
marrow sample was added, followed by RNase A solution (100 mg/ml). Samples were 
homogenised by pulse-vortexing and incubated at 56°C for 10 minutes, before brief 
centrifugation to remove condensation from the inside of the lid. Pure ethanol (96–100%) 
(Merck KGaA, Darmstadt, Germany) was added to the samples before they were loaded 
onto a QIAamp Mini spin column and centrifuged at 6000 x g for 1 minute in a Scanspeed 
1524 centrifuge (LaboGene ApS, Bjarkesvej, Denmark). A series of kit buffer additions 
to the column and centrifugation steps were carried out to complete the bind-wash-elute 
protocol ensuring high quality DNA was eluted off the column. DNA samples were stored 
at -20°C. DNA was quantified as outlined in section 2.7. 
 
2.4 Red cell lysis 
Prior to RNA extraction, removal of the red blood cells is required to enrich for leucocytes 
and ensure a clean extraction eluate. Red cell lysis buffer (RCLB) was prepared by 
dissolving 8.29g (155mM) Ammonium Chloride, (Sigma, Merck KGaA, Darmstadt, 
Germany), 1.2g (12mM) Potassium Bicarbonate, (Sigma, Merck KGaA, Darmstadt, 
Germany), and 200µl 0.5M EDTA (pH 7.4) (0.1mM) (Sigma, Merck KGaA, Darmstadt, 
Germany) in 1 litre of sterile water. Samples were processed at a ratio of 1:10 blood (5ml) 
or bone marrow (15ml): RCLB, were mixed well and the mixture was incubated at room 
temperature for 10 minutes, before centrifugation at 1500 rpm (500g) for 10 minutes at 
83 
 
room temperature in a Centra GP8 centrifuge (Thermo Scientific, Waltham, USA). The 
supernatant was decanted, leaving a pellet of nucleated cells.  A volume of 40ml of RCLB 
was added to the pellet and resuspended before repeated centrifugation at 1500 rpm 
(500g) for 10 minutes to ensure removal of red cell debris.  The nucleated cells were 
resuspended and washed in a total volume of 30ml phosphate buffered saline (PBS) 
(Merck KgaA, Darmstadt, Germany) and centrifuged at 1500 rpm (500g) for 10 minutes. 
The supernatant was decanted and remaining PBS was removed by gently inverting the 
tubes onto blotting paper to draw off residual liquid. The pellet was fully resuspended by 
repeated aspiration in 600µl RLT buffer (Qiagen, Hilden, Germany). The homogenised 
samples were transferred to 1.5ml Sarstedt screw cap tubes for storage at -20°C. 
 
2.5 RNA extraction from leucocytes 
RNA was extracted from leucocyte lysates prepared during the Red Cell Lysis protocol 
described above (Section 2.4), using the QIAGEN QIAamp RNA blood mini kit 
(QIAGEN, Hilden, Germany). Briefly, 600µl lysate was spun through a QIAshredder spin 
column (QIAGEN, Hilden, Germany) in a 2 ml collection tube to create a homogenous 
solution. Following this, 600µl of 70% Ethanol (Merck KGaA, Darmstasdt, Germany) 
was mixed into the sample before it was passed through a QIAamp spin column to bind 
the RNA. Genomic DNA was removed using DNase I before a wash-elute protocol was 
followed and the RNA was eluted in 50µl RNase-free water. Samples were stored at -
20°C until quantified and at -80°C long term. 
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2.6 cDNA synthesis 
First strand cDNA was generated from RNA by reverse transcription. This process used 
random hexamers to prime transcription of RNA, and Superscript III (Invitrogen, 
Carlsbad, USA) reverse transcriptase to convert single stranded RNA into cDNA. One 
microgram (1µg) of RNA in a total volume of 10µl was used in each cDNA reaction. 
RNA samples with a concentration of less than 100ng/µl were placed into an Eppendorf 
Concentrator (Eppendorf, Hamburg, Germany) at 60°C for 8 minutes and re-quantified 
to ensure the concentration threshold was achieved. A water negative control was 
generated for each batch of cDNA produced. RNA samples were slowly thawed on ice, 
before 1µg RNA was added to a 0.2ml PCR tube and made up to a total volume of 10µl 
with RNAse free water. Samples were incubated at 70°C for 10 minutes to denature any 
secondary structures in the RNA before being stored on ice to ensure the RNA remained 
in single stranded conformation prior to the reverse transcriptase reaction. A volume of 
10µl of a mastermix containing 4µl of 5X RT Buffer (Invitrogen, Carlsbad, USA), 2µl of 
dNTPs (10mM) (Promega, Wisconsin, USA), 2µl of DTT (0.1M) (Invitrogen, Carlsbad, 
USA), 0.33µl of Random primers (3µg/µl) (Invitrogen, Carlsbad, USA), 0.5µl of 
RnaseOut Ribonuclease inhibitor (40U/µl) (Invitrogen, Carlsbad, USA), 1µl of 
SuperScript III Reverse transcriptase (200U/µl) (Invitrogen, Carlsbad, USA) and 0.67µl 
nuclease free water was added to each RNA sample. Samples were vortexed and spun 
down briefly to produce a homogenous 20µl cDNA reaction and placed into a Veriti 
thermal cycler (Thermo Scientific, Waltham, USA) at 25°C for 10mins, followed by 42°C 
for 45mins and 99°C for 3 minutes. Samples were placed on ice for 5 minutes, spun down 
using a microfuge to remove condensation and stored at -20°C until required for use. 
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2.7 Determination of DNA/RNA purity and concentration 
To determine the concentration and purity of DNA/RNA extracted from peripheral blood 
or bone marrow aspirates, a NanoDrop ND-1000 (Thermo Scientific, Waltham, USA) 
spectrophotometer was used. This technology applies a surface tension for sample 
retention and requires 2µl of sample applied directly. After the instrument was blanked 
using nuclease free water/relevant elution buffer, 2µl of sample was applied to the 
nanodrop and measured for absorbance at 260/280nm for nucleic acid purity and 
260/230nm for sample contaminants. Samples were deemed sufficient for downstream 
applications if the DNA absorbance ratio was ~1.8 and RNA absorbance was ~2.0 at 
260/280 and ratios at 260/230 were greater than 2.0.   
 
2.8 Primer sequences 
All primers were ordered online from Eurofins Genomics® Ebersberg, Germany. On 
receipt of lyophilised primers, 100 pmol/µl stocks were prepared by adding nuclease free 
water as indicated on the synthesis report. The tubes were vortexed briefly and allowed 
rest at room temperature for 30 minutes to ensure full dilution before storage at -20°C 
until required. Primer sequences used for the study are provided in Table 2.1 below. 
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Table 2.1 Primer sets used for target amplification 
Gene Name 
Forward Primer 
name Forward Primer 5’-3’ 
Reverse Primer 
name Reverse Primer 5’-3’ 
Chapter 3/4: 
JAK2 V617F qualitative: 
(Janus Kinase 2) 
JAK2-F AGCATTTGGTTTTAAATTATGGAGTATATT JAK2-R CTGAATAGTCCTACAGTGTTTTCAGTTTCA 
 JAK2-IC ATCTATAGTCATGCTGAAAGTAGGAGAAAG 
JAK2 qPCR: JAK2-Forward CTTTCTTTGAAGCAGCAAGTATGA JAK2-Wild type GTAGTTTTACTTACTCTCGTCTCCACATAC 
    JAK2-Mutated GTAGTTTTACTTACTCTCGTCTCCACATAA 
    JAK2 probe Fam-TGAGCAAGCTTTCTCACAAGCATTTGGTTT-
Tamra 
CALR 
(calreticulin) 
CALR-ex-9-F FAM-GGCAAGGCCCTGAGGTGT CALR-ex9-R GGCCTCAGTCCAGCCCTG 
SETBP1 
(SET binding protein 1) 
SETBP1_E_F CAACACAGACAGTCTTACTGTGATC  SETBP1_E_R TTGGTTGGAAGAGCACTGATG 
SETBP1 
 
SETBP1_F_F CCACTTTCAACACAGTTAGGTG SETBP1_F_R TCTCGTGGTAGAAGGTGTAACTC 
CSF3R  
(Colony Stimulating Factor 3 
Receptor) 
CSF3R exon 14_F GTAAAACGACGGCCAGTCCACGGAGGCAGCTTTA
C 
CSF3R exon 14_R CAGGAAACAGCTATGACCAAATCAGCATCCTTTGG
GTG 
CSF3R Exon 17_F GTAAAACGACGGCCAGTAGTGGCCCAAAGACACA
GTC 
CSF3R Exon 17_R CAGGAAACAGCTATGACCGGGAGTCCCATAACAG
CTCA 
Chapter 5: 
FLT3-ITD:  
(fms-like tyrosine kinase 3) 
 
11F GCAATTTAGGTATGAAAGCCAGC 12R CTTTCAGCATTTTGACGGCAACC 
NPM1: 
(nucleophosmin) 
NPM-F-FAM FAM-GATGTCTATGAAGTGTTGTGGTTCC NPM-R GGACAGCCAGATATCAACTG 
CDC25C  
(Cell Division Cycle 25C) 
CDC25-F TGCAGACACACTTGGAGGAG CDC25-R CCTTCCTGAGCTTTCCTTGG 
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2.9 PCR conditions 
2.9.1 Standard PCR conditions 
The following reaction conditions were used to generate PCR products for primer pairs unless 
otherwise indicated. Total volume (25µl) PCR reactions were prepared in a 0.2ml PCR tube 
(Table 2.2). Template cDNA (2.5µl) was added to each tube and mixed to generate a 
homogenous solution. A water negative sample was included as a negative control. PCR 
mixtures were inserted into a Veriti PCR machine under the following cycling conditions: 95°C 
for 11 minutes hot start to activate enzyme, followed by 35 cycles of 95°C for 30 seconds 
denature, 65°C for 30 seconds annealing, and 72°C for 60 seconds extension, with a final 
extension at 72°C for 7 minutes, before being held at 4°C. 
 
Table 2.2 Standard PCR reaction reagent preparation. 
Reagent Volume (l) 
Forward Primer (10μM) 1 
Reverse Primer (10μM) 1 
dNTPs (10mM) (Promega, Wisconsin, USA) 0.5 
10X AmpliTaq Buffer Gold (Thermo Scientific, Waltham, USA) 2.5 
Magnesium Chloride (25mM) (Thermo Scientific, Waltham, 
USA), 
3 
AmpliTaq Gold (5U/µl) (Thermo Scientific, Waltham, USA)  0.1 
Nuclease Free Water 14.4 
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2.9.2 JAK2 V617F PCR 
This assay was an allele-specific PCR that employs a common internal control reverse primer, 
a mutation specific forward primer and a wild type forward primer to detect JAK2 V617F 
mutations. The method is based on that published by Baxter et al., 2005 with modification 
(Baxter et al., 2005). The method results in the amplification of a 203 base pair mutant product, 
if present, and a 364 base pair band from wild type alleles that serve as an internal PCR control. 
The assay is qualitative, with PCR products visualised by gel electrophoresis outlined in section 
2.9.8. A homogenous mastermix was prepared for n+1 samples to produce a final volume of 
11.2µl (Table 2.3). The mastermix (11.2µl) was added to 0.2ml PCR tubes, followed by 50ng 
DNA and nuclease free water to a final volume of 25µl. The samples were vortexed and briefly 
spun down before being placed into a Veriti PCR cycler. Cycling conditions were 95°C for 10 
minutes, followed by 35 cycles of 94°C for 30 seconds, 58°C for 30 seconds, 72°C for 30 
seconds, and a final extension of 72°C for 6 minutes. PCR products were electrophoresed on a 
2% agarose gel at 100V for 45 minutes and photographed under a UV transilluminator as 
outlined in section 2.9.8.    
Table 2.3 JAK2 V617F mastermix 
Reagent Volume (l) 
Forward primer (JAK-F)  (10pmol/µl) 1.25 
Internal control forward primer (JAK-IC)  (10pmol/µl) 1.25 
Reverse primer (JAK-R) (10pmol/µl) 2.5 
dNTPs (1mM) 2 
10X AmpliTaq Buffer Gold 2.5 
Magnesium Chloride (25mM) 2.5 
AmpliTaq Gold (5U/µl)  0.2 
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2.9.3 JAK2 V617F semi-nested PCR 
A homogenous mastermix was prepared for n+1 samples as outlined in Table 2.3. Cycling 
conditions were as described above in Section 2.9.1. A volume of 1µl of the PCR product was 
subsequently used as the template in a second, nested PCR reaction (Table 2.4) to produce a 
final volume of 11.2µl. The mastermix was added to 0.2ml PCR tubes, 1µl template and 
nuclease free water to a final volume of 25µl. Cycling conditions were as described above in 
section 2.9.1. PCR products were electrophoresed on a 2% agarose gel at 100V for 45 minutes 
and photographed under a UV transilluminator as outlined in section 2.9.8. 
 
Table 2.4 JAK2 V617F semi-nested mastermix 
Reagent Volume (l) 
Forward primer (JAK2-F) (10pmol/µl) 2.5 
Reverse primer (JAK-R) (10pmol/µl) 2.5 
dNTPs (1mM) 2 
10X AmpliTaq Buffer Gold 2.5 
Magnesium Chloride (25mM) 2.5 
AmpliTaq Gold (5U/µl) 0.2 
 
2.9.4 FLT3-ITD PCR 
FLT3 internal tandem duplications (ITDs) are in-frame duplications within the juxtamembrane 
domain of the protein, resulting in constitutive tyrosine kinase activity. The duplicated 
sequence of the mutant FLT3 varies in length and involves exon 11, 12 or the intervening 
intron. This protocol is derived from the method established by Kottaridis et al. with 
modification and amplifies a 328bp wild type fragment which acts as an internal control and a 
second longer fragment that contains the ITD if present (Kottaridis et al., 2001). Reactions 
(20µl ) were prepared using 50ng template DNA and nuclease free water to a final volume of 
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20µl (Table 2.5). Three control reactions, a FLT3-ITD positive sample (MV4-11 cell line 
DNA), a FLT3-ITD wild type sample (HL-60 cell line DNA) and a water blank were included 
in every run. Samples were placed into a Veriti thermal cycler and run under the following 
cycling conditions: 95°C for 10 minutes denature, followed by 35 cycles of 94°C for 30 
seconds, 65°C for 60 seconds, 72°C for 60 seconds, followed by a final extension of 72°C for 
5 minutes. PCR products were electrophoresed on a 3% agarose gel at 100V for 90 minutes 
and photographed under a UV transilluminator as outlined in section 2.9.8 
 
Table 2.5 FLT3-ITD mastermix. 
Reagent Volume (l) 
Forward primer (0.5pmoles/µl) 1 
Reverse primer (0.5 pmoles/µl) 1 
dNTPs (1mM) 4 
10X AmpliTaq Gold Buffer 2 
MgCl2 (25mM) 3.2 
AmpliTaq Gold polymerase (5U/ml) 0.25 
 
2.9.5 NPM1 exon 12 mutation PCR 
Mutations in Nucleophosmin (NPM1) on chromosome 5q35 have been identified in normal 
karyotype AML, of which 90-95% result in a heterozygous tetranucleotide insertion thought 
likely to contribute to leukaemogenesis. Genomic DNA from patient samples is amplified with 
a hi-fidelity DNA polymerase using a 6-FAM labelled forward primer located within the intron 
between NPM1 exons 11 and 12, and a reverse primer that results in amplification of a fragment 
containing the coding region of NPM1 exon 12. Wild type NPM1 allele is used as an internal 
control for DNA extraction and amplification. Amplified product produces a 168-170 bp wild 
type fragment and in mutated cases an additional 172 bp or 175 bp fragment (the latter in very 
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rare cases of a net 5 bp insertion). Reactions to a final volume of 20l were prepared with 10ng 
template DNA and nuclease free water to 20µl (Table 2.6). Samples were placed into a Veriti 
thermal cycler under the following conditions: 94°C for 2 minutes, followed 35 cycles of 94°C 
for 29 seconds, 60°C for 20 seconds, 72°C for 20 seconds, and a final extension of 72°C for 2 
minutes. An NPM1 mutation positive control, negative control and a water template blank were 
included in each run. Following amplification, NPM1 PCR products were visualised by 
capillary electrophoresis (see section 2.10.1). 
Table 2.6 NPM1 exon 12 mastermix 
Reagent Volume (l) 
Forward primer (4pmol/µl)  1 
Reverse primer (4pmol/µl) 1 
 dNTPs (1mmol/L) 4 
10X Cloned Pfu DNA polymerase Reaction Buffer (Agilent, Santa 
Clara, USA)  
2 
MgCl2 (25mmol/L) 1.6 
Pfu Turbo Hotstart DNA polymerase (Agilent, Santa Clara, USA) 0.5 
 
2.9.6 CALR exon 9 mutation PCR 
Insertion and/or deletion mutations within exon 9 of the CALR gene result in a frame-shift 
mutation producing a protein product with an altered C-terminal. For detection, genomic DNA 
from patient peripheral blood or bone marrow is amplified using a 6-FAM labelled forward 
primer and reverse primer spanning CALR exon 9. The wild type CALR allele is used as an 
internal control for DNA extraction and amplification and produces a 262 bp wild type 
fragment. Over 80% of mutated CALR indels are of type 1 (52 bp deletion) or type 2 (5 bp 
insertion), however more than 40 types have been identified to date. This assay is based on that 
of Klampfl et al., 2013 with modification. Reactions to a total volume of 20µl were prepared 
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with 50ng template DNA and nuclease free water to 25µl in 0.2ml PCR tubes (Table 2.7). 
Samples were placed into a Veriti thermal cycler under the following conditions: 95°C for 10 
minutes denature, followed by 11 cycles (with a decreasing annealing temperature of 1°C) of 
94°C for 15 seconds, 65°C-55°C annealing for 15 seconds, 72°C for 30 seconds extension, 21 
cycles of 89°C for 15 seconds, 55°C for 15 seconds, 72°C for 30 seconds, followed by 72°C 
for 20 minutes final extension. PCR products were visualised by capillary electrophoresis (see 
section 2.10.2). 
Table 2.7. CALR exon 9 mastermix 
Reagent Volume (l) 
Forward primer (10pmol/µl) 1.25 
 Reverse primer (10pmol/µl) 1.25 
dNTPs (1mmol/L) 2 
10X GeneAmp Gold PCR Buffer (Thermo Scientific, Waltham, 
USA) 
2.5 
MgCl2 (25mmol/L) 1.5 
Amplitaq Gold polymerase (5U/µl) 0.2 
 
2.9.7 Donor Chimerism STR-PCR 
Short tandem repeat (STR) loci exhibit alleles that may differ in length between individuals. 
STR loci have been identified throughout the human genome and consist of a core DNA 
sequence, usually 2-8 bases long that is repeated a variable number of times within a discrete 
genetic locus. Amplification of a selected number of these highly variable regions allows for 
discrimination between closely related individuals and can be applied to screen donor/recipient 
pairs prior to stem cell transplantation to identify informative STRs for use in monitoring 
patient engraftment in the post-transplantation scenario. To monitor donor chimerism, the 
Promega PowerPlex16 kit (Promega, Wisconsin, USA) was used as per manufacturer’s 
93 
 
instructions. This kit amplifies 15 STR distributed across the genome, namely Penta E, 
D18S51, D21S11, TH01, D3S1358, FGA, TPOX, D8S1179, vWA, Penta D, CSF1PO, 
D16S539, D7S820, D13S317, D5S818 plus Amelogenin, a gene located on the sex 
chromosomes that differs in intronic sequence on the X chromosome relative to the Y 
chromosome and allows for sex discrimination in the majority of cases. Briefly, 10µl reactions 
were prepared as laid out in Table 2.8. One positive and one negative amplification control was 
included in each run. Samples were placed on a Veriti thermal cycler under the following 
cycling conditions; 95°C for 11 minutes, 96°C for 1 minute, 10 cycles of 94°C for 30 seconds, 
ramp to 68°C over 68 seconds, hold for 30 seconds, ramp to 70°C over 50 seconds, hold for 45 
seconds. 21 cycles of 90°C for 30 seconds, ramp to 60°C over 60 seconds, hold for 30 seconds, 
ramp to 70°C over 50 seconds, hold for 45 seconds. 60°C for 30 minutes final extension, hold 
at 4°C. PCR products were visualised by capillary electrophoresis (see section 2.10.3). 
Table 2.8 Powerplex16 PCR mastermix. 
Reagent Volume (l) 
Gold Star 10xBuffer 1 
PP16 10X Primer Pairs, 1 
AmpliTaq Gold DNA polymerase 0.32 
Nuclease-free H2O 6.68 
DNA template (2ng/µl) 1 
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2.9.8 Gel Electrophoresis and visualisation of PCR products 
To visualise PCR products, 5µl of 6X Orange G, (Thermo Scientific, Waltham, USA) was 
added into each 25µl PCR reaction tube and samples were added to wells on a 2% agarose 
(Conda, Madrid, Spain) gel containing 5µl of SYBR Safe DNA Gel Stain/50 ml gel (Thermo 
Scientific, Waltham, USA). Samples were electrophoresed in 1X Ultrapure TAE Buffer, 
(Thermo Scientific, Waltham, USA) with 10µl of 100bp DNA ladder (Thermo Scientific, 
Waltham, USA) loaded at either end of the gel (first and last well) for 40 minutes at 100Volts 
and 500mA. The gel tray was removed and placed into the SynGene GeneGenius UV 
transilluminator (SynGene, Cambridge, UK), and a photo was taken of the image under ultra-
violet light illumination. 
2.10 Capillary electrophoresis of PCR products 
During capillary electrophoresis, the products of a PCR containing fluorescent labelled primers 
are injected electrokinetically into capillaries filled with polymer. High voltage is applied so 
that the fluorescent DNA fragments are separated by size and are detected by a laser/camera 
system. The intensity of each fragment determines the relative fluorescence unit value (RFU) 
and is shown as a peak height in the electropherogram (Figure 2.1).   
Figure 2.1 Electropherogram of DNA fragments. Different coloured peaks correspond to 
different fluorophores attached to the DNA fragments during previous PCR cycling. 
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2.10.1 NPM1 PCR product capillary electrophoresis 
A volume of 1µl of a 1:20 dilution of each PCR product was added to a 96 well PCR plate 
containing 9µl HiDi formamide and 1µl GeneScan 400HD ROX Size Standard (Thermo 
Scientific, Waltham, USA). Samples were denatured at 95°C for 3 minutes and placed on ice 
for 5 minutes before being briefly spun down and loaded into a 3130XL Genetic analyser for 
electrophoresis using POP-7 polymer and an injection setting of 2kV for 5 seconds. 
Electropherograms were analysed using GeneMapper Version 4.0 Software (Applied 
Biosystems, Foster City, CA, USA). 
2.10.2 CALR capillary electrophoresis 
A volume of 1µl of a 1:25 dilution of each PCR product was added to a 96 well PCR plate 
containing 9µl HiDi formamide and 1µl GeneScan 400HD ROX Size Standard. Samples were 
denatured at 95°C for 3 minutes and placed on ice for 5 minutes before being briefly spun down 
and loaded into a 3130XL Genetic analyser for electrophoresis using POP-7 polymer and an 
injection setting of 3kV for 23 seconds. Electropherograms were analysed using GeneMapper 
Version 4.0 Software (Applied Biosystems, Foster City, CA, USA). 
2.10.3 Donor chimerism capillary electrophoresis 
A volume of 1µl of STR-PCR product was dissolved into 9µl of HiDi Formamide (Thermo 
Scientific, Waltham, USA) containing 1µl internal lane standard ILS-600 (Promega, 
Wisconsin, USA) denatured at 95°C for 5 minutes and held on ice for 5 minutes before being 
electrophoresed on a 3130xl Genetic Analyzer 3130xl (Thermo Scientific, Waltham, USA) at 
2kVolts for 5 seconds injection time. Electropherograms were analysed using GeneMapper 
Version 4.0 Software (Applied Biosystems, Foster City, USA). Peak height analysis was used 
to quantify the percentage donor chimerism (donor/donor + recipient)*100. 
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2.11 JAK2 V617F qPCR 
This assay was performed as defined by Larsen et al. with modification (Larsen et al., 2007).  
The assay is composed of two allele-specific PCR reactions; one for the JAK2 V617F mutated 
allele and one for the wild type allele. The reverse primers are mutation or wild type-specific 
and primers differ only by the 3’ nucleotide. The mutation and wild type reactions use the same 
forward primer and the same FAM-TAMRA probe. Reactions containing 25µl were prepared 
with mastermix (Table 2.9) and 10µl of DNA at a concentration of 20 ng/µl added to make up 
the final volume 
Table 2.9 JAK2 qPCR Mastermix 
Reagent Volume (l) 
10x concentrate of primer/probe mix  
(300 nmol/l of primers,  200 nmol/l of probe) 
2.5 
2x TaqMan Universal PCR Master Mix (with UNG) 12.5 
 
Cycling conditions were 2 minutes at 50°C (uracil-N-glycosylase (UNG) treatment), 10 
minutes at 95°C to activate the Taq polymerase, followed by 50 cycles of 15 seconds at 95°C 
for denaturation, and 60 seconds at 60°C for annealing and extension. PCR reactions for mutant 
JAK2 V617F were performed in triplicate and for wild type JAK2 in duplicate on an Applied 
Biosystems 7500 Real Time PCR System (Thermo Scientific, Waltham, USA) using standard 
or 9600 emulation mode and a ramp rate -1.6°C/sec. Commercial plasmids were used in 
duplicate for construction of both JAK2 V617F mutant and wild type standard qPCR four-point 
standard curves (50, 500, 5000, 50,000 copies) (Ipsogen SA/QIAGEN, Marseille, France). All 
assays included a wild type control, a JAK2 V617F positive control, and a water negative 
control. An automatic baseline (3–15 cycles) and a fixed threshold of 0.1 (ΔRn) was selected 
to ensure consistency of analysis. Copy number for both mutant and wild type JAK2 was 
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calculated using the slope and Y-intercept from the standard curve, where copy number 
=POWER(10;Y-intercept-Sample Ct)/slope. Results were expressed as a percentage of JAK2 
V617F alleles of the total of JAK2 alleles. i.e. mutant copy number/(wild type copy number + 
mutant copy number)*100.  As the reverse primers used in both assays differed by only one 
base at the 3′ end, non-specific amplification was observed in the JAK2 V617F assay when 
performed on the target negative control sample, see Figure 2.2. The specificity and sensitivity 
for each run was therefore calculated using the ΔCt value for the target negative sample 
(number of cycles between wild type and V617F Ct values) where the specificity corresponds 
to 2ΔCt (i.e. 2 to the power of the number of cycles between the two thresholds. For example if 
the delta Ct was 14, specificity = 214 or >1:10000). The sensitivity was set at 10-fold less than 
the value for specificity to ensure the identification of true positive measurements. 
 
Figure 2.2. Non-specific amplification of JAK2 V617F observed in a wild type sample 
generated by the JAK2 V617F primer set (Table 2.1).  
 
Non-specific 
amplification 
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2.12 Sanger Sequencing process 
This technique consists of target DNA being copied by DNA polymerase in the presence of 
dNTPs that include fluorescently labelled dideoxy nucleotides (ddNTPs) present at a lower 
ratio (~1:100). Incorporation of a ddNTPs during synthesis causes the strand to end as no 
further dNTPs can be added. This process is repeated for multiple cycles, resulting in the 
incorporation of ddNTPs at every position of the target DNA and production of fragments 
varying in length by one base pair. As each ddNTP (ddATP, ddCTP, ddTTP, ddGTP) is 
labelled with a fluorophore that emits light at a separate wavelength, capillary electrophoresis 
on a genetic analyser generates a chromatogram that allows the sequence to be read base by 
base and aligned to generate a contiguous sequence. To produce a clean chromatogram for 
analysis, the relevant target region must be PCR amplified, purified, undergo a sequencing 
reaction and be purified again before capillary electrophoresis. Target regions for sequencing 
were PCR amplified using the relevant set of primers and standard PCR cycling conditions as 
described in Section 2.9. 
 
2.12.1 PCR product clean up 
PCR products were cleaned using the QIAquick PCR purification kit (QIAGEN, Hilden, 
Germany) as per manufacturer instructions. Briefly, Buffer PB and the PCR product were 
mixed together and transferred to a QIAquick spin column for centrifugation at 13,000rpm for 
1 minute. Buffer PE was added to the column and another centrifugation step was carried out. 
PE Buffer was used to elute the purified PCR product.  
2.12.2 PCR product sequencing 
Each cleaned PCR product was sequenced using the BigDye™ Terminator v3.1 Cycle 
Sequencing Kit (Thermo Scientific, Waltham, USA) with the relevant forward and reverse 
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primer separately, leading to the generation of two sequencing products per sample as outlined 
in Table 2.10 below. 
Table 2.10 Sanger Sequencing Mix 
Reagent Volume (l) 
5X sequencing buffer 4 
Sequencing ready reaction mix RR-100 2 
primer (2pmol/µl), 1.6 
nuclease free water 2.4 
DNA Template 10 
 
A separate positive sequencing control from the kit was made up with 4µl of 5X sequencing 
buffer, 2µl sequencing ready reaction mix RR-100, 12µl primer (M13), 1µl template (pGEM 
plasmid) and 11µl nuclease free water. Tubes were transferred to a Veriti thermal cycler and 
run under the following cycling conditions: 96°C for 1 min, followed by 25 cycles of 96°C for 
10 seconds, 50°C for 5 seconds, 60°C for 4 minutes, followed by holding at 4°C. Sequencing 
products were cleaned by removing unincorporated fluorescently labelled nucleotides using a 
DyeEx 2.0 spin kit (QIAGEN, Hilden, Germany) as per manufacturer’s instructions, The 
purified sequencing products were placed into an Eppendorf concentrator at 30°C for 30 
minutes or until dry. Samples were resuspended in 10µl HiDi formamide, transferred to a 96 
well plate and denatured at 95°C for 3 minutes before being placed on ice. The plate was 
centrifuged briefly to remove condensation before being placed onto a 3130XL genetic 
analyser and run using POP-7 polymer matrix (Thermo Scientific, Waltham, USA) for 
separation. Sample files were analysed using SeqMan Pro (DNASTAR®, Madison, USA) 
software by alignment against a reference sequence (RefSeq) imported from NCBI nucleotide. 
Mutations detected were analysed using the Megalign (DNASTAR®, Madison, USA) software 
for any potential alterations in the amino acid sequence. 
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2.13 Next Generation Sequencing with AML targeted panel 
The adoption of targeted gene panels comprising a refined set of disease relevant genes has 
shown promise for translation of NGS into clinical practice (Kohlmann et al., 2013; McCourt 
et al., 2013; Ivanova et al., 2015).  To evaluate the utility of a newly available commercial 
AML 19 gene panel, DNA from six pre-characterised AML patients with NPM1 and FLT3-
ITD mutation status previously assessed were used for quality control (QC#1-6), distributed to 
each participating centre and processed using standardised workflows for the Ion Ampliseq 
AML Panel (Life Technologies, Paisley, UK) before sequencing on an Ion Torrent 
Personalized Genome Machine (PGM), (Life Technologies, Paisley, UK). A designated sample 
(QC#3, QC#5, and QC#6) was repeated in duplicate on separate runs in centres 1, 3 and 2 
respectively to assess inter- and intra-centre reproducibility. In addition, Acrometrix controls 
(Life Technologies, Paisley, UK) a highly multiplexed quality control used to assess the 
performance of NGS assays was employed in one centre to determine variant detection at 
known low variant allelic frequencies.  
2.13.1 Library preparation 
The Ion AmpliSeq Library Kit 2.0 (Life Technologies, Paisley, UK) was used as per 
manufacturer’s instructions, to prepare libraries using the Ion AmpliSeq AML Community 
Panel primers which were split into 4 separate pools. Pools 1 and 2 contained approximately 
120 primer pairs each and pools 3 and 4 contained 12 and 15 pairs respectively. Six/seven 
samples were prepared per run. The AML Panel amplicon libraries generated 237 amplicons 
covering 19 commonly mutated genes implicated in AML (Table 2.11). The entire coding 
region of DNMT3A, CEBPA, GATA2, TET2 and TP53 and mutational hotspots of the others 
including NPM1 and FLT-3 were amplified. 
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Table 2.11. Overview of AML panel 19 gene targets, protein function, gene coverage and 
number of amplicons generated for each gene. 
Gene 
Symbol 
Gene Name Protein Function Panel 
Target 
(basepair) 
Amplicons 
KIT KIT Proto-Oncogene 
Receptor Tyrosine Kinase 
Activated signalling 632 8 
NRAS Neuroblastoma RAS Viral 
Oncogene Homolog 
Activated signalling 370 3 
KRAS Kirsten Rat Sarcoma Viral 
Oncogene Homolog  
Activated signalling 370 4 
GATA2 GATA Binding Protein 2  Transcription factor 1,643 20 
FLT3 Fms-Related Tyrosine 
Kinase 3  
Activated signalling 66 3 
BRAF B-Raf Proto-Oncogene, 
Serine/Threonine Kinase  
Activated signalling 11 1 
ASXL1 ASXL Transcriptional 
Regulator 1 
Chromatin 
modification 
2,947 28 
JAK2 Janus Kinase 2 Activated signalling 128 1 
IDH1 Isocitrate Dehydrogenase 1  DNA Methylation 332 3 
CBL Cbl Proto-Oncogene, E3 
Ubiquitin Protein Ligase  
Ubiquitination 416 5 
PTPN11 Protein Tyrosine 
Phosphatase, Non-
Receptor Type 11  
Activated signalling 427 5 
RUNX1 Runt Related Transcription 
Factor 1 
Transcription factor 1,149 15 
TET2 Tet Methylcytosine 
Dioxygenase 2  
DNA Methylation 6,369 59 
CEBPA CCAAT Enhancer Binding 
Protein Alpha 
Transcription factor 1,117 9 
DNMT3A DNA (Cytosine-5-)-
Methyltransferase 3 Alpha  
DNA Methylation 3,619 42 
IDH2 Isocitrate Dehydrogenase 2 DNA Methylation 201 2 
WT1 Wilms Tumor 1 Tumour suppressor 324 4 
NPM1 Nucleophosmin 1 Protein Chaperone, 
Cell proliferation 
79 1 
TP53 Tumor Protein P53 Tumour Suppressor 1,773 24 
 
2.13.2 Amplify target sequences 
To prepare libraries, a 10µl reaction containing 2µl 5X Ampliseq HiFi Mi,x 5µl 2x Ion 
Ampliseq Primer pool, 10ng gDNA and nuclease free water to a final volume of 10µl was 
created for each of the four primer pools. Pools 1 and 2 were placed into a Veriti thermal cycler 
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at 99°C for 2 minutes followed by 18 cycles of 99°C for 20 seconds denature and annealing at 
60°C for 4 minutes. Samples were then held at 10°C until required. Pools 3 and 4 were placed 
into a Veriti thermal cycler at 99°C for 2 minutes followed by 21 cycles of 99°C for 20 seconds 
denature, 62°C for 4 minutes annealing. Samples were then held at 10°C until required. The 
four pools were then reduced to two on a 96 well plate by combining 3.7µl of pool 1, 10µl of 
pool 3 and 6.3µl nuclease free water to produce one new pool and 3.7µl of pool 2, 10µl of pool 
4 and 6.3µl nuclease free water to produce a second new pool. 
2.13.3 Partially digest amplicons 
To each primer pool 2µl of FuPa reagent (ThermoFisher) was added to partially digest the 
primers and phosphorylate the amplicon, the sample was vortexed to mix and centrifuged to 
collect droplets. Samples were placed into the Veriti thermal cycler for 50°C for 10 minutes, 
55°C for 10 minutes, and 60°C for 20 minutes, 10°C hold. 
2.13.4 Ligate adapters 
Ion Xpress barcoded adapters were selected and prepared by diluting 1:4 individually by 
combining 2µl Ion P1 Adapter, 2µl Ion Xpress Barcode (X- barcode of choice) and 4µl 
nuclease free water. To the partially digested samples 4µl Switch solution, 2µl diluted Ion 
Xpress barcode adapters and 2µl DNA Ligase were added sequentially. The samples were 
vortexed, centrifuged and placed into a thermal cycler at 22°C for 30 minutes, 68°C for 5 
minutes and 72°C for 5 minutes before holding at 10°C. 
2.13.5 Library Purification 
To each library preparation 45µl (1.5X) Agencourt™ AMPure™ XP reagent (Thermo 
Scientific, Waltham, USA) was added, the suspension was mixed by pipetting and incubated 
at room temperature for 5 minutes before being placed into a DynaMag™ -96 Side Magnet 
(Thermo Scientific, Waltham, USA) and incubated for 2 minutes until the solution cleared. The 
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supernatant was discarded without disturbing the bead pellet. The pellet was washed twice by 
adding 150µl of 70% Ethanol and mixing the beads through the liquid by moving the plate 
from side to side in the magnet, aspirating and repeating. Residual ethanol was removed by 
pipetting and the beads were allowed air dry on the plate for 5 minutes whilst held in the 
magnet. 
2.13.6 Quantification of library by qPCR 
Purified libraries were resuspended in 50µl Low TE (Promega, Wisconsin, USA), vortexed, 
briefly centrifuged and incubated at room temperature for 2 minutes before being placed back 
into the magnet. A volume of 2µl of supernatant was combined with 198µl nuclease free water 
(1:100 dilution). Three 10-fold serial dilutions of E.Coli DH10B Ion Control Library 
(68pMol/L) at 6.8pM, 0.68pM and 0.068pM were prepared as standards. Reaction mixtures for 
each sample were prepared by combining 20µl of 2X TaqMan MasterMix and 2µl of 20X Ion 
TaqMan Assay and mixing thoroughly. Aliquots (11µl) were dispensed into the wells of a 96 
well PCR plate. A volume of 9µl of diluted library, control or samples were added (as 
duplicates) to a final volume of 20µl. The qPCR plate was run on an Applied Biosystems 9700 
PCR System with ROX™ Reference Dye as the passive reference. FAM™ was selected as the 
TaqMan probe reporter and the standard concentrations were entered. Cycling was in standard 
mode at 50°C for 2 minutes, 95°C for 2 minutes, followed by 40 cycles of 95°C for 15 seconds 
and 60°C for 1 minute. Concentrations were calculated from the standard curve produced and 
a dilution to 100pM for each library was determined. Diluted libraries were then combined by 
adding 10µl of the six sample libraries to a single tube. 
2.13.7 Library template amplification 
Libraries were amplified using the Ion OneTouch 2 System (Thermo Scientific, Waltham, 
USA) and the Ion PGM™ Template OT2 200 Reagent Mix which enables automated delivery 
of templated Ion Sphere™ particles by creating millions of microreactors in which clonal 
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amplification occurs and recovering the templated Ion Sphere™ particles (Thermo Scientific, 
Waltham, USA) therefore allowing massively parallel clonal amplification and recovery. To a 
1.5ml Eppendorf Lo-Bind™ tube (Eppendorf, Hamburg, Germany) at room temperature, 25µl 
of nuclease free water, 500µl Ion PGM™ Template OT2 200 Reagent Mix, 300µl Ion PGM™ 
Template OT2 200 PCR reagent B, 50µl Ion PGM™ Template OT2 200 Enzyme Mix, 25µl 
diluted library were added to a final volume of 900µl. The solution was vortexed and briefly 
centrifuged and 100µl of Ion PGM™ Template OT2 200 Ion Sphere™ Particles were added. 
The solution was vortexed for 5 seconds at full speed and 1000µl was added to the Ion PGM™ 
OneTouch reaction filter followed by 1500µl of Ion OneTouch™ Reaction Oil, inverted and 
installed onto the Ion OneTouch™ 2 Instrument and run. When the run was completed, 
template positive ISPs were recovered by centrifugation in Recovery Solution into two 
Recovery tubes per sample. All but 50µl of solution was decanted off and the ISPs were 
resuspended in the remaining solution. The sample (template-positive ISPs) was transferred 
into the first well of an eight well strip (100µl total volume) and the other subsequent wells 
were filled with 130 µL of Dynabeads™ MyOne™ Streptavidin C1 Beads resuspended in 
MyOne™ Beads Wash (Thermo Scientific, Waltham, USA), three wells of 300 µL of Ion 
OneTouch™ Wash Solution (Thermo Scientific, Waltham, USA), an empty well (no.6), 300µl 
Melt-Off Solution (280µl Tween™ Solution (BioRad, Hercules, USA) plus 40µl 1M NaOH 
(Merck KGaA, Darmstadt, Germany) and a final empty well. The strip was loaded on the Ion 
OneTouch™ ES (Thermo Scientific, Waltham, USA) and initialised. Immediately after the run 
the enriched ISPs are eluted into a 0.2ml PCR tube containing 10µl Neutralisation Solution. 
The sample library was mixed by gentle inversion and sequenced on an Ion Torrent PGM using 
the Ion PGM™ Sequencing 200 Kit v2 (Life Technologies, Paisley, UK) according to 
manufacturer’s instruction. 
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2.13.8 Library sequencing 
Before sequencing the sample library, the Ion PGM™ system was cleaned with chlorite/water 
and initialised according to the manufacturer’s instruction. For sequencing, 5µl of Control Ion 
Sphere™ Particles were added to the enriched template-positive ISPs. The contents were mixed 
and centrifuged for 2 minutes at 15,000g. The supernatant was removed without disturbing the 
pellet with 15µl left in reserve. Sequencing Primer (12µl) was added to make a final volume 
of 27µl. The mixture was mixed by pipetting to disrupt the pellet and create a homogenous 
solution. The tube was then placed into a thermal cycler at 95°C for 2 minutes, followed by 
37°C for 2 minutes using the heated lid option. Following a Chip Check on the Ion PGM to 
ensure the chips used were functioning, 3µl of Ion PGM Sequencing 200 v2 Polymerase was 
added to the ISPs and mixed by pipette to make a final volume of 30µl, left to stand at room 
temperature for 5 minutes before being loaded onto the chip manually by dialling down a 
pipette containing the 30µl sample. The chip was spun in the Ion Chip MiniFuge (Thermo 
Scientific, Waltham, USA) to distribute the sample evenly across the chip, loaded onto the Ion 
PGM™ and sequenced at 500 flows under the Ion PGM™ Sequencing 200 kit v2 settings.  
 
2.13.9 Data Processing 
Data was reviewed using Torrent Suite™ software v4.2.1.0 (Life Technologies, Paisley, UK) 
using a low stringency parameter configuration. Samples were uploaded to Ion Reporter™ v4.2 
cloud-based software (Life Technologies, Paisley, UK) as BAM or VCF files for subsequent 
variant annotation. Coverage in highly sampled locations was capped at 2000X to reduce 
computational time. Calling of somatic mutations was achieved using an algorithm that 
excluded synonymous mutations, variants located within intronic or un-translated regions and 
variants present at a frequency of <5%. Insertions/deletions called using Ion Reporter™ were 
confirmed by reviewing data with the Broad Institute’s Integrative Genomics Viewer (IGV) 
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(Broad Institute, Cambridge, MA, USA). To maximise confidence in variant calling, a 
minimum target depth of coverage for variant calls was set at 500X, with potential somatic 
variants reviewed and screened using relevant public databases including dbSNP, ClinVar, 
COSMIC, and PubMed.  
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3.0 Molecular monitoring post-allogeneic 
transplantation in myeloproliferative neoplasms  
The aim of this chapter is to validate the utility of specific mutations to monitor 
myeloproliferative neoplasm disease burden post-transplantation. Data in this chapter is the 
result of work that culminated in four publications (Appendix 1/2A). My personal contribution 
to each paper is outlined below and confirmed by co-authors in Appendix 3. 
1:  Haslam K, Molloy KM, Conneally E, Langabeer SE. Evaluation of a JAK2 V617F 
quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell 
transplantation for myeloproliferative neoplasms. Clin Chem Lab Med. 2014;52(3):e29-3. 
Personal Contribution: Designed original concept for the study, validated assay, gathered 
patient material, performed analysis and data interpretation. Primary author and wrote original 
draft. Finalised and approved manuscript for publication. Corresponding author.  
 
2: Haslam K, Langabeer SE, Molloy K, McMullin MF, Conneally E. Assessment of CALR 
mutations in myelofibrosis patients, post-allogeneic stem cell transplantation. Br J Haematol. 
2014;166(5):800-2. 
Personal Contribution: Collaborated on original concept for the study, gathered patient 
material, performed CALR mutation analysis, collated all data and interpreted results from all 
analyses. Wrote first draft and revised and approved finalised version prior to publication.  
 
3: Langabeer SE, McCarron SL, Haslam K, O'Donovan MT, Conneally E. The CSF3R T618I 
mutation as a disease-specific marker of atypical CML post allo-SCT. Bone Marrow 
Transplant. 2014 Jun;49(6):843-4. 
Personal Contribution: Input on design of study and collation of patient samples and details. 
Carried out Sanger sequencing analysis and interpretation of results. Collated results 
contributed to compilation and critical review of clinical data. Reviewed final draft of paper 
prior to publication.  
 
4: Langabeer SE, Nolan J, Haslam K, Clarke L, Flavin R, Conneally E. Evading Capture by 
Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary 
Myelofibrosis After Allogeneic Stem Cell Transplantation. Case Rep Hematol. 2015 
Personal Contribution: Carried out technical analysis (donor chimerism – via short tandem 
repeat multiplex PCR analysis of donor and recipient, JAK2 qualitative PCR and JAK2 real-
time quantitative PCR), collated and interpreted all resultant data. Contributed to writing, 
review and approval of paper. 
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3.1 Introduction 
 
Myeloproliferative neoplasms (MPN) are clonal haematopoietic stem cell disorders and whilst 
some patients have an indolent course, all are at risk of progressing to severe marrow failure 
or transforming into acute leukaemia, with allogeneic stem cell transplantation (ASCT) being 
the only potential curative therapy at present (Salit and Deeg, 2014).  In the past, ASCT was 
only considered for those patients with advanced or transformed disease, however 
improvements in candidate patient selection and stratification, timing of transplantation, and 
conditioning regimens have significantly reduced the transplant related morbidity and 
increased the overall survival for MPN patients undergoing this procedure (McLornan et al., 
2012; Fleischman and Maziarz, 2013). However, as relapse is a major cause of treatment failure 
post-ASCT, with salvage options limited and subsequent outcome relatively poor, 
identification of those patients at high-risk of relapse is highly desirable, and could potentially 
enable therapeutic intervention before overt relapse.  
 The fact that relapse occurs even if transplantation was performed in complete 
remission is evidence that minimal residual disease (MRD) remains in the recipient although 
not morphologically evident. The clinical relationship between post-transplant MRD and the 
risk of relapse was recognised early in chronic myeloid leukaemia (CML) using cytogenetic 
techniques and the BCR-ABL1 fusion gene to monitor residual disease (Sawyers et al., 1990). 
MRD detection can now be applied using immunophenotyping or molecular techniques in 
acute and chronic leukaemia’s, however the clinical relevance of residual disease can be 
markedly different depending on the disease type. Standardised and optimised MRD 
monitoring schedules in the post-transplant period has been established for CML as the BCR-
ABL1 fusion is a defining feature (Baccarani et al., 2006; Hughes et al., 2006).  For other 
myeloid malignancies such as acute myeloid leukaemia (AML) and MPN, the diseases are 
more heterogenous, with diverse molecular and cytogenetic aberrations and the full utility of 
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molecular monitoring yet to be established. Conventionally, donor chimerism status has been 
used to assess engraftment and establishment of donor stem cells in the marrow of the recipient 
post-ASCT for haematological malignancies. The major benefit of this approach is that it is 
disease agnostic and can be applied in all cases, however the sensitivity of 1-2% routinely 
achieved can be limiting. 
Post-ASCT monitoring utilising additional patient-specific markers is most likely to 
provide a more beneficial, personalised profile, with early studies demonstrating the 
achievement of a molecular remission in JAK2 V617F-positive MPN post-ASCT using 
qualitative PCR (Steckel et al., 2007). In those reported MPL-mutation positive MPN who have 
undergone ASCT, rapid clearance of the MPL W515L mutation correlated well with peripheral 
blood counts and donor chimerism status (Alchalby et al., 2010a). The JAK2 V617F mutation 
has been shown to disappear post-ASCT and then reappear upon relapse (Ditschkowski et al., 
2006), and can be used as a stable MRD marker to help guide therapies such as donor 
lymphocyte infusion (Kroger et al., 2006; Kroger et al., 2009). Patients who cleared JAK2 
mutation level in peripheral blood 6 months after ASCT were also shown to have significantly 
lower risk of relapse relative to those that did not (Alchalby et al., 2010b). In JAK2 V617F 
positive MPN, the development of improved detection sensitivities using JAK2 V617F-specific 
qPCR methodologies capable of detecting one mutant allele in 104 wild type copies has the 
potential to provide improved clinical information on the rate of disease eradication and the 
identification of patients, at defined time points post-ASCT, at an increased risk of relapse.  
In addition, the recent discovery of insertion and/or deletion mutations within the CALR 
gene in a significant proportion of JAK2-and MPL-unmutated ET and PMF patients which are 
likely initiating events in MPN pathogenesis, affords an opportunity to assess these mutations 
as potential markers of residual disease in myelofibrosis patients post-ASCT also (Klampfl et 
al., 2013; Nangalia et al., 2013). Likewise, the recent characterisation of mutations within the 
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genes encoding the G-CSF receptor (CSF3R) and SET binding protein 1 (SETBP1) in a 
significant proportion of patients with aCML and CNL suggests that these mutations could also 
be used for residual disease (Maxson et al., 2013; Piazza et al., 2013) Publications presented 
in this chapter aimed to further develop an understanding of the use of patient-specific markers 
to monitor disease burden and response to transplantation therapy, utilising disease specific 
markers in different MPN cohorts post-transplantation. These studies assessed the performance 
of three separate molecular approaches to monitor disease burden; quantitating JAK2 V617F 
in JAK2 positive MPN, application of a semi-quantitative PCR assay to measure CALR exon 9 
mutations in CALR positive MPN and Sanger sequencing of CSF3R p.Thr618Ile (T618I) 
mutation (c.15482C>T) in atypical CML. 
The methods used in this chapter are outlined in detail in Chapter 2 and include nucleic 
acid extraction and QC (section 2.3-2.7), JAK2 V617F PCR (section 2.9.2, 2.11), Donor 
Chimerism STR-PCR (section 2.9.7, 2.10.3), CALR exon 9 mutation PCR (section 2.9.6, 
2.10.2) and Sanger Sequencing (section 2.12).  
  
3.2 Results 
 
3.2.1 Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-
allogeneic haematopoietic stem cell transplantation for myeloproliferative neoplasms 
Developments in the field of transplantation have led to the application of reduced intensity 
conditioning regimen in MPN patients and have shown improvement in overall survival for an 
increasing number of patients (Kroger et al., 2009b). Traditionally in haematological 
malignancies, engraftment post-transplantation is monitored by donor chimerism status, which 
allows for comparison of donor and recipient profiles to estimate the level of engraftment 
present in the peripheral blood or bone marrow within the context of clinical and 
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haematological parameters. This  can be used to predict full engraftment, failure to engraft or 
indeed loss of engraftment and impending relapse. Donor chimerism is usually monitored at 1-
3 monthly intervals depending on engraftment kinetics. A corollary of this idea is to use a 
disease specific marker to monitor engraftment and response to the transplantation regimen. In 
the first part of Chapter three, quantification of the burden of JAK2 V617F alleles post-ASCT 
as a sensitive marker of residual disease was assessed. In order to gather the patient samples 
that would inform the study, an audit of MPN patients that had received transplantation therapy 
and had samples available for analysis was conducted. This required mining of the patient 
sample database for patients with a diagnosed MPN who had results for both donor chimerism 
and a positive JAK2 V617F. The audit returned 43 cases, of which 16 had JAK2 V617F detected 
at diagnosis, with thirteen (11 male, 2 female) with an age range of 18–58 years (median 50 
years) having sufficient sample for analysis. MPN types were PMF (n = 6), post-PV MF (n = 
2), chronic myelomonocytic leukaemia transformed to AML (n = 3), PV transformed to AML 
(n = 1) and AML (n = 1) with a median follow-up of 11 months (range 3–52 months) (Table 
3.1). 
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Table 3.1.   Characteristics of JAK2 V617F positive MPN patients who received a transplant. 
Patient Gender  Age @ ASCT MPN    Donor type ASCT  Follow up Response to ASCT   
   (years)        (months) 
 
1. F  49  PV>MF  Related   RIC  4  Failure to engraft    
2. M  18  PMF  Related  My  52  Full engraftment    
3. M  54  PMF  Related  RIC  19  Full engraftment    
4. M  53  CMML>AML Related  RIC  11  Failure to engraft    
5. M  52  PV>MF  Related  RIC  7  Full engraftment  
6. M  55  PMF  Related  RIC  38  Full engraftment    
7. M  45  PMF  Unrelated RIC  6  Full engraftment → relapse  
8. M  49  PMF  Unrelated RIC  11  Full engraftment    
9. M  58  CMML>AML Related  RIC  3  Full engraftment    
10. M  55  AML  Unrelated RIC  22  Full engraftment  
11. M  50  PMF   Unrelated RIC  11  Failure to engraft  
12. M  46  CMML>AML Unrelated My  39  Full engraftment    
13. F  41  PV>AML Related  My  34  Full engraftment  
F; female, M; male, PV; Polycythaemia Vera, PMF; primary myelofibrosis, CMML; chronic myelomonocytic leukaemia, AML; acute myeloid leukaemia, RIC; reduced 
intensity conditioning, MY; myeloablative conditioning.   
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The JAK2 V617F allele-specific qPCR assay employed had a specificity of at least 2.0x10–3 
which gave a routine sensitivity and cut-off value for sample negativity of 0.02% mutant 
(Section 2.11). The slope and R2 value of the standard curves generated were robust across the 
dynamic range of the assay, allowing for consistent and accurate quantification of JAK2 wild 
type and JAK2 V617F mutant in the patient samples (Figure 3.1). 
 
 
Figure 3.1. Example of linearity of JAK2 V617F qPCR standard curves across plasmid 
dilutions. Ct; cycle threshold. Calculated Slope = -3.48, Y-intercept = 41.4, R2 = 0.98.Standard 
curve prepared as per Section 2.11. 
 
 
Donor chimerism was assessed using a standardised methodology (Section 2.9.7, 2.10.3). 
Examples of electropherograms generated are outlined in Figure 3.2/3.3. 
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Figure 3.2. An example of electropherograms generated during the study across 5 specific short 
tandem repeat (STR) markers D3S1358, THO1, D21S11, D18S5, Penta E. A: 
Electropherogram for a control DNA ladder containing all repeats for each marker, B: example 
profile of a donor at the five STR. Donor is heterozygous at D3S1358, THO1, D21S11 and 
Penta E, C: recipient specific profile. Recipient is heterozygous for all five markers. Donor 
chimerism is estimated from markers where donor and recipient STR profiles are dissimilar at 
a given STR (Section 2.10.3). 
 
 
Figure 3.3. STR-PCR electropherogram at a single marker. A: Example of a heterozygous 
recipient profile for a single marker pre-transplantation, B: a heterozygous donor profile for 
the same marker, C: recipient profile post-transplantation showing predominance of the donor 
profile, D: subsequent relapse showing predominance of the recipient profile.  
A 
B 
C 
A 
B
. 
C
 
D 
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The percentage donor chimerism and percentage JAK2 V617F were calculated for each patient 
at diagnosis and at specific time points post-transplantation where sufficient DNA was 
available (Table 3.2). The values for donor chimerism and JAK2 V617F were subsequently 
used to generate graphs to allow for a visual demonstration of the molecular kinetics of residual 
disease for each patient post-transplantation (Figures 3.4 - 3.5).  
 
Seven of 13 (54%) patients were homozygous for JAK2 V617F pre-ASCT (allelic burden 
exceeding 50% mutant), with the remaining six patients being heterozygous. Of 49 samples 
tested for both JAK2 V617F and donor chimerism, a significant Pearson’s correlation was 
observed (r = −0.97) (Figure 3.6), however, it should be noted that 22 of these samples were 
100% donor chimerism and the JAK2 V617F undetectable. Ten of 13 (77%) patients became 
negative for JAK2 V617F post-ASCT with a follow-up of 3–52 months (median 6 months). 
Three patients either failed to engraft or displayed autologous recovery. Post-ASCT, increasing 
levels of the JAK2 V617F mutation were demonstrated three weeks prior to detection of 
decreasing donor chimerism levels (100%–91%) in one PMF patient (Patient 7), highlighting 
the higher sensitivity of the JAK2 V617F qPCR in detecting a biological change in the patient. 
An inverse correlation between the kinetics of donor chimerism and JAK2 V617F across the 
dynamic range was observed, showing the stability of the JAK2 V617F as a marker for 
molecular monitoring throughout the disease course, which was reflected in the clinical 
observation of donor stem cell engraftment and reduction of disease burden. 
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Table 3.2. Percentage donor chimerism and JAK2 V617F quantification results for JAK2 positive patient cohort samples. 
Patient No. Time post  
transplantation 
 (months) 
% 
Donor chimerism 
% 
JAK2 V617F 
Patient No. Time post 
transplantation 
(months) 
% 
Donor chimerism 
% 
JAK2 V617F 
Patient No. Time post 
transplantation 
(months) 
% 
Donor 
chimerism 
% 
JAK2 V617F 
1 
  
  
  
  
0  N/A 44.9 7   
  
0.0   N/A 36.98 11  0.0   N/A 94.05 
1.4 38 51.3 2.5 100 Not Detected  3.0 1 96.09 
2.1 19 63.5 3.6 100 Not Detected  5.2 0 81.53 
2.5 13 63.7 4.8 100 Not Detected  7.0 0 97.99 
3.8 5 65.9 5.0 99 Not Detected  11.4 0 97.98 
2 
  
  
  
  
  
  
0.0  N/A 11.4 5.5 100 0.03 12  0.0   N/A 76.58 
6.2  N/A Not Detected 6.1 91.0 3.76  1.1 91 6.96 
8.4 100 Not Detected 6.2 87 6.75  1.8 91 6.21 
11.8 98 Not Detected 8 
  
  
  
  
0.0  N/A 52.39  15.8 100 Not Detected 
16.7 100 Not Detected 2.1  N/A 59.66  38.9 100 Not Detected 
18.8 100 Not Detected 8.4  N/A 88.17 13   0.0   N/A 31.03 
40.0 100 Not Detected 8.8  N/A 16.92  4.3 100 Not Detected 
52.2  N/A Not Detected 10.4  N/A Not Detected  6.8 98 Not Detected 
3 
  
  
  
  
0.0  N/A 30.70  
9 
  
0 N/A 26.23  9.5 100 Not Detected 
10.5 97 0.46 2.5 N/A Not Detected  10.4 100 Not Detected 
10.9  N/A 0.45 10.5  100 Not Detected  11.9 100 Not Detected 
14.4 96 0.79 10.6   99 Not Detected  16.9 100 Not Detected 
16.5  N/A Not Detected   Not Detected  18.1 99 Not Detected 
16.7  N/A 0.06 10 
 
0.0   N/A 1.82  19.9 100 Not Detected 
 18.7  N/A Not Detected 6.2   N/A   9.15  26.2 100 Not Detected 
4 0.0   N/A 2.90 9.7 100 Not Detected  30.0 100 Not Detected 
11.3 28 38.30 9.9 99 Not Detected  34.4 100 Not Detected 
5 
  
0.0   N/A 77.02 12.8 100 Not Detected  
6.8 96 0.59 21.6 99 Not Detected 
7.2 97 Not Detected  
6 
  
  
0.0   N/A 41.00 
37.1 98 0.40 
38.4   N/A Not Detected 
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Figure 3.4 Patients 1-6, molecular kinetics of residual disease post-ASCT. Donor chimerism is denoted by filled squares and JAK2 V617F by open circles. 
1 2 3 
4 
6 5 
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Figure 3.5 Patients 7-13, molecular kinetics of residual disease post-ASCT. Donor chimerism is denoted by filled squares and JAK2 V617F by open circles. 
7 
10 
9 8 
11 12 
13 
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Figure 3.6. Correlation of % JAK2 V617F and % donor chimerism (r = - 0.97). Data was 
obtained from Table 3.2 where 49 patient samples had a % donor chimerism and % JAK2 
V617F available for the same sample.   
 
3.2.2 Assessment of CALR mutations in myelofibrosis patients, post-allogeneic stem cell 
transplantation 
The discovery of CALR exon 9 mutations in ET/PMF patients toward the end of 2013 showed 
that the mutations were an early event occurring at the stem cell level and remained stable 
throughout disease evolution (Klampfl et al., 2013; Nangalia et al., 2013). This observation 
created an opportunity to assess the potential for CALR mutations to be used as markers of 
residual disease in those MPN patients who were positive for the mutation and had received a 
transplantation as part of their clinical treatment.  
To initiate this study a review of JAK2 V617F negative MPN patients who had 
progressed through a transplant regimen was carried out. Of 15 patients identified in an audit 
of cases, screening for evidence of CALR exon 9 mutations by DNA fragment analysis 
(Klampfl et al., 2013) in pre-ASCT samples identified four CALR mutation-positive patients, 
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all of whom received reduced intensity conditioning (Table 3.3).  CALR mutant allele burden 
was calculated using area under the peak (mutated/mutated + wild type) x100 and compared to 
known donor chimerism status performed according to guidelines (Lion et al., 2012). The 
CALR assay allowed the reproducible detection of approximately 1% mutant allele burden for 
type 1 (52 bp deletion) and type 2 (5 bp insertion) mutations. An example of the 
electropherograms generated in the assay are outlined in Figure 3.7. All four patient donor 
samples were wild type CALR exon 9. Characteristics of the four CALR mutated patients are 
outlined (Table 3.4). A further 19 informative follow up samples evaluated for donor 
chimerism status were available for retrospective mutant CALR allele burden estimation from 
these four patients (Table 3.5). 
Patients 3, 5 and 12 achieved full engraftment as assessed by donor chimerism (≥99%) at 5, 8 
and 14 weeks respectively with very low levels of mutant CALR alleles (<1%) detectable in 
patients 5 and 12 at these time points (Table 3.5). Patient 14 failed to achieve full donor 
chimerism, reflected in levels of mutant CALR alleles of >1% (Fig 3.9). As with the JAK2 
V617F kinetics observed previously, an inverse correlation between the kinetics of donor 
chimerism and CALR mutation was observed. Loss of engraftment, indicated by falling donor 
chimerism and mirrored by a significant increase in mutant CALR allele burden, prompted 
clinical intervention with a donor lymphocyte infusion (DLI) at week 22 post-ASCT. The result 
of this was further engraftment of the donor cells and a reduction in disease allele burden, 
reflected in an increased donor chimerism of 99% and undetectable mutant CALR alleles. 
By demonstrating both persistence and eradication of both type 1 and type 2 CALR 
mutations and their correlation with the clinical course, this study provides initial validation of 
serial monitoring of CALR mutations as a useful adjunct in the assessment of transplant efficacy 
in myelofibrosis patients. CALR mutation burdens were shown to reflect clinical course and 
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therapeutic intervention and remained stable markers of disease throughout the clinical course 
of the patients assessed. 
Table 3.3. Transplanted JAK2 V617F negative MPN patients identified and screened for 
CALR exon 9 mutations. 
Patient No. Diagnosis pre-transplantation CALR mutation 
1 MDS/MPN Not Detected 
2 PMF Not Detected 
3 PMF>AML Detected 
4 PMF Not Detected 
5 Post-ET MF Detected 
6 PMF Not Detected 
7 PMF Not Detected 
8 PMF Not Detected 
9 MDS/AA with thrombocytosis Not Detected 
10 PMF pre-ASCT Not Detected 
11 PMF > AML Not Detected 
12 PMF Detected 
13 PMF Not Detected 
14 PMF Detected 
15 PMF Not Detected 
 
MDS: Myelodysplastic syndrome, MPN: Myeloproliferative Neoplasms, PMF: Primary 
Myelofibrosis, AML: Acute Myeloid Leukaemia, ET: Essential Thrombocythemia, AA: 
Aplastic Anaemia, ASCT: Autologous Stem Cell Transplant 
 
122 
 
 
Figure 3.7. An example of the electropherograms generated for CALR exon 9 type 1 (52bp 
deletion) mutation after PCR and fragment analysis (Section 2.9.6). A: Positive control sample 
with internal control peak at 262bp and type 1 mutation at 210 bp (red arrow), B: Control 
sample with internal peak at 262bp only, C: Patient sample with type 1 mutation detected, D: 
patient sample with low level type 1 mutation detected.  
 
 
Table 3.4. Patient Characteristics of CALR mutated JAK2 V617F negative MPN detected. 
Patient  Gender Age at ASCT (years) Donor type CALR mutation 
3 Male 59 Unrelated 52-bp deletion 
5 Male 46 Related 5-bp insertion 
12 Male 48 Related  52-bp deletion 
14 Female 52 Unrelated 5-bp insertion 
 
A B 
C D 
Positive Control Negative Control 
Patient X Patient Y 
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Table 3.5. Donor chimerism and CALR mutation burden status of CALR mutated patient 
cohort post-transplantation.  
Patient 
No. 
Weeks post-
transplantation 
Donor chimerism 
(%) 
CALR mutation burden 
(%) 
3 N/A N/A 55.7 
5 100.0 0.0 
11 100.0 0.0 
22 100.0 0.0 
5 N/A N/A 42.0 
8 100.0 1.0 
26 100.0 0.0 
26 100.0 0.0 
12 N/A N/A 55.2 
4 96.0 1.0 
14 99.0 1.0 
25 100.0 0.0 
37 100.0 0.0 
14 N/A N/A 58.3 
7 87.0 2.0 
13 76.0 5.0 
20 54.0 20.0 
24 86.0 1.0 
27 99.0 0.2 
 
The values for donor chimerism and CALR mutation burden were subsequently used to 
generate a graph of the molecular kinetics of residual disease for each patient post-
transplantation (Figure 3.8).  
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Figure 3.8 Molecular kinetics of residual disease post-ASCT in Patients 3,5,12 and 14. Donor chimerism denoted by filled squares, CALR 
mutation burden represented as open circles. Donor lymphocyte infusion (DLI). 
 
3 5 
12 14 
DLI 
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Figure 3.9 shows the electropherograms from patient 14 stacked on top of one another to enable 
a clear visual of the reduction and re-emergence of the type 2 CALR mutation over time. The 
peak on the left side of each pane is wild type CALR, which acts as an internal control for the 
assay. 
 
Figure 3.9. Electropherograms showing pre-ASCT and follow up samples for patient 14. Note 
the reduction, re-emergence and subsequent reduction in type 2 mutation peak (5bp insertion- 
black arrow). 
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3.2.3 The CSF3R T618I mutation as a disease-specific marker of atypical CML post-
ASCT 
The most prevalent CSF3R mutation in aCML and CNL is the membrane proximal T618I 
(Maxson et al., 2013; Pardanani et al., 2013).  The discovery of mutations in CSF3R in these 
patients opened up the possibility that in addition to the potential for targeted therapy as 
outlined in section 1.10, identification of aCML-specific CSF3R mutations affords the 
opportunity for evaluation of these mutations as disease-specific markers of residual disease in 
those patients undergoing ASCT. 
To develop and extend this idea an audit was carried out of aCML, CNL, or atypical 
MPN that had received transplantation therapy and had samples available at diagnosis for 
analysis. The audit returned eight cases that were available for further analysis. Given the rarity 
of these cases and the mutations they may possess, Sanger sequencing was applied to determine 
the mutation status of the patients as this method was already developed and standardised and 
could be deployed rapidly. Mutations of the SETBP1 Ski domain and CSF3R exons 14 and 17 
were sought in this retrospective series. An overview of the available characteristics for the 
eight cases are outlined in Table 3.6. Two patients were identified as having CSF3R T618I 
mutations.  
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Table 3.6. Characteristics and mutation status of eight patients analysed. 
Patient 
No. 
Age at 
Diagnosis 
Initial 
Diagnosis 
SETBP1 SKI Domain 
(706aa-917aa) 
mutation status 
CSF3R exon 14/exon 17 
mutation status 
1 57 aCML Not Detected Not Detected 
2 62 aCML Not Detected Not Detected 
3 59 aCML Not Detected Not Detected 
4 48 aCML Not Detected Detected  
p. Thr618Ile (T618I) 
(c.15482C>T) 
5 61 aCML Not Detected Detected  
p. Thr618Ile (T618I) 
(c.15482C>T) 
6 53 aMPN Not Detected Not Detected 
7 58 aMPN Not Detected Not Detected 
8 33 aPMF Not Detected Not Detected 
 
The two patients found positive for CSF3R T618I were followed up to determine their clinical 
course. A 60-year-old woman (Patient #4) presented in 2002 with what appeared 
morphologically to be CML but had a normal karyotype with no evidence of BCR-ABL1 by 
fluorescence in situ hybridization (FISH) or reverse transcription-PCR. The karyotype was: 
(46,XX[17] .nuc ish 9q34(ABLx2),22q11(BCRx2)[98] / 9q34(ABLx1),22q11(BCRx1)(ABL 
con BCRx1)[2]).  She had no haematological response to 1 month of imatinib and commenced 
hydroxyurea. The pre-transplant work-up revealed worsening constitutional symptoms and 
lymphadenopathy. Retrospectively, a CSF3R T618I mutation was detected three months pre-
transplant (Figure 3.10, A: upper panel). A reduced-intensity conditioning, sibling donor 
(CSF3R wild type) ASCT was performed. The initial post-ASCT course was unremarkable; 
however, by day 72, whole blood donor chimerism was only 20% with the T618I mutation 
retrospectively still evident (Figure 3.10 A: centre panel). Full donor chimerism was not 
achieved and the patient relapsed 9 months post-ASCT with increasing BM myeloblasts. Two 
doses of DLI and a subsequent course of daunorubicin, cytarabine, thioguanine (3+10) did not 
improve the chimerism status; the marrow remained hypoplastic with 10–15% blasts and 
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continued evidence of the CSF3R T618I (Figure 3.10 A; lower panel). The patient became red 
cell and platelet transfusion dependent, deteriorated and died 17 months post-ASCT. 
In the second case, a 48-year-old man (Patient #5) presented with an elevated white cell 
count and a hypercellular BM consistent with aCML. The patient had a normal karyotype, no 
evidence of BCR-ABL1, PDGFRA or PDGFRB rearrangements by FISH (46,XY[20].nuc 
ish(FIP1L1,CHIC2,PDGFRA,PDGFRB)x2[300]), with molecular studies demonstrating the 
absence of the JAK2 V617F and BCR-ABL1 transcripts but the presence of the CSF3R T618I 
mutation (Figure 3.10 B: upper panel). The patient commenced treatment with hydroxyurea 
and six weeks prior to ASCT the CSF3R T618I clone remained evident but at a reduced level 
(Figure 3.10, B: centre panel). He underwent a myeloablative ASCT with a sibling donor 
(CSF3R wild type). At day 30 post-ASCT, the patient developed skin GvHD. The T618I 
mutation was not detected by sequencing on day 46 in whole peripheral blood (Figure 3.10 B: 
lower panel). At the time of reporting the patient remained well on a tapering steroid dose with 
improving GvHD.  
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Figure 3.10. Sequencing of DNA isolated from unfractionated peripheral blood demonstrating 
CSF3R c.15482C>T (p.Thr618Ile) mutation (arrows) throughout clinical course. A: Patient #4 
pre-ASCT (upper panel), day 72 post-ASCT (centre panel) and 12 months post-ASCT (lower 
panel). B: Patient #5 at diagnosis (upper panel), pre ASCT (centre panel) and day 46 post-
ASCT (lower panel). 
 
In this study, both persistence and eradication of the CSF3R T618I was described and 
correlated well with the clinical course in both patients. This indicates that the CSF3R mutation 
is a stable mutation that can persist post-ASCT and can reflect disease burden, suggesting serial 
monitoring of CSF3R mutations in aCML patients undergoing allo-SCT is a useful adjunct in 
the assessment of transplant efficacy. 
 
 
 
 
A B 
Pre-ASCT 
Day 72 post-ASCT 
12 months post-ASCT 
pre-ASCT 
Day 46 post-ASCT 
At Diagnosis 
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3.2.4 Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation 
of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell 
Transplantation. 
Whilst tracking disease burden utilising patient-specific mutations has the potential to provide 
an individualised assessment of disease clearance as described above, the biological and 
clinical presentation of each patient is unique, and pitfalls and limitations of the technology 
must be appreciated. To highlight this issue, a case study is described in which JAK2 V617F 
residual disease monitoring failed to detect an extramedullary manifestation of PMF in a patient 
after ASCT and serves to highlight a pitfall of this approach. 
Whilst undergoing imaging of a knee replacement for osteoarthritis three years 
previously, a 54-year-old male was noted to have patchy skeletal sclerosis. Further 
investigations revealed splenomegaly with a nine-month history of progressive constitutional 
symptoms (generalised un-wellness), lethargy, night sweats, and weight loss. Initial 
haematological investigation revealed a haemoglobin of 10.3 g/dL, a white cell count of 7.8 × 
109/L, platelets of 53 × 109/L and elevated reticulocyte count (212 × 109/L) and lactate 
dehydrogenase (LDH; 990 IU/L). The blood film was leucoerythroblastic with red cell 
anisopoikilocytosis, tear drop cells, basophilic stippling, and 2% circulating blasts. Bone 
marrow aspirate was unsuccessful; however, the bone marrow biopsy showed abnormal 
marrow architecture and grade IV reticulin fibrosis. The JAK2 V617F mutation was detected 
by qualitative PCR confirming the diagnosis of PMF. Four months later the platelet count had 
fallen to 24 × 109/L with 3% blast cells in the peripheral blood.  The patient proceeded to 
reduced intensity conditioning ASCT with a matched sibling donor.  
The JAK2 V617F qPCR assay described in section 2.11 was employed to determine the 
allele burden prior to ASCT (30.7%).  At two months post-ASCT, donor chimerism was 97% 
and JAK2 V617F 0.46% and at six months after ASCT donor chimerism was 96% and JAK2 
131 
 
V617F 0.79%. Full donor chimerism (100%) and undetectable JAK2 V61F were concurrently 
noted at eleven months after ASCT and remained so at prospective three-monthly assessments 
(Figure 3.11). 
 
Figure 3.11. Molecular kinetics of residual disease post-ASCT. Donor chimerism; filled 
squares, JAK2 V617F; clear circles. 
 
In the long-term follow-up clinic at 32 months after ASCT, a 1 cm hard lump was noted beneath 
the left eye. Subsequent imaging noted a mass lesion arising within the inferolateral aspect of 
the left orbit, displacing the globe anteromedially and which appeared to lie within the 
extraconal space (Figure 3.12, A: arrow). Excision of the periorbital bulk mass was undertaken 
with histopathological examination revealing adipose/connective tissue infiltrated by blasts 
(Figure 3.12, B: dark nuclei, arrows) which stained positively for CD34 (Figure 3.12, C), 
CD117, and CD45 and negatively for CD20, TdT, Granzyme B, CD68, and CD1a suggesting 
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a myeloid origin. The blasts were also JAK2 V617F-positive consistent with a diagnosis of 
myeloid sarcoma, an extramedullary tumour. 
 
Figure 3.12. Histopathological analysis of periorbital mass A: CT showing left periorbital 
myeloid sarcoma (arrowed), B: periorbital biopsy showing blast infiltration by myeloid 
sarcoma (yellow arrows) (Haematoxylin and Eosin; magnification ×40), C: positive 
immunohistochemical staining for CD34 in the myeloid sarcoma (magnification ×40). 
 
At this time the patient had a haemoglobin level of 14.0 g/dL, white cell count of 4.2 × 109/L, 
neutrophils of 2.0 × 109/L, and an unchanged, maintained platelet count of 115 × 109/L. The 
JAK2 V617F was undetectable in both the peripheral blood and the bone marrow aspirate, the 
latter showing no morphological evidence of PMF. The patient was not a candidate for further 
intensive chemotherapy and underwent involved field radiotherapy to the left orbit (30 Gy in 
15 fractions) and at last follow-up 41 months after ASCT, the JAK2 V617F remained 
undetectable in the peripheral blood. 
Relapse is the major cause of treatment failure in PMF patients post-transplantation and 
is often associated with an aggressive clinical course, primarily due to clonal evolution (Gupta 
et al., 2014). Residual disease monitoring using JAK2 V617F qPCR in PMF after ASCT is 
effective in predicting relapse in those patients in whom the disease is driven by this mutation 
as described above. However, vigilance is required as extramedullary manifestations of PMF, 
although rare, may evade early capture by this approach. 
A B C
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3.3 Discussion 
 
In this chapter the utility and potential for disease specific mutations to be used to monitor 
disease burden post-transplantation therapy was explored. Given the continuous improvement 
in transplantation science over the last few decades and the growing application of reduced 
intensity conditioning regimens which are not fully ablative, there is a growing need for new 
ways to monitor efficacy, including indicators of early relapse. Conventionally, STR-PCR 
based donor chimerism is the molecular method of choice to monitor engraftment of donor 
stem cells post-transplant. The major benefit of this approach is that it is disease agnostic and 
can be applied in all cases, however the sensitivity of 1-2% routinely achieved can be limiting. 
That said, there are more sensitive qPCR and digital droplet PCR based methodologies in 
development (Debeljak et al., 2017; Waterhouse et al., 2018).  
In the case of diseases where there is the ability to measure a specific and sensitive 
marker of disease burden that remains stable over the course of the disease, there is the 
potential, in tandem with donor chimerism to enhance a clinicians view of the clinico-
pathological state of disease in the patient, which will enhance their ability to intervene 
therapeutically. In a series of retrospective analyses this potential was tested in three diagnostic 
disease markers (JAK2 V617F, CALR exon 9 mutations, CSF3R T618I) in three separate MPN 
cohorts. In the JAK2 V617F positive cohort study, the utility of a robust and sensitive qPCR 
assay was proven and allowed for a thorough examination of mutation burden post-ASCT with 
a strong correlation between donor chimerism and levels of JAK2 V617F observed. In patient 
#7 the improved sensitivity of the JAK2 V617F assay over donor chimerism provided evidence 
of rising mutational burden several weeks prior to a change in donor chimerism, thus providing 
a potential window of opportunity for clinical intervention.  In the study of CALR mutations 
post-ASCT, the CALR mutated burden reflected the disease state and inversely correlated with 
engraftment as measured by donor chimerism. Indeed, CALR mutation burden reflected the 
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kinetics also observed in the JAK2 V617F study, particularly in patient #14, where post-
transplantation and post subsequent intervention with donor lymphocyte infusion the allele 
burden reflected the clinical course, proving that this marker was stable throughout the disease 
and therapy and is useful as a clinical tool in the assessment of transplantation efficacy in 
myelofibrosis patients. 
This theme was extended again after the discovery of recurrent mutations in the CSF3R gene 
strongly associated with aCML and CNL. This created the opportunity to apply the 
methodology of molecular monitoring of disease burden post-transplant in this rare condition. 
In the two cases described carrying CSF3R T618I mutations, the mutation burden reflected the 
disease course in both cases and was stable throughout, adding clinical value as a robust marker 
of disease post-transplant. For these rare cases where numbers are limited, confirmation in a 
larger cohort would be warranted. The case study of extramedullary relapse of PMF serves to 
highlight that whilst residual disease monitoring with disease specific markers in the peripheral 
blood and bone marrow of MPN patients has great potential to enhance clinical knowledge and 
understanding, vigilance is required when interpreting these test result data in the clinical 
setting. 
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4.0 Incidence and clinical application of molecular 
diagnostic markers in myeloproliferative neoplasms 
The aim of this chapter was to investigate the incidence and significance of MPN mutations in 
various clinical contexts. The data in this chapter is the result of work that culminated in the 
eleven  publications listed below  and in Appendix 1/2B. My personal contribution to the work 
in each paper is outlined beneath each of the citations below and verified by my co-authors in 
Appendix 3. 
1. Haslam K, Conneally E, Flynn CM, Cahill MR, Gilligan O, O'Shea D, Langabeer SE. CALR 
mutation profile in Irish patients with myeloproliferative neoplasms. Hematol Oncol Stem Cell 
Ther. 2016;9(3):112-5. 
Personal Contribution: Contribution to design of study, analysis of CALR mutation status and 
interpretation of all analytical and clinical data. Wrote paper and contributed to finalised 
version approval. Primary author of paper. 
2. Haslam K, Langabeer SE. Incidence of CALR mutations in patients with splanchnic vein 
thrombosis. Br J Haematol. 2015;168(3):459-60.  
Personal Contribution: Conceived and designed study, carried out CALR mutation analysis. 
Interpreted collated data. Reviewed and approved draft and final manuscript for submission. 
Primary author of paper. 
3. Langabeer SE, Haslam K, Linders J, Percy MJ, Conneally E, Hayat A, Hennessy B, Leahy 
M, Murphy K, Murray M, Ni Ainle F, Thornton P, Sargent J. Molecular heterogeneity of 
familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, 
CALR and MPL mutations. Fam Cancer. 2014 Dec;13(4):659-63. 
Personal Contribution: Input on design of study and collation of patient samples and details. 
Carried out JAK2/CALR mutation analysis and interpretation of results. Contributed to writing 
and review of paper. Approved final version of manuscript for submission. 
4. Langabeer SE, Haslam K, McMahon C. CALR mutations are rare in childhood essential 
thrombocythemia. Pediatr Blood Cancer. 2014 Aug;61(8):1523.  
5. Langabeer SE, Haslam K, McMahon C. Distinct driver mutation profiles of childhood and 
adolescent essential thrombocythemia. Pediatr Blood Cancer. 2015 ;62(1):175-6.  
Personal Contribution: Input on design of study and collation of patient samples and details. 
Carried out CALR mutation and JAK2 V617F qualitative PCR analysis. Interpreted result of 
experimental analysis and clinical context. Contributed to writing and review of manuscripts. 
Approved final drafts prior to submission.  
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6. Langabeer SE, Haslam K, McMahon C. A prenatal origin of childhood essential 
thrombocythaemia. Br J Haematol. 2013 Dec;163(5):676-8. 5YIF: 5.31.  
Personal Contribution: Input on design of study and collation of patient samples and details. 
Carried out experimental analysis of JAK2 V617F qualitative and quantitative mutation 
analysis and interpretation of all data. Contributed to writing, review and approval of all 
manuscript drafts.  
7. Haslam K, Conneally E, Langabeer SE. Capricious CALR mutated clones in 
myeloproliferative neoplasms. Blood Cells Mol Dis. 2016;57:110-1.  
Personal Contribution: Substantial contribution to design of study, carried out analysis and 
interpretation of data. Primary author of paper. Reviewed and approved final draft for 
submission.  
8. Langabeer SE, Haslam K, Elhassadi E. The mutant CALR allele burden in essential 
thrombocythemia at transformation to acute myeloid leukaemia. Blood Cells Mol Dis. 2017 
Jun;65:66-67. doi: 10.1016/j.bcmd.2017.05.004 
Personal Contribution: Input on study design, carried out experimental analysis of CALR 
mutation. Collated and interpreted results. Contributed to writing, review and approval of draft 
and final manuscript for submission. 
9. Langabeer SE, Haslam K, O'Brien D, Enright H, Leahy M. Transient JAK2 V617F mutation 
in an aplastic anaemia patient with a paroxysmal nocturnal haemoglobinuria clone. Br J 
Haematol. 2013;161(2):297-8. 
Personal Contribution: Input on study design, carried out JAK2 V617F quantitative analysis 
and results interpretation. Contributed to writing and review of paper. Approved final version 
of manuscript for submission. 
10. Haslam K, Langabeer SE. Considerations and recommendations for a new molecular 
diagnostic algorithm for the myeloproliferative neoplasms. Genet Test Mol Biomarkers. 
2014;18(11):749-53.  
Personal Contribution: Contributed to design of study, carried out data review and audit. 
Collated and interpreted data. Designed final algorithm and recommendations. Primary author 
of paper. Approved manuscript prior to submission. 
11. Haslam K, Langabeer SE.  Who to screen for CALR mutations? An audit of real-life 
practice and review of current evidence. Eur J Intern Med. 2017 Jan 26. pii: S0953-
6205(17)30040-7 
Personal Contribution: Contributed to design of study, carried out data review and audit. 
Collated and interpreted data. Designed final algorithm and recommendations. Primary author 
of paper. Approved manuscript prior to submission. 
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4.1 Introduction 
 
As outlined in the WHO 2016 classification (Arber et al., 2016), identification of an MPN 
associated driver mutation provides clear evidence for malignant, clonal haematopoiesis, 
however further clinical and biological features are required to allow a final diagnosis. 
According to the National Cancer Registry in Ireland, 124 cases of MPN were diagnosed per 
year between 1994-2012 with trends in diagnosis unclear (Cancer Trends No 26. 
Myeloproliferative neoplasms & myelodysplastic syndromes, 2015).  
As the interpretation of molecular diagnostic results produced in MPN related clinical cohorts 
is yet to be fully elucidated, this study sought to extend the breadth of knowledge in this arena. 
Specifically, the incidence of MPN mutations ( i.e. JAK2 V617F, CALR exon 9 mutations and 
where MPL exon 10 mutations where relevant) as molecular diagnostic markers in a clinically 
relevant Irish patient population was examined, in specific patient cohorts including paediatric 
MPN, familial MPN and patients presenting with splanchnic vein thrombosis. Using the data 
from these studies with that from specific case reports an understanding of the biological  and 
clinical behaviour of MPN mutated clones was developed. In addition, clinical referral data 
was used to audit the real-world application of molecular diagnostic testing which together, 
enabled the development of a framework for a molecular diagnostic algorithm for MPN 
molecular diagnostics and expanded current understanding of the application of molecular 
diagnostic markers in MPN.  
The methods used in this chapter are outlined in detail in Chapter 2 and include nucleic 
acid extraction and QC (section 2.3-2.7), JAK2 V617F PCR (section 2.9.2, 2.9.3, 2.11), Donor 
Chimerism STR-PCR (section 2.9.7, 2.10.3), CALR exon 9 mutation PCR (section 2.9.6, 
2.10.2).  
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4.2 Results 
 
4.2.1 CALR mutation profile in Irish patients with myeloproliferative neoplasms 
CALR exon 9 mutation analysis is now an essential component of the molecular diagnostic 
algorithm for MPN, with initial studies of incidence showing that some geographical 
heterogeneity exists in both the frequency and profile of CALR mutations in ET and PMF when 
considering patients from North America (Tefferi et al., 2014), Europe (Klampfl et al., 2013; 
Nangalia et al., 2013; Jeromin et al., 2015; Grinsztejn et al., 2016), Central and South America 
(Labastida-Mercado et al., 2015; Nunes et al., 2015), India (Sazawal et al., 2015), and the Far 
East (Li et al., 2014; Shirane et al., 2015). Given the importance of CALR mutational analysis 
in the diagnosis and prognosis of ET and PMF, this study investigated the pattern of CALR 
mutations in a cohort of adult Irish patients with MPN.  
An audit conducted on a cohort of confirmed or suspected MPN patients from two large 
Irish haematology centres returned 202 JAK2 V617F negative samples that were subjected to 
retrospective CALR exon 9 mutational analysis as outlined in section 2.9.6. CALR mutations 
were detected in archival genomic DNA from peripheral blood (n = 190) or bone marrow (n = 
12) by fluorescent PCR followed by fragment length analysis (Appendix 4). CALR mutations 
were detected in 58 patients (30 female and 28 male) from the 202 patient samples analysed, 
with a median age of 56 years (range, 25–86 years). The differential diagnosis for these patients 
was ET (n = 45), PMF (n = 10), post-ET myelofibrosis (n = 2), and myelodysplastic/MPNs (n 
= 1). Type 1 CALR mutations were the most prevalent, being detected in 60.3% of patients 
(35/58), followed by Type 2 mutations which were detected in 27.6% of patients (16/58) (Table 
4.1). Of the remaining seven cases, 8.6% (5/58) had Type 1-like deletions, one had a Type 2-
like insertion, and one patient harboured two mutated clones. The distribution of these 
mutations in the MPN subtypes is given in Table 4.1. 
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Table 4.1. Incidence of CALR Mutations in Irish MPN Patients. 
             
   Type 1  Type 1-like Type 2  Type 2-like Other 
             
 
ET (n=45)  26   5   12   1   1  
PMF (n=10)  8   0  2   0  0 
Post-ET-MF (n=2) 1   0  1  0  0 
MDS/MPN (n=1) 0  0   1  0  0 
             
Total   35 (60.3%) 5 (8.6%) 16 (27.6%) 1 (1.7%) 1 (1.7%) 
             
ET = essential thrombocythemia; MDS/MPN = myelodysplastic/myeloproliferative neoplasm; 
MF = myelofibrosis; PMF = primary myelofibrosis. 
 
Given the near mutual exclusivity of the JAK2 V617F and CALR mutations but acknowledging 
the rarity of these mutations co-existing (Broséus et al., 2014b; McGaffin et al., 2014; Mansier 
et al., 2016), this retrospective study was limited to known and suspected ET and PMF patients 
in whom the JAK2 V617F was previously undetected. The CALR mutation profile and 
frequency in this cohort of Irish patients are broadly in line with that of other series from Europe 
and North America, with Type 1 and Type 1-like mutations being more prevalent than Type 2 
and Type 2-like in both ET and PMF patients and confirming these driver mutations as the 
second most frequently observed in ET and PMF. 
 
4.2.2 Incidence of CALR mutations in patients with splanchnic vein thrombosis. 
MPNs are a common cause of splanchnic vein thrombosis (SVT) including Budd-Chiari 
syndrome and portal vein thrombosis, with a substantial proportion of these patients being 
JAK2 V617F positive, often in the absence of overt MPN symptoms (Boissinot et al., 2006).  
Given the recent description of CALR exon 9 mutations in ET and PMF patients, the incidence 
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and significance of CALR mutations in SVT patients was investigated. An audit of patients 
prospectively referred from 23 secondary/tertiary healthcare institutions within the Republic of 
Ireland for JAK2 V617F molecular analysis with a presentation of confirmed SVT returned a 
cohort of 144 patients. The median patient age was 52 years (range 1–87) and consisted of 77 
male and 67 female patients. Patients were assigned to six distinct groups according to the site 
of thrombosis: Budd Chiari syndrome (BCS), mesenteric vein thrombosis (MVT), portal vein 
thrombosis (PVT), renal vein thrombosis (RVT), splenic vein thrombosis (SpVT), and 
splanchnic vein thrombosis unspecified (SVT-U). The JAK2 V617F was detected in 18.8% 
(27/144) of patients and specifically in 4/9 (44.4%) BCS, 4/19 (21.1%) MVT, 13/82 (15.9%) 
PVT, 0/7 RVT (0%), 5/12 (41.7%) SpVT and 1/15 (6.7%) SVT-U patients. Fifty-nine of these 
patients were previously screened for the presence of the common MPL exon 10 mutations of 
which two patients (3.4%) possessed an MPL W515L mutation (McCarthy, McCarron and 
Langabeer, 2010). CALR exon 9 mutations were not detected in any of the 144 SVT patients 
(Appendix 5). 
The finding of no CALR mutations in this group of patients is noteworthy when 
considering the incidence of the JAK2 V617F (18.8%) in the entire cohort and the MPL W515L 
in a subset of this cohort. Whether the absence of CALR mutations in SVT patients is a 
reflection of the size of the study population is unknown, with verification of these results being 
required in independent cohorts.  
 
4.2.3 Molecular heterogeneity of familial myeloproliferative neoplasms revealed by 
analysis of the commonly acquired JAK2, CALR and MPL mutations  
While most cases of MPNs are sporadic in nature, a familial pattern of inheritance is well 
recognised. Characterisation of these FMPN kindred allows for the investigation of molecular 
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events that contribute to this inheritance and prompted an audit of MPN referrals where the 
index case had at least one affected first-degree family member (parent, sibling, or child) and 
a diagnosis of MPN was made according to WHO criteria. 
Ten FMPN families were identified during the audit that met the above criteria (Figure 
4.1). Affected individuals from nine of these families possessed the classical MPN phenotypes 
of ET, PV and PMF whereas one family had a phenotype suggestive of hereditary 
thrombocytosis (HT) (Figure 4.1. Family 5). Of the nine families with classical MPN 
phenotypes, there were 24 affected individuals with ET (n = 13), PV (n = 8), PMF (n = 1), post-
PV MF (n = 1) and MPN of unknown phenotype (MPN unknown; n = 1). Samples were 
unavailable for analysis from four ET patients (Figure 4.1. Family 7: I-2 and II-2; Family 9: I-
2 and II-2). Molecular testing was carried out for detection of the JAK2 exon 12 and MPL 
W515L/K mutations as previously described (Percy et al., 2007; Daly, Conneally and 
Langabeer, 2009). Analysis of the JAK2 V617F and MPL W515L/K mutations were performed 
in all affected individuals. CALR mutation screening was only performed on those individuals 
without the JAK2 V617F mutation. CALR mutation allele burden was calculated from the area 
under the curve as mentioned in section 2.9.6. In selected patients, Sanger sequencing of JAK2 
exons 13 and 14, MPL and THPO was performed (Hussein et al., 2014). No MPL W515L/K 
mutations were detected in any of the affected patients. The JAK2 V617F was present in 3/8 
(37.5 %) of ET cases, 7/8 (87.5 %) of PV cases, and in three patients with PMF, post-PV MF 
and MPN unknown. CALR exon 9 mutations were detected in two ET patients, both of whom 
were JAK2 V617F-negative (Figure 4.1. Family 7: II-1; Family 8: II-1). Both patients 
harboured the common CALR Type 1 mutation L367fs*46 that results in a 52 base pair 
deletion, at allele burdens of 9.9% and 38.1% respectively. Two kindred underwent further 
molecular investigations. The index case of Family 1 (Figure 4.1. Family 1: II-1) presented 
with thrombocytosis but no splenomegaly. Her bone marrow showed evidence of hyperplasia 
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consistent with ET but had no evidence of either JAK2 exon 14 (including the V617F) or JAK2 
exon 12 mutations. Her father (Figure 4.1. Family 1: I-2) has ischemic heart disease, peripheral 
vascular disease and was diagnosed with JAK2 V617F-negative PV that is treated with 
hydroxycarbamide and venesection for a raised haemoglobin and haematocrit.  
The index case of Family 5 (Figure 4.1. Family 5: II-1) had a persistent thrombocytosis 
noted for 9 years with no mutation evident within JAK2 exons 13 and 14, CALR exon 9 or the 
coding exons of MPL and THPO, including the intron–exon boundaries of both genes. One 
sibling (Figure 4.1. Family 5: II-5) and two daughters (Figure 4.1. Family 5: III-1 and III-2) of 
the index case also have a mild thrombocytosis. The absence of demonstrable clonality in this 
kindred suggests a HT phenotype as opposed to familial ET. The affected individuals from the 
kindred described displayed considerable phenotypic heterogeneity, with ET and PV the most 
prevalent phenotypes, whereas the genotypic incidence of JAK2 V617F, CALR exon 9 and 
MPL W515L/K mutations was also in keeping with other studies (Malak et al., 2012; Ranjan 
et al., 2013; Maffioli et al., 2014; Rumi et al., 2014d). Furthermore, JAK2 and CALR exon 9 
mutations were mutually exclusive in this cohort and appear to be acquired independently. Two 
of the three affected individuals from Family 1 had ET, with a further individual having JAK2 
V617F-negative PV (Figure 4.1. Family 1: I-2). As both JAK2 exon 12 and exon 14 mutations 
were not detected in the index case (II-1), non-JAK2 V617F germ-line variants are most likely 
not a contributory factor for the FMPN (Mead et al., 2012; Etheridge et al., 2014; Rumi et al., 
2014d). The phenotype of PV in I-2 of Family 1 also argues against a germ-line mutation in 
either THPO or MPL genes as responsible for the FMPN as inherited mutations in these genes 
invariably result in a phenotype characterised by isolated thrombocytosis (Skoda, Duek and 
Grisouard, 2015). As evidenced in Family 5, absence of any mutations in JAK2 exons 13 and 
14, CALR exon 9, MPL or THPO, together with absence of hematopoietic clonality suggests 
that these patients are likely to be cases of HT.  
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Figure 4.1: Ten kindred with FMPN. ET; essential thrombocythemia, PV; polycythaemia vera, PMF; primary myelofibrosis, NT; not tested, wt; 
wild type, mut; mutation detected. Squares; males, Circles; females. Filled shapes; affected individuals, empty shapes; unaffected individuals.  
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4.2.4 CALR mutations are rare in childhood essential thrombocythemia 
Given the discovery of CALR exon 9 mutations in adult ET/PMF and the understanding 
that there is a prenatal origin of JAK2 positive MPN, an investigation of CALR mutations 
in paediatric MPN was prompted. An audit of sporadic paediatric MPN, referred from a 
single paediatric institution, classified according to established WHO haematological, 
histo-morphological and molecular criteria (Swerdlow et al., 2008) returned a total of 17 
patients. This cohort was comprised of JAK2 V617F-negative ET (n = 4), JAK2 V617F-
positive ET (n = 2), JAK2 V617F-positive PV (n=1), JAK2 V617F-negative 
polycythaemia (n = 2), and reactive thrombocytosis (n = 8). The presence of CALR exon 
9 mutations was retrospectively investigated in the blood or bone marrow DNA of the six 
identified ET patients (Table 4.2). All MPN patients tested negative for MPL W515L or 
W515K mutations. CALR mutations were not detected in the three JAK2 positive MPN 
patients, the four JAK2 negative ET patients or in the eight children with reactive 
thrombocytosis. Data for the ET patient subset is presented in Table 4.2 below. 
 
Table 4.2. Clinical features of the six Essential Thrombocythaemia patients. 
Case Diagnosis Age 
(years) 
 Platelet 
Count 
Range 
(x109/l) 
JAK2 
V617F 
MPL 
515L/K 
CALR 
exon 9 
1 ET 4 721-1167 Positive ND ND 
2 ET 15 953-1240 Positive ND ND 
3 ET 9 296-2718 ND ND ND 
4 ET 9 343-3054 ND ND ND 
5 ET 9 606-872 ND ND ND 
6 ET 11 413-1233 ND ND ND 
ET; essential thrombocythaemia, ND; not detected. 
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This study demonstrates the absence of CALR exon 9 mutations in JAK2 V617F-positive 
childhood MPN and in the four JAK2 V617F-negative children with ET. If the molecular 
pathogenesis of paediatric and adult MPN was similar, one might expect to detect CALR 
mutations in a certain proportion of young JAK2- and MPL-negative ET patients. 
However as paediatric MPNs are rare disorders, and the patient numbers available in this 
cohort are small, combination with a larger cohort can help to determine if CALR 
mutations have a role in the diagnosis and classification of childhood MPN.  
To further extend this analysis our initial findings were combined with a 
subsequent larger analysis of thirty four patients diagnosed with ET when less than twenty 
years of age (Giona et al., 2014). The JAK2 V617F, CALR, MPL and triple negative 
mutation status of ET patients from these two studies was combined to create a larger 
cohort (n=40). Analysis of this combined cohort revealed that adolescent ET patients had 
a strikingly similar molecular profile to that observed in adults (Klampfl et al., 2013), 
whereas the majority of childhood ET patients (diagnosed at ≤11 yrs) were triple negative, 
i.e. no JAK2 V617F, CALR or MPL driver mutations (Figure 4.2). This analysis further 
highlighted the difference in the molecular pathogenesis of adolescent and childhood ET 
and gives an insight into age related distribution of CALR exon 9 mutations.  
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Figure 4.2. Distribution of the common driver mutations in adult, adolescent (≥14 years 
to ≤20 years) and childhood (≤11 years) ET at time of diagnosis. Adult data derived from 
Klampfl et al. 2013. ET: essential thrombocythaemia. 
 
4.2.5 A prenatal origin of childhood essential thrombocythaemia  
Genetic analysis of antenatal blood spots has demonstrated that clonotypic translocations, 
mutations and gene rearrangements associated with many subtypes of paediatric ALL, 
and to a lesser extent, paediatric AML, are present at birth and have therefore been 
generated in utero, providing significant insights into the pathogenesis, natural history 
and aetiology of these leukaemia’s  (Wiemels, Kang and Greaves, 2009). In children, 
MPNs are estimated to have a prevalence of 40- to 90- fold lower than that seen in adults 
with sporadic, paediatric ET patients exhibiting a significantly lower prevalence of the 
JAK2 V617F and at lower allele burdens than observed in adult disease, inferring 
differences in both the aetiology and molecular pathogenesis of these diseases in adults 
and children (Teofili et al., 2008, 2009). Whether all genotypes and phenotypes of 
paediatric MPNs, especially those seen in younger patients, have a prenatal origin is 
unknown. However, a somatically acquired, in utero origin of the JAK2 V617F mutation 
in an infant with PV has provided some insight into the origins of childhood MPN  (Kelly 
et al., 2008). 
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 The case of a four-and-a-half year-old female that presented with persistent 
urinary tract infections associated with a thrombocytosis (platelet count 801–989 x 109/l) 
is presented. Whilst antibiotic treatment ameliorated the infections, the thrombocytosis 
remained. Significant platelet anisocytosis and giant platelets were observed on the 
peripheral blood film. A bone marrow aspirate revealed a normocellular, particular 
marrow with evidence of trilineage haematopoiesis. All cell lines were represented to 
maturity with abundant megakaryocytes, some with dysmorphic features, such as 
hyperchromatic and naked nuclei. Megakaryocyte clustering was evident and there was 
no obvious reticulin fibrosis.  The JAK2 V617F was detected in the peripheral blood by 
qPCR and determined as 31.2% of total JAK2 alleles by quantitative PCR. Parental 
consent was sought and granted to access the archived antenatal blood spots and DNA 
was extracted from these spots which had been taken from the patient 4 days postnatally 
using the method described by Wiemels et al., 2009. JAK2 V617F qPCR analysis was 
unable to reliably detect the JAK2 V617F in these samples (Ct >40 cycles). A more 
sensitive but qualitative, semi-nested allele-specific PCR (as described in section 2.9.3) 
was used to amplify mutant JAK2 alleles. This semi-nested PCR had a limit of detection 
of mutant alleles of approximately 1x10-5, determined by dilution of genomic DNA from 
a known heterozygous JAK2 V617F patient into DNA from a pool of 20 normal controls. 
Using this approach JAK2 V617F was detected in PCR duplicate reactions from both 
antenatal blood spots (Figure 4.3).  
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Figure 4.3. Agarose gel electrophoresis of JAK2 V617F-specific, semi-nested PCR 
products. Lane 1 & 14: 100bp DNA ladder; Lanes 2-5: 1/1000, 1/10,000, 1/100,000, 
1/1,000,000 dilution controls; Lanes 6,9 &12L: semi-nested PCR negative controls; 
Lanes 7 & 8: PCR duplicates from ante-natal blood spot (ABS) 1, Lane 10 & 11: PCR 
duplicates from antenatal blood spot 2; Lane 13: first round PCR negative control. 
 
One-year post-diagnosis, the patients’ platelet count (841 x 109/l) and JAK2 V617F allele 
burden (26.1%) remained stable, with no evidence of splenomegaly or thrombotic 
episodes. No MPN specific treatment has been received by the patient to date. As both 
parents of the child did not have a clinical history of sporadic or familial MPN, the 
detection of JAK2 V617F mutation in the antenatal bloodspots suggests a sporadic, in 
utero acquisition of the driver somatic mutation. 
 
4.2.6 Capricious CALR mutated clones in myeloproliferative neoplasms  
In a recently published large cohort of CALR mutated patients (n=685), it was found that 
ten (1.5%) possessed complex CALR mutations of which four possessed multiple clones 
(Jeromin et al., 2016). In a second study, Shuly et al. described a stable CALR mutant 
allele burden in ET patients over time with moderate variability observed (Shuly et al., 
2015). To explore the implications of these findings, CALR mutation patterns in a 
retrospective, independent cohort of JAK2 V617F negative CALR mutated ET and PMF 
patients was examined. 
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Of 55 CALR mutated patients identified, 34 (61.8%) had a type 1 (52-bp deletion) 
mutation, 15 (27.3%) had a type 2 (5-bp insertion) mutation, four (7.3%) had a type 1-
like mutation and one (1.8%) had a type 2-like mutation. One (1.8%) further ET patient 
who presented in July 2005 harboured both a type 1 (14.4% allele burden) and a 13-bp 
deletion (28.1% allele burden) in their diagnostic peripheral blood (Figure 4.4 panel A). 
Repeat analysis of peripheral blood more than ten years post presentation and after seven 
years of hydroxyurea therapy revealed fluctuation in the level of the two different clones 
with type 1 mutation and 13-bp deletion mutation allele burdens of 29.3% and 10.6% 
respectively (Figure 4.4 panel B). This analysis confirmed the presence of multiple CALR 
mutated clones in MPN patients at a frequency similar to that initially reported by Jeromin 
et al. in 2016. 
 
Figure 4.4. CALR mutation profile of patient with essential thrombocythemia at diagnosis 
(panel A) and ten years later (panel B). 
 
 
 
B A 
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4.2.7 The mutant CALR allele burden in essential thrombocythemia at 
transformation to acute myeloid leukaemia 
Transformation to AML occurs in approximately 5% of patients with ET. In the majority 
of JAK2 V617F-positive MPN patients who undergo transformation, this mutation is also 
present in the AML cell population. However, the phenomenon of JAK2 V617F-negative 
AML following a JAK2 V617F-positive MPN implies the transformation of a myeloid 
progenitor at a stage before acquisition of the JAK2 V617F or in a clone distinct from that 
harbouring the JAK2 V617F (Campbell et al., 2006; Theocharides et al., 2007). In those 
few CALR mutation-positive patients studied to date, this phenomenon has rarely been 
described (P. Lundberg et al., 2014; Anelli et al., 2016).  
Evidence for this latter course of disease evolution is outlined below in a patient 
in whom ET transformed to AML. A 51 year-old male with a history of peptic ulcer 
disease and hiatus hernia presented in February 2003 with a haemoglobin of 14.8 g/dL, a 
white cell count of 6.2 x 109/L and a platelet count of 1160 x 109/L. Bone marrow aspirate 
and biopsy showed increased, morphologically atypical megakaryocytes with clustering 
and minor evidence of reticulin fibrosis in keeping with a diagnosis of ET. The patient 
was commenced on hydroxyurea and aspirin. The JAK2 V617F was not detected in 
peripheral blood in October 2009. By March 2017, the patient had developed anaemia 
(haemoglobin 8.9 g/dL) with red cell anisocytosis and occasional myeloblasts noted on 
the peripheral blood film. Bone marrow biopsy showed an infiltration of myeloblasts that 
were CD34 positive by immunohistochemistry accounting for approximately 25% of 
nucleated cells with no increase in reticulin fibrosis. Bone marrow aspirate 
immunophenotyping revealed the myeloblasts were positive for MPO, HLA DR, CD13, 
CD33, CD34, CD64 and CD117 consistent with AML. The patient had a complex 
karyotype with aberrations involving chromosomes 5q, 7q, 8p, 12p, and 14q. Given the 
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previous absence of the JAK2 V617F mutation, CALR exon nine mutation analysis was 
performed as previously described. In the bone marrow at the time of leukaemic 
transformation, this approach detected a CALR type 1, 52 bp deletion mutation at a low 
allele burden of 5.7%. Analysis of the archived October 2009 peripheral blood sample 
demonstrated the CALR mutation allele burden to be 49.7% at that time, approximating 
heterozygosity (Figure 4.5). The patient received one cycle of daunorubicin and 
cytarabine 3 + 10 chemotherapy but did not achieve morphological remission with bone 
marrow myeloblasts representing 15% of nucleated cells and repeat bone marrow CALR 
analysis demonstrating an unchanged mutant allele burden of 5.6% (Figure 4.5 lower 
panel). 
 
Figure 4.5. CALR mutation fragment length analysis. CALR mutation at diagnosis (upper 
panel), leukaemic transformation (centre panel), and post-chemotherapy (lower panel). 
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Given that the mutant CALR allele burden generally increases over time and is largely 
unaffected by hydroxyurea therapy (Verger et al., 2015; Cavalloni et al., 2017) the 
significant reduction correlating with disease progression noted in the patient described 
herein likely represents a true reflection of the underlying disease evolution.  
 
4.2.8 Transient JAK2 V617F mutation in an aplastic anaemia patient with a 
paroxysmal nocturnal haemoglobinuria clone 
A recent report identifying a JAK2 V617F mutation in GPI-AP deficient cells of three 
PNH patients suggested this coexistence could explain clonal expansion (Sugimori et al., 
2012). These findings prompted investigation into the frequency of the JAK2 V617F in 
other patients harbouring a PNH clone. Archival DNA samples from blood (n = 3) and 
bone marrow aspirate smears (n = 19) from 22 patients (PNH, n = 5; AA, n = 13; 
hypoplastic MDS, n = 4) with an immunophenotypically detectable PNH clone of both 
RBC and granulocytes were retrospectively analysed for JAK2 V617F by qualitative 
allele-specific polymerase chain reaction (as described in section 2.9.2). The JAK2 V617F 
mutation was detected in one AA patient.  
This female patient, who presented with severe AA and no evidence of a PNH 
clone (nor retrospectively the JAK2 V617F), was initially successfully treated with two 
courses of anti-thymocyte globulin (ATG) and cyclosporin. She relapsed in pregnancy 2 
years later and was treated with immunoglobulin, and RBC and platelet transfusions. 
Post-partum treatment included G-CSF, ATG (2 courses) and ciclosporin, the latter being 
discontinued after achieving RBC and platelet transfusion independence. Ten years after 
the initial presentation, progressive pancytopenia suggested relapse of AA with a PNH 
clone detected within the granulocytes (17.7%) and RBCs (5.4%). At this relapse, the 
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JAK2 V617F was detected in the bone marrow and confirmed by qPCR at a reproducible 
level of 18% of total JAK2 alleles.  Ciclosporin was recommenced with a good response 
attained. Three years post-relapse, the PNH clone remained stable in granulocytes 
(18.9%) and RBCs (6.0%) with the JAK2 V617F not detected in the bone marrow by both 
allele-specific and qPCR. At no point during the clinical course did the patient have a 
persistent leucocytosis, erythrocytosis or thrombocytosis. The patient was subsequently 
diagnosed with malignant melanoma to which she succumbed.  An extended analysis for 
JAK2 V617F was conducted in diagnostic or pre-allogeneic haematopoietic stem cell 
transplantation samples from a further 38 AA patients without evidence of PNH, none of 
which were found to harbour this mutation.  This was the first report of JAK2 V617F 
positivity in AA with PNH, which although transient was reproducibly detected at a 
relatively high allelic frequency suggesting the development of a sizable clone in the bone 
marrow sample.  
 
4.2.9 Considerations and Recommendations for a New Molecular Diagnostic 
Algorithm for the Myeloproliferative Neoplasms 
By developing an understanding of the incidence, significance and behaviour of mutated 
MPN clones across different cohorts and through time, the development of 
recommendations for molecular diagnostic algorithms that can be implemented in the 
clinical diagnostic setting can be achieved. However, to fully inform the development of 
these algorithms, the ‘real-life’ experience of managing a testing service and the referrals 
for testing it receives is required. To further understand if requests for CALR mutation 
testing were being made on appropriate  samples and given a previously noted referral 
centre variation in JAK2 V617F requesting patterns in the Republic of Ireland, where 
increasing numbers of JAK2 V617F requests were made despite the annual incidence of 
154 
 
MPN diagnosis remaining steady (Langabeer, 2012), an audit was conducted on 1244 
CALR mutation requests made both prospectively and retrospectively (2005-2016) since 
the launch of the test. A total of 73 patients (5.9%) were found to harbour CALR exon 9 
indel mutations, with the distribution of CALR positive patients on an annual basis 
ranging from 3.3%-8.2% (Figure 4.6).  With regard to requesting criteria, 513 requests 
(41.2%) had no clinical details provided while the clinical details provided on the 
remainder could be categorised as outlined in Table 4.3 below. 
 
Figure 4.6. Distribution of CALR mutation requests 2005-2016. CALR mutation positive 
samples in black. 
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Table 4.3: Incidence of CALR mutations according to requesting details category. 
Category  No. 
Patients 
CALR mutation 
Detected 
Known JAK2 V617F negative ET  74 44 (59.5%) 
Known JAK2 V617F negative PMF  18  10 (55.5%) 
Known JAK2 V617F negative MPN 
unspecified  
17  2 (11.8%) 
? ET  109  9 (8.3%) 
? PMF  28  2 (7.1%) 
? MPN unspecified  24  1 (4.2%) 
Persistent thrombocytosis  124  3 (2.4%) 
Thrombocytosis  189  1 (0.5%) 
Erythrocytosis/raised haematocrit  37  0 (0%) 
Other 
(splenomegaly/neutrophilia/thrombosis/etc.)  
111  0 (0%) 
No clinical details provided 513 1 (0.2%) 513  1 (0.2%) 
Total  1244  73 
 
CALR mutations were primarily detected in those patients with either a known or 
suspected diagnosis of ET or PMF. The detection rate of CALR mutations did not differ 
significantly between those patients analysed retrospectively (5.7%) and those analysed 
prospectively (6.1%). Of note, no CALR mutations were detected in patients with clinical 
details provided of erythrocytosis or raised haematocrit or in those patients with isolated 
thrombosis, which has been supported elsewhere (Chauveau et al., 2017).  A lack of clear 
clinical details when submitting patient samples for referral in combination with testing 
of cohorts such a SVT and patients with isolated thrombosis that do not benefit from 
CALR mutation analysis highlights the constraints in implementing evolving diagnostic 
guidelines in real-life practice, which is acknowledged to influence subsequent treatment 
approaches and outcomes (Peterson et al., 2011) and affirms the requirement for continual 
education and adoption of such guidelines for the systematic investigation of a suspected 
MPN.  
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To further understand the quality of test referral requests received in the Diagnostic 
Laboratory, a review of the quality of clinical information and appropriateness of JAK2 
V617F test requests over a 12 month period was conducted.  A total of 1228 requests 
received for JAK2 V617F testing during a 12-month period (January-December 2013) 
were assigned to the following nine categories based on clinical details provided: No 
clinical details provided (n = 525), PV/?PV (n = 321), ET/?ET (n = 266), PMF/?PMF (n 
= 18), thrombosis (n= 57), splenomegaly (n = 17), neutrophilia/eosinophilia (n = 40), 
other myeloid malignancies (n = 24), and miscellaneous (n = 20) (Figure. 4.7). Overall, 
205 patients (15.9%) had evidence of the JAK2 V617F. Of immediate note was the 
significant proportion (40.8%) of referrals received with no clinical details provided.  
 
 
Figure 4.7. Indications for JAK2 V617F analysis. Black: JAK2 V617F detected; gray: 
JAK2 V617F not detected. 
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The capacity of a diagnostic laboratory service to provide a rational MPN molecular 
diagnostic service is reliant upon sufficient clinical detail to best triage sample referrals 
and assign appropriate testing. By combining the information gleaned from the CALR and 
JAK2 referral audits, recommendations that could support a new MPN diagnostic 
algorithm which incorporated CALR mutation analysis could be developed. The 
recommendations are outlined below. 
 
Recommendation 1: Provide sufficient, relevant clinical details, including 
provisional diagnosis, to enable application of the testing algorithm. 
These audits have demonstrated a consistent increase in requesting patterns despite the 
number of newly diagnosed MPN patients remaining constant. Awareness of service 
availability might explain this phenomenon yet the rising request rate most likely 
represents an increasing use of testing as an inappropriate, advance exclusionary test in 
the initial work up of patients for whom secondary causes have not been fully ruled out. 
 
Recommendation 2: Ensure alternative causes of MPN-like haematological indices 
are excluded prior to request for molecular diagnostic testing. 
Recognising the impact of inappropriate referrals and adherence to best practice 
guidelines when investigating cases of suspected MPN will directly increase the 
prevalence of MPN diagnostic mutations in the tested population by reducing the number 
of inappropriate samples received, improve the positive predictive value or proportion of 
patients with a positive test result that have the disease, and reduce false positive results 
issued. 
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Recommendation 3: Acknowledge the effect of inappropriate referrals on the 
predictive value of the testing algorithm. 
In only those cases of suspected ET and PMF that are JAK2 V617F negative, next-step 
reflexive testing for CALR mutations is advocated  (Tefferi and Pardanani, 2014) 
reinforcing the inclusion of appropriate clinical details. This would minimise the 
compounding effect on the clinical sensitivity of test results, and also ensure appropriate 
allocation of resources at testing laboratories. 
 
Recommendation 4: Adopt and adhere to the MPN molecular diagnostic algorithm. 
To support the correct allocation of resource in this scenario, a rational testing algorithm 
for the JAK2 V617F, CALR and BCR-ABL1 rearrangements was proposed (Figure 4.8). 
Adoption of this algorithm has the capacity to streamline testing for those patients who 
truly warrant investigation and to minimise turnaround times thus enabling prompt 
clinical decision making. 
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Figure 4.8. Proposed molecular diagnostic algorithm for suspected MPN. PV: 
polycythaemia vera; CML: chronic myeloid leukaemia; ET: essential thrombocythemia; 
PMF: primary myelofibrosis; BM: bone marrow.  
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4.3 Discussion 
 
This chapter investigated the incidence and significance of MPN mutations in various 
clinical scenarios and cohorts. By establishing the existing rate of CALR mutations in 
Irish patients and relevant cohorts such as SVT and paediatric MPN, considered 
incorporation of CALR mutation testing into a relevant prospective MPN molecular 
diagnostic algorithm can be achieved and will optimise the number of patients benefitting 
from such testing within existing laboratory resources. Given the previously described 
variability in requesting JAK2 V617F analysis within Ireland (Langabeer, 2012), limiting 
testing to those patients with suspected ET and PMF appears judicious.  
In the SVT cohort, the low incidence of CALR mutations detected (0/144) is supported 
by initial data on the haematological and clinical phenotype suggesting CALR+ ET is a 
distinct entity with an indolent clinical course associated with higher platelet counts, 
lower white cell counts and a lower risk of thrombosis when compared to JAK2 V617F+ 
ET (Rotunno et al., 2014; Rumi et al., 2014c). Subsequent studies have since confirmed 
the low rate of CALR mutations in this cohort (Turon et al., 2014). These studies have 
implications for the diagnostic screening and workup of SVT patients in whom an 
underlying MPN is suspected. Investigating the mutational profile of FMPN patients and 
including CALR mutations in this study allowed for clarified molecular profiling and 
enhanced our ability to deliver a definitive diagnosis to familial MPN patients. This is of 
added importance due to the fact that there is evidence to suggest disease anticipation in 
FMPN i.e. an earlier age of onset in subsequent generations (Rumi et al., 2007) and the 
incidence of several non-haematological cancers is increased in FMPN (Olcaydu et al., 
2011). This apparent increased frequency of secondary malignancies might possibly be 
due to an inherent underlying genomic instability (Scott and Rebel, 2012) or due to a 
common environmental factor (Anderson et al., 2012). A thorough investigation of family 
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history at the initial diagnosis of MPN patients is advocated with consideration given to 
suggestive MPN-related symptoms in relatives.  
Paediatric ET patients are a rare cohort of patients and understanding the 
contribution of MPN mutations in driving the disease remains poorly understood. By 
combining our data with that of Giona et al. to enhance cohort size and age distribution 
of the cohort  (Giona et al., 2014), it was shown that MPN mutations appear to be 
represented in younger children at a lower rate to older adolescents and adults, 
highlighting a difference in the pathogenesis of this disease in children or indeed in the 
classification of the triple negative paediatric MPN cases, as has been suggested 
(Langabeer, 2016). 
To further develop our understanding of paediatric ET, a case for the potential for 
the MPN mutation to be present in utero was investigated. Both parents of the child 
assessed had normal full blood counts and no evidence of the JAK2 V617F. Indeed, there 
was no clinical history of an MPN in either parent or their families, so the likelihood of 
FMPN was diminished, suggesting that in this case the ET is non-familial and the JAK2 
V617F detected in the antenatal bloodspots was somatically acquired in utero, further 
extending our understanding of the aetiology and biology of MPN. An explanation as to 
when this mutation arose remains elusive: an early acquisition during foetal 
haematopoiesis is postulated as significant expansions of the JAK2 V617F clone must 
have occurred both in utero and in the post-natal periods in tandem with normal foetal 
and neonatal haematopoietic development. Other genetic or epigenetic events, be they 
acquired or inherited, may have contributed to the acquisition of the JAK2 V617F and its 
subsequent capacity to elicit the disease phenotype in early childhood in this case. Other 
MPN relevant mutations, such as those in TET2, CBL, IDH1 and IDH2 have not been 
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detected in a limited study of childhood MPN (Ismael et al., 2012). This was the first 
report indicating a prenatal origin of childhood ET. 
The identification of a patient case that harboured two different CALR clones that 
were shown to fluctuate in allelic frequency after 10 years post presentation and seven 
years after hydroxyurea therapy has implications for selection of molecular diagnostic 
methodology. Sanger sequencing, fragment length analysis, high resolution melt curve 
analysis, quantitative PCR, digital PCR and NGS technologies have been used to detect 
CALR mutations (Jones et al., 2015; Park et al., 2015). The ability to detect low levels of 
multiple CALR mutations in the same assay is advantageous, however considerations of 
sensitivity, detection of the range of CALR mutation types, ease of use, availability and 
cost must be weighed before clinical implementation. Initial reports suggest that unlike 
interferon alpha, hydroxyurea therapy has no significant impact on the mutant CALR 
allele burden (Verger et al., 2015) implying that the phenomenon described represents an 
authentic variation in the clonal architecture of this patient. Given the variability in 
mutated CALR allele burden over time, caution must be advised when interpreting 
residual disease responses.  
The description of a rare case of CALR+ ET that transformed to AML signified 
that the AML clone was not derived from the CALR mutation-bearing MPN clone but 
from either a myeloid progenitor prior to acquisition of the CALR mutation or in a clone 
distinct from that with the CALR mutation similar to that previously encountered in 
transformation of JAK2 V617F-positive MPN. Transformation of CALR+ ET to CALR- 
AML is a rare event as the CALR mutation is generally acquired as an early event in the 
clonal development of the disease. Transformation is thus usually to a CALR+  AML. In 
this case, transformation to CALR- AML highlights potential for early clonal 
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heterogeneity in ET and MPN patients and provides further insight into the pathogenetic 
mechanisms of leukaemic transformation. 
The description of the hitherto unreported detection of the JAK2 V617F in a PNH-
related bone marrow failure syndrome (AA) was at a similarly low frequency to that 
previously described in classical PNH  (Fouassier et al., 2009; Sugimori et al., 2012). As 
this case was identified retrospectively, existence of the JAK2 V617F in the PNH clone 
could not be verified by fluorescence-activated cell-sorting of the GPI-AP-negative 
population. However, the transient nature of the JAK2 mutation in the presence of a 
relatively stable PNH clone, taken together with the evidence of different JAK2 V617F 
and PNH clone sizes signifies two distinct populations as opposed to the co-existence of 
mutations within one clone. The phenomenon of transient JAK2 V617F-positivity may 
be explained by the acquisition of the mutation in a more differentiated haematopoietic 
progenitor than that in patients with MPN. If this progenitor had reduced self-renewal 
potential and capacity for differentiation, then the clone generated might therefore be 
short-lived and not result in a clinical phenotype (Passamonti et al., 2007). 
Characterisation of the role of JAK2 signalling in PNH and PNH-related disorders may 
provide some insight into JAK2 AA disease development, maintenance or progression. 
The detection of the JAK2 V617F and other molecular lesions that contribute to clonal 
expansion, such as deregulation of HMGA2 expression, evident in PNH (Inoue et al., 
2006) and both typical MPN and atypical myeloid malignancies (Odero et al., 2005; Ueda 
et al., 2017) suggests some common pathogenetic mechanisms of PNH and MPN that 
warrants further investigation. 
Given the current knowledge of the frequencies and specificities of diagnostically 
relevant MPN-associated mutations, adherence to recommendations and guidelines for 
both the diagnosis and treatment of MPN is essential. Using information gleaned from 
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CALR and JAK2 referral audits, recommendations to support a new MPN diagnostic 
algorithm that would support appropriate allocation of resources to meet clinical need and 
reinforce the value of interaction between the clinic and laboratory to enhance patient 
care was developed. 
To conclude, by examining the incidence of MPN mutations in the cohorts 
described, insight into the clinical phenotype of CALR mutated MPN was developed, i.e. 
that it is reflected in the low incidence of CALR mutation in SVT patients, that CALR 
mutations can also occur in FMPN and have value as a diagnostic marker in these patients. 
CALR mutations were also shown to occur infrequently in paediatric ET, suggesting 
alternative disease mechanisms in the majority of these patients. However, it has been 
shown here that MPN driver mutations can occur in utero. Also demonstrated was that 
multiple CALR mutated clones can co-exist and remain stable over time, however the 
individual clone size may fluctuate, suggesting caution with interpretation of mutation 
data post treatment. Reflecting this phenomenon, it was shown that JAK2 V617F clones 
can be transient in nature in some clinical settings also. Taken together, this new data 
adds to the body of knowledge in understanding how to interpret MPN mutations in the 
clinical setting, in both classical MPN and other cohorts. 
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5.0 Application of somatic molecular diagnostic 
markers in Acute Myeloid Leukaemia 
The aim of this chapter was to validate the introduction of next generation sequencing 
(NGS) techniques for detection of somatic mutations in AML clinical cohorts. The data 
in this chapter is the result of work that culminated in the four publications listed below 
(Appendix 1/2C). My personal contribution to the work in each paper is outlined beneath 
each of the citations and verified by my co-authors in Appendix 3. 
1. Haslam K, Chadwick N, Kelly J, Browne P, Vandenberghe E, Flynn C, Conneally E, 
Langabeer SE. Incidence and significance of FLT3-ITD and NPM1 mutations in patients 
with normal karyotype acute myeloid leukaemia. Ir J Med Sci. 2010 Dec;179(4):507-10.  
Personal Contribution: Contributed to design of study, carried out analysis of FLT3-ITD 
and NPM1 mutation status. Interpreted and collated experimental and clinical data. 
Primary author of paper.  Reviewed and approved final version of manuscript for 
submission. 
2. Haslam K, Catherwood MA, Dobbin E, Sproul A, Langabeer SE, Mills KI. Inter-
Laboratory Evaluation of a Next-Generation Sequencing Panel for Acute Myeloid 
Leukemia. Mol Diagn Ther. 2016 Oct;20(5):457-61. 
Personal Contribution: Designed study. Performed experimental NGS work for Dublin 
centre. Collated, analysed and interpreted data from all collaborating centres. Wrote 
paper, reviewed and approved finalised version for publication. Corresponding author. 
3. Haslam K, Appleby N, Armstrong C, Kelly J, Langabeer SE, Flynn CM, Conneally 
E. Mutation profiling in patients with high-risk myeloid malignancies undergoing 
fludarabine, cytosine, arabinoside, amsacrine, cyclophosphamide, and busulfan 
conditioning and allogeneic transplantation. Manuscript. 
Personal Contribution: Contributed to design of study, carried out all NGS technical 
analysis. Collated, analysed and interpreted clinical and technical data. Primary author of 
paper. Reviewed and approved final version for submission. 
4. Haslam K, Langabeer SE, Hayat A, Conneally E, Vandenberghe E. Targeted next-
generation sequencing of familial platelet disorder with predisposition to acute myeloid 
leukaemia. Br J Haematol. 2016 Oct;175(1):161-3. 
166 
 
Personal Contribution: Contributed to design of study, carried out NGS experimental 
analysis. Analysed and interpreted mutational output data. Contributed to review and 
approval of paper prior to publication.  
 
5.1 Introduction 
 
With the recent movement towards implementation of NGS in the clinical scenario, 
application of this technology has the potential to further elucidate the mutational profile 
of clinical cohorts, allow for molecular stratification and the identification of additional 
markers for molecular monitoring prior to transplantation.  
 The Ion Torrent (ThermoFisher) NGS technology used in this chapter 
allows for sequencing of a large number of targets in multiple samples in parallel. The 
performance of this technology was assessed against the conventional ISO15189 
accredited single gene assay methods (where available) as part of an interlaboratory 
technology performance assessment between clinical molecular diagnostic facilities in 
Dublin, Edinburgh and Belfast.  
 In AML for many years the only molecular markers tested for in a routine 
setting were FLT3-ITD and NPM1 mutations, as they had a direct bearing on prognosis, 
with CEBPα tested for in specialist centres. For other markers of significance there was 
no methodology readily available for these patients, so the commercial development of a  
NGS targeted panels that covered 19 genes that are recurrently mutated  in AML was a 
significant step forward for these patients and offered the potential to deploy this new 
technology into specific cohorts to further understand the underlying genetic instability, 
offering the potential to enhance genetic testing in these patients, and improve clinical 
management. 
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The methods used in this chapter are outlined in detail in Chapter 2 and include nucleic 
acid extraction and QC (section 2.3- 2.7), FLT3-ITD PCR (section 2.9.4), NPM1 exon 12 
mutation PCR (section 2.9.2, 2.10.1), Next generation sequencing protocol (section 2.13). 
 
5.2 Results 
5.2.1. Incidence and significance of FLT3-ITD and NPM1 mutations in patients 
with normal karyotype acute myeloid leukaemia. 
Up to half of AML intermediate risk group patients have a normal karyotype (NK-AML) 
and a wide heterogeneity exists in terms of responses to treatment. At the molecular level, 
the most common mutations in this group are FLT3-ITD (40%) and those in NPM1 exon 
12 (50%) (Bacher et al., 2009) with the genotype of mutated NPM1 without FLT3-ITD 
in NK-AML associated with a high remission rate and favourable outcome (Gale et al., 
2008), with no difference in relapse-free survival whether a sibling donor was available 
for ASCT or not, suggesting that sibling ASCT may not improve outcome in first 
remission in this group of patients (Schlenk et al., 2008). As the molecular genotype of 
NK-AML has an increasingly important impact on clinical decision making, including 
transplantation options, the incidence and significance of NPM1 and FLT3-ITD mutations 
were therefore sought in a series of patients referred for molecular investigation. 
 A retrospective audit of patients with a diagnosis of NK-AML returned a 
total of 44 adult patients all of whom were less than 65 years of age and therefore potential 
recipients of ASCT. The median age of patients was 46 years (range 17–65) with 26 males 
and 18 females and a median follow-up of 19 months (range 1–68 months). DNA was 
extracted from presentation BM (n = 36) or peripheral blood (n = 8) with greater than 
20% myeloblasts before FLT3-ITD and NPM1 mutation assays were performed. A 
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representative agarose gel electrophoresis of a FLT3-ITD PCR (Figure 5.1A) and a NPM1 
mutation electropherogram are shown below (Figure 5.1B). 
 
 
 
 
 
Figure 5.1. Agarose gel image of FLT3-ITD and electropherograms of NPM1 reactions.  
A; Agarose gel electrophoresis of FLT3-ITD PCR reactions. Lanes 1 and 12, 100-bp 
ladder; lanes 2–7, NK-AML patients; lane 8, 5% FLT3-ITD control; lane 9, FLT3 wild-
type control; lane 10, 100% FLT3-ITD control; lane 11, water control. B; 
Electropherogram of a wild type NPM1 sample (single peak, left panel) and a 
heterozygous mutated NPM1 sample (additional mutated peak – black arrow, right panel).  
Two peaks with a 4 base pair difference in size are clearly visible in the mutated sample.  
 
FLT3-ITD mutations were identified in 20 (45.5%) and NPM1 mutations in 24 (54.5%) 
of the 44 NK-AML patients investigated. Patients were further stratified into groups 
according to genotype (Table 5.1). Thirteen (29.5%) patients were NPM1-/FLT3-ITD- , 7 
(16%) were NPM1-/FLT3-ITD+, 11 (25%) were NPM1+/FLT3-ITD- and 13 (29.5%) were 
NPM1+/FLT3-ITD+.  
 
FLT3-ITD 
FLT3 wild 
type 
  1       2       3       4        5      6       7      8       9     10     11     12 A 
B 
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Table 5.1 Distribution of NPM1 mutation and FLT3-ITD status. 
 
 
 
 
Follow-up data were evaluable for 84% (37/44) of the patients analysed. Kaplan–Meier 
analysis showed no significant differences in the overall survival between those NK-
AML patients who were either FLT3-ITD positive or negative or in those who were 
NPM1 mutation positive or negative (data not shown). No statistically significant 
differences in overall survival were noted between each of the aforementioned four 
genotypic subtypes but, of note, 8/11 (73%) of FLT3-ITD negative/NPM1 positive 
patients remain alive, six of whom are in first complete remission. 
 
5.2.2 Inter-Laboratory Evaluation of a Next-Generation Sequencing Panel for 
Acute Myeloid Leukaemia. 
Recent application of genomic techniques such as whole genome sequencing has yielded 
a broad view of the mutational landscape of AML and highlighted 25–30 recurrent 
somatic mutations. The adoption of targeted gene panels comprising a refined set of 
disease relevant genes has shown promise for translation of NGS into clinical practice 
(Kohlmann et al., 2013; McCourt et al., 2013; Ivanova et al., 2015).  To evaluate the 
utility of a newly available commercial AML gene panel, an inter-laboratory evaluation 
was conducted across three clinical diagnostic centres in the UK (Belfast City Hospital, 
Western General Hospital, Edinburgh) and Ireland (St. James’s hospital, Dublin). DNA 
Genotype No. of patients % of total 
NPM1- / FLT3-ITD- 13 29.5 
NPM1- / FLT3-ITD+ 7 16.0 
NPM1+ / FLT3-ITD- 11 25.0 
NPM1+ / FLT3-ITD+ 13 29.5 
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from six pre-characterised AML patients were distributed to each centre, processed and 
sequenced as outlined in section 2.13. Platform performance, somatic mutation detection 
and reproducibility were determined. 
 
5.2.2.1 Platform Performance 
Performance of the Ion Torrent PGM platform and workflow at each centre was assessed 
using the sequencing QC data generated for each sample. Variables assessed were the 
number of reads generated, average depth of coverage across the bases (both highlighted 
in grey), the AQ20 (1 % error rate) quality score of bases and the average read length 
generated (Table 5.2). An average read count of 602,354 reads per sample (range 
150,312–1,212,941) was generated. Mean read length at AQ20 was consistent at 123 bp 
(CV 3.3 %) for all samples analysed. An average sample read depth of 2725X (range 
629–5600) was achieved using six samples on a 318v2 chip, with significant variability 
observed in the depth of coverage generated for individual QC samples and between 
centres. AcroMetrix Oncology Hotspot controls (run alongside the duplicate of QC #6) 
showed detection of applicable variants present in IDH1/2, KIT, NPM1, PTPN11, FLT3, 
TP53, KRAS and NRAS at VAFs of between 5 and 10 % (25 % for NPM1) at 500X as 
expected. 
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Table 5.2 Performance variables for Ion Torrent Ampliseq AML Panel across six QC samples. 
 
 
 
Criterion QC #1 QC #2 QC #3 QC #4 QC #5 QC #6 Mean 
Standard 
Deviation 
CV 
Centre 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3       
Number of reads 161708 537984 851897 1212941 974719 802420 608123 150312 441551 762608 733111 722889 243565 502320 724439 520442 304244 587109 602354.56 281704.44 46.8 
No. of Bases (Mbp) 22 72 114 164 129 108 77 18 56 102 96 95 32 67 98 67 39 75 79.48 38.22 48.1 
No. of bases AQ20 
(Mbp) 
19 64 99 145 114 94 67 16 48 89 84 83 29 59 85 59 34 65 69.65 33.61 48.3 
Mean base coverage 
depth (fold) 
750 2463 3905 5600 4451 3699 2639 629 1902 3485 3305 3260 1116 2290 3360 2294 1334 2581 2725.81 1309.67 48.0 
Mean Read Length 
AQ20 
128 126 124 128 126 125 119 114 117 126 123 123 127 126 125 121 121 119 123.25 4.05 3.3 
Mean reads per 
sample 517196 996693 399995 739536 490108 470598 
  
Standard Deviation 
per sample 345564 206141 231717 20624 240669 147873 
CV per sample 
67 21 58 3 49 31 
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5.2.2.2 Somatic Mutation Detection 
To analyse somatic mutation detection, unfiltered data files from each centre were 
downloaded from Ion Reporter and analysed using the algorithm outlined below in Figure 
5.2. Unfiltered data was exported into Microsoft Excel, tabulated and filtered by column. 
To exclude mutations with no effect on protein amino acid constitution, synonymous 
mutations and those present within intronic and untranslated regions were removed. 
Following this, non-synonymous mutations that were present at <5% allelic frequency 
were excluded as the sensitivity of the assay could not guarantee a positive call at this 
level from background interference.  Remaining non-synonymous mutations were 
individually reviewed using IGV genome browser and various public databases to 
confirm pathogenic potential (Figure 5.2). 
 
 
Figure 5.2 Bioinformatic algorithm for filtering and calling of somatic mutations 
detected. 
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A total of 16 somatic mutations were identified in the six AML patient samples tested. 
Centres 1 and 3 identified all 16 mutations, whereas Centre 2 identified 15/16, producing 
an analytical specificity for the gene panel of 97.9 % (95 % CI 89–99 %) (Table 5.3). A 
mean of 2.7 somatic mutations were detected in each AML patient sample (range 1–4), 
representing nine genes on the panel (ASXL1, DNMT3A, IDH1, IDH2, NPM1, NRAS, 
PTPN11, RUNX1, TET2), with ASXL1 and DNMT3A being the most frequent. NPM1 
mutations were identified in one of the six QC samples, confirming results obtained at 
diagnosis by standard methodology at the referring centre. In addition, two frameshift 
deletions in ASXL1 not currently represented in COSMIC were identified in all centres 
and confirmed using IGV. Allelic frequencies of the 16 mutations detected ranged from 
5.6 to 53.3 % (median 44.4 %), with a high concordance between Centres for mutations 
detected (Figure 5.3).  
 Of note, Centre 2 did not report detection of the PTPN11 c.215C>A 
p.Ala72Asp mutation in sample three. Reanalysis of the data confirmed the presence of 
the missed mutation at a read depth of 302X, initially omitted as the read depth was 
<500X (in bold italics Table 5.3 and Figure 5.3, mutation number 7). 
 
5.2.2.3 Reproducibility 
Analysis of duplicate sample data showed both within and between run concordance, with 
the same number of variants detected at similar frequencies by all centres (Figure 5.3). 
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Centre QC Sample Locus  Gene Exon Type Coverage  Frequency  Coding Protein  
1 1 chr2:25470011 DNMT3A 9 missense 723 46.6 c.1031T>A p.Leu344Gln 
chr5:170837546 NPM1 11 frameshiftInsertion 935 53.3 c.862_863insGCTC p.Trp288fs 
2 1 chr2:25470011 DNMT3A 9 missense 2000 48.6 c.1031T>A p.Leu344Gln 
chr5:170837546 NPM1 11 frameshiftInsertion 521 43.8 c.862_863insGCTC p.Trp288fs 
3 1 chr2:25470011 DNMT3A 9 missense 1996 48.2 c.1031T>A p.Leu344Gln 
chr5:170837546 NPM1 11 frameshiftInsertion 1983 46.7 c.862_863insGCTC p.Trp288fs 
1 2 chr1:115258747 NRAS|CSDE1 2 missense 1926 28.8 c.35G>A p.Gly12Asp 
chr1:115258748 NRAS|CSDE1 2 missense 2000 5.7 c.34G>A p.Gly12Ser 
chr4:106164778 TET2 6 nonsense 948 46.8 c.3646C>T p.Arg1216Ter 
chr21:36231773 RUNX1 6 missense 1997 47.3 c.611G>A p.Arg204Gln 
2 2 chr1:115258747 NRAS|CSDE1 2 missense 1919 28.5 c.35G>A p.Gly12Asp 
chr1:115258748 NRAS|CSDE1 2 missense 2000 6.9 c.34G>A p.Gly12Ser 
chr4:106164778 TET2 6 nonsense 2000 48.4 c.3646C>T p.Arg1216Ter 
chr21:36231773 RUNX1 6 missense 1997 46.0 c.611G>A p.Arg204Gln 
3 2 chr1:115258747 NRAS|CSDE1 2 missense 1919 30.3 c.35G>A p.Gly12Asp 
chr1:115258748 NRAS|CSDE1 2 missense 1999 5.6 c.34G>A p.Gly12Ser 
chr4:106164778 TET2 6 nonsense 1999 47.2 c.3646C>T p.Arg1216Ter 
chr21:36231773 RUNX1 6 missense 1993 48.4 c.611G>A p.Arg204Gln 
1 3 chr12:112888199 PTPN11 3 missense 1848 16.6 c.215C>A p.Ala72Asp 
chr20:31023180 ASXL1 12 frameshiftDeletion 1944 48.1 c.2666_2667delCT p.Leu890fs 
1 duplicate 3 chr12:112888199 PTPN11 3 missense 1994 19.6 c.215C>A p.Ala72Asp 
chr20:31023180 ASXL1 12 frameshiftDeletion 1954 46.2 c.2666_2667delCT p.Leu890fs 
2 3 chr12:112888199 PTPN11 3 missense 302 24.2 c.215C>A p.Ala72Asp 
chr20:31023180 ASXL1 12 frameshiftDeletion 1135 48.0 c.2666_2667delCT p.Leu890fs 
3 3 chr12:112888199 PTPN11 3 missense 886 17.0 c.215C>A p.Ala72Asp 
chr20:31023180 ASXL1 12 frameshiftDeletion 1899 49.7 c.2666_2667delCT p.Leu890fs 
1 4 chr2:25457242 DNMT3A 23 missense 1976 46.1 c.2645G>A p.Arg882His 
Table 5.3 Somatic mutations identified. 
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chr2:209113113 IDH1 4 missense 1470 44.8 c.394C>T p.Arg132Cys 
chr20:31022592 ASXL1 12 nonsense 1990 45.5 c.2077C>T p.Arg693Ter 
chr20:31023408 ASXL1 12 nonframeshiftDeletion 1991 46.1 c.2894_2896delGAG p.Gly966del 
2 4 chr2:25457242 DNMT3A 23 missense 1991 44.6 c.2645G>A p.Arg882His 
chr2:209113113 IDH1 4 missense 1990 44.0 c.394C>T p.Arg132Cys 
chr20:31022592 ASXL1 12 nonsense 1986 45.9 c.2077C>T p.Arg693Ter 
chr20:31023408 ASXL1 12 nonframeshiftDeletion 1972 49.4 c.2894_2896delGAG p.Gly966del 
3 4 chr2:25457242 DNMT3A 23 missense 1997 46.3 c.2645G>A p.Arg882His 
chr2:209113113 IDH1 4 missense 1878 44.2 c.394C>T p.Arg132Cys 
chr20:31022592 ASXL1 12 nonsense 1993 46.4 c.2077C>T p.Arg693Ter 
chr20:31023408 ASXL1 12 nonframeshiftDeletion 1983 51.2 c.2894_2896delGAG p.Gly966del 
1 5 chr2:25457243 DNMT3A 23 missense 1374 24.1 c.2644C>T p.Arg882Cys 
chr2:25462032 DNMT3A 20 missense 1312 18.8 c.2375G>A p.Arg792His 
chr15:90631838 IDH2 4 missense 886 25.2 c.515G>A p.Arg172Lys 
2 5 chr2:25457243 DNMT3A 23 missense 1997 27.1 c.2644C>T p.Arg882Cys 
chr2:25462032 DNMT3A 20 missense 1998 20.4 c.2375G>A p.Arg792His 
chr15:90631838 IDH2 4 missense 2000 25.9 c.515G>A p.Arg172Lys 
3 5 chr2:25457243 DNMT3A 23 missense 1998 25.1 c.2644C>T p.Arg882Cys 
chr2:25462032 DNMT3A 20 missense 1997 21.5 c.2375G>A p.Arg792His 
chr15:90631838 IDH2 4 missense 1998 25.8 c.515G>A p.Arg172Lys 
3 duplicate 5 chr2:25457243 DNMT3A 23 missense 2000 23.8 c.2644C>T p.Arg882Cys 
chr2:25462032 DNMT3A 20 missense 1995 18.1 c.2375G>A p.Arg792His 
chr15:90631838 IDH2 4 missense 1999 22.5 c.515G>A p.Arg172Lys 
1 6 chr20:31022904 ASXL1 12 frameshiftDeletion 1985 32.7 c.2390_2391delAA p.Ser798fs 
2 6 chr20:31022904 ASXL1 12 frameshiftDeletion 1718 25.8 c.2390_2391delAA p.Ser798fs 
2  duplicate 6 chr20:31022904 ASXL1 12 frameshiftDeletion 1976 28.4 c.2390_2391delAA p.Ser798fs 
3 6 chr20:31022904 ASXL1 12 frameshiftDeletion 1826 31.5 c.2390_2391delAA p.Ser798fs 
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Figure 5.3 Allelic frequency of mutations detected in quality-control samples. Mutation 
1: DNMT3A p.Leu344Gln; Mutation 2: NPM1 p.Trp288fs; Mutation 3: NRAS 
p.Gly12Asp; Mutation 4: NRAS p.Gly12Ser; Mutation 5: TET2 pArg1216Ter; Mutation 
6: RUNX1 p.Arg204Gln; Mutation 7: PTPN11 p.Ala72Asp; Mutation 8: ASXL1 
p.Leu890fs; Mutation 9: DNMT3A p.Arg882His; Mutation 10: IDH1 p.Arg132Cys; 
Mutation 11: ASXL1 p.Arg693Ter; Mutation 12: ASXL1 p.Gly966del; Mutation 13: 
DNMT3A p.Arg882Cys; Mutation14: DNMT3A p.Arg792His; Mutation 15: IDH2, 
p.Arg172Lys; Mutation 16: ASXL1 p.Ser798fs. 
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5.2.3 Mutation profiling in patients with high-risk myeloid malignancies undergoing 
fludarabine, cytosine, arabinoside, amsacrine, cyclophosphamide, and busulfan 
conditioning and haematopoietic allogeneic stem cell transplantation 
The application of NGS technologies in myeloid malignancies has uncovered somatic 
mutations associated with adverse outcomes including mutations affecting ASXL1, FLT3, 
TP53, RUNX1, EZH2, (Patel et al., 2012; Bejar et al., 2014b; Patnaik et al., 2014) with 
subsequent studies indicating an association between somatic mutations and response to 
therapy (Klco et al., 2015; Woo et al., 2017). For high-risk MDS patients who undergo 
ASCT, the use of pre-defined mutations can enable prediction of relapse risk (Fu et al., 
2014), with somatic mutation in ASXL1, RUNX1, TET2, DNMT3A and TP53 associated 
with shorter survival in MDS and MDS/AML patients (Bejar et al., 2014b; Della Porta et 
al., 2016). Moreover, detection of somatic mutations prior to transplantation have shown 
potential as molecular targets of residual disease in the post-transplant setting (Bacher et 
al., 2009b; Fu et al., 2014; Salem et al., 2017). 
 To further characterise the mutational profile in this context, a 
retrospective analysis of patients with high-risk myeloid malignancies treated with 
FLAMSA-Bu conditioned ASCT was conducted. Twenty-one patients (10 male, 11 
female; median age 55 years; range 36-64 years) were included.  Patients were identified 
as having poor risk disease on the basis of AML with primary induction failure (n=5), 
MDS with high or very high-risk Revised International Prognostic Scoring System (R-
IPSS) scores (n=8, 4 of whom had therapy-related MDS), therapy-related AML with 
MLL rearrangement (n=1), intermediate-2 or high-risk  CMML-specific prognostic 
scoring system (CPSS) chronic myelomonocytic leukaemia (CMML) (n=4), blast crisis 
of chronic myeloid leukaemia (n=1), PMF with > 10% myeloblasts on bone marrow 
(n=1), and mixed phenotype acute leukaemia (T/myeloid) with complex karyotype (n=1) 
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(Table 5.4). Karyotype was available on 20/21 patient samples with a 
complex/monosomal karyotype detected in 10/21 (47.6%) patients, an intermediate risk 
karyotype in 6/21 (28.6%), and a normal karyotype in 4/21 (19%) (Table 5.4). The median 
Haematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) score for patients 
was 4 (range 0-10). Patient details and previous induction chemotherapy are outlined in 
Table 5.4. 
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Table 5.4 Clinical details and transplant characteristics on 21 high-risk myeloid 
malignancy patients analysed.  
Number of Patients 21 Transplant 
characteristics 
 
Median age in years 
(range) 
55 years (36-64 
years) 
Donor type 9 Sibling donors 
12 Matched unrelated donors 
Gender (male: female) 10 male: 11 female Patient/donor CMV 
serostatus 
4 Positive/Positive  
2 Positive/Negative  
1 Negative/Positive  
13 Negative/Negative 
1 Unknown 
  Post-transplant 
immunosuppression 
19 Ciclosporin/Mycophenolate 
2 Tacrolimus/Mycophenolate 
WHO 2008 Diagnosis   Graft versus Host 
Disease 
 
Acute myeloid leukaemia 5 (23.8%) Acute 7/21 
Therapy-related myeloid 
neoplasm 
5 (23.8%) Chronic 5/17 
Chronic myelomonocytic 
leukaemia 
4 (19%) Outcome  
Myelodysplasia 4 (19%) Treatment related 
mortality 
2/21 
Chronic myeloid 
leukaemia; blast crisis 
1 (4.8%) Death from 
relapsed disease 
prior to 100 days 
2/21 
Primary myelofibrosis 1 (4.8%) Survival at 100 
days  
17/21 
Mixed phenotype acute 
leukaemia, T/myeloid, 
NOS 
1 (4.8%) Median Progression 
Free Survival 
841 days 
Cytogenetics   Median Overall 
Survival  
Not reached 
Normal karyotype 4  
Complex karyotype 8 
Monosomal karyotype as 
a sole abnormality 
2 
Other karyotype 
abnormality 
6 
Not available 1 
Initial pre-transplant 
chemotherapy 
 
Azacytidine 3/21 
DAT 3+10 induction 11/21 
FLAG-IDA induction 3/21 
Other pre-transplant 
treatment 
5/21 
Bone marrow blasts prior 
to ASCT 
 
<5% 11/21 
5-10% 7/21 
>10% 3/21 
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5.2.3.1 Mutation profiling 
Tumour genomic DNA was available on 17/21 patient samples (peripheral blood (n=4), 
bone marrow (n=13)) prior to conditioning. FLT3-ITD were identified as previously 
described. NGS was carried out using the Ion Ampliseq AML Panel as described in 
section 2.13. 
 Results demonstrate an FLT3-ITD mutation in one patient sample (patient 
9). All 17 patient samples were sequenced by NGS at a sufficient depth and quality to 
permit bioinformatics analysis. A total of 423 variants were initially detected in 14/17 
(82.4%) patient samples sequenced. Exclusion of non-exonic and synonymous variants 
reduced the number of variants to 124, before bioinformatic analysis of the remaining 
variants further reduced the field to a final number of 33 somatic driver mutations. 
Missense mutations predominated (n=22), followed by frame-shift (n=6) and nonsense 
(n=5).  A median of 2 mutations (range 0-5) was detected, with 5/6 MDS, 4/5 AML, 3/3 
CMML, and 2/3 other, harbouring mutations detectable by the panel. TET2 mutations 
were the most common lesion, detected in 7/17 (41.2%) cases, followed by RUNX1 and 
DNMT3A mutations in 4/17 (23.5%) patients each, (Figure 5.4).  Allelic frequencies of 
the 33 mutations detected ranged from 3% - 87%, with samples harbouring multiple 
mutations displaying variable allelic frequencies. Details of somatic mutations detected 
by NGS are given in Table 5.5. 
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Figure 5.4. Frequency of mutated genes across patient cohort. The number of times an 
individual gene on the panel was mutated in the patient population was determined. TET2;  
Tet Methylcytosine Dioxygenase 2, RUNX1; Runt Related Transcription Factor 1, 
DNMT3A; DNA (Cytosine-5-)-Methyltransferase 3 Alpha, ASXL1; ASXL 
Transcriptional Regulator 1, TP53; Tumor Protein P53, KRAS; Kirsten Rat Sarcoma Viral 
Oncogene Homolog, IDH2; Isocitrate Dehydrogenase 2, CBL; Cbl Proto-Oncogene, E3 
Ubiquitin Protein Ligase, NPM1; Nucleophosmin 1, NRAS; Neuroblastoma RAS Viral 
Oncogene Homolog, PTPN11; Protein Tyrosine Phosphatase, Non-Receptor Type 11, 
GATA2; GATA Binding Protein 2; WT1; Wilms Tumor 1. 
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Table 5.5. Frequency of mutated genes across patient cohort. 
Patient Locus  Gene Exon Coverage  Alellic 
Frequency  
Coding Protein  Type 
1 chr4:106155920 TET2 3 1993 53 c.822_822delC p.Asn275fs Frameshift Deletion 
chr4:106156432 TET2 3 1995 27 c.1334_1334delT p.Leu446fs Frameshift Deletion 
chr20:31024371 ASXL1 12 2000 47 c.3856C>T p.Gln1286Ter nonsense 
chr21:36231782 RUNX1 6 1990 42 c.602G>A p.Arg201Gln missense 
2 chr1:115256528 NRAS 3 1996 25 c.183A>T p.Gln61His missense 
chr4:106164898 TET2 6 1253 51 c.3766G>C p.Gly1256Arg missense 
chr20:31024274 ASXL1 12 1556 16 c.3759T>A|c.3759T>C p.Ser1253Arg/p.(=) missense/synonymous 
chr12:112926888 PTPN11 13 821 4 c.1508G>T p.Gly503Val missense 
3 chr4:106158490 TET2 3 1701 3 c.3391C>A p.Pro1131Thr missense 
4 chr20:31022981 ASXL1 12 1990 47 c.2467_2467delT p.Leu823fs Frameshift Deletion 
5 chr4:106155755 TET2 3 737 87 c.657_658delAC p.His222fs Frameshift Deletion 
chr5:170837543 NPM1 11 233 43 c.859_860insTCTG p.Trp288fs Frameshift Insertion 
chr2:25470554 DNMT3A 8 1191 45 c.920C>T p.Pro307Leu missense 
6 chr2:25457243 DNMT3A 23 1629 30 c.2644C>T p.Arg882Cys missense 
chr12:25398281 KRAS 2 799 21 c.38G>A p.Gly13Asp missense 
chr12:25398284 KRAS 2 798 6 c.35G>T p.Gly12Val missense 
7 chr11:119148919 CBL 8 915 4 c.1139T>C p.Leu380Pro missense 
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8 chr2:25464535 DNMT3A 17 1891 70 c.1978T>C p.Tyr660His missense 
chr15:90631838 IDH2 4 1636 32 c.515G>A p.Arg172Lys missense 
9 chr4:106158490 TET2 3 1999 3 c.3391C>A p.Pro1131Thr missense 
chr21:36231783 RUNX1 6 1997 38 c.601C>T p.Arg201Ter nonsense 
10 chr4:106158228 TET2 3 1084 45 c.3129_3130insAA p.Ala1045fs Frameshift Insertion 
chr11:119148877 CBL 8 1596 22 c.1097A>G p.Glu366Gly missense 
chr17:7578212 TP53 6 1996 14 c.637C>T p.Arg213Ter nonsense 
11 chr17:7578461 TP53 5 678 8 c.469G>T p.Val157Phe missense 
chr3:128200073 GATA2 6 355 49 c.1232C>T p.Ala411Val missense 
12 chr21:36231783 RUNX1 6 1103 24 c.601C>T p.Arg201Ter nonsense 
chr21:36252866 RUNX1 5 665 5 c.496C>T p.Arg166Ter nonsense 
13 chr12:25398285 KRAS 2 750 35 c.34G>A p.Gly12Ser missense 
chr17:7578190 TP53 6 212 78 c.659A>G p.Tyr220Cys missense 
14 chr15:90631838 IDH2 4 387 12 c.515G>A p.Arg172Lys missense 
chr11:32417832 WT1 7 366 7 c.1220A>G p.His407Arg missense 
chr2:25457249 DNMT3A 23 816 43 c.2638A>G p.Met880Val missense 
15   No pathogenic mutations detected         
16 
 
No pathogenic mutations detected 
    
17   No pathogenic mutations detected         
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Circos plots were used to order mutations by disease group. These plots are generated to 
visualise the data in a circular layout, making it easier to explore relationships between 
positions. The plots revealed predominant associations of RUNX1 and TP53 within the 
MDS group, ASXL1 and TET2 within the CMML group, TET2 and DNMT3A within the 
AML group, and KRAS within the other grouping (Figure 5.5). 
 
 
Figure 5.5. Circos plot connecting disease groups and mutated genes. Each segment on 
the plot corresponds to a gene or disease group. Genes mutated in a particular disease 
group are linked to that disease group by a line. The width of the linking line shows the 
percentage of disease group patients that have mutations in the associated gene. For 
example, 30% of CMML patients have an ASXL1 mutation, whereas all ASXL1 mutations 
are found in CMML patients. 
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Analysis of gene-gene co-mutation within samples revealed the underlying heterogeneity 
within samples (Figure 5.6) with TET2 as the gene with the highest number of associated 
mutations (n=12), followed by DNMT3A (n=9). Two de novo AML samples detected 
possessed an IDH2 R172 mutation with co-mutated DNMT3A (patients 8 and 14, Table 
5.5).  
 
Figure 5.6. Circos plot showing gene-gene co-mutation in patient cohort. For example, 
TP53 mutations were associated with mutations in CBL, GATA2, KRAS and TET2, 
whereas GATA2 was found only associated with TP53 mutations.   
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5.2.3.2  Statistical Analysis 
Estimates of overall survival (OS) and progression free survival (PFS) were calculated 
using GraphPad Prism® 7 (GraphPad Software, California, USA) and expressed as 
Kaplan-Meier curves. OS and PFS were calculated from time of transplantation to event, 
which was defined as death and progression or death for OS and PFS respectively. Non-
relapse mortality (NRM) was defined as death from any cause other than refractory 
disease or relapse. Statistical significance was set as a p value <0.05, i.e. the observed 
quantitative difference occurs by chance <5% of the time. 
 
5.2.3.3 Mutations versus outcome  
Assessment of age and number of mutations detected showed no significance, with 
patients <49 years versus those >50 years with a PFS/OS p-value of 0.8384 and 0.9166 
respectively. Both groups had a median of two mutations (range 0-4) (p 0.7414). Analysis 
of the impact of individual genes on outcome was precluded by the limited patient cohort. 
 
5.2.3.4 Clinical outcome 
Twelve (57.1%) patients received stem cells from fully HLA matched unrelated donors. 
All patients achieved neutrophil engraftment, occurring at a median of 24 days (range 11-
124 days) and platelet engraftment at a median of 26 days (range 10-221 days) post-
ASCT. Ten (47.6%) patients received planned donor lymphocyte infusions and seven 
(33.3%) patients developed acute GvHD. Two treatment-related deaths occurred; one 
from sepsis in the context of steroid-refractory GvHD and another from toxoplasmosis 
infection. Ten (47.6%) patients remain alive and disease-free after a median of 513 days 
follow-up. Nine (42.9%) patients have relapsed post-ASCT, three of whom remain alive 
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following salvage therapy. The median time to relapse was 109 days (62-751), with 
median progression free survival (PFS) at 841 days and median overall survival (OS) 
having not yet been reached. The impact of donor source (related versus unrelated donor) 
did not impact on PFS (p=0.2568) or OS (p=0.7389). Of note, all four CMML patients 
relapsed at a median of 694 days post-FLAMSA-Bu ASCT. The median PFS for de novo 
AML and MDS has not been reached (Figure 5.7). Overall non-relapse mortality (NRM) 
was 9.5%, with a median predicted two-year NRM of 41% using the HCT-CI Score. 
 
 
Figure 5.7 Progression free survival of FLAMSA patient cohort by WHO 2008 disease 
category. 
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5.2.4 Targeted NGS of familial platelet disorder with predisposition to acute 
myeloid leukaemia 
The application of emerging NGS technologies, platforms and disease targeted panels 
allow the simultaneous identification of numerous mutational events. Such a targeted 
NGS approach was applied to a known RUNX1 mutated FPD-AML kindred to identify 
additional molecular events that co-operate with the germ line RUNX1 mutation in driving 
leukaemic transformation. A 56-year-old male and a 45-year-old female sibling both 
presented with AML with myelodysplastic features (Figure 5.8, I–3 and I–7 respectively). 
At diagnosis, I-3 had trisomy 8 and I-7 had monosomy 7. The eldest son of patient I-7 
(Figure 5.9, II-1) has thrombocytopenia. The history of familial thrombocytopenia 
coupled with development of AML suggested a diagnosis of FPD-AML, which was 
confirmed by Sanger sequencing identification of a heterozygous RUNX1 p.Arg166X 
mutation in the leukaemic blasts and constitutional buccal scrapes of both affected 
patients (Figure 5.9).  
 
Figure 5.8 Pedigree of the familial platelet disorder with propensity to acute myeloid 
leukaemia (FPD-AML) kindred. The index cases (I-3, I-7) are indicated as black symbols. 
II-1 (grey symbol) suffered from thrombocytopenia. 
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Figure 5.9 Sanger Sequencing electropherogram showing RUNX1 c.496C>T 
heterozygous mutation in bone marrow and buccal swab of patient. 
 
Patient I-3 underwent a reduced intensity conditioning ASCT from RUNX1 wild type 
sibling donor I-5. Patient I-7 underwent a myeloablative ASCT from RUNX1 wild type 
sibling donor I-6. Both patients achieved 100% donor chimerism by day-100 post-ASCT. 
For NGS, amplicon libraries were generated from AML diagnostic bone marrow DNA of 
I-3 and I-7 using the Ion Ampliseq AML panel as previously detailed. Criteria to allow 
confident calling of somatic mutations were set to a minimum target coverage of 500X, 
the presence of a mutation at >5% and a predicted change in amino acid sequence. Sanger 
sequencing was also performed on exon 8 of CDC25C, encompassing the mutation 
hotspot previously described (Yoshimi et al., 2014). Analysis of the NGS data confirmed 
the presence of the heterozygous RUNX1 p.Arg166X mutation and also demonstrated the 
presence of further mutations in the genes known to disrupt epigenetic (ASXL1, IDH1, 
TET2) and transcription factor (CEBPA, RUNX1) function in AML (Table 5.6). 
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Table 5.6 Mutations identified by targeted next-generation sequencing in two affected siblings (I-3 and I-7 as presented in Figure 5.9). 
                   
  
Patient Mutated gene  Nucleotide change Amino acid change  Variant effect % Mutant allele COSMIC (Disease association) 
                   
           
 
I-3 RUNX1  c.496C>T  p.Arg166X  nonsense 53%   COSM24769 (AML, ETP-ALL) 
 
 ASXL1   c.2083C>T  p.Gln695X  nonsense 26%   COSM1738037  (MDS) 
 
 IDH1   c.394C>T  p.Arg132Cys  missense 14%   COSM28747 (AML, Glioma) 
   
 RUNX1  c.608C>G  p.Pro203Arg  missense 6%   ---    
 
 
I-7 RUNX1  c.496C>T  p.Arg166X  nonsense 50%   COSM24769 (AML, ETP-ALL) 
 
 TET2   c.5162T>G  p.Leu1721Trp  missense 50%   ---    
 
 RUNX1  c.497G>A  p.Arg166Gln  missense 11%   COSM36055 (AML) 
 
 CEBPA  c.898C>T  p.Arg300Cys  missense 5%   --- 
                    
 
RUNX1; Runt Related Transcription Factor 1, ASXL1; ASXL Transcriptional Regulator 1, IDH1; Isocitrate Dehydrogenase 1, TET2; Tet 
Methylcytosine Dioxygenase 2, CEBPA; CCAAT Enhancer Binding Protein Alpha, AML; Acute Myeloid Leukaemia, ETP-ALL, Early T-cell 
precursor acute lymphoblastic leukaemia, MDS; myelodysplastic syndrome.
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Although matched germ line material was not studied by NGS, the fact that several of 
these mutations outlined in Table 5.6 have been previously described in haematological 
malignancies and that they are present at allele frequencies less than 50%, implies they 
are somatic and not heterozygous germ line in nature. No mutations of CDC25C exon 8 
were detected in either patient.  
 
5.3 Discussion 
 
The ability to routinely apply molecular methods to stratify patients based on genotype 
in a clinical setting has rapidly evolved. In the last decade there has been a move from 
single-gene test methods toward the application of NGS panel-based approaches. As this 
evolution has occurred, this study applied these techniques and methodologies to 
interrogate their value in AML related patient cohorts and to develop a deeper 
understanding of disease genotype in clinical cohorts. 
In an initial study, the incidence of the four different FLT3-ITD/NPM1 genotypes 
in the cohort studied was found to be consistent with that previously reported in larger 
studies (Gale et al., 2008; Schlenk et al., 2008; Schneider et al., 2009). Unfortunately, no 
differences in overall survival were observed and this may be attributable to the fact that 
this study was retrospective, small numbers of patients were studied and that these 
patients had a relatively short follow-up. Nevertheless, identification of both FLT3-ITD 
and NPM1 mutations is now considered the minimum molecular diagnostic requirement 
for NK-AML patients contributing to a prognostic stratification (Mrozek et al., 2007) and  
is therefore advocated in all new NK-AML patients. 
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With the availability of NGS technology, the inter- and intra-laboratory reproducibility 
and robustness of a commercial 19-gene AML panel in three separate clinical centres in 
the UK and Ireland was evaluated. Performance of the panel was assessed using six AML 
patient samples run on the Ion Torrent PGM platform across all centres. A high level of 
concordance was observed, with 15/16 mutations detected. Centre 2 did not report a 
PTPN11 c.215C>A p.Ala72Asp mutation, that was excluded as the number of reads 
generated for the sample was low (150,312) and the subsequent read depth at the target 
site did not achieve 500X. As a depth of coverage of 500X is necessary for confidence in 
calling low-level mutations (25 mutated reads are required for a 5 % burden), it is 
therefore essential to ensure appropriate coverage of all relevant amplicons to enable 
appropriate interrogation and interpretation of data produced. Improving efficiencies 
during the pre-analytic stages can help achieve this and would reduce the variability in 
reads generated between samples and between centres. Optimisation of library 
equalisation or implementation of automated template preparation and chip loading 
(using the Ion Chef in this case) could increase reads generated and improve preanalytical 
consistency. Reduction of sample number per chip or repeat testing and combination of 
results for samples that prove difficult to sequence would help deliver sufficient read 
depth for further analysis. Nevertheless, given the variation in reads generated per sample 
by each centre, the high concordance in the identification and coverage depth of somatic 
mutations in the samples tested proved the capacity of the Ion Ampliseq AML Research 
Panel and Ion Torrent as a robust platform for generating reproducible results in a clinical 
diagnostic setting.  
 A limitation of this study was the limited number of genes available for 
analysis. Expansion of the panel to incorporate a greater number of relevant genes 
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mutated in AML (e.g. splicing factors) would further improve its applicability. The 
implementation of common platforms and workflows to interrogate the mutational profile 
of AML patients will further enable standardisation of results and collaborative efforts 
between centres. 
 Once the performance of the Ion Torrent using the AML panel had been 
established, the technique was applied in specific clinical cohorts. The mutational 
landscape of myeloid diseases has been delineated in recent years (Bejar et al., 2011; 
Patel et al., 2012; Papaemmanuil et al., 2013; Haferlach et al., 2014), however the 
mutational profile in specific clinical scenarios such as ASCT has yet to be fully explored, 
with variation in mutational impact observed (Christopeit et al., 2015).   The mutation 
status and clinical outcome in a cohort of high-risk myeloid malignancy patients 
uniformly treated with FLAMSA-Bu conditioning and ASCT was investigated. This 
study was funded through a HAI Fellowship Award (Appendix 6). Fourteen out of 17 
(82.4%) patients had somatic mutations detected, with a median of 2 mutations per 
patient. The frequency of mutations in this cohort was consistent with that observed in 
myeloid disorders reported elsewhere, (Papaemmanuil et al., 2013; Haferlach et al., 2014; 
Christopeit et al., 2015) with variable allelic burdens observed in patients harbouring 
multiple mutations indicating the presence of subclones and a complex clonal 
architecture. Of note, two AML patient samples displayed an IDH2 R172 mutation, which 
has recently been proposed as a distinct AML genomic entity with a prevalence of 
approximately 1% based on mutual exclusivity with NPM1 or other class defining lesions 
and a gene-expression and DNA methylation profile that differs from other IDH 
mutations leading to more severe aberrations in metabolic activity (Papaemmanuil, 
Gerstung, Bullinger, Verena I Gaidzik, et al., 2016). 
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Further analysis by disease group reflected the high-risk status of the patients with 
mutations associated with poor outcome such as RUNX1 and TP53 predominant within 
the MDS group and ASXL1 within the CMML group. Clear gene-gene co-mutation 
associations were not found, likely reflecting the underlying heterogeneity of the patients 
and the limited number of patients studied. An association between patient age and 
number of mutations was not detected, nor between individual mutated genes and patient 
outcome, again probably due to the low patient number. A recent large-scale landmark 
study matching mutation and clinical data in MDS has reinforced the poor risk of TP53 
mutation regardless of conditioning intensity prior to transplant, questioning the benefit 
of conventional myeloablative conditioning over reduced intensity approaches in patients 
with TP53-mutated MDS (Lindsley et al., 2017). It is therefore interesting to speculate 
on a growing role for FLAMSA-Bu based conditioning in these patients in the future, 
however further larger scale studies are needed to determine the true effect of 
conditioning on TP53-mutated patients.   
 In the cohort tested, the FLAMSA-Bu regimen was clinically well 
tolerated with an NRM below that predicted by HCT-CI scoring (9.5% versus 41%). 
However, the outcome for CMML patients and those with therapy related myeloid 
neoplasms was poor indicating a need for alternative therapeutic approaches. 
Notwithstanding the limitations of a small patient cohort and a limited gene panel, 
mutational profiling of patients prior to ASCT aids clinical understanding of patient 
genotype. Knowledge of the clonal/subclonal architecture provides potential markers for 
disease monitoring post-ASCT in this cohort of patients at high risk of relapse. 
 In an FPD-AML kindred the AML gene panel was applied to determine 
its feasibility to reveal additional driver mutations present in these kindred. In addition to 
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the expected RUNX1 mutations, disrupted epigenetic (ASXL1, IDH1, TET2) and 
transcription factor (CEBPA, RUNX1) mutations in AML was revealed, allowing for an 
appreciation of the underlying genotype and genetic instability beyond the diagnostic 
germ-line RUNX1 mutation. While no CDC25C mutations were detected in the two FPD-
AML affected patients described, the role of these abnormalities requires clarification in 
other FPD-AML kindred. Given that the AML panel is limited to 19 genes, this approach 
offers several advantages over standard sequencing methodologies in familial AML: 
identification of the causative germ line mutation may be possible where the phenotype 
may be uninformative (Obata et al., 2015); the simultaneous detection of co-operating 
mutations that may be clinically actionable, such as IDH and TET2 demonstrated in the 
FPD-AML kindred described herein (Falini et al., 2015); the ability to infer patterns of 
clonal evolution in patients with overt AML (Tawana et al., 2015). It also affords an 
opportunity to monitor identified thrombocytopenic individuals from FPD-AML kindred 
to identify progression to MDS or AML, thus allowing earlier clinical intervention. If 
NGS technologies become integrated into routine practice, more cases of familial 
leukaemia are likely to be resolved with this approach which could enhance genetic 
testing and improve clinical management. 
 Whilst application of the AML specific panel in the clinical molecular 
diagnostic setting proved robust and reproducible, the limited number of genes on the 
panel combined with the limited number of applicable patients for testing would make it 
difficult to justify from a resource or cost perspective. For NGS implementation in the 
clinical molecular diagnostic setting, the majority of laboratories would require a panel 
that allowed for the interrogation of a greater number of relevant genes that would be 
applicable to a larger set of patients. Since publication of these studies, further 
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collaboration has taken place with the commercial company involved in producing the 
AML panel assay. In this instance, the authors have acted as subject matter experts on 
gene and hotspot content for the development of a broader myeloid specific commercial 
panel that incorporates more genes and mutations to expand the clinical relevance and 
applicability of the assay to other myeloid disorders such as MPN and MDS in addition 
to AML. 
Taken together these studies allow for a greater clinical appreciation of patient 
genotype and can inform clinical decision making with regard to patient stratification, 
monitoring of disease evolution and gauging response to therapy. 
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6.0 General Discussion 
  
The last decade has seen significant developments in the understanding of the genetic 
basis of myeloid disorders, with the underlying somatic mutational landscape revealed by 
whole genome and whole exome sequencing (Welch et al., 2012; Cancer Genome Atlas 
Research Network et al., 2013; Klampfl et al., 2013b; Nangalia et al., 2013b; Haferlach 
et al., 2014; Papaemmanuil, Gerstung, Bullinger, Verena I. Gaidzik, et al., 2016). 
Subsequent studies have revealed a biological impact for some of these mutations and 
their consequence in some clinical scenarios (Patnaik et al., 2012; Ayalew Tefferi et al., 
2014; R. Bejar, Stevenson, et al., 2014; Rumi, Daniela Pietra, Ferretti, Klampfl, 
Harutyunyan, Jelena, et al., 2014; O’Sullivan and Harrison, 2017). However, there 
remains a range of clinically relevant scenarios for which the incidence and significance 
of these mutations needs to be elucidated, including whether some of these mutations 
have potential to be used as clinical markers of response to therapeutic modalities such 
as allogeneic transplantation. This thesis investigated whether  mutation burden was 
correlated with response to allogeneic transplantation therapy and also whether 
knowledge of mutation status informs clinical insight in myeloid neoplasia. By 
conducting a series of original investigations into the relevance of somatic mutations in 
myeloid neoplasia, an insight into the utility and clinical application of these disease 
markers has been developed. The result of this work has culminated in the 19 peer 
reviewed publications that form the basis of this thesis. 
Chapter 3 sought to establish whether recently identified disease specific 
molecular markers could be used to measure the burden of disease in MPN patients and 
correlate the results with the more established donor chimerism method.  Three different 
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technical approaches were used in separate studies on different MPN disease cohorts in 
order to determine the allelic burden of the mutation. Methods used included qPCR for 
the JAK2 V617F mutation, capillary electrophoresis and area under the curve analysis, a 
semi quantitative method for measurement of CALR mutations and Sanger sequencing 
for detection of CSF3R mutations. In the JAK2 V617F study, a sensitive and robust qPCR 
assay for JAK2 V617F detection was evaluated and offered improved detail of patient 
responses to therapy relative to the conventional donor chimerism method. This approach 
offers the potential for clinical intervention earlier than previously available using less 
sensitive methods such as donor chimerism, immunophenotyping or morphology.  From 
a minimal residual disease perspective, an assay that is specific and sensitive such as the 
JAK2 qPCR method, requires further validation before deployment on a routine clinical 
basis. In subsequent work, we contributed to an international external quality assurance 
(EQA) programme using this method  to identify parameters critical for the quantification 
of JAK2 V617F. In this programme as members of the MPN&MPNr-EuroNet group, an 
EU sponsored network of experts on the molecular diagnosis of myeloproliferative 
neoplasm (MPN) and MPN-related congenital diseases (MPNr), we participated in two 
rounds of EQA with up to 25 laboratories from 17 countries across Europe. The EQA 
samples were quantified for JAK2 V617F and results were returned to the central 
laboratory in Denmark for analysis. This study showed that variations in methods due to 
the starting material, assay set-up, or qPCR equipment did not result in significant outliers 
in the EQA programme carried out and was a significant step towards standardisation of 
the methodology for use in a molecular diagnostic laboratory (Asp et al., 2019).  
In the second study CALR mutations were used as a marker of disease burden, 
with a capillary based method of detection chosen to reliably detect CALR exon 9 
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mutations. Although a semi-quantitative method, the assay detected CALR mutations at 
levels that reflected disease burden across a dynamic range and were stable throughout 
disease course. In the diagnostic setting, CALR mutation levels are usually detected at 
>15% allele burden and therefore assay sensitivity below this level is generally sufficient 
to consistently make a diagnosis of CALR mutation positive MPN. This is in contrast to 
JAK2 positive MPN where levels of 1% mutant allele burden have been shown to be of 
diagnostic and clinical relevance (Langabeer et al., 2015). In a minimal residual disease 
context, that a semi-quantitative method can be used to reflect clinical response to therapy 
and therefore can be used to make clinical decisions was shown. The ability of this assay 
to identify the majority of CALR exon 9 mutation types clinically observed and to detect 
the common Type I/II mutations at a sensitivity of approximately 1% makes it attractive 
for routine application in a clinical diagnostic setting. There have been a number of recent 
efforts to develop more sensitive and specific quantitative methods targeted at the CALR 
Type I/II mutations. A range of approaches have been developed using pyrosequencing, 
digital droplet PCR, quantitative PCR and NGS and offer enhanced sensitivities that 
allow for MRD monitoring at a deeper level (Fehse et al., 2015; Badbaran et al., 2016; 
Gardner et al., 2016; Kjær et al., 2016; Mansier et al., 2016; Keaney et al., 2017; Oh et 
al., 2018). Orthogonal verification of the quantification of Type I/II CALR mutations 
detected by the capillary based method used in this thesis and a qPCR based method 
showed an r2 value of 0.96 (Kjaer L & Langabeer S, personal communication). Our initial 
validation of serial monitoring of CALR mutations proved its utility as a useful adjunct in 
the assessment of transplant efficacy in myelofibrosis patients. 
The final study in this chapter followed up on the recent discovery of CSF3R 
T618I mutations in aCML. Sanger sequencing was deployed as a readily available 
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methodology to follow the clinical course post-transplantation in two cases where both 
persistence and eradication of the mutation was described and correlated well with the 
clinical course in both patients. As Sanger sequencing has a sensitivity of approximately 
20%, it is not suited to minimal residual disease monitoring, however in rare diseases 
such as aCML it is well suited as a screen at diagnosis to enhance and support other 
clinicopathological indices. Incorporation of CSF3R mutations into panel based NGS 
methods by commercial companies or in-house designs using bespoke economical 
methods such as molecular inversion probe based panels would allow for accurate 
quantification of allelic burden and lower sensitivities that allow for MRD level 
monitoring and can provide clinically relevant information on disease course (Waalkes et 
al., 2017). Taken together, the data generated in these studies affirms that mutation burden 
is inversely correlated with response to allogeneic transplantation therapy. All three 
mutation markers were shown to be stable and robust for monitoring purposes throughout 
the disease course and are therefore a useful adjunct in the assessment of transplantation 
efficacy. 
Chapter 4 investigated the incidence and significance of MPN mutations in 
various clinical scenarios and cohorts. A baseline for the incidence of CALR mutations in 
Irish patients referred for suspected MPN was established, which could then be 
incorporated into the development of a molecular diagnostic algorithm for suspected 
MPN. Our group was the first to identify the low incidence of CALR mutations in patients 
presenting with SVT, an important finding that complemented clinical observations of a 
lower risk of thrombosis and more indolent clinical course in CALR+ ET patients. This 
finding has been cited over 40 times in subsequent publications. We went on to establish 
CALR mutations in familial MPN cases, which gives our clinical colleagues an additional 
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tool to clarify some of these cases in the future. Also clarified, was  the understanding of 
MPN mutations in paediatric ET patients, detecting for the first time JAK2 V617F 
mutations in the blood spots of a paediatric ET patient, suggesting the mutation can be 
acquired in utero in this disease, a theory which has been supported by the identification 
of intra-placental spread of a CALR+ MPN-precursor hematopoietic stem cell clone 
between two monozygotic twins that developed ET symptoms at 16 years of age (Valdes-
Mas et al., 2016) and the detection of JAK2 V617F in DNA extracted from the Guthrie 
Card of a paediatric PRV case (Kelly et al., 2008). 
We published several reports that highlighted the dynamic nature of MPN disease 
clones (Langabeer et al., 2013; Haslam, Conneally and Langabeer, 2016; Langabeer, 
Haslam and Elhassadi, 2017). The identification of two CALR mutated clones in a MPN 
patient that fluctuated but remained stable throughout the disease course of over a decade, 
a transient JAK2 V617F positive clone that was transient in a case of PNH positive 
aplastic anaemia and a CALR+ ET case that transformed to AML that was CALR mutation 
negative. These identifications informed clinical insight into the underlying clonal 
heterogeneity of MPN patients. From a routine diagnostic perspective, this information 
has helped inform the choice of method used to detect CALR mutations. Whilst specific 
quantitative methods that target select mutations can be highly sensitive and specific, they 
will miss rare cases, such as the bi-clonal case outlined. These considerations need to be 
evaluated when making decisions on how to screen and follow up patients with suspected 
and confirmed MPN. All of the information generated in this chapter was used to help 
develop and refine a molecular diagnostic algorithm that would suit a busy clinical 
molecular diagnostic service. The written article associated with this study was published 
in an Irish medical journal as a means of engaging and informing clinical colleagues 
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throughout the country and opening up a conversation on the application of best practice 
in the real world. The diagnostic algorithm has been implemented into the routine 
molecular diagnostic test setting, with scientific/clinical dialogue to refine best practice 
referral ongoing. 
In a subsequent study, and given that the detection of mutations in CALR, JAK2 
and MPL has been incorporated into the recent World Health Organization (WHO) 
diagnostic criteria for MPN, a targeted next-generation sequencing (NGS) assay for the 
detection of MPN-associated mutations located in JAK2 exon 14, JAK2 exon 12, CALR 
exon 9, and MPL exon 10 to provide a single platform alternative to reflexive, stepwise 
diagnostic algorithms such as that outlined above was developed. This assay showed 
100% concordance between previously-identified mutations and those detected by NGS, 
with no false positives, nor any known mutations missed and a provides a novel solution 
to step-wise screening in suspected classical MPN (Frawley et al., 2018). Taken together, 
the studies in Chapter 4 have informed the conversation between clinical scientists and 
our clinical consultant colleagues that has opened a path to a more refined MPN 
diagnostic service, borne out of a deeper understanding of the interplay between the 
clinical, diagnostic and biological aspects of MPNs. The application of NGS technologies 
is continuously moving from the research environment into the clinical diagnostic service 
space, as health services develop the capacity, resources and technical capability to 
deliver consistent high-quality results back to the clinic (Haslam and Langabeer, 2016). 
  In Chapter 5, the application of methods for detection of somatic mutations in 
AML related cohorts was investigated. In an early study (Haslam et al., 2010), a 
conventional single assay approach to determine the incidence of FLT3-ITD and NPM1 
mutation status in Irish AML patients was used. This study allowed us to understand the 
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mutation profile of Irish AML patients for the first time and to use this information to 
stratify the patients based on genotype. Our results showed that the profile of Irish patients 
was consistent with that observed in larger European cohort studies and led to the 
subsequent launch of the NPM1 mutation status assay as a validated clinical service 
offering to inform clinical insight in these patients. As NGS based approaches became 
available, our group worked on an early-access basis to evaluate a commercial 19 gene 
AML panel. As part of this process, this panel was evaluated by three clinical molecular 
diagnostic centres in Ireland and the United Kingdom, with our laboratory coordinating 
the process. This study proved the technology to be robust and stable across all centres 
and would further enable standardisation of results and collaborative efforts between 
centres. The study also highlighted the limitations of a 19 gene panel for use in a clinical 
diagnostic setting. For clinical molecular diagnostic laboratories to deliver an NGS based 
assay in the area of myeloid malignancies, any panel-based approach would need to have 
a broader base of genes available for interrogation  for example, myeloid differentiation 
primary response 88 (MYD88), Splicing Factor 3b Subunit 1 (SF3B1), BCL6 Co-
repressor (BCOR),  Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit 
(EZH2) or U2 Small Nuclear RNA Auxiliary Factor 1 (U2AF1). 
In addition, recognition that targeting AML patients alone was not sustainable for 
a clinical molecular diagnostic service due to the limited number of diagnostic cases seen 
by services covering populations of up to 3 million people was realised. Increasing the 
number of genes present in the assay would allow more common associated myeloid 
malignancies such as MDS and MPN to be incorporated into a run, therefore making the 
panel a more viable option for the clinical setting. This information was communicated 
to the commercial manufacturer of the panel (ThermoFisher) and led to our involvement 
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in the development of a broader myeloid panel by the company, highlighting the potential 
for collaboration in applied research between industry and clinical/scientific services to 
ensure products launched on the market are optimised for the intended end users. 
 In subsequent studies, the application of the 19 gene AML panel in specific 
clinical cohorts was assessed, namely high risk MDS-AML patients that underwent 
transplantation therapy and FPD-AML patients. In both cases mutational profiling using 
the panel gave a clearer understanding of the genotype and clonal/sub-clonal architecture 
of the patients and informed clinical insight, such as identification of additional driver 
mutations in both studies that are currently being exploited as therapeutic targets. Of note, 
NPM1 was identified in one case (AML), whereas no JAK2 or FLT3 mutations were 
detected in this high risk cohort.  
The research work in this thesis is original in its design and has positively 
impacted on the field of myeloid malignancies as evidenced by its acceptance as peer 
reviewed publications. These studies inform clinical decision-making by providing 
reliable data on minimal residual disease burdens post-transplant, allowing for early 
therapeutic intervention, delineating potentially aggressive sub-clones occurring within 
individual patients for which targeted therapeutics may be clinically available and  
providing novel insight into the molecular mechanisms driving myeloid malignancies. 
The association between the aetiology of splanchnic vein thrombosis and the low rate of 
CALR mutation and that JAK2 mutations can occur in utero for example, extends our 
knowledge of the molecular pathogenesis of the diseases and the involvement of JAK-
STAT pathway mutations throughout all cohorts investigated. The data has shown that 
utilising these molecular tools can deliver actionable results and clarify the underlying 
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biological behaviour and responses of MPN cohorts, thus informing and enabling 
optimised clinical treatment of MPN patients.  
 
6.1 Future work 
 
As technologies that allow for broader and deeper mutation analysis become available in 
the clinical molecular diagnostic setting, multiple lines of investigation can be pursued to 
build on the work achieved in this thesis. Further investigation of molecular monitoring 
in the post-therapy setting is warranted. A recent proof of principle study that utilised 
NGS in a small number of genes to identify molecular mutations in MDS/MPN patients 
pre- ASCT, showed detection of the corresponding mutation in the post-ASCT period to 
be predictive of relapse (Fu et al., 2014). The application of a pan-myeloid NGS gene 
panel at patient diagnosis to identify multiple markers for monitoring in a post-transplant 
or post-therapy setting using NGS is of interest for further investigation. The ability of 
NGS methodologies to quantify multiple markers in parallel would also enable studies 
focused on the clonal evolution of a patients disease over time and the potential for 
clinical interventions in cases where emerging clones carried actionable mutations 
(Langabeer, Haslam and Conneally, 2014; Haslam and Langabeer, 2016).  
The addition of highly sensitive digital PCR based methods in tandem with NGS 
panel screening to monitor stable markers in the MRD setting could enable absolute 
quantitation of mutant alleles and lead to detection of a greater number of impending 
relapses. The optimal testing frequency required for each therapeutic modality remains to 
be determined. In MPN specifically, the clinical validity of determining JAK2, CALR, 
and MPL responses to novel targeted agents in development - alone or in combination 
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with established therapies, is still outstanding and requires assessment of efficacy. These 
agents include specific JAK2 protein inhibitors, CALR mutated protein inhibitors, histone 
deacetylase inhibitors, hypomethylating agents, PI3-AKT-mTOR inhibitors, and 
telomerase inhibitors (Geyer and Mesa, 2015; Pronier et al., 2018). Together these studies 
could enable further provision of an individual and optimised pathway of patient 
management. 
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To the Editor, 
 
Myeloproliferative neoplasms (MPN) are a group of clonal 
hematopoietic diseases characterized by bone marrow pro- 
liferation of one or more of the myeloid cell lineages with 
no marked alterations in cellular maturation. The Phila- 
delphia chromosome-negative MPNs classically comprise 
of the clinically and pathologically related polycythemia 
vera (PV), essential thromobocythemia (ET) and primary 
myelofibrosis (PMF). Identification of an acquired muta- 
tion within exon 14 of the JAK2 gene (G1849T) resulting 
in a V617F has revolutionized the molecular diagnosis of 
MPN as this mutation is present in 95% of patients with 
PV, approximately 50% of patients with ET and PMF and is 
also detected at a lower frequency in several other myeloid 
malignancies. In PV and ET patients, the disease can 
transform to a myelofibrotic stage or acute myeloid leuke- 
mia (AML). Front-line therapy for these disorders includes 
venesection for maintenance of hematocrit and aspirin for 
low-risk PV and ET whereas hydroxyurea and -interferon 
may be used for higher risk PV and ET cases. In PMF, obser- 
vation may be adequate for low-risk disease with sple- 
nectomy and conventional or experimental drug therapy 
required for higher risk patients [1]. While the introduction 
 
of targeted inhibitors of the JAK pathway has improved the 
outlook for some patients with PMF, allogeneic hematopoi- 
etic stem cell transplantation (AHSCT) remains the only 
curative option. Though AHSCT was previously only con- 
sidered for those patients with advanced or transformed 
disease, improved selection of PMF patients using refined 
scoring systems and the adoption of reduced intensity con- 
ditioning regimens has led to significant improvements in 
overall survival for an increasing number of patients [2]. 
For hematological malignancies, comparison of 
donor and recipient profiles allows assessment of donor 
chimerism (DC) status which complements hematological 
and clinical parameters providing information on engraft- 
ment kinetics, graft rejection or impending relapse and is 
usually performed at monthly to three monthly intervals 
post-AHSCT [3]. Techniques to quantify hematopoietic 
donor and recipient cells possess a level of sensitivity of 
approximately 1–2%, dependent upon methodology. The 
presence of the JAK2 V617F in MPN patients undergoing 
AHSCT therefore affords the opportunity to use this muta- 
tion as a sensitive marker of residual disease with studies 
previously demonstrating clearance of the JAK2 V617F 
post-AHSCT [4]. A qPCR assay was evaluated to determine 
whether quantitation of JAK2 V617F alleles post-AHSCT 
could serve as a sensitive marker of residual disease. 
Thirteen JAK2 V617F-positive MPN patients who under- 
went an AHSCT were identified (11 male, 2 female) with an 
age range of 18–58 years (median 50 years). MPN types 
were PMF (n=6), post-PV MF (n=2), chronic myelomono- 
cytic leukemia transformed to AML (n=3), PV transformed 
to AML (n=1) and AML (n=1) with a median follow-up of 
11 months (range 2–48 months). DNA was extracted from 
peripheral blood samples collected in accordance  with  the 
Helsinki Declaration. For the JAK2 V617F quantitation, 
patient DNA was amplified in two allele-specific PCR reac- 
tions, one for the JAK2 V617F mutated allele and one for 
the wild type JAK2 allele where the same forward primer 
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and probe are used but reverse primers are mutation or 
wild-type specific [5]. Commercial plasmids were used 
for construction of both JAK2 V617F mutant and wild type 
standard qPCR standard curves (Ipsogen SA, Marseille, 
France). PCR reactions were performed in duplicate in a 
7500 Real Time PCR System (Applied Biosystems, Foster 
City, CA, USA). All qPCR assays included a wild type control, 
a JAK2 V617F positive control, and a water negative control. 
An automatic baseline (3–15 cycles) and a fixed threshold 
of 0.1 (Rn) were selected to ensure consistency of analy- 
sis. Results were expressed as a percentage of JAK2 V617F 
alleles of the total of JAK2 alleles. As the reverse primers 
used in both assays differed by only one base at the 3′ end, 
non-specific amplification is observed in the JAK2 V617F 
assay when performed on the target negative control 
sample (Figure 1A). The specificity and sensitivity for each 
run was calculated using the Ct value for the target nega- 
tive sample (number of cycles between wild type and V617F 
Ct values) where the specificity corresponds to 2Ct. The 
sensitivity was set at 10-fold less than the value for speci- 
ficity to ensure the identification of true positive measure- 
ments. DC status was assessed using the PowerPlex® 16 
System (Promega, Madison, WI, USA). Donor and recipient 
(pre- and post-AHSCT) DNA samples were amplified sepa- 
rately and products electrophoresed on a 3130xl Genetic 
Analyzer prior to analysis with GeneMapper® Version 4.0 
Software (both Applied Biosystems, Foster City, CA, USA). 
Peak height analysis was used to quantify the percentage 
DC with the assay capable of detecting 1–2% of the minor 
cell population consistent with guidelines [6]. 
The JAK2 V617F allele-specific qPCR assay had a spec- 
ificity of at least 2.010–3 which gave a routine sensitivity 
and cut-off value for sample negativity of 0.02% mutant. 
The slope and R2 value of the standard curves gener- ated 
were robust across the dynamic range of the assay 
(Figure 1B). Seven of 13 (54%) patients were homozy- 
gous for JAK2 V617F pre-AHSCT (50% mutant), with 
the remaining six patients heterozygous. Of 49 samples 
tested for both JAK2 V617F and DC a significant Pearson’s 
correlation was observed (r=−0.98), however, it should 
be noted that 22 of these samples were 100% donor chi- 
merism and the JAK2 V617F undetectable. Ten of 13 (77%) 
patients became negative for JAK2 V617F post-AHSCT with 
a follow-up of 1–48 months (median 6 months). Three 
patients either failed to engraft or displayed autologous 
recovery. Post-AHSCT, increasing levels of the JAK2 V617F 
mutation were demonstrated 3 weeks prior to detection 
of decreasing DC levels (100%–91%) in one PMF patient 
(Figure 2). 
The identification of the JAK2 V617F mutation in a sig- 
nificant proportion of MPN patients provides a means of 
assessing the response to a number of treatment modali- 
ties. In the AHSCT setting, a qPCR approach allows for 
specific and sensitive measurement of the allele burden 
at very low levels and is therefore an appropriate meth- 
odology. The primer/probe combination of this JAK2 
V167F qPCR assay showed a high degree of specificity 
and was capable of distinguishing between wild type and 
mutated alleles to a level of 0.002% mutant in peripheral 
blood DNA. Using a cut-off for routine sensitivity of 0.02% 
mutant to ensure true JAK2 V617F positivity, the assay 
provided a gain of approximately two logs in sensitivity 
over the routine STR PCR-based DC assay and has a sen- 
sitivity comparable to those achieved by alternative qPCR 
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be robust and reliable, performing consistently across a 
range of platforms [8]. 
Both the presence of a JAK2 V617F mutation and the 
allelic burden in PMF patient’s pre-AHSCT impact on 
survival, with rapid clearance of the mutation asso- 
ciated with a reduced risk of relapse [9]. In cases where 
residual disease persists post-AHSCT, pre-emptive donor 
lymphocyte infusions guided by JAK2 V617F qPCR can 
induce molecular remissions [10]. This sensitive qPCR 
assay to serially monitor JAK2 V617F-positive MPN 
patients post-AHSCT permits detection of changes in 
disease burden and has the potential to augment clinical 
decision-making. 
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Figure 2 Molecular kinetics of residual disease post-AHSCT. 
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methods for JAK2 V617F [7]. Previously, there has been 
no consistent approach to JAK2 V617F quantitation with 
qPCR assays varying markedly in performance thus limit- 
ing clinical applicability. Most recently, the qPCR primer/ 
probe combination employed herein has been shown to 
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Assessment of CALR mutations in myelofibrosis patients, 
post-allogeneic stem cell transplantation 
 
 
 
 
The recent discovery of insertion and/or deletion mutations 
within the CALR gene in a significant proportion of JAK2-  and 
MPL-unmutated essential thrombocythaemia (ET) and primary 
myelofibrosis (PMF) patients compels the incorpora- tion of 
CALR exon 9 mutational analysis into the molecular diagnostic 
algorithm for these myeloproliferative neoplasms (MPN) 
(Klampfl et al, 2013; Nangalia et al, 2013; Tefferi & Pardanani, 
2014). Identification and monitoring of the com- mon MPN-
associated mutations of JAK2 and MPL have been shown to be 
of prognostic value and enhance assessment of treatment 
effectiveness in those MPN patients undergoing allogeneic stem 
cell transplantation (ASCT) (Alchalby et al, 2010a,b). Despite 
the introduction of JAK inhibitors for the treatment of PMF, 
ASCT remains the only potentially cura- tive option. 
Improvements in candidate patient selection and stratification, 
timing of transplantation and conditioning regimens have 
significantly reduced the transplant-related morbidity and 
increased the overall survival for patients undergoing this 
procedure (McLornan et al, 2012). Post- ASCT monitoring 
utilizing additional patient-specific mark- ers could provide a 
more beneficial, individualized approach. 
As CALR mutations are likely initiating events in MPN patho- 
genesis, the scenario arises to assess these mutations as potential 
markers of residual disease in myelofibrosis patients, post-
ASCT. 
Screening for evidence of CALR exon 9 mutations by DNA 
fragment analysis (Klampfl et al, 2013) of pre-ASCT samples 
from 15 JAK2 V617F-negative MPN patients identified four 
CALR mutation-positive patients, all of whom received reduced 
intensity conditioning (Table I). CALR mutant allele burden was 
calculated using area under the peak (mutated/ mutated + wild 
type) x100 and compared to known donor chimerism status  
performed  according  to  guidelines  (Lion et al, 2012). The 
CALR assay allowed the reproducible detec- tion of 
approximately 1% mutant allele burden. All four donors were 
wild type CALR exon 9. A further 14 informative follow up 
samples evaluated for donor chimerism status were available for 
retrospective mutant CALR allele burden estima- tion. Patients 
1–3 achieved full engraftment as assessed by donor chimerism 
(≥99%) at 5, 8 and 14 weeks respectively with very low levels 
of mutant CALR alleles (<1%) detectable in patients 2 and 3 
at these time points (Table I). Patient 4 
 
 
Table I. Features and molecular follow up of four myelofibrosis patients with CALR mutations. 
 
Patient Gender 
Age at 
ASCT (years) MPN Donor type CALR mutation 
Weeks 
post-ASCT 
Mutant CALR 
allele burden (%) 
Donor 
chimerism (%) 
 
 
1 Male 59 PMF > AML Unrelated 52-bp deletion Pre-ASCT 55·7 – 
5 ND 100 
11 ND 100 
22 ND 100 
2 Male 46 Post-ET MF Related 5-bp insertion Pre-ASCT 42·0 – 
8 0·7 100 
26 ND 100 
3 Male 48 PMF Related 52-bp deletion Pre-ASCT 55·2 – 
4 0·6 96 
14 0·5 99 
25 ND 100 
37 ND 100 
4 Female 52 PMF Unrelated 5-bp insertion Pre-ASCT 58·3 – 
7 1·9 87 
13 5·0 81 
20 19·8 54 
24 1·3 86 
27 ND 99 
ASCT, allogeneic stem cell transplant; MPN, myeloproliferative neoplasm; AML, acute myeloid leukaemia; ET, essential thrombocythaemia; MF, 
myelofibrosis; ND, not detected. 
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Fig 1. Correlation of CALR mutation allele burden with donor chimerism status in Patient 4. ASCT, allogeneic stem cell transplant; DLI, donor 
lymphocyte infusion. 
 
failed to achieve full donor chimerism, reflected in levels of 
mutant CALR alleles of >1% (Fig 1). Loss of engraftment, 
indicated by falling donor chimerism and mirrored by a sig- 
nificant increase in mutant CALR allele burden, prompted donor 
lymphocyte infusion (DLI) at week 22  post-ASCT  with 
subsequent attainment of 99% donor chimerism and 
undetectable mutant CALR alleles. 
The utility of MPN-specific mutations to monitor disease 
kinetics post-ASCT has been demonstrated for those patients 
harbouring a JAK2 V617F mutation. Assessment of the JAK2 
V617F allele burden at 1 month post-ASCT can be highly 
predictive of outcome and risk of relapse (Lange et al, 2013) 
whereas serial monitoring of JAK2 V617F levels has been used  
to  trigger  pre-emptive  intervention  with  DLI  (Kro€ger et al, 
2009). Initial data suggests that the CALR mutation  status is a 
valuable prognostic marker in  myelofibrosis patients who 
undergo ASCT, with CALR mutation-positive patients having a 
superior overall survival and a lower rate of non-relapse 
mortality (Panagiota et al, 2014).  The  presence of CALR 
mutations in the majority of JAK2  V617F-  and  MPL exon 10-
negative MPN patients therefore allows these mutations to serve 
as disease-specific markers of residual dis- ease in conjunction 
with donor chimerism analysis. It is envisaged that development 
of CALR mutation-specific quan- titative polymerase chain 
reaction assays, similar to those established for the JAK2 
V617F, will further improve the  limit of mutation detection. 
By demonstrating both persistence and eradication of CALR 
mutations  that  correlate  with  the  clinical  course,  this  brief 
“proof of principle” study provides initial validation of serial 
monitoring of CALR mutations as a useful adjunct in the 
assessment of transplant efficacy in myelofibrosis patients. 
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Atypical CML (aCML) is a rare myelodysplastic/myeloproliferative 
neoplasm (MDS/MPN) characterized by neutrophilia with left-shift 
maturation and dysgranulopoietic features. Diagnosis also requires 
the exclusion of BCR-ABL1, PDGFRA and PDFRB rearrangements.1 
The prognosis of aCML is poor with survival times of generally o30 
months: patients may undergo transformation to AML or succumb 
to the effects of BM failure.2 To date, allo-SCT in the chronic phase 
of the disease has been the only option to improve OS.3 
No specific, recurrent cytogenetic or molecular abnormalities 
have been described in aCML until the recent characterization of 
mutations within the genes encoding the G-CSF receptor (CSF3R) 
and SET binding protein 1 (SETBP1) in a significant proportion of 
patients with aCML and chronic neutrophilic leukaemia (CNL).4,5 
Whereas the functional significance of SETBP1 mutations in aCML 
and CNL are not yet fully understood, the characterization of 
CSF3R mutations has revealed a possibility for targeted therapeu- 
tic intervention with tyrosine kinase inhibitors. Approximately 
50–60% of CNL and aCML patients harbour an acquired CSF3R 
mutation that can be either membrane proximal or in the 
cytoplasmic tail of the receptor. These two classes of mutations 
exhibit different downstream signalling patterns: membrane 
proximal mutations activate the JAK/STAT pathway and are 
therefore potentially amenable to inhibition with JAK inhibitors 
such as ruxolitinib, whereas truncation mutations predominantly 
signal through SRC family kinases and therefore may be targeted 
by SRC inhibitors such as dasatinib. The most prevalent CSF3R 
mutation in aCML and CNL is the membrane proximal T618I.4,6 In 
addition to this potential for targeted therapy, identification of 
aCML-specific CSF3R mutations affords the opportunity for 
evaluation of these mutations as disease-specific markers of 
residual disease in those patients undergoing allo-SCT. Mutations 
of SETBP1 and CSF3R exons 14 and 17 were sought by Sanger 
sequencing in a retrospective series of eight patients with aCML, 
CNL or atypical MPN. The clinical courses of two aCML patients are 
described, both of whom possessed a heterozygous CSF3R p. 
Thr618Ile (T618I) mutation (c.15482C>T, reference sequence 
NG_016270.1). 
A 60-year-old woman (Patient #1) presented in 2002 with what 
appeared to be morphologically CML but had a normal karyotype 
with no evidence of BCR-ABL1 by fluorescence in situ hybridization 
(FISH) or reverse transcription-PCR. She had no haematological 
response to 1 month of imatinib and commenced hydroxyurea. 
The pre-transplant work-up revealed worsening constitutional 
symptoms and adenopathy. Retrospectively, a CSF3R T618I 
mutation was detected 3 months pre-transplant (Figure 1a, 
upper). A reduced-intensity conditioning, sibling donor (CSF3R 
wild type) allo-SCT was performed. The initial post-allo-SCT course 
was unremarkable; however by day 72, whole blood donor 
chimerism was only 20% with the T618I mutation retrospectively 
still evident (Figure 1a, centre). Full donor chimerism was not 
achieved and she relapsed 9 months post allo-SCT with increasing 
BM myeloblasts. Two doses of DLI and a subsequent course of 
daunorubicin, cytarabine, thioguanine (3+10) did not improve the 
chimerism status; the marrow remained hypoplastic with 10–15% 
blasts and continued evidence of the CSF3R T618I (Figure 1a, 
lower). The patient became red cell and platelet transfusion 
dependent, deteriorated and died 17 months post allo-SCT. No 
constitutional material was available from Patient #1 to demon- 
strate the somatic nature of the CSF3R T618I mutation. 
A 48-year-old man (Patient #2) presented with an elevated white 
cell count and a hypercellular BM consistent with aCML. The patient 
had a normal karyotype, no evidence of BCR-ABL1, PDGFRA or 
PDGFRB rearrangements by FISH, with molecular studies demon- 
strating the absence of the JAK2 V617F and BCR-ABL1 transcripts 
but the presence of the CSF3R T618I mutation (Figure 1b, upper). 
He commenced treatment with hydroxyurea and 6 weeks before 
allo-SCT the CSF3R T618I clone remained evident but at a reduced 
level (Figure 1b, centre). He underwent a myeloablative allo-SCT 
with a sibling donor (CSF3R wild type). At day 30 post allo-SCT, he 
developed skin GvHD. The T618I mutation was not detected by 
sequencing on day 46 in whole peripheral blood (Figure 1b, lower). 
He remains well on a tapering steroid dose with improving GvHD. 
In other forms of MPN, allele-specific monitoring of disease- 
associated mutations, such as the JAK2 V617F and those within 
MPL exon 10 at defined time points, has been shown to be of 
value in predicting response to allo-SCT and may also aid in 
 
 
Figure 1. Sequencing of DNA isolated from unfractionated periph- 
eral blood demonstrating CSF3R c.15482C>T (p.Thr618Ile) mutation 
(arrows) throughout clinical course. (a) Patient #1 pre-allo-SCT 
(upper), day 72 post allo-SCT (centre) and 12 months post allo-SCT 
(lower). (b) Patient #2 at diagnosis (upper), pre-allo-SCT (centre) and 
day 46 post allo-SCT (lower). 
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directing adoptive immunotherapy in those patients who 
relapse.7–10 Such approaches would improve the detection 
sensitivity above that of Sanger sequencing and potentially allow 
quantitation of mutation level. Both persistence and eradication of 
the CSF3R T618I described above, correlating with the clinical 
course in both patients, indicate that serial monitoring of CSF3R 
mutations in aCML patients undergoing allo-SCT is a useful 
adjunct in the assessment of transplant efficacy. 
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Monitoring of the JAK2 V617F allele burden in myeloproliferative neoplasms after allogeneic stem cell transplantation is useful to 
determine levels of residual disease and has the potential to detect early relapse and guide subsequent clinical intervention. A case is 
described of a JAK2 V617F-positive primary myelofibrosis patient who underwent allogeneic stem cell transplantation. Prospective 
residual disease monitoring of the peripheral blood failed to detect an extramedullary manifestation of the disease, a periorbital 
myeloid sarcoma, arising nearly three years after transplant. This case serves to highlight a pitfall in residual disease monitoring for 
myeloproliferative neoplasm-associated mutations in the post-allogeneic stem cell transplantation setting. 
 
 
1. Introduction 
Primary myelofibrosis (PMF) is one of the classical Philadel- 
phia chromosome-negative myeloproliferative neoplasms 
and is clinically characterized by cytopenias, splenomegaly, 
and multiple disease-related symptoms that reduce the qual- 
ity of life. The clinical course of PMF is variable with an 
increased risk of progression to acute myeloid leukemia 
(AML) as compared to essential thrombocythemia and poly- 
cythemia vera [1]. While the introduction of JAK2 inhibitors 
has improved the outlook for many patients with PMF [2], 
the only curative option that remains is allogeneic stem cell 
transplantation (ASCT). Improvements in candidate patient 
selection and stratification, timing of transplantation, and 
conditioning regimens have significantly reduced the trans- 
plant related morbidity and increased the overall survival for 
patients undergoing this procedure [3]. The most commonly 
observed acquired mutations in PMF are the JAK2 V617F, 
CALR exon 9 mutations, and MPL exon 10 mutations with 
JAK2 V617F and CALR mutation status indicative of overall 
survival after ASCT [4, 5]. Tracking disease burden utilising 
these patient-specific mutations provides an individualized 
approach allowing assessment of disease clearance and pro- 
viding a marker with which to guide adoptive immunother- 
apy [6–9]. 
A case is described in which JAK2 V617F residual disease 
monitoring failed to detect an extramedullary manifestation 
of PMF in a patient after ASCT and which serves to highlight 
a pitfall of this approach. 
2. Case Report 
Whilst undergoing imaging of a knee replacement for 
osteoarthritis three years previously, a 54-year-old male was 
noted to have patchy skeletal sclerosis. Further investigations 
revealed splenomegaly with a nine-month history of pro- 
gressive constitutional symptoms (generalised unwellness), 
lethargy, night sweats, and weight loss. Initial hematological 
investigation revealed a hemoglobin of 10.3 g/dL, a white cell 
10 /L, and elevated 
× 
× 
platelet count had fallen to 24 × 9 
× 9 
× 10 /L. The JAK2 V617F was undetectable in 
× 10  /L, and an unchanged, maintained platelet
9
 
globin level of 14.0 g/dL, white cell count of 4.2 × 
9 
9 
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(a) 
  
(b) (c) 
Figure 1: (a) CT showing left periorbital myeloid sarcoma (arrowed); (b) periorbital biopsy showing blast infiltration by myeloid sarcoma 
(Hematoxylin and Eosin; magnification 40); (c) positive immunohistochemical staining for CD34 in the myeloid sarcoma (magnification 
40). 
 
reticulocyte count (212 10 /L) and lactate dehydrogenase 
(LDH; 990 IU/L). The blood film was leukoerythroblastic 
with red cell anisopoikilocytosis, tear drop cells, basophilic 
stippling, and 2% circulating blasts. Bone marrow aspirate 
was unsuccessful; however the bone marrow biopsy showed 
abnormal marrow architecture and grade IV reticulin fibro- 
sis. The JAK2 V617F mutation was detected by qualitative 
PCR confirming the diagnosis of PMF. Four months later the 
10 /L with 3% blast cells 
in the peripheral blood. The LDH was markedly elevated at 
1912 IU/L with the patient now noted to have a splenomegaly 
12 cm below the costal margin. His risk status based on Inter- 
national Prognostic Scoring System was intermediate-2 [10]. 
The patient proceeded to reduced intensity conditioning 
ASCT [11] with a matched sibling donor. The posttransplant 
course was complicated by Klebsiella bacteremia and grade II 
skin graft-versus-host disease (GVHD). With the introduc- 
tion of corticosteroids the patient developed Cytomegalovirus 
reactivation requiring readmission, steroid-induced hypo- 
mania, and steroid-induced insulin-dependent diabetes mel- 
litus. A robust and validated quantitative PCR (qPCR) assay 
for JAK2 V617F [12–14] was employed to determine the 
allele burden before ASCT (30.7%). At two months after 
ASCT donor chimerism (DC) was 97% and JAK2 V617F 
0.46% and at six months after ASCT DC was 96% and JAK2 
V617F 0.79%. Full DC (100%) and undetectable JAK2 V61F 
were concurrently noted at eleven months after ASCT and 
remained so at prospective three monthly assessments. 
In the long-term follow-up clinic at 32 months after 
ASCT,a1 cm hard lump was noted beneath the left eye. Sub- 
sequent imaging noted a mass lesion arising within the 
inferolateral aspect of the left orbit, displacing the globe 
anteromedially and which appeared to lie within the extra- 
conal space (Figure 1(a)). Excision of the periorbital bulk 
mass was undertaken with histopathological examination 
revealing adipose/connective tissue infiltrated by blasts 
(Figure 1(b)) which stained positively for CD34, CD117, and 
CD45 (Figure 1(c)) and negatively for CD20, TdT, Granzyme 
B, CD68, and CD1a. The blasts were also JAK2 V617F-posi- 
tive consistent with a diagnosis of myeloid sarcoma, an extra- 
medullary tumor (EMT). At this time the patient had a hemo- 
10 /L, neu- 
trophils of 2.0 
count of 115 
both the peripheral blood and the bone marrow aspirate, the 
latter showing no morphological evidence of PMF. 
The patient was not a candidate for further intensive 
chemotherapy and underwent involved field radiotherapy to 
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the left orbit (30 Gy in 15 fractions) and at last follow-up 41 
months after ASCT, the JAK2 V617F remained undetectable 
in the peripheral blood. 
3. Discussion 
Despite the fact that ASCT remains the only curative option 
for PMF, the five-year overall survival with reduced intensity 
conditioning is approximately 50%, with relapse being the 
major cause of treatment failure which is often associated 
with an aggressive clinical course, primarily due to clonal 
evolution [15]. Close molecular monitoring after ASCT is 
employed to determine the rate and status of disease clearance 
and to predict impending relapse allowing prompt clinical 
intervention. In those PMF patients in whom sensitive, 
residual disease monitoring of the JAK2 V617F allele burden 
has been performed, reemergence of this clone in either the 
peripheral blood or bone marrow precedes loss of DC and 
clinical relapse [16, 17]. A potential confounding factor of 
this qPCR approach is the possibility of clonal evolution   in 
which the JAK2 V617F relinquishes its role as the main 
driving mutation of this disease. While early detection of 
extramedullary relapse of AML cases using residual disease 
monitoring of AML-associated genetic markers has been 
documented, evidence for a similar benefit in JAK2 V617F- 
positive PMF, particularly after ASCT, is scarce [18–20]. 
EMT arising after ASCT for hematological malignan- 
cies appears to be predominantly associated with an initial 
diagnosis of AML but has been noted in association with 
other myeloid and lymphoid malignancies and they may 
occur in the skin and soft tissues, central nervous system, and 
gastrointestinal tract and at other sites [21]. EMTs are due to 
the migration of abnormal neoplastic hematopoietic 
precursor cells into the tissues and therefore formation 
should be considered a metastatic process [22, 23]. EMTs 
occurring after ASCT may possess different clinical char- 
acteristics compared to bone marrow relapses such as a 
longer duration of onset and an association with GVHD, both 
apparent in the case described herein [21]. The mechanism(s) 
by which extramedullary disease relapse remains molecularly 
undetected in the peripheral blood remains unknown: one 
possibility is evasion of PMF stem cells from immunological 
detection by residing in a shielded niche. 
Residual disease monitoring using JAK2 V617F qPCR in 
PMF after ASCT is  effective in  predicting relapse  in the 
majority of those patients in whom the disease  is  driven by 
this mutation. However, vigilance is required as 
extramedullary manifestations of PMF, although rare, may 
evade early capture by this approach. 
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Abstract 
Insertion and/or deletion mutations of the CALR gene have recently been demonstrated to be 
the second most common driver mutations in the myeloproliferative neoplasms (MPNs) of 
essential thrombocythemia (ET) and primary myelofibrosis (PMF). Given the diagnostic and 
emerging prognostic significance of these mutations, in addition to the geographical hetero- 
geneity reported, the incidence of CALR mutations was determined in an Irish cohort of 
patients with MPNs with a view to incorporate this analysis into a prospective screening pro- 
gram. A series of 202 patients with known or suspected ET and PMF were screened for the pres- 
ence of CALR mutations. CALR mutations were detected in 58 patients. Type 1 and Type 1-like 
deletion mutations were the most common (n = 40) followed by Type 2 and Type 2-like insertion 
mutations (n = 17). The CALR mutation profile in Irish ET and PMF patients appears similar to 
that in other European populations. Establishment of this mutational profile allows the intro- 
duction of a rational, molecular diagnostic algorithm in cases of suspected ET and PMF that will 
improve clinical management. 
© 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an 
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc- 
nd/4.0/). 
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thrombocythemia (ET), and primary myelofibrosis (PMF). 
These diseases are characterized by an over production of 
mature hematopoietic cells, extramedullary hematopoiesis, 
and clinically by a tendency for thrombosis, hemorrhage, 
and a potential to transform into acute leukemia. While 
almost all PV patients are characterized by the Exon 14 
JAK2 V617F and Exon 12 mutations, until recently, the only 
known driver mutations of ET and PMF were the JAK2 V617F 
and MPL Exon 10 mutations present in up to two-thirds of 
patients. The landmark discovery of insertion and/or dele- 
tion (indel) CALR Exon 9 mutations in 60–80% of JAK2 V617F- 
and MPL Exon 10-negative ET and PMF cases compels the 
inclusion of CALR mutation analysis into the molecular 
diagnostic algorithm for these MPNs. The two common CALR 
mutations are the Type 1 52-bp deletion (p.L367fs*46) and 
the Type 2 5-bp insertion (p.K385fs*47), which account for 
more than 85% of indels [1,2] with most other mutations 
being Type 1-like deletions or Type 2-like insertions. CALR 
mutations are thought to exert their function by perturba- 
tion of the intracellular Janus kinase/signal transducers and 
activators of transcription (JAK/STAT) signaling path- way 
by activation of MPL [3]. Molecular analysis of these three 
driver mutation types is likely to be a major criterion in the 
next revision of the World Health Organization classi- 
fication of hematopoietic tumors [4]. Aside from their diag- 
nostic importance, it is becoming increasingly apparent that 
the different types of CALR mutations impart prognostic 
information about thrombotic potential and leukemic trans- 
formation [5–7]. Furthermore, some geographical hetero- 
geneity exists in both the frequency and profile of CALR 
mutations in ET and PMF when considering patients from 
North America [8,9], Europe [1,2,10,11], Central and South 
America [12,13], India [14], and Far East Asia [15,16]. 
Given the importance of CALR mutational analysis in the 
diagnosis and prognosis of ET and PMF, the pattern of CALR 
mutations was investigated in a cohort of adult Irish patients 
with MPN. These data are likely to provide information about 
how to efficiently incorporate CALR mutation analysis into a 
prospective MPN molecular diagnostic service. 
 
Materials and methods 
 
A series of 202 confirmed and suspected MPN cases from two 
large Irish hematology centers were subjected to retrospec- 
tive CALR mutational analysis. None of the patients had evi- 
dence of the JAK2 V617F mutation by allele-specific 
polymerase chain reaction (PCR) [17]. CALR mutations were 
detected in archival genomic DNA from peripheral blood 
(n = 190) or bone marrow (n = 12) by fluorescent PCR fol- 
lowed by fragment length analysis. The CALR assay has been 
previously demonstrated to possess a detection sensitivity 
of ~1% mutant allele burden [18]. 
Results 
 
CALR mutations were detected in 58 patients (30 female 
and 28 male) with a median age of  56 years  (range,  25–86 
years) in whom the diagnosis was ET (n = 45), PMF  (n = 10), 
post-ET myelofibrosis (n = 2), and myelodysplas- tic/MPNs 
(n = 1). Type 1 CALR mutations were the most prevalent, (n 
= 35) followed by Type 2 mutations (n = 16; Table 1). Of the 
remaining seven cases, five had Type 1-like deletions, one 
had a Type 2-like insertion, and one previously described 
patient harbored two mutated clones [19]. The distribution 
of these mutations in the MPN sub- types is given in Table 
1. 
 
Discussion 
 
The description of CALR Exon 9 mutations in ET and PMF 
patients has changed the molecular diagnostic algorithm for 
MPN as they are now considered the second most com- mon 
type of driver mutations in ET and PMF cases. Provision of a 
confirmatory molecular diagnosis in a significantly higher 
number of patients will enhance risk stratification and 
allows for appropriate treatment: retrospective screen- ing 
has demonstrated the efficacy of existing therapeutic 
modalities such as interferon-alpha and JAK inhibitors in 
CALR-mutated MPN patients [20,21]. 
Because of the diagnostic and emerging prognostic signif- 
icance of these mutations, in addition to the geographical 
and ethnic variation previously reported, the incidence of 
CALR indels was investigated in a retrospective cohort of 
Irish MPN patients to determine the existing mutational 
spectrum. Given the near mutual exclusivity of the JAK2 
V617F and CALR mutations but acknowledging the rarity of 
these mutations co-existing in ET and a report of CALR 
mutations in JAK2-negative PV [22–24], this retrospective 
study was limited to known and suspected ET and PMF 
patients in whom the JAK2 V617F was previously unde- 
tected. Although a number of methodological approaches 
exist to detect CALR mutations [25], the sensitivity of the 
fragment length analysis used in this study was deemed suf- 
ficient to detect clinically relevant mutations: CALR mutant 
allele burdens are usually much higher [26]. 
 
 
Table 1 Incidence of CALR Mutations in Irish MPN Patients 
 Type 1 Type 1 like Type 2 Type 2 like Other 
ET (n = 45) 26 5 12 1 1 
PMF (n = 10) 8 0 2 0 0 
Post-ET MF (n = 2) 1 0 1 0 0 
MDS/MPN (n = 1) 0 0 1 0 0 
Total 35 (60.3%) 5 (8.6%) 16 (27.6%) 1 (1.7%) 1 (1.7%) 
 
 
Note: ET = essential thrombocythemia; MDS/MPN = myelodysplastic/myeloproliferative neoplasm; MF = myelofibrosis; PMF = primary 
myelofibrosis. 
114 K. Haslam et al. 
 
 
The CALR mutation profile and frequency in this cohort 
of Irish patients are broadly in line with that of other series 
from Europe and North America, with Type 1 and Type 1-like 
mutations being more prevalent than Type 2 and Type 2-like 
in both ET and PMF patients. Establishing this mutational 
profile allows considered incorporation of CALR mutation 
testing into a prospective MPN molecular diagnostic algo- 
rithm so as to optimize the number of patients who would 
benefit from such testing within existing laboratory 
resources. Given the previously described variability in 
requesting JAK2 V617F analysis within this country [27], 
together with the knowledge of the near absence of CALR 
mutations in splanchnic, cerebral, and other cases of unpro- 
voked venous thrombosis [28–30], limiting testing to those 
patients with suspected ET and PMF appears judicious. 
In conclusion, the incidence and spectrum of CALR 
mutations in Irish MPN patients are similar to those of other 
European cohorts confirming these driver mutations as the 
second most frequently observed in ET and PMF. This 
knowledge allows the effective incorporation of CALR 
mutation analysis into a prospective testing algorithm, thus 
enabling an enhanced diagnosis and improved clinical 
management. 
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Incidence of CALR mutations in patients with splanchnic vein 
thrombosis 
 
 
 
 
Splanchnic vein thrombosis (SVT) is a common and serious 
complication of both overt and latent myloproliferative neo- 
plasms (MPN) with molecular features such as the JAK2 
V617F, MPL exon 10 mutations and the JAK2 46/1 haplo- type, 
risk factors for SVT (Kiladjian et al, 2008; Smalberg     et al, 
2011; Sekhar et al, 2013). Given the notable occurrence of the 
JAK2 V617F mutation in SVT patients, the recent description 
of CALR exon 9 insertion and/or deletion muta- tions in up to 
80% of JAK2- and MPL-unmutated essential thrombocythaemia 
(ET) and primary myelofibrosis patients (Klampfl et al, 2013; 
Nangalia et al, 2013) prompted investi- gation of the incidence 
and significance of CALR mutations   in SVT patients. 
A  cohort  of  144  patients  prospectively  referred  from 23 
institutions within the Republic of Ireland for JAK2 V617F 
analysis with a presentation of confirmed SVT was identi- fied. 
The median patient age was 52  years  (range  <1–87) and 
consisted of 77 male and 67 female patients. Patients could be 
assigned to six distinct groups according to site of thrombosis: 
Budd Chiari syndrome (BCS), mesenteric vein thrombosis 
(MVT), portal vein  thrombosis  (PVT),  renal  vein thrombosis 
(RVT), splenic vein  thrombosis  (SpVT),  and splanchnic vein 
thrombosis unspecified (SVT-U). CALR exon 9 mutations were 
detected by fluorescent polymerase chain reaction fragment 
analysis (Klampfl et al, 2013) capa- ble of detecting an allele 
burden  of  1%  (Haslam  et al,  2014). The JAK2 V617F was 
detected in 18·8% (27/144) of patients and specifically in 4/9 
(44·4%) BCS, 4/19 (21·1%) MVT,  13/82  (15·9%)  PVT,  0/7  
RVT,  5/12  (41·7%)  SpVT 
and 1/15 (6·7%) SVT-U patients. Fifty nine of these patients 
were previously screened for the presence of the  common MPL 
exon 10 mutations of which two patients (3·4%) pos- sessed a 
MPL W515L mutation (McCarthy et al,  2010).  CALR exon 9 
mutations were not  detected  in  any  of  the  144 SVT patients. 
The finding of no CALR mutations in this  group  of  patients 
is noteworthy when considering the incidence of the JAK2 
V617F (18·8%) in the entire cohort and the  MPL W515L in a 
subset of this cohort. Whether the absence of CALR mutations 
in SVT patients is a reflection of the size of the study population 
is unknown with verification of these results required in 
independent cohorts. Initial data on the haematological and 
clinical phenotype suggests CALR+ ET is a distinct entity with 
an indolent clinical course associated with higher platelet 
counts, lower white cell counts and  a lower risk of thrombosis 
when compared to  JAK2  V617F+ ET (Rotunno et al, 2014; 
Rumi et al, 2014); the latter sup- ported by this study. These 
initial data may also have impli- cations for the diagnostic 
screening and workup of SVT patients in whom an underlying 
MPN is suspected. 
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Aldehyde dehydrogenase-2 polymorphism contributes to the 
progression of bone marrow failure in children with idiopathic 
aplastic anaemia 
 
 
 
 
 
Aplastic anaemia is a syndrome of bone marrow failure  (BMF) 
that is characterized by peripheral pancytopenia and marrow 
hypoplasia. Injury to haematopoietic stem cells (HSCs), such as 
immune-mediated cytotoxicity, can cause aplastic anaemia; the 
successful treatment of aplastic anaemia using 
immunosuppressive therapy (IST) supports this hypothesis 
(Kulagin et al, 2014). Another proposed mecha- nism is an 
intrinsic defect of HSCs, which is the presumed major cause of 
congenital BMF. However, this has not been definitively 
established in idiopathic aplastic anaemia. 
The aldehyde dehydrogenases (ALDHs) are a group of 
enzymes that are involved in critically important biological 
processes, such as detoxification of exogenous and endoge- 
nous aldehydes. ALDH2 deficiency, resulting from a 
Glu504Lys substitution (rs671, c.1510G>A) in the ALDH2 
gene, is prevalent in the Japanese population. AA homozyg- 
otes show very low catalysis of aldehydes, and GA heterozyg- 
otes display strongly reduced catalysis compared with GG 
homozygotes. Recently, ALDH2 deficiency was shown to be 
associated with accelerated progression of BMF in Japanese 
 
patients with Fanconi anaemia (FA), the most frequent inherited 
cause of BMF (Hira et al, 2013). 
We hypothesized that ALDH2 deficiency underlies the 
progression of BMF in patients with idiopathic aplastic anae- 
mia as well as in FA patients. 
Seventy-nine  Japanese  children  aged  ≤15 years,  referred 
to our institution between January 1990  and  April  2011,  were 
included in this study. Patients were excluded if they   had 
paroxysmal nocturnal haemoglobinuria  (PNH),  expo- sure to 
toxic chemicals, chromosomal fragility, or mutations  in TERC, 
TERT, SBDS or SH2D1A (Liang et al, 2006; Wang  et al, 2007). 
Disease severity was classified based on the cri- teria of the 
International Aplastic Anaemia Study Group (Camitta et al, 
1975; Bacigalupo et al, 1988). The ALDH2 Glu504Lys 
polymorphism was genotyped using a duplex polymerase chain 
reaction with confronting  two-pair  prim- ers (Tamakoshi et al, 
2003). Statistical analysis was per- formed using the Fisher’s 
exact test and the Kruskal-Wallis test. Failure-free survival 
(defined  by  survival  in the absence of  relapse,  additional  
therapy,  PNH, or secondary malignancy) 
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Abstract The myeloproliferative neoplasms (MPN) are 
clonal, hematological malignancies that include polycythe- 
mia vera, essential thrombocythemia and primary myelofi- 
brosis. While most cases of MPN are sporadic in nature, a 
familial pattern of inheritance is well recognised. The phe- 
notype and status of the commonly acquired JAK2 V617F, 
CALR exon 9 and MPL W515L/K mutations in affected 
individuals from a consecutive series of ten familial MPN 
(FMPN) kindred are described. Affected individuals display 
the classical MPN phenotypes together with one kindred 
identified suggestive of hereditary thrombocytosis. In 
affected patients the JAK2 V617F mutation is the most 
commonly acquired followed by CALR exon nine mutations 
with no MPL W515L/K mutations detected. The JAK2 
V617F and CALR exon 9 mutations appear to occur at 
approximately the same frequency in FMPN as in the spo- 
radic forms of these diseases. The familial nature of MPN 
may often be overlooked and accordingly more common 
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than previously considered. Characterisation of these FMPN 
kindred may allow for the investigation of molecular events 
that contribute to this inheritance. 
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Introduction 
 
The myeloproliferative neoplasms (MPN) are clonal, 
hematopoietic stem cell-derived diseases characterised by 
bone marrow proliferation of one or more of the myeloid 
cell lineages with the main classical subtypes of MPN being 
polycythemia vera (PV), essential thrombocythemia (ET), 
and primary myelofibrosis (PMF). The primary goal of 
therapy in PV and ET is to prevent thrombotic or 
hemorrhagic complications and in PMF, to alleviate ane- 
mia, symptomatic splenomegaly or constitutional 
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symptoms [1, 2]. A potential exists in a minority of cases for 
these disorders to progress to a myelofibrotic stage or acute 
leukemia. The most commonly acquired mutation 
associated with MPN is the JAK2 exon 14 V617F, occur- 
ring in greater than 98 % of PV cases and in approximately 
half of ET and PMF patients [3]. This mutation disrupts the 
function of the intracellular JAK2 molecule that is required 
for normal hematopoietic cytokine signalling and has 
become a target for therapeutic intervention [4]. Mutations 
within JAK2 exon 12 can be detected in those remaining 
JAK2 V617F-negative PV patients [5]. The next most 
frequent mutations observed in sporadic MPN are those 
more recently described in CALR, a gene that encodes the 
endoplasmic reticulum-associated, calcium binding pro- 
tein, calreticulin. These mutations occur exclusively in 
CALR exon nine, appear not to be found in PV, but are 
present in up to 80 % of ET and PMF patients who are JAK2 
V617F-negative [6, 7]. Several other genetic abnor- malities 
have described in MPN which occur at a much lower 
frequency than the JAK2 V617F and CALR muta- tions, the 
most common of which are those of MPL which encodes the 
receptor for thrombopoietin, a major regulator of 
megakaryocyte and platelet development. Most MPN- 
associated mutations of MPL are located within exon 10 
with the W515L and W515K mutations the most frequent 
and detected in approximately 5 and 3 % of PMF and ET 
patients respectively [8]. Other genetic and epigenetic 
events that disrupt myeloid cell differentiation and prolif- 
eration have been described at a lower frequency in MPN 
but are usually associated with rare phenotypes or leukemic 
transformation [9]. 
While the vast majority of MPN cases are sporadic in 
nature, familial clusters do occur. Patients usually have 
classical MPN phenotypes with the incidence of throm- 
botic complications and risk of progression to myelofi- 
brosis or leukemia not appearing to differ between the 
sporadic and familial forms of the disease [10–12]. Familial 
MPN (FMPN) should be distinguished from the non-clonal, 
inherited disorders of single hematopoietic lineage 
proliferation, namely hereditary erythrocytosis (HE) and 
hereditary thrombocytosis (HT). HE or congen- ital 
erythrocytosis/polycythemia is a rare and heterogenous 
clinical entity that may be primary due to EPOR mutations 
or secondary due to mutations of genes involved in the 
hypoxia sensing pathway such as VHL, EPAS1 and EGLN1 
[13]. Similar to HE, the genetic basis for the majority of HT 
cases has not been fully elucidated yet germ-line mutations 
in MPL, THPO and JAK2 have all been reported [14, 15]. 
Although a particular inherited haplotype has been 
identified that is associated with the development of spo- 
radic JAK2 V617F-positive, JAK2 exon 12-positive and 
MPL exon 10 mutation-positive MPN [16–20], it remains 
largely unknown as to what germ-line factors are respon- 
sible for inheritance of the majority of FMPN. Character- 
isation of FMPN kindred may therefore be of value in 
identification of putative germ-line factors. Here we report 
the phenotypes and the incidence of the three most com- 
monly observed molecular abnormalities associated with 
sporadic MPN in a series of FMPN kindred. 
 
 
Materials and methods 
 
A review of the referral institutions’ MPN database iden- 
tified families with the index case having at least one 
affected first-degree family member (parent, sibling, or 
child) with MPN. The diagnosis of MPN was made 
according to WHO criteria [21]. Detection of the common 
JAK2 V617F, JAK2 exon 12, CALR exon 9, and MPL 
W515L/K mutations and assessment of hematopoietic 
clonality was performed as previously described [6, 22– 25]. 
Analysis of the JAK2 V617F and MPL W515L/K mutations 
were performed in all affected individuals. As CALR 
mutations appear to be mutually exclusive of the JAK2 
V617F [6, 7], CALR mutation screening was only performed 
on those individuals without the JAK2 V617F mutation. 
Where appropriate, CALR mutation allele burden was 
calculated from area under the curve mutant allele / (mutant 
? wild type) 9 100 post-PCR fragment analysis. In selected 
patients, Sanger sequencing of JAK2 exons 13 and 14, MPL 
and THPO sequencing was performed [26]. 
 
 
Results 
 
Ten FMPN families were identified who met the above 
criteria for FMPN (Fig. 1). Affected individuals from nine 
of these families possessed the classical MPN phenotypes of 
ET, PV and PMF whereas one family has a phenotype 
suggestive of HT (Fig. 1. Family 5). 
Of the nine families with classical MPN phenotypes, there 
were 24 affected individuals with ET (n = 13), PV (n = 8), 
PMF (n = 1), post-PV MF (n = 1) and MPN of unknown 
phenotype (MPN unknown; n = 1). Samples were unavail- 
able for analysis from four ET patients (Fig. 1. Family 7: I-2 
and II-2; Family 9: I-2 and II-2). No MPL W515L/K muta- 
tions were detected in any of the affected patients. The JAK2 
V617F was present in 3/8 (37.5 %) of ET cases, 7/8 (87.5 %) 
of PV cases, and in those three patients with PMF, post-PV 
MF and MPN unknown. CALR exon 9 mutations were 
detected in two ET patients, both of whom were JAK2 
V617F-negative (Fig. 1. Family 7: II-1; Family 8: II-1). Both 
patients harboured the common CALR Type 1 mutation 
L367fs*46 that results in a 52 base pair deletion [6, 7], at 
allele burdens of 9.9 and 38.1 % respectively. 
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Fig. 1 Ten kindred with FMPN. ET essential thrombocythemia, PV polycythemia vera, PMF primary myelofibrosis, NT not tested, wt wild type, 
mut mutation detected 
 
 
Two kindred underwent further molecular investiga- 
tions. The index case of Family 1 (Fig. 1. Family 1: II-1) 
presented with thrombocytosis but no splenomegaly. Her 
bone marrow showed evidence of hyperplasia consistent 
with ET but had no evidence of either JAK2 exon 14 
(including the V617F) or JAK2 exon 12 mutations. Her 
father (Fig. 1. Family 1: I-2) has ischemic heart disease, 
peripheral vascular disease and was diagnosed with JAK2 
V617F-negative PV that is treated with hydroxycarbam- ide 
and venesection for a raised hemoglobin and hematocrit. 
The index case of Family 5 (Fig. 1. Family 5: II-1) has  a 
persistent thrombocytosis noted for 9 years with no 
mutation evident within JAK2 exons 13 and 14, CALR exon 
9 or the coding exons of MPL and THPO, including the 
intron–exon boundaries of both genes. One sibling (Fig. 1. 
Family 5: II-5) and two daughters (Fig. 1. Family 5: III-1 
and III-2) of the index case also have a mild thrombocytosis. 
Therefore demonstrable absence of clo- nality in this 
kindred suggests a HT phenotype as opposed to familial ET. 
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Family 5 Family 6 Family 7 Family 8 
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Discussion 
 
FMPN has been estimated to comprise between approxi- 
mately 1–7 % of all MPN [11] with the commonly observed 
JAK2 V617F mutation acquired as in sporadic cases. The 
recent identification of mutations within CALR in a signifi- 
cant number of patients with JAK2 V617F-negative, MPL 
exon 10 mutation-negative, sporadic ET and PMF [6, 7] 
prompted investigation into the mutational status of the 
these three sets of mutations (JAK2 V617F, CALR exon 9, 
and MPL W515L/K) in patients with FMPN. 
The affected individuals from the kindred described 
herein display considerable phenotypic heterogeneity with 
ET and PV the most prevalent phenotypes. This variety in 
presenting phenotypes is in keeping with previous reports 
[11, 12]. The incidence of the common JAK2 V617F, 
CALR exon 9 and MPL W515L/K mutations confirms the 
frequency noted in two recent reports. In a study of 10 
FMPN pedigrees, 68 % of affected patients with known 
mutational status for JAK2 were JAK2 V617F positive with 
two of six JAK2 wild type patients harbouring CALR exon 
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9 mutations [27]. A subsequent investigation of a larger 
FMPN cohort again found 94/127 (74 %) patients to carry 
JAK2 mutations with 12 of 75 (16 %) with ET and PMF 
[28]. No FMPN patients with ET or PMF within this study 
had evidence of the common MPL W515K/L mutations in 
keeping with that previously reported [27, 28]. Further- 
more, JAK2 and CALR exon 9 mutations are mutually 
exclusive in this cohort and appear to be acquired 
independently. 
Two of the three affected individuals from Family 1  had 
ET, with a further individual having JAK2 V617F- negative 
PV (Fig. 1. Family  1: I-2). As both JAK2 exon  12 and exon 
14 mutations were not detected in the index case (II-1), non-
JAK2 V617F germ-line variants [15, 29, 30] are most likely 
not a contributory factor the FMPN. The phenotype of PV 
in I-2 of Family 1 also argues  against a germ-line mutation 
in either THPO or MPL  genes as responsible for the FMPN 
as inherited mutations in these genes invariably result in a 
phenotype charac- terised by isolated thrombocytosis [14]. 
As evidenced in Family 5, absence of any mutations in JAK2 
exons 13 and 14, CALR exon 9, MPL or THPO, together 
with absence  of hematopoietic clonality suggests that these 
patients are likely to be cases of HT. 
Identification of FMPN is important for several reasons. 
There is evidence to suggest disease anticipation in FMPN 
i.e. an earlier age of onset in subsequent generations. A 
study of 35 FMPN pedigrees has shown a significantly 
younger age at diagnosis in second-generation patients [31]: 
a phenomenon apparent in other FMPN studies [27]. In 
addition to the inherent increased risk of MPN, the incidence 
of several non-hematological cancers also appears to be 
increased in FMPN with a differing spectrum of 
malignancies to that observed in patients with sporadic 
MPN [32]. This apparent increased frequency of secondary 
malignancies might possibly be due to an inherent under- 
lying genomic instability [33]. Nevertheless, it remains a 
possibility that members of the same family could be 
affected with an MPN either by chance or due to a common 
environmental factor [34]. 
While the JAK2 46/1 haplotype is a strong predisposi- 
tion factor for JAK2-mutated, sporadic MPN, what genetic 
variants predispose to FMPN are largely unknown. Iden- 
tification of these elusive variants may prove difficult due to 
the phenotypic and genotypic heterogeneity described 
herein. The inherited factors that predispose to the devel- 
opment of MPN are also likely to influence the clinical 
course [35]. Further genome sequencing and genome wide 
association studies are required to define these risk vari- 
ants. Finally, a thorough investigation of the family history 
at the initial diagnosis of MPN patients is therefore advo- 
cated with regard paid to suggestive MPN-related symp- 
toms in relatives. 
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CALR Mutations are Rare in Childhood Essential Thrombocythemia 
 
 
 
To the Editor: The incidence of childhood myeloproliferative 
neoplasms is significantly lower than that in adults. Also, the 
common JAK2 V617F mutation and other MPN-associated 
mutations are detected less frequently [1] inferring differences in 
both the etiology and molecular pathogenesis of these diseases in 
adults and children. Two recent reports have identified acquired 
insertion/deletion mutations of CALR, exclusively in exon 9, in 
approximately 70–80% of adult essential thrombocythemia (ET) 
and primary myelofibrosis (PMF) that do not possess JAK2 or MPL 
mutations by exome sequencing approaches. Furthermore they have 
demonstrated a previously unrecognized  molecular  complexity to 
these malignancies [2,3]. These two studies prompted the 
investigation of CALR mutations in pediatric MPN. 
The presence of CALR exon 9 mutations was retrospectively 
investigated using fluorescent PCR fragment analysis [2] in the 
blood or bone marrow DNA from a relatively small single-center 
cohort of unrelated, sporadic pediatric MPN classified according to 
established hematological, histo-morphological and molecular 
criteria [4]. This comprised of JAK2 V617F-negative ET (n 4), 
JAK2 V617F-positive ET (n 2) (Table I), JAK2 V617F-positive 
polycythemia vera (PV; n 1), JAK2 V617F-negative polycythe- mia 
(n 2), and reactive thrombocytosis (n 8). All MPN patients had no 
MPL W515L or W515K mutations. Two different mutations found 
in adult MPN acted as positive controls. CALR mutations were not 
detected in the four JAK2 V617F-negative ET patients. Also, no 
CALR mutations were detected in three JAK2 V617F- positive 
MPN patients or in the eight children with reactive thrombocytosis 
(Table I). 
While this brief study demonstrates absence of CALR exon 9 
mutations in JAK2 V617F-positive childhood MPN, no CALR exon 
9 mutations were found in the four JAK2 V617F-negative children 
with ET. If the molecular pathogenesis of pediatric and adult MPN 
was similar then one might expect to detect CALR mutations in a 
certain proportion of young JAK2- and MPL-negative ET patients. 
Whether CALR mutations are present and will have a role in the 
diagnosis and classification of childhood MPN requires verification 
in a larger cohort. This study serves to highlight another potential 
biological difference between childhood and adult MPN. 
 
Stephen E. Langabeer, PhD* 
Cancer Molecular Diagnostics 
St. James’s Hospital 
Dublin, Ireland 
 
Karl Haslam, MPhIL 
Cancer Molecular Diagnostics 
St. James’s Hospital 
Dublin, Ireland 
 
Corrina McMahon, MD 
Department of Haematology 
Our Lady’s Children’s Hospital Crumlin 
Dublin, Ireland 
 
 
 
REFERENCES 
 
1. Giona F, Teofili L, Moleti ML, et al. Thrombocythemia and polycythemia in patients younger than 
20 years at diagnosis: Clinical and biologic features, treatment, and long-term outcome. Blood 
2012;119:2219–2227. 
2. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative 
neoplasms. N Engl J Med 2013;369:2379–2390. 
3. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with 
nonmutated JAK2. N Engl J Med 2013;369:2391–2405. 
4. Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and 
lymphoid tissue. Lyon: International Agency for Research on Cancer; 2008. 
 
TABLE I. Features of the Six ET Patients 
Median platelet Platelet count 
9 
Case Diagnosis Age (years) count (×10 /l) 
9 
range (×10 /l) JAK2 V617F MPL W515L/K CALR exon 9 
1. ET 4 915 721–1,167 Positive ND ND 
2. ET 15 1,192 953–1,240 Positive ND ND 
3. ET 9 1,355 296–2,718 ND ND ND 
4. ET 9 879 343–3,054 ND ND ND 
5. ET 9 773 606–872 ND ND ND 
6. ET 11 613 413–1,233 ND ND ND 
ND, not detected. 
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Distinct Driver Mutation Profiles of Childhood and Adolescent Essential 
Thrombocythemia 
 
 
 
To the Editor: The incidence of the Philadelphia chromosome- 
negative myeloproliferative neoplasms (MPN), polycythemia vera 
(PV), essential thrombocythemia (ET) and primary myelofibrosis 
(PMF) is significantly lower in children than in adults with the most 
commonly acquired molecular drivers, JAK2 V617F and myelo- 
proliferative leukemia (MPL) exon 10 mutations, detected in fewer 
pediatric patients. Childhood MPN therefore appears to be more 
genetically na¨ ıve than adult MPN suggesting an alternative 
molecular pathogenesis in the majority of cases. Most studies 
investigating the presence and consequences of driver mutations in 
childhood MPN have included both younger children and 
adolescents up to 18–20 years of age [1]. 
Disease-initiating insertion and/or deletion mutations within 
exon nine of the CALR gene, that encodes the intracellular calcium 
binding protein calreticulin, have been described in up to 80% of 
adult ET and PMF patients without JAK2 or MPL mutations [2,3]. 
This revelatory discovery compels the incorporation of CALR 
mutational analysis into the molecular diagnostic algorithm for 
MPN. To date, two studies have investigated the incidence of CALR 
mutations in childhood ET: a small, single-centre study in which no 
CALR mutations were detected and a larger analysis of 34 patients 
diagnosed with ET when less than 20 years of age [4,5]. Inspection 
of the ages of presentation in the latter study reveals a conspicuous 
divergence between those adolescent ( 14 yrs; n 22) and  childhood 
( 11 yrs; n 12) ET patients [5]. The JAK2 V617F, CALR, MPL and 
triple negative mutation status of ET patients from these two studies 
may  be  combined  to  create  a  larger  cohort (n 40). Analysis of 
this combined cohort reveals that adolescent ET patients have a 
strikingly similar molecular profile to that 
 
the pathogenesis of adolescent and childhood ET, but raises further 
questions regarding the causes and treatment of pediatric ET. 
Whether adolescent ET patients should be considered the same as 
adults for treatment purposes is certainly debatable: the most 
pressing clinical issues in adult ETare thrombosis and myelofibrotic 
or leukemic transformation, yet the incidence of these events is 
much lower in childhood and adolescent ET, even with substantial 
follow up [1]. A pre-natal origin of the disease has been established 
in cases of JAK2 V617F-positive PVand ET [6,7]: demonstration of 
an in-utero acquisition of CALR mutations in those younger patients 
would provide further insights into disease initiation and natural 
history. It is clear that in the majority of young children with ET, 
disease initiating and driving mutations remain unknown. While 
whole exome sequencing has been successful indentifying CALR 
mutations and other mutational events in adult MPN, these 
approaches have yet to be applied to pediatric MPN patients. 
Identification of these elusive driver mutations could potentially 
uncover targets for therapeutic intervention. 
 
Stephen E. Langabeer, PhD* 
Karl Haslam, MPHIL 
Cancer Molecular Diagnostics 
St. James’s Hospital 
Dublin, Ireland 
 
Corrina McMahon, MD 
Department of Haematology 
Our Lady’s Children’s Hospital 
Crumlin, Dublin, Ireland 
 
Adult ET 
(n=311) 
Adolescent ET 
(n=23) 
Childhood ET 
(n=17) 
 
 
Triple negative Triple negative 
 
MPL 
 
 
 
Triple negative 
 
 
JAK2 V617F 
 
 
CALR CALR 
 
JAK2 V617F JAK2 V617F 
 
CALR 
 
Fig. 1. Distribution of the common driver mutations in adult, adolescent (≤14 to ≤20 yrs) and childhood (≤11 yrs) ET at time of diagnosis. 
 
observed in adults [2], whereas the majority of childhood    
(diagnosed at 11 yrs) ET patients are triple negative, that is, no 
JAK2 V617F, CALR or MPL driver mutations (Fig. 1). 
Acknowledging that the numbers of ET patients are compara- 
tively small, not only does this observation highlight differences in 
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A prenatal origin of childhood essential thrombocythaemia 
 
 
 
In children, the myeloproliferative neoplasms (MPN) polycy- 
thaemia vera (PV) and essential thrombocythaemia (ET) are 
estimated to have a prevalence of approximately 40- to 90- fold 
lower than that seen in adults with sporadic, paediatric  ET 
patients exhibiting a significantly lower prevalence of the JAK2 
V617F (Teofili et al, 2008). The incidence of the JAK2 V617F 
is known to increase with age, in both ET and PV, through  
adolescence,  into  adulthood  and  old  age  (Cario   et al, 2008; 
Randi et al, 2011), suggesting that an increasing degree of 
underlying genomic instability is partly responsible for the 
acquisition of this mutation. Furthermore, those chil- dren with 
ET harbouring this mutation also display a lower JAK2 V617F 
allele burden (Teofili et al, 2009). Although sev- eral clinical 
and biological similarities exist  between  adult and paediatric 
ET, these aforementioned observations suggest differences in 
the aetiology of this disease in childhood and implicate some 
alternative pathogenetic mechanism(s). 
Genetic  analysis  of  antenatal  blood  spots  (ABS; Guthrie 
cards) has demonstrated that clonotypic translocations, 
mutations and gene rearrangements associated with many 
subtypes of paediatric acute lymphoblastic leukaemia,  and to a 
lesser extent, paediatric acute myeloid leukaemia, are pres- ent 
at birth and have therefore been  generated  in  utero.  These 
backtracking studies have provided significant insights into the 
pathogenesis, natural history and aetiology of these 
leukaemias (Wiemels et al, 2009). We have previously 
described the somatically acquired, in utero origin of  the  JAK2 
V617F mutation in an infant with PV, thus providing some 
insight into the origins of childhood MPN (Kelly et al, 2008). 
Whether all genotypes and phenotypes of paediatric MPN, 
especially those seen in younger patients, have a pre- natal 
origin is unknown. To expand on this theme,  we  describe 
herein the prenatal origin of the JAK2 V617F in a child with 
ET. 
A four-and-a-half year-old female presented with persis- tent 
urinary tract infections associated with a thrombocytosis 
(platelet count 801–989 9 109/l). Antibiotic treatment ame- 
liorated the infections yet the thrombocytosis remained. Sig- 
nificant platelet anisocytosis and giant platelets  were  observed 
on the peripheral blood film. A bone marrow aspi- 
rate revealed a normocellular, particular marrow with evi- dence 
of trilineage haematopoiesis. All cell lines were represented to 
maturity with abundant megakaryocytes, some with 
dysmorphic features, such as hyperchromatic and naked nuclei. 
Megakaryocyte clustering was evident and there was no 
obvious reticulin fibrosis. The JAK2 V617F was detected  in the 
peripheral blood by qualitative polymerase chain reac- tion 
(PCR) (Baxter et al, 2005) and determined as 31·2% of total 
JAK2 alleles by quantitative PCR (qPCR; Larsen et al, 2007). 
Parental consent was sought and granted to access the 
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presence of the JAK2 V617F in this case of typical ET  allowed 
the retrospective demonstration of the  mutation  at the time of 
birth, indicating  a  prenatal  origin.  An explanation as to when 
this mutation arose remains elusive:   an early acquisition during 
fetal haematopoiesis is postulated as significant expansions of 
the JAK2 V617F clone must have 
Fig 1. Agarose gel electrophoresis of JAK2 V617F-specific, semi- 
nested polymerase chain reaction (PCR) products.  Lanes  1  &  14: 100 
bp ladder; Lanes 2–5: 1/103, 1/104, 1/105, 1/106 dilution controls; Lanes 
6, 9 & 12: semi-nested PCR negative controls; Lanes 7 & 8: PCR 
duplicates from ABS 1; Lane 10 & 11: PCR duplicates from  ABS 2; 
Lane 13: first round PCR negative control. 
 
 
archived antenatal blood spots. DNA extractions were per- 
formed from sections of two separate ABS taken from the 
patient 4 days post-natally (Wiemels et al, 2009). qPCR anal- 
ysis was unable to reliably detect the JAK2 V617F in these 
samples (Ct >40 cycles). A more sensitive but qualitative, semi-
nested allele-specific PCR was used to amplify both  wild type 
and mutant JAK2 alleles using a first round for- ward primer 
(Larsen et al, 2007) with a common reverse pri- mer (Baxter et 
al, 2005). A second round of PCR used a forward  JAK2  
V617F-specific  primer  (Baxter  et al,  2005). 
This semi-nested PCR had a limit of detection of mutant  alleles 
of approximately 1 9 10—5, determined by dilution of genomic 
DNA from a known heterozygous JAK2 V617F patient into 
DNA from a pool of 20 normal controls (Fig 1). This  approach  
was  able  to  demonstrate  the  presence  of the 
JAK2 V617F in PCR duplicate reactions  from  both  ABS  (Fig 
1). Both parents had normal full blood counts and had    no 
evidence of the JAK2 V617F. Furthermore, there was no clinical 
history of an MPN in either parent or their families, thus 
diminishing the likelihood of familial MPN. A younger female 
sibling was not investigated. We therefore conclude that in this 
case, the ET is non-familial and the JAK2 V617F was 
somatically acquired in utero. One year post-diagnosis, 
the  patients’  platelet  count  (841  9 109/l)  and  JAK2 V617F 
allele burden (26·1%) remain stable. The patient is closely 
monitored, shows no evidence of splenomegaly or throm- botic 
episodes, and has not received any MPN-specific treatment. 
Paediatric ET is a rare disease with most patients reported 
within single institution studies. Nevertheless, it is apparent that 
this disease in children, analogous to many other hae- 
matological malignancies, has certain clinical and molecular 
dissimilarities with the same disease observed in adults. The 
occurred both in utero and in the post-natal periods in tan-  dem 
with normal fetal and neonatal haematopoietic develop- ment. 
Other genetic or epigenetic events, be they acquired or 
inherited, may have contributed to the acquisition  of  the  JAK2 
V617F and its subsequent capacity to elicit the disease 
phenotype in early childhood in this case. 
Do other childhood MPNs have a similar prenatal origin? 
The next most commonly acquired mutations  in  adult  ET  are 
those of MPL exon 10, however to date, this mutation     has 
rarely been documented in paediatric ET (Farruggia et al, 2013). 
Other mutations, such as those in TET2, CBL, IDH1 and IDH2 
have not been detected in a limited study of child- hood MPN 
(Ismael et al, 2012). The identification of further markers of 
clonality is necessary to expand the limited molecular 
comprehension of childhood MPN and  improve  our 
understanding of the natural history of these diseases. 
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Normal prion protein is expressed on exosomes isolated from 
human plasma 
 
 
 
Four probable cases of blood products spreading variant 
Creutzfeldt-Jakob Disease (vCJD) have been reported, with two 
additional cases linked through possible receipt of blood 
products from a single donor (Chohan et al, 2010). In the UK, 
leucodepletion and donor-exclusion have been employed to 
minimize the risk of blood product-mediated transmission. 
However uncertainty regarding the sources and risks of vCJD 
transmission mean asymptomatic carriers may inadvertently 
cause transmission of vCJD through blood donation. 
The causative agent of vCJD is the abnormally  folded  form 
of the prion protein (PrPSc), and this protein is also known to 
cause other transmissible spongiform encephalopa- thies 
(TSEs). The prion protein normally exists in a native, cellular 
form (PrPC). The paucity of samples from vCJD- infected 
humans, plus difficulties in distinguishing PrPC and PrPSc, mean 
that the experimental focus of human in vivo studies has been 
on PrPC, while animals models and in vitro work has been able 
to explore both. Animal models have clearly shown that TSEs 
can be transmitted by blood transfu- sion (Houston et al, 2000; 
Hunter et al, 2002; Siso  et  al, 2006; McCutcheon et al, 2011). 
Exosomes are the smallest recognized subset of microvesi- 
cles, being under 100 nm in diameter, and are released  through 
the fusion of multivesicular bodies with the plasma membrane. 
They have a distinctive protein composition and can be detected  
in  human  plasma  (Caby  et  al,  2005;  Ren et al, 2011). Work 
by others has shown that both PrPC and PrPSc can be detected in 
association with exosomes generated in vitro by animal cell 
lines, and that such exosomes can spread TSEs (Fevrier et al, 
2004; Vella et al, 2007; Alais et al, 2008). These findings have 
highlighted exosomes as a poten- tial source of transmission for 
TSEs, but it is not known whether such concerns are valid for 
circulating exosomes in human blood. Here, we confirm that 
PrPC is indeed 
associated with exosomes isolated from human plasma. These 
findings are consistent with the potential for exosomes in human 
plasma to spread vCJD. 
Plasma units from healthy donors were obtained from 
National Health Service Blood and Transplant (NHSBT, 
Bristol, UK), mixed 1:1·5 with phosphate-buffered saline, and 
vesicles isolated following the technique of Caby et al (2005). 
Electron microscopy revealed a heterogeneous population of 
membrane-bound vesicles ranging in size from 30 to 250 nm, 
with the majority of vesicles in  the  50  to  100  nm  range  (Fig 
1A), demonstrating that vesicles that have the morpho- logical 
characteristics of exosomes make up the bulk of the vesicle 
preparation. Western blotting revealed the presence of the 
exosome-associated tetraspanins CD9 and CD63; the 
endoplasmic reticulum marker calnexin was absent (Fig 1B). 
Flow cytometric analysis of exosomes bound to anti-CD63 
coated beads confirmed that the isolated vesicles expressed  the 
typical surface-marker profile of exosomes: they strongly 
expressed the exosome-associated tetraspanin molecules CD9, 
CD63, and CD81, as well as HLAI (Fig 1C). To explore the 
cellular source/s of these exosomes, markers previously asso- 
ciated with exosomes from various cell types were analysed. 
There was no detectable staining for human leucocyte anti- gen 
(HLA) Class II (antigen presenting cells), CD3 (T cells), CD11c 
(myeloid dendritic cells), CD20 (B cells), or CD86 (dendritic 
cells and B cells), while there was strong staining for CD41a 
(platelets and megakaryocytes) (Fig 1C). This sug- gests that the 
majority of exosomes isolated were derived  from platelets 
and/or their precursors. This finding is consis- tent with the only 
previously published report on CD41a and human plasma 
exosomes (Caby et al, 2005), although the absence of HLA 
Class II on human plasma exosomes was contrary to the 
findings of two previous studies (Caby et al, 2005; Ren et al, 
2011). It remains possible that other cell 
678 ª 2013 John Wiley & Sons Ltd 
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Letter to the Editor 
Capricious CALR Thutated clones in 
Thyeloproliferative neoplasThs 
 
 
To the Editor. 
 
Insertion and/or deletion mutations of CALR, the gene that encodes 
the endoplasmic reticulum-associated, calcium binding protein 
calreticulin, are the second most common driver mutations observed  in the 
myeloproliferative neoplasms (MPN) of essential thrombocythemia (ET) 
and primary myelofibrosis (PMF). Identification of CALR mutations, along 
with the JAK2 V617F and MPL exon 10 mutations, is likely to be a major 
diagnostic criterion for these two entities in the forthcoming revi- sion of 
the World Health Organization classification of haematopoietic 
malignancies [1]. CALR mutations are usually heterozygous with a single 
mutated clone present in most ET and PMF patients. In a recently pub- 
lished large cohort of CALR mutated patients (n = 685), it was shown 
that ten (1.5%) possessed complex CALR mutations of which four patients 
had multiple clones [2]. Furthermore, in a recent Blood Cells, Molecules 
and Diseases report, Shuly et al. describe a stable CALR mutant allele bur- 
den in ET patients over time: the mean length of time between first and 
second assessments was 3.7 years, however, despite revealing a modest, 
mean increase in CALR mutant allele burden of 5.7% over this period, 
there existed a considerable inter-patient heterogeneity [3]. 
In order to explore the implications of these findings, we exam- 
ined CALR mutation patterns in an independent cohort of CALR mu- 
tated ET and PMF patients. Retrospective screening of JAK2 V617F 
negative ET and PMF patients was performed by fragment length 
analysis with a validated detection sensitivity of 1% mutant allele 
burden as previously described [4]. Of 55 CALR mutated patients 
34 (61.8%) had a type 1 (52-bp deletion) mutation, 15 (27.3%) 
had a type 2 (5-bp insertion) mutation, four (7.3%) had a type 1- 
like mutation and one (1.8%) had a type 2-like mutation. One 
(1.8%) further ET patient who presented in July 2005 harboured 
both a type 1 (14.4% allele burden) and a 13-bp deletion (28.1% al- 
lele burden) in their diagnostic peripheral blood (Fig. 1). Repeat 
analysis of peripheral blood more than ten years post presentation 
and after seven years of hydroxyurea therapy revealed fluctuation 
in the level of the two different clones with type 1 mutation and 
13-bp deletion mutation allele burdens of 29.3% and 10.6% respec- 
tively (Fig. 1). 
Firstly, we confirm the presence of multiple CALR mutated clones 
in MPN patients at a frequency similar to that initially reported [2]. 
The presence of multiple clones in a minority of patients therefore 
has implications for selection of molecular diagnostic methodology. 
Sanger sequencing, fragment length analysis, high resolution melt 
curve analysis, quantitative PCR, digital PCR and next-generation se- 
quencing can all be used for CALR mutation detection in the diagnos- 
tic and residual disease monitoring settings, with each approach 
possessing advantages and disadvantages in regard to sensitivity, 
ease of use, availability and cost [5–7]. Those methods unable to 
 
 
primarily distinguish multiple clones and lacking sufficient sensitiv- 
ity, as most minor clones appear to be present at low levels [2], would 
clearly be disadvantageous for diagnostic purposes. 
 
 
Fig. 1. CALR mutation profile of patient with essential thrombocythemia at diagnosis 
(upper panel) and ten years later (lower panel). 
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Secondly, initial reports suggest that unlike interferon alpha, hy- 
droxyurea therapy has no significant impact on the mutant CALR allele 
burden [8] implying that the phenomenon described represents an au- 
thentic variation in the clonal architecture of this patient. Given the ac- 
knowledged moderate variability in mutated CALR allele burden also 
observed by Shuly et al. [3], caution must therefore be advised when 
interpreting residual disease responses. Further studies are warranted 
in larger cohorts comparing ET and PMF patients with similar diagnostic 
characteristics and similar treatment modalities to identify any biologi- 
cal effects of CALR mutant clonal diversity over time. 
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The mutant CALR allele burden in essential thrombocythemia at transformation to acute myeloid leukemia 
 
To the Editor. 
Transformation to acute myeloid leukemia (AML) occurs in approximately 5% of patients with the myeloproliferative neoplasm (MPN) of 
essential thrombocythemia (ET). Risk factors for leukemic transformation include advancing age, degree of anemia, platelet count, the presence of 
two or more somatic mutations, and prior treatment with either radioactive phosphorus or alkylating agents. Also, AML following ET is often 
associated with an unfavorable karyotype and a poor prognosis [1]. Advances in understanding the underlying pathogenesis of MPN have led to the 
demonstration of molecularly annotated, clonally divergent routes to leukemic transformation in patients with MPN. In the majority of JAK2 V617F- 
positive MPN patients who undergo transformation, this mutation is also present in the AML cell population. However, the phenomenon of JAK2 
V617F-negative AML following a JAK2 V617F-positive MPN implies the transformation of a myeloid progenitor at a stage before acquisition of the 
JAK2 V617F or in a clone distinct from that harboring the JAK2 V617F [2,3]. In those few CALR mutation-positive patients studied to date, this 
phenomenon has not been described [4,5]. Evidence for this latter course of disease evolution is outlined below in a patient in whom ET transformed 
to AML. 
A 51 year-old male with a history of peptic ulcer disease and hiatus hernia presented in February 2003 with a hemoglobin of 14.8 g/dL, a white 
cell count of 6.2 × 109/L and a platelet count of 1160 × 109/L. Bone marrow aspirate and biopsy showed increased, morphologically atypical 
megakaryocytes with clustering and minor evidence of reticulin fibrosis in keeping with a diagnosis of ET. The patient commenced on hydroxyurea 
and aspirin. The JAK2 V617F was not detected in peripheral blood in October 2009. By March 2017, the patient had developed anemia (hemoglobin 
8.9 g/dL) with red cell anisocytosis and occasional myeloblasts noted on the peripheral blood film. Bone marrow biopsy showed an infiltration of 
myeloblasts that were CD34 positive by immunohistochemistry accounting for approximately 25% of nucleated cells with no increase in reticulin 
fibrosis. Bone marrow aspirate immunophenotyping revealed the myeloblasts were positive for MPO, HLA DR, CD13, CD33, CD34, CD64 and CD117 
consistent with AML. The patient had a complex karyotype with aberrations involving chromosomes 5q, 7q, 8p, 12p, and 14q. Given the previous 
absence of the JAK2 V617F mutation, CALR exon nine mutation analysis was performed by fragment length analysis with a validated detection 
sensitivity of 1% mutant allele burden as previously described [6]. In the bone marrow at the time of leukemic transformation, this approach detected 
a CALR type 1, 52 bp deletion mutation at a low allele burden of 5.7%. Analysis of the archived October 2009 peripheral blood sample demonstrated 
the CALR mutation allele burden to be 49.7% at that time, approximating heterozygosity (Fig. 1). The patient received one cycle of daunorubicin and 
cytarabine 3 + 10 chemotherapy but did not achieve morphological remission with bone marrow myeloblasts representing 15% of nucleated cells 
and repeat bone marrow CALR analysis demonstrating an unchanged mutant allele burden of 5.6% (Fig. 1). 
Mutations in JAK2, CALR and MPL are recognised as driver mutations of MPN yet the timing and order of acquisition of both these driver and 
additional disease modifying mutations, and in which clone these mutations prevail, is becoming more pertinent to understanding mechanisms of 
disease progression [4,5]. Given that the mutant CALR allele burden generally increases over time [7] and is largely unaffected by hydroxyurea 
therapy [8], the significant reduction correlating with disease progression noted in the patient described herein likely represents a true reflection of 
the underlying disease evolution. This finding signifies that the AML clone is not derived from the CALR mutation-bearing MPN clone but from either 
a myeloid progenitor prior to acquisition of the CALR mutation or in a clone distinct from that with the CALR mutation similar to that previously 
encountered in transformation of JAK2 V617F-positive MPN. This hitherto unreported phenomenon in a CALR mutated case of ET provides further 
insights into the pathogenetic mechanisms of leukemic transformation and emphasizes the underlying clonal heterogeneity in ET and MPN patients. 
This observation requires confirmation in other CALR mutant ET patients transformed to AML. 
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Fig. 1. CALR mutation fragment length analysis of a patient with essential thrombocythemia at diagnosis (upper panel), leukemic transformation (center panel), and post-chemotherapy (lower panel). 
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Transient JAK2 V617F mutation in an aplastic anaemia patient 
with a paroxysmal nocturnal haemoglobinuria clone 
 
 
 
 
In 1969, William Dameshek proposed that paroxysmal 
nocturnal haemoglobinuria (PNH) should be considered a 
candidate myeloproliferative neoplasm (MPN) based on the 
evidence of red blood cell abnormalities in the context  of bone 
marrow pancytopenia, low leucocyte alkaline phospha- tase and 
the potential for leukaemic transformation (Dame- shek, 1969). 
Further similarities between MPN and PNH include expansion 
of subsequent or simultaneous myeloid clones and an increased 
frequency of abdominal vein throm- bosis. PNH is an acquired, 
stem cell disorder associated with mutations of the PIGA gene 
that encodes a protein required  for the synthesis of 
glycosylphosphatidyl-inositol anchored proteins (GPI-AP). 
PNH blood cells are therefore deficient in cell surface proteins 
that use the GPI anchor and may be detected 
immunophenotypically by absent or reduced expres- sion of 
CD55 and CD59 on red blood  cells  (RBC)  and  CD16, CD24, 
CD66b and FLAER (fluorescence labelled aer- olysin) on 
granulocytes. PNH clones are also present in a sig- nificant 
number of patients with the related marrow failure syndromes 
aplastic anaemia (AA) and hypoplastic myelodys- plastic 
syndrome (MDS). Although PNH originates from a multipotent 
haematopoietic stem cell, PIGA mutations are insufficient to 
drive clonal expansion and several  models  have attempted to 
explain this phenomenon: GPI-AP may be immunogenic and 
their deficiency enables evasion from immunological 
surveillance or the possibility that PIGA mutations themselves 
confer an intrinsic resistance to apop- tosis (Brodsky, 2008). 
Another theory postulates the acquisi- tion of a second genetic 
event that enables clonal expansion   in co-operation with the 
PIGA mutation, some evidence for which comes from the 
deregulated expression of HMGA2 in    a minority of PNH 
patients (Inoue et al, 2006). 
A  recent  report  identified  the  JAK2  V617F  mutation  in 
GPI-AP deficient cells of three PNH patients and suggested this 
coexistence could  explain  clonal  expansion  (Sugimori  et al, 
2012). These findings prompted investigation into the 
frequency of the JAK2 V617F in other patients harbouring a 
PNH clone. Archival DNA samples from blood (n = 3) and bone 
marrow aspirate smears (n = 19) from 22  patients  (PNH, n = 
5; AA, n = 13; hypoplastic MDS, n = 4) with an 
immunophenotypically detectable PNH clone of both RBC and 
granulocytes were retrospectively analysed for JAK2 V617F by 
qualitative allele-specific polymerase chain reaction (PCR) 
(Baxter et al, 2005) with a sensitivity of 2% mutant alleles. The 
JAK2 V617F mutation was detected in one patient with AA. 
This female patient, who presented with severe AA 
and no evidence of a PNH clone (nor retrospectively  the  JAK2 
V617F), was initially successfully treated with two courses of 
antithymocyte globulin (ATG) and cyclosporin.  She relapsed 
in pregnancy 2 years later and was treated with 
immunoglobulin, and RBC and platelet transfusions. Post 
partum treatment included G-CSF, ATG (2 courses) and 
ciclosporin, the latter being discontinued after achieving RBC 
and platelet transfusion independence. Ten years after the initial 
presentation, progressive pancytopenia suggested relapse of AA 
with a PNH clone detected within the granulocytes (17·7%) and 
RBCs (5·4%). At this relapse, the JAK2 V617F was detected in 
the bone marrow and confirmed by quantita- tive PCR (qPCR; 
Larsen et al, 2007) at a reproducible level of 1·8% of total JAK2 
alleles (Fig 1). Ciclosporin was recom- menced with a good 
response attained. 3 years post-relapse, the PNH clone remained 
stable in granulocytes (18·9%) and RBCs (6·0%) with the JAK2 
V617F not detected in the bone marrow by both allele-specific 
and qPCR. At no point during the clinical course did the patient 
have a persistent leucocyto- sis, erythrocytosis or 
thrombocytosis. The patient was subse- quently diagnosed with 
malignant melanoma to which she succumbed. Diagnostic or 
pre-allogeneic haematopoietic stem cell transplantation samples 
from a further 38 AA patients without evidence of PNH were 
screened for the JAK2 V617F, none of which were found to 
harbour this mutation. 
We describe the hitherto unreported detection of the JAK2 
V617F in a PNH-related bone marrow failure syndrome at a 
similarly low frequency to that previously described in classi- 
cal PNH (Fouassier et al, 2009; Sugimori et al, 2012). As this 
case was identified retrospectively, existence of the JAK2 
V617F in the PNH clone could not be verified by fluores- cence-
activated cell-sorting of the GPI-AP-negative popula- tion 
(Sugimori et al, 2012). However, the transient nature of the 
JAK2 mutation in the presence of a relatively stable PNH clone, 
taken together with the evidence of different JAK2 V617F and 
PNH clone sizes implies two distinct populations as opposed to 
the co-existence of  mutations  within  one  clone. The 
phenomenon of transient JAK2 V617F-positivity may be 
explained by the acquisition of the mutation  in  a  more 
differentiated haematopoietic progenitor than that in patients 
with MPN. If this progenitor had reduced self-  renewal 
potential and capacity for differentiation then the clone 
generated might therefore be short-lived and  not result in a 
clinical phenotype (Passamonti et al, 2007). 
Characterization  of  the  role  of  JAK2  signalling  in  PNH 
and  PNH-related  disorders  may  provide  some  insight  into 
ª 2013 Blackwell Publishing Ltd 297 
Correspondence 
 
(A) 10 
 
1 
 
 
0·1 
(B) 
 
10 
 
 
1 
 
0·1
 0·1  
 
 
0·01 
 
 
0·001 
0·01 
 
 
0·001 
 
 
JAK2        JAK2 JAK2 
wild type     V617F         V617F 
patient non-specific 
 
0·0001 
 
10 20 30 40 50 
0·0001 
 
10 20 30 40 50 
Cycle Cycle 
 
Fig 1.  Quantitative polymerase chain reaction (qPCR) standard curves were derived from diluted commercial plasmids (MutaQuante;  Ipsogen     SA, 
Marseille, France) ranging from 25 000 to 25 copies of JAK2 V617F (A). The assay was composed of two allele-specific PCR reactions in duplicate: 
one for the JAK2 V617F and one for the wild type allele. As the reverse primers used in both reactions differed by only one base at the 30 end, non-
specific amplification is observed in the JAK2 V617F assay when performed on target negative controls. The specificity and sensitivity was calculated 
using the DCt value for the target negative control (number of cycles between wild type and JAK2 V617F Ct values) where the specificity corresponds 
to 2DCt . The assay sensitivity (0·02%) was set at ten-fold less than this value to ensure the identification of true positive measurements (B). 
 
disease development, maintenance or progression. The detec- 
tion of the JAK2 V617F and other molecular lesions that 
contribute to clonal expansion, such as deregulation of HMGA2 
expression, evident in PNH (Inoue et al, 2006) and both typical 
MPN and atypical myeloid malignancies (Odero et al, 2005; 
Bruchova et al, 2008) suggests some common pathogenetic 
mechanisms of PNH and MPN that warrant further 
investigation. 
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Considerations and Recommendations 
for a New Molecular Diagnostic Algorithm 
for the Myeloproliferative Neoplasms 
 
Karl Haslam and Stephen E. Langabeer 
 
 
 
The classical Philadelphia chromosome-negative myeloproliferative neoplasms consist of three main pathological 
and clinical entities with the recurrent JAK2 V617F mutation present in *98% of patients with polycythemia vera 
and *50% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF). The recent discovery 
of mutations within the CALR gene in up to 80% of JAK2 V617F-negative ET and PMF patients compels em- 
ployment of CALR mutational analysis for the molecular diagnosis of these diseases. Evidence derived from a 
retrospective audit of JAK2 V617F testing provides a framework for the proposal of a diagnostic algorithm that 
incorporates CALR mutation assessment. It is recommended that relevant clinical details, including a provisional 
morphological and clinical diagnosis, are provided and that exclusion of alternative causes of erythrocytosis, leu- 
cocytosis, or thrombocytosis is required before molecular testing. It should be acknowledged that over-requesting 
such investigations can impact on the clinical predictive value of these tests when considering the disease specificity 
of such mutations, with adherence to the diagnostic algorithm necessary to ensure appropriate use of resources. 
 
 
 
Introduction 
 
he myeloproliferative neoplasms (MPN) are clonal 
hematopoietic stem cell-derived diseases characterized 
by bone marrow proliferation of one or more of the myeloid 
cell lineages, with the main subtypes of MPN being poly- 
cythemia vera (PV), essential thrombocythemia (ET), and 
primary myelofibrosis (PMF). The diagnosis and classification 
of these diseases are dependent on clinical, hematological, 
histomorphological, and molecular genetic findings (Swerdlow 
et al., 2008). 
The most commonly acquired mutation associated with 
MPN is the JAK2 V617F, occurring in 98% of PV cases and 
in approximately half of ET and PMF patients (Gong et al., 
2013). This mutation disrupts the function of the intracellular 
JAK2 molecule that is required for normal hematopoietic 
cytokine signaling and has become a target for therapeutic 
intervention (Ga¨bler et al., 2013). Alternative  mutations of 
JAK2 within exon 12 can be detected in the majority of those 
remaining V617F-negative PV patients (Scott et al., 2007). 
Several other genetic abnormalities have been described in 
MPN, which occur at a much lower frequency than the JAK2 
V617F. Mutations in MPL exon 10, which encodes the re- 
ceptor for thrombopoietin, a major regulator of megakaryo- 
cyte and platelet development, are present in *5% and 3% of 
PMF and ET patients, respectively (Pardanani et al., 2006). 
Recent whole-exome sequencing studies of MPN patients 
 
have led to the discovery of insertion and/or deletion muta- 
tions in exon 9 of CALR, a gene that encodes the endoplasmic 
reticulum-associated calcium-binding protein, calreticulin. 
These disease-driving mutations of CALR result in a frame- 
shift of the coding sequence, altered amino acid composition 
of the translated protein, and loss of the endoplasmic retic- 
ulum retention motif. CALR mutations do not occur in PV 
patients, but are present in up to 80% of ET and PMF patients 
who are JAK2 V617F and MPL mutation negative (Klampfl 
et al., 2013; Nangalia et al., 2013). In rare instances of MPN, 
CALR and MPL mutations may coexist with the JAK2 V617F 
(Lasho et al., 2006; Lundberg et al., 2014; McGaffin et al., 
2014; Tefferi et al., 2014). Other mutational events that result in 
disruption of myeloid cell differentiation and proliferation have 
been described in MPN but are usually associated with rare 
phenotypes or leukemic transformation and are also observed 
in other myeloid malignancies, thus limiting their diagnostic 
relevance (Tefferi, 2010). Despite these recent advances, bone 
marrow aspirate and biopsy remain essential for the assess- 
ment of megakaryocyte morphology and degree of reticulin 
fibrosis required to differentiate ET from early PMF (Tefferi 
and Vardiman, 2008; Qureshi and Harrison, 2013). 
Not only is the detection of BCR-ABL1 transcripts neces- 
sary for the diagnosis of chronic myeloid leukemia (CML) 
but also the exclusion of this rearrangement was, before the 
description of CALR mutations, a diagnostic criterion for 
many other MPN such as PMF, ET, chronic myelomonocytic 
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leukemia, and chronic neutrophilic leukemia that may pres- 
ent with a leucocytosis and/or thrombocytosis (Swerdlow et 
al., 2008). As CML also can rarely present as an isolated 
thrombocytosis, the identification of BCR-ABL1 transcripts 
can also be incorporated into the diagnostic algorithm for 
such cases (Harrison et al., 2013). Bone marrow examination 
is also necessary for staging CML at diagnosis; increased 
myeloblast numbers, extra copies of the Philadelphia chro- 
mosome, or other additional cytogenetic abnormalities are all 
indicators of advanced disease, which require a more inten- 
sive treatment approach (Vardiman, 2009). 
Given the high frequency and specificity of CALR muta- 
tions in ET and PMF, there is an urgent need to incorporate 
identification of these mutations into the diagnostic algorithm 
of patients with suspected MPN to facilitate the increasing 
demand for confirmatory molecular diagnostics (Tefferi and 
Pardanani, 2014). Previous efforts to streamline this pro- 
cess, in which BCR-ABL1 testing was advocated as a first- 
or second-line investigation (Schnittger et al., 2012; Bench 
et al., 2013), require revisiting in light of the description of 
CALR mutations to avoid en masse screening deemed sci- 
entifically irrational and economically irresponsible in this 
clinical scenario (Tefferi et al., 2011). 
 
Materials and Methods 
To provide a comprehensive MPN molecular diagnostic 
service and to manage future demand for such a service, a 
review of the quality of clinical information provided and the 
appropriateness of JAK2 V617F tests requested at a 
molecular diagnostic facility for testing of hematological 
malignancies over a 12-month period was performed. This 
information, together with results from previous audits and 
incorporating current knowledge of the molecular landscape 
of MPN, was used to develop recommendations that could 
support a new MPN diagnostic algorithm, which incorpo- 
rates CALR mutation analysis. 
Results and Recommendations 
A total of 1228 requests received for JAK2 V617F testing 
during a 12-month period were assigned to the following nine 
categories based on clinical details provided: No clinical details 
provided (n = 525), PV/?PV (n = 321), ET/?ET (n = 266), PMF/ 
?PMF (n = 18), thrombosis (n = 57), splenomegaly (n = 17), 
neutrophilia/eosinophilia (n = 40), other myeloid malignancies 
(n = 24), and miscellaneous (n = 20) (Fig. 1). Overall, two 
hundred five patients (15.9%) had evidence of the JAK2 V617F. 
Of immediate note was the significant proportion (40.8%) of 
referrals received with no clinical details provided. The capacity 
of a laboratory to provide a rational MPN molecular diagnostic 
service is reliant upon sufficient clinical detail to best triage 
sample referrals and assign appropriate testing. 
Recommendation 1: Provide sufficient relevant clinical 
details, including provisional diagnosis, to enable application 
of the testing algorithm. 
The incidence of JAK2 V617F-positive patient samples 
across all categories varied from 0% to 27% (median across 
all nine categories 16.7%) with a notably low prevalence in 
those patients with suspected PV (10.3%). While investiga- 
tion of the JAK2 V617F in patients presenting with persistent 
erythrocytosis or persistent thrombocytosis is necessary, a 
tendency to prematurely refer samples for up-front testing of 
both the JAK2 V617F and BCR-ABL1 rearrangement has 
been previously described (Langabeer, 2012; McCarron and 
Langabeer, 2014). These audits have demonstrated consis- 
tently increasing requesting patterns, despite the number of 
newly diagnosed JAK2 V617F-positive MPN and CML pa- 
tients remaining constant. Awareness of service availability 
might explain this phenomenon, yet the rising request rate 
most likely represents an increasing use of JAK2 V617F and 
BCR-ABL1 testing as an inappropriate advance exclusionary 
test in the initial work up of patients for whom secondary 
causes have not been fully ruled out. For example, according 
to guidelines, diagnosis of ET requires documentation of a 
 
 
 
 
 
 
 
 
 
 
 
FIG. 1. Indications for 
JAK2 V617F analysis. 
Black: JAK2 V617F de- 
tected; gray: JAK2 V617F 
not detected. 
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FIG. 2. Proposed molecu- 
lar diagnostic algorithm for 
suspected MPN. PV, poly- 
cythemia vera; CML, chronic 
myeloid leukemia; ET, es- 
sential thrombocythemia; 
PMF, primary myelofibrosis; 
BM, bone marrow. 
 
 
 
 
 
 
 
 
 
 
sustained, as opposed to a transient, thrombocytosis with 
exclusion of all other possible causes (Swerdlow et al., 2008; 
Harrison et al., 2010). 
Recommendation 2: Ensure alternative causes of MPN- 
like hematological indices are excluded before testing. 
The benefit of clinical information acquired from testing in 
these scenarios must be weighed against the potential negative 
impact of inappropriate requests upon the clinical predictive 
value of the test, which itself is directly influenced by the 
prevalence of the disease in the population tested. The sen- 
sitivity of the JAK2 V617F screening assay employed (Baxter 
et al., 2005) or its capacity to correctly identify those patients 
with disease is 99%, that is, 1% of patients will remain un- 
detected (false negatives). This is due to the limit of detection 
of the assay (1% JAK2 V617F allele burden), below which 
positive patients will evade detection by this method. The 
clinical relevance of such low allele burdens remains con- 
troversial (Lippert et al., 2014). The specificity of the test or 
its ability to correctly identify patients without disease is 
> 99%, that is, < 1% of patients without disease will test 
positive (false positive) by this method. Calculation of the 
positive predictive value (PPV) or proportion of patients with 
a positive test result who have the disease, and the negative 
predictive value (NPV) or proportion of patients with a neg- 
ative test result who do not have the disease, can help define 
this impact (O’Brien et al., 2014). The positive and negative 
predictive values are calculated using the formulae below. 
 
PPV: (sensitivity)(prevalence)/(sensitivity)(prevalence) + (1 - 
specificity)(1 - prevalence) 
NPV: (specificity)(1 - prevalence)/(specificity)(1 - 
prevalence) + (1 - sensitivity)(prevalence) 
Given the frequency of 15.9% JAK2 V617F-positive sam- 
ples in the audited population, the PPV and NPV predictive 
values are 0.949 and 0.998, respectively. In the population 
audited, this translates into the potential for *10 false-positive 
and 2 false-negative results per annum. Recognizing the im- 
pact of inappropriate referrals and adherence to best practice 
guidelines when investigating cases of suspected MPN will 
directly increase the prevalence of JAK2 V617F in the tested 
population by reducing the number of inappropriate samples 
received, improving the PPV, and reducing false-positive 
results issued; a prevalence of 50% would result in a predicted 
two false-positive results per annum. 
Recommendation 3: Acknowledge the effect of inappro- 
priate referrals on the predictive value of the testing algo- 
rithm. 
In only those cases of suspected ET and PMF that are JAK2 
V617F negative, next-step reflexive testing for CALR muta- 
tions is now advocated (Tefferi and Pardanani, 2014), re- 
inforcing the inclusion of appropriate clinical details. This 
would minimize the compounding effect on the clinical sen- 
sitivity of test results, and also ensure appropriate allocation of 
testing laboratory resources. It must also be noted that a sig- 
nificant center-to-center variation exists in JAK2 V617F re- 
questing criteria (Langabeer, 2012). To support the correct 
allocation of resources in this scenario, a rational testing al- 
gorithm for the JAK2 V617F, CALR, and BCR-ABL1 re- 
arrangements is proposed (Fig. 2). Adoption of this algorithm 
has the capacity to streamline testing for those patients who 
truly warrant investigation and to minimize turnaround times, 
thus enabling prompt clinical decision-making. 
Recommendation 4: Adopt and adhere to the MPN mo- 
lecular diagnostic algorithm. 
 
Discussion 
The underlying molecular landscape of the MPNs is con- 
tinually evolving. Currently, mutations found within just two 
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genes, JAK2 and CALR, are diagnostically relevant in up to 
80% of the three most common subtypes of MPN (Cazzola 
and Kralovics, 2014). However, which patients with sus- 
pected MPN should be tested when for these abnormalities 
remains debatable. It has been previously shown that con- 
siderable center-to-center variation already exists within re- 
questing patterns for the JAK2 V617F (Langabeer, 2012) 
with variation also likely from the requesting clinician to 
requesting clinician dependent on the presenting medical 
scenario (Xavier et al., 2011). Addition of further genetic 
markers such as CALR exon 9 mutations into the diagnostic 
algorithm requires considered implementation so as to match 
the optimum number of patients who would benefit from this 
testing with the ability to provide such a service within the 
existing laboratory resources. Clearly, given the current 
knowledge of the frequencies and specificities of those di- 
agnostically relevant MPN-associated mutations, reflexive 
testing for CALR mutations in those 1083 JAK2 V617F- 
negative patients analyzed in a single year audited above 
would be irrational from a scientific and economical per- 
spective. Adherence to recommendations and guidelines for 
both the diagnosis and treatment of the common MPN is 
essential; reports from real-life practice have shown that 
implementation of such guidelines is suboptimal with the 
lack of adoption of molecular diagnostic strategies capable of 
impacting on subsequent therapeutic interventions (Peterson 
et al., 2011; Roda et al., 2014). 
It is likely that in the near future, emerging technologies 
such as next-generation sequencing, capable of detecting 
numerous mutations in multiple genes simultaneously, al- 
ready demonstrated to have diagnostic and prognostic values 
in other myeloid malignancies with multigenic pathologies 
such as acute myeloid leukemia and myelodysplastic syn- 
dromes (White and DiPersio, 2014), will demonstrate suffi- 
cient flexibility to address this evolving diagnostic issue. 
It is acknowledged that guidelines such as those outlined 
above require a degree of flexibility in implementation as a 
significant heterogeneity exists within the molecular, mor- 
phological, and clinical features of MPN patients. Debate on 
implementation of these recommendations is welcomed that 
would intentionally reinforce the value of interaction between 
the clinic and laboratory, ultimately ensuring improved pa- 
tient diagnoses and outcomes. 
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inclusive) and for the previous eight years since introduction of JAK2 
V617F testing (in order to capture those tests performed on archived 
material: 2006–2013 inclusive). In addition to testing frequency, the 
   clinical comments provided on each request form were collated. Muta- 
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The myeloproliferative neoplasms (MPN) are clonal, hematopoietic 
stem cell-derived diseases characterised by bone marrow proliferation 
of one or more of the myeloid cell lineages with the main subtypes being 
polycythemia vera (PV), essential thrombocythemia (ET), and primary 
myelofibrosis (PMF). The diagnosis and classification of these diseases 
is dependent on clinical, hematological, histo-morphological and 
molecular genetic findings. The most commonly acquired mutation 
associated with MPN is the JAK2 V617F, occurring in approximately 95% 
of PV cases and in 50–60% of ET and PMF patients. Further mutations in 
MPL exon 10 are present in approximately 5% and 3% of PMF and ET pa- 
tients respectively. In 2013, whole exome sequencing studies reported 
insertion and/or deletion (indel) mutations in exon 9 of CALR, the gene 
that encodes the endoplasmic reticulum-associated, calcium bind- ing 
protein, calreticulin. These MPN disease driving mutations of CALR 
result in a frame shift of the coding sequence, altered amino acid com- 
position of the translated protein and loss of the endoplasmic reticulum 
retention motif. CALR mutations appear not to occur in PV patients but 
are present in up to 80% of ET and PMF patients who are JAK2 V617F- 
and MPL-mutation negative [1]. Analysis of CALR mutations has rapidly 
been adopted into MPN molecular diagnostic algorithms with identifi- 
cation now a major diagnostic criterion for ET and PMF [2]. In addition 
to their diagnostic value, CALR mutations are associated with a higher 
platelet count, a reduced hemoglobin level and a reduced risk of throm- 
bosis when compared to their JAK2 V617F-positive counterparts with 
patients responding to therapies such as interferon and JAK 1/2 inhibi- 
tors. While numerous studies have addressed the technical aspects of 
CALR mutation identification and mutant allele burden estimation and 
despite guidelines clearly indicating analysis for the diagnosis of ET and 
PMF, limited information exists on the criteria for requesting mo- 
lecular testing of CALR mutations and the reproducibility of application of 
these criteria in a real world situation. Given the previously noted re- 
ferral centre variation in JAK2 V617F requesting patterns in the Republic 
of Ireland [3], an audit was performed on the CALR mutation requests in 
order to determine if requests were being made on appropriate patients 
and to refine the currently adopted molecular diagnostic algorithm for 
MPN. 
A retrospective audit was performed of CALR mutations requests re- 
ceived at a hematological malignancy molecular diagnostic laboratory 
for the three calendar years since introduction of testing (2014–2016 
tion analysis was performed by fluorescent PCR followed by fragment 
length analysis allowing detection of all CALR exon 9 insertion and/or 
deletion mutations with a sensitivity of detection of 1% mutant allele 
burden and was unchanged throughout the audit period. 
From January 1st, 2014 until December 31st, 2016 inclusive, 1244 re- 
quests were received for CALR mutation analysis of which 632 (50.8%) 
were retrospective and 612 (49.2%) were prospective. A total of 73 pa- 
tients (5.9%) were found to harbour CALR exon 9 indel mutations with 
the highest number of requests received during 2016 (n = 398). The 
detection rate of CALR mutations did not differ significantly between 
those patients analysed retrospectively (5.7%) and those analysed pro- 
spectively (6.1%). With regard to requesting criteria, 513 requests 
(41.2%) had no clinical details provided while the clinical details provid- 
ed on the remainder could be categorised as per Table 1. CALR mutations 
were primarily detected in those patients with either a known or 
suspected diagnosis of ET or PMF. Of note, no CALR mutations were de- 
tected in patients with clinical details provided of erythrocytosis or 
raised hematocrit and in those patients with isolated thrombosis. 
Indel mutations of CALR exon 9 are the second most common disease 
driving mutations in patients with ET or PMF. While the JAK2 V617F mu- 
tation is present in a proportion of myelodysplastic syndromes (MDS) 
and MDS/MPN, CALR mutations are rare in these diseases. To date, 
CALR mutations have been demonstrated primarily in ET and PMF, but 
nevertheless, two cases not entirely fulfilling all diagnostic criteria for 
PV have been reported to harbour such mutations [4]. Analysis of fur- 
ther 578 cases of JAK2-negative unexplained erythrocytosis revealed 
two patients with CALR exon 9 mutations, one of which was re- 
classified as ET [5], and together with the data presented herein, empha- 
sizes the unproductive practice in this group of patients. It is acknowl- 
edged that some patients with ET possess a high normal or raised 
hemoglobin level, however several studies have established that CALR- 
positive ET patients display a significantly lower hemoglobin level 
than those patients with the JAK2 V617F. Both CALR and JAK2 mutations 
may be present in a small minority of MPN patients however the diag- 
nostic or prognostic value of this association has yet to be proven. 
Splanchnic vein thrombosis (SVT) can be the presenting feature of ei- 
ther an overt or latent MPN: the JAK2 V617F mutation is present in up 
to 40% of SVT patients. Several groups have sought to determine the in- 
cidence of CALR mutations in SVT cohorts with a recent review clearly 
demonstrating that screening for CALR mutations is ineffective unless 
other clinical or laboratory features of an MPN are also present [6]. Sim- 
ilarly, CALR mutations have not been detected in sizeable patient co- 
horts with a first unprovoked venous thromboembolism (VTE), with 
recurrent VTE, and in coronary patients including those with peripheral 
arterial disease [7–9]. 
We have previously documented an increasing number JAK2 V617F 
requests  despite  the  annual  incidence  of  MPN  diagnosis remaining 
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Table 1 
Incidence of CALR mutations according to requesting details category. 
Category No. patients CALR 
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constant [3] consequently prompting this audit of the more recently in- 
troduced CALR analysis. Subsequently to introduction of testing, a re- 
vised classification of MPN [4] has been introduced which includes 
detection of a CALR mutation as a major diagnostic criterion for ET and 
PMF but not PV. This brief but informative audit highlights the con- 
straints in implementing evolving diagnostic guidelines in real-life prac- 
tice, acknowledged to influence subsequent treatment approaches and 
outcomes [10] and affirms the requirement for awareness, adoption and 
adherence of such guidelines for the systematic investigation of a 
suspected MPN. 
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Abstract 
Background Acute myeloid leukaemia (AML) is a het- 
erogeneous clonal disorder of haematopoietic progenitor 
cells. Approximately half of all adult AML patients have a 
normal karyotype (NK-AML) and an intermediate risk 
prognosis. 
Aims To determine the incidence and prognostic signifi- 
cance of NPM1 and FLT3-ITD mutations in a population of 
patients with NK-AML. 
Methods FLT3-ITD and NPM1 mutation status was ret- 
rospectively sought in presentation samples from 44 NK- 
AML patients. 
Results FLT3-ITD and NPM1 mutations were detected in 
45.5 and 54.5% of patients, respectively, allowing stratifi- 
cation according to genotype. 
Conclusions FLT3-ITD and NPM1 mutation status can be 
defined in NK-AML. Prospective screening for these 
mutations is advocated in all NK-AML patients, as the 
genotype is of clinical importance when considering 
treatment options including stem cell transplantation. 
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Introduction 
 
Acute myeloid leukaemia (AML) is a clonal, malignant 
disorder that results from genetic alterations in normal 
haematopoietic progenitor cells. A diagnosis of AML is 
made by the presence of at least 20% myeloblasts in the 
bone marrow and is a clinically, morphologically, cytoge- 
netically, and molecularly heterogeneous disease [1]. 
Despite advances in the understanding of the molecular 
biology of AML, treatment remains a challenge with most 
standard regimens using cytarabine and anthracylines for 
induction followed by some form of postremission therapy 
that may include allogeneic haematopoietic stem cell 
transplantation (ASCT). The outcome of AML depends on 
several factors including age, presenting white cell count 
and the absence or presence of specific cytogenetic 
abnormalities present in the myeloblasts [2]. 
Over the last 12 years, the karyotype at diagnosis in adult 
AML patients less than 60 years of age has become one of 
the principal predictors of treatment response and of which 
three groups may be  distinguished.  The  rela-  tively 
favourable group consists of patients with the 
t(8;21)(q22;q22),  inv(16)(p13q22),  t(16;16)(p13;q22) and 
t(15;17)(q22;q21) abnormalities, associated with specific 
clinical, morphological and immunophenotypic character- 
istics. The high risk patients have either monosomies or 
deletions of chromosomes 5 and 7, abnormalities of chro- 
mosome 3q or abnormalities that involve multiple chro- 
mosomes (complex abnormalities). The remaining group 
has an intermediate risk prognosis and includes patients with 
various trisomies and other less frequently occurring 
abnormalities, with the majority having a normal karyotype 
[3]. More recent studies of large numbers of AML patients 
with these less frequently occurring abnormalities has 
enabled  a better  understanding of each  of their prognostic 
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significance [4] but, nevertheless, 40–50% of patients are 
considered to have a normal karyotype (NK-AML) and 
within this group a wide heterogeneity exists in terms of 
responses to treatment. 
Insights into the complex network of molecular aberra- 
tions responsible for the underlying diversity of NK-AML 
have come from the detection of acquired mutations, rear- 
rangements and atypical expression of several genes 
involved in normal myeloid cell growth, proliferation and 
maturation. Each of these genetic abnormalities is postu- 
lated to potentially have its own prognostic significance [5]. 
The most common molecular mutations in NK-AML 
involve the FLT3, NPM1, MLL, CEBPA, NRAS, C-KIT and 
RUNX1 genes with internal tandem duplications of the FLT3 
gene (FLT3-ITD, approximately 40%) and mutations in 
NPM1 (approximately 50%) being the most frequent [6]. 
FLT3 is a receptor tyrosine kinase normally expressed on 
early myeloid cell precursors. The gene encoding FLT3 is 
located on chromosome 13q12 and in AML; in-frame ITD 
mutations in the juxta-membrane region or point mutations 
in the tyrosine kinase domain may occur that result in con- 
stitutive tyrosine kinase activity [7]. Indication that the 
presence of an FLT3-ITD had an impact on overall survival 
in NK-AML was noted over 10 years ago [8] and was sub- 
sequently shown to stratify NK-AML patients in several 
larger series of patients with the ITD, predicting an increased 
relapse risk and a poorer overall survival [9–11]. Nucleo- 
phosmin (NPM1) is a phosphoprotein that shuttles between 
the nucleus and cytoplasm, and is thought to be involved in 
the regulation of function and stability of various other 
nuclear proteins [12]. NPM1 is located on chromosome 5q35 
with specific mutations of this gene in AML patients first 
described in 2005, which were associated with a normal 
karyotype and responsiveness to induction chemotherapy 
[13]. Heterozygous mutations occur in NPM1 exon 12 and 
the majority result in a tetranucleotide insertion that creates 
an additional nuclear export signal motif, leading to dislo- 
cation of the mutant protein into the cytoplasm. The rela- 
tively high incidence of NPM1 mutations and their 
association with specific biological and clinical features in 
NK-AML have been confirmed [14–16]. More recently, the 
genotype of mutated NPM1 without FLT3-ITD in NK-AML 
has been associated with a high remission rate and favour- 
able outcome [17], with no difference in relapse-free sur- 
vival whether a sibling donor was available for ASCT or not, 
suggesting that sibling ASCT may not improve outcome in 
first remission in this group of patients [18]. 
As the molecular genotype of NK-AML has an 
increasingly important impact on clinical decision making, 
including transplantation options, the incidence and sig- 
nificance of NPM1 and FLT3-ITD mutations were therefore 
sought in a series of patients referred for molecular 
investigation. 
 
 
 
Fig. 1 Agarose gel electrophoresis of FLT3-ITD PCR reactions. 
Lanes 1 and 12, 100-bp ladder; lanes 2–7, NK-AML patients; lane 8, 
5% FLT3-ITD control; lane 9, FLT3 wild-type control; lane 10, 100% 
FLT3-ITD control; lane 11, water control 
 
Methodology 
 
A total of 44 adult patients with a diagnosis of NK-AML 
were retrospectively identified. All patients were less than 
65 years of age and therefore potential recipients of ASCT. 
The median age of patients was 46 years (range 17–65) with 
26 males and 18 females and a median follow-up of 19 
months (range 1–68 months). All DNA from presenta- tion 
BM (n = 36) or peripheral blood (n = 8) with greater than 
20% myeloblasts was extracted using the QIAmp DNA 
Blood Mini Kit (Qiagen, Crawley, UK). 
FLT3-ITD mutations were identified as previously 
described [9]. Briefly, the duplicated sequence involves 
exons 11, 12 or the intervening intron. Wild-type FLT3 
produces a 328-bp fragment, whilst alleles possessing an 
ITD are between 3 and\420 bp greater in length. Genomic 
DNA PCR products were electrophoresed on 3% agarose 
gels containing SYBr Green (Invitrogen, Oregon, USA) 
(Fig. 1). Detection of NPM1 mutations was performed using 
a capillary electrophoresis methodology as previ- ously 
described [19]. Genomic DNA was amplified with a high-
fidelity DNA polymerase using a 6-FAM labelled forward 
primer located within the intron between NPM1 exons 11 
and 12, and a reverse primer that resulted in amplification 
of a fragment containing the coding region of NPM1 exon 
12. Wild-type NPM1 allele was used as an internal control 
for DNA extraction and amplification. The amplified 
product produces a 169-bp wild-type fragment and in 
mutated cases an additional 173- or 174-bp fragment (the 
latter in very rare cases of  a  net  5-bp  insertion)  (Fig. 2). 
This methodology enables identification of all reported 
heterozygous NPM1 mutations to date. Mutated patient 
DNA was serially diluted into DNA of haemato- logically 
normal controls to determine assay sensitivities. 
 
 
Results 
 
From serial dilution experiments, both assays were found to 
consistently detect heterozygous FLT3-ITD and NPM1 
mutations  when  present  at  a  level  of \5%  of  total  DNA. 
FLT3-ITD mutations were identified in 20 (45.5%) NK- 
AML patients and NPM1 mutations in 24 (54.5%). Patients 
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Fig. 2 Electropherogram of wild-type NPM1 (upper panel) and 
heterozygous mutated NPM1 (lower panel) PCR reactions: two peaks 
with a four base pair difference in size are clearly visible 
 
could be further stratified into groups according to genotype: 
FLT3-ITD negative/NPM1 negative, n = 13 (29.5%); FLT3-
ITD negative/NPM1 positive, n = 11 (25.0%); FLT3- ITD 
positive/NPM1 negative, n = 7 (16.0%) and FLT3-ITD 
positive/NPM1 positive, n = 13 (29.5%). Follow-up data 
were evaluable for 84% (37/44) of patients. By Kaplan– 
Meier analysis no significant differences were observed in 
the overall survival between those NK-AML patients who 
were either FLT3-ITD positive or negative or in those who 
were NPM1 mutation positive or negative. No statistically 
significant differences in overall survival were noted 
between each of the aforementioned four genotypic sub- 
types but, of note, 8/11 (73%) of FLT3-ITD negative/NPM1 
positive patients remain alive, six of whom are in first 
complete remission. 
 
 
Discussion 
 
Many adult AML cases are characterised by the presence of 
a number of recurring chromosomal abnormalities and in 
many instances these abnormalities correlate closely with 
specific clinical characteristics. The karyotype at diagnosis 
therefore provides a framework for treatment stratification. 
Approximately, 40–50% of patients with adult AML do not 
have any evidence of such chromosome aberrations and are 
classified as having an intermediate risk prognosis, but 
within this group a spectrum of responses to treatment and 
long-term outcomes exists. It has become increasingly 
apparent that numerous molecular abnormalities within NK-
AML patients underlie this heterogeneity and that these 
specific molecular genetic alterations are associated with 
prognostic significance. Recently, the combined FLT3-ITD 
and NPM1 mutation status has been shown to confer par- 
ticular responses to standard induction therapy in NK-AML 
with the mutant NPM1 without FLT3-ITD patients pos- 
sessing a relatively favourable outcome [18]. Molecular 
screening was therefore performed to determine the inci- 
dence and any potential prognostic importance of these 
mutations in NK-AML patients referred for molecular 
analysis. 
The assays utilised to detect FLT3-ITD and NPM1 
mutations were validated, reproducible and found to reliably 
detect these mutations when present at a clinically relevant 
level. The incidence of the four different FLT3-ITD/NPM1 
genotypes in the cohort studied was consistent with that 
previously reported in larger studies [17, 18, 20]. Unfortu- 
nately, no differences in overall survival were observed and 
this may be attributable to the fact that this study was ret- 
rospective, small numbers of patients were studied and that 
these patients had a relatively short follow-up. Nevertheless, 
identification of both FLT3-ITD and NPM1 mutations is 
now considered the minimum molecular diagnostic 
requirement for NK-AML patients contributing to a prog- 
nostic stratification [21]. 
In addition to FLT3-ITD and NPM1, mutations and over-
expression of numerous other genes associated with either 
myeloid cell proliferation or differentiation have been 
reported in NK-AML. These include mutations of CEBPA, 
FLT3 kinase domain, NRAS, MLL, WT1, C-KIT 
and dysregulated expression of BAALC, ERG, MN1 and 
specific microRNAs with each of these abnormalities 
potentially associated with a particular prognosis [22]. 
Molecular findings, along with clinical, morphological, 
immunophenotypic and cytogenetic features, are becoming 
of increasing value in determining the optimal therapy for 
AML patients. In addition, new molecularly targeted 
therapies are becoming available, e.g. FLT3 inhibitors. 
These agents may be integrated into current treatment 
strategies for AML, although their optimal usage remains to 
be determined. Identification of FLT3-ITD and NPM1 
mutation status is therefore advocated in all new NK-AML 
patients. 
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Abstract 
Introduction Acute myeloid leukemia (AML) is a hetero- 
geneous clonal disorder often associated with dismal overall 
survival. The clinical diversity of AML is reflected in the 
range of recurrent somatic mutations in several genes, many 
of which have a prognostic and therapeutic value. Targeted 
next-generation sequencing (NGS) of these genes has the 
potential for translation into clinical practice. In order to 
assess this potential, an inter-laboratory evalu- ation of a 
commercially available AML gene panel across three 
diagnostic centres in the UK and Ireland was performed. 
Methods DNA from six AML patient samples was dis- 
tributed to each centre and processed using a standardised 
workflow, including a common sequencing platform, 
sequencing chips and bioinformatics pipeline. A duplicate 
sample in each centre was run to assess inter- and intra- 
laboratory performance. 
Results An average sample read depth of 2725X (range 629–
5600) was achieved using six samples per chip, with some 
variability observed in the depth of coverage 
generated for individual samples and between centres. A 
total of 16 somatic mutations were detected in the six AML 
samples, with a mean of 2.7 mutations per sample (range 1–
4) representing nine genes on the panel. 15/16 mutations 
were identified by all three centres. Allelic frequencies of 
the mutations ranged from 5.6 to 53.3 % (median 44.4 %), 
with a high level of concordance of these frequencies 
between centres, for mutations detected. 
Conclusion In this inter-laboratory comparison, a high 
concordance, reproducibility and robustness was demon- 
strated using a commercially available NGS AML gene 
panel and platform. 
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1 Introduction 
 
Acute myeloid leukemia (AML) is a heterogeneous clonal 
disorder characterised by infiltration of the bone marrow, 
blood and other tissues by abnormal or poorly differenti- 
ated myeloid cells of the haematopoietic system. Diagnosis 
is based on bone marrow and peripheral blood morphology, 
immunophenotype and the presence of typical chromoso- 
mal alterations or recurrent mutations. Treatment for AML 
Key Points 
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Inter-laboratory evaluation of a commercial next- 
generation sequencing, acute myeloid leukemia panel 
proves robust, with high concordance and 
reproducibility. 
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patients is primarily based on delivery of an intensive 
course of induction chemotherapy, such as cytarabine plus 
anthracycline, followed by post-remission consolidation 
chemotherapy. Up to 80 % of patients achieve complete 
remission, however a significant proportion will eventually 
relapse [1]. Allogeneic transplantation offers the potential 
of a curative therapy in eligible patients after careful 
assessment of co-existing morbidities based on donor 
availability and genetic profile. Recurrent genetic lesions 
such as Fms-related tyrosine kinase 3 (FLT3), CCAAT/ 
enhancer binding protein-a (CEBPA) and nucleophosmin 
(NPM1) are commonly used as prognostic markers in 
clinical practice, with markers associated with poor out- 
come, such as tumour protein 53 (TP53), additional sex 
combs like transcriptional regulator 1 (ASXL1) and runt- 
related transcription factor 1 (RUNX1), likely to be rec- 
ommended for stratification in forthcoming guidelines [2]. 
Next-generation sequencing (NGS) technologies allow 
massive parallel sequencing of multiple DNA regions of 
interest, including large or GC-rich genes, and offer the 
potential for increased throughput, sensitivity and quan- 
tification of variant allelic frequencies relative to standard 
Sanger sequencing. Recent application of genomic tech- 
niques such as whole genome sequencing have yielded a 
broad view of the mutational landscape of AML, and 
highlighted 25–30 recurrent somatic mutations that can be 
organised into functional categories. These genes encode 
for transcription factors and tumour suppressors, genes 
related to DNA methylation, haematopoietic cytokine sig- 
nalling, chromatin modification, the cohesin complex and 
the spliceosome complex [3]. Further studies have descri- 
bed patterns of clonal and subclonal evolution, mutation 
clearance rates post-induction therapy and the monitoring 
of minimal residual disease [4–7]. Together, these advan- 
ces are helping unravel the potential for new personalised 
therapies and targeted treatments with specific agents used 
in combinations with standard chemotherapy to maintain 
remission or bridge to transplantation [2, 8]. The adoption 
of targeted gene panels comprising a refined set of disease- 
relevant genes has shown promise for translation of NGS 
into clinical practice [9–11]. Here we present an inter- 
laboratory evaluation of a commercially available AML 
gene panel across three clinical diagnostic centres in the 
UK and Ireland. 
 
 
2 Material and Methods 
 
To evaluate the AML NGS panel, DNA from six pre- 
characterised AML patients (NPM1 and FLT3-ITD muta- 
tion status assessed by polymerase chain reaction [PCR] and 
capillary electrophoresis using alternative laboratory 
methods) was used for quality control (QC#1–6), 
distributed to each centre and processed using standardised 
workflows for the Ion AmpliseqTM AML Panel (Life 
Technologies/Thermo Fisher Scientific, Paisley, UK) before 
sequencing on an Ion Torrent Personalized Genome 
Machine (PGMTM; Life Technologies/Thermo Fisher Sci- 
entific). A designated sample (QC#3, QC#5, and QC#6) was 
repeated in duplicate on separate runs in centres 1, 3 and 2, 
respectively, to assess inter- and intra-centre reproducibility. 
Amplicon libraries covering 19 commonly mutated genes 
implicated in AML and covering the entire coding region of 
DNA (cytosine-5-)-methyltransferase 3-a (DNMT3A), 
CEBPA, GATA binding protein 2 (GATA2), tet 
methylcytosine dioxygenase 2 (TET2), TP53 and muta- 
tional hot-spot regions of ASXL1, B-raf proto-oncogene, 
serine/threonine kinase (BRAF), Cbl proto-oncogene, E3 
ubiquitin protein ligase (CBL), FLT3 (tyrosine kinase 
domain mutations), isocitrate dehydrogenase 1 (IDH1), 
isocitrate dehydrogenase 2 (IDH2), Janus kinase 2 (JAK2), 
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog (KIT), Kirsten rat sarcoma viral oncogene 
homolog (KRAS), NPM1, neuroblastoma RAS viral (v-ras) 
oncogene homolog (NRAS), protein tyrosine phosphatase, 
non-receptor type 11 (PTPN11), RUNX1 and Wilms tumour 
1 (WT1), were generated using 10 ng genomic DNA in each 
of four primer-pooled reactions generating 264 amplicons. 
Amplified targets were combined from four pools to two, 
primer sequences were partly digested and barcoded 
adapters were ligated for sample identification. The 
resulting product was purified using Agencourt® AMPure® 
XP beads as per the manufacturer’s instructions (Beckman 
Coulter, Brea, CA, USA). The unamplified libraries were 
quantified using qPCR with the Ion Library Quantification 
Kit (Life Technologies/Thermo Fisher Scientific) and 
equalised to 100 pM prior to combination. Emulsion PCR, 
recovery and enrichment of templated Ion SphereTM par- 
ticles (ISP) was performed using the Ion OneTouchTM 2 
System or Ion ChefTM System (automated), before loading 
onto Ion 318TM v2 chips and sequencing on the Ion Torrent 
PGMTM platform with the Ion PGMTM Sequencing 200 Kit 
v2. Data were reviewed using Torrent SuiteTM software 
v4.2.1.0 (Thermo Fisher Scientific/Life Technologies) using 
a low stringency parameter configuration. Samples were 
uploaded to Ion ReporterTM v4.2 cloud-based soft- ware 
(Thermo Fisher Scientific/Life Technologies) as BAM or 
VCF files for subsequent variant annotation. 
Coverage in highly sampled locations was capped at 
2000X to reduce computational time. Calling of somatic 
mutations was achieved using an algorithm that excluded 
synonymous mutations, variants located within intronic or 
untranslated regions, and variants present at a frequency of 
\5 %.  Insertions/deletions  called  using  Ion  ReporterTM 
were  confirmed  by  reviewing  data  with  the Broad 
Inter-Lab Evaluation of NGS AML Panel 
 
 
 
Institute’s Integrative Genomics Viewer (IGV) [12]. In 
addition, AcroMetrix controls (Life Technologies/Thermo 
Fisher Scientific), a highly multiplexed QC used to assess 
the performance of NGS assays, was employed in one centre 
to determine variant detection at low variant allele 
frequencies (VAFs). To maximise confidence in variant 
calling, a minimum target depth of coverage for variant calls 
was set at 500X based on these data, with potential somatic 
variants reviewed and screened using relevant public 
databases, such as dbSNP, ClinVar, COSMIC, and PubMed. 
No homozygous mutations of somatic relevance were 
detected using the aforementioned public databases. 
 
 
3 Results 
 
3.1 Platform Performance 
 
Performance of the Ion PGMTM platform and workflow at 
each centre was assessed using the QC data generated for 
each sample. Variables assessed were the number of reads 
generated, the number and AQ20 (1 % error rate) quality 
score of bases, the average depth of coverage across the bases 
and the average read length generated. A mean read count of 
602,354 reads per sample (range 150,312–1,212,941) was 
generated. Mean read length at AQ20 was consistent at  123 
bp (CV 3.3 %) for all samples analysed. An average sample 
read depth of 2725X (range 629–5600) was achieved using 
six samples on a 318TM v2 chip, with significant variability 
observed in the depth of coverage generated for individual 
QC samples and between centres (electronic supplementary 
Table 1). AcroMetrix controls showed detection of 
applicable variants present in IDH1/2, KIT, NPM1, 
PTPN11, FLT3, TP53, KRAS and NRAS at VAFs of 
between 5 and 10 % (25 % for NPM1) at 500X as expected. 
 
3.2 Somatic Mutation Detection 
 
Unfiltered data files from each centre were downloaded 
from Ion ReporterTM and analysed using the filtering 
algorithm outlined above. A total of 16 somatic mutations 
were identified in the six AML patient samples tested. 
Centres 1 and 3 identified all 16 mutations, whereas Centre 
2 identified 15/16, producing an analytical specificity for the 
gene panel of 97.9 % (95 % CI 89–99 %) [electronic 
supplementary Table 2]. A mean of 2.7 somatic mutations 
were detected in each AML patient sample (range 1–4), 
representing nine genes on the panel (ASXL1, DNMT3A, 
IDH1, IDH2, NPM1, NRAS, PTPN11, RUNX1, TET2), with 
ASXL1 and DNMT3A being the most frequent. NPM1 
mutations were identified in one of the six QC samples, 
confirming results obtained at diagnosis by standard 
methodology  at  the  referring  centre.  In  addition,  two 
frameshift deletions in ASXL1 not currently represented in 
COSMIC were identified in all centres and confirmed using 
IGV. 
Allelic frequencies of the 16 mutations detected ranged 
from 5.6 to 53.3 % (median 44.4 %), with a high concor- 
dance between centres for mutations detected (Fig. 1). Of 
note, Centre 2 did not report detection of the PTPN11 
c.215C[A   p.Ala72Asp   mutation   in   sample   three.   Re- 
analysis of the data confirmed the presence of the missed 
mutation at a read depth of 302X, initially omitted as the 
read  depth  was \500X  (in  italics  in  electronic  supple- 
mentary Table 2 and Fig. 1, mutation number 7). 
 
3.3 Reproducibility 
 
Analysis of duplicate sample data showed both within and 
between run concordance, with the same number of vari- 
ants detected at similar frequencies by all centres (elec- 
tronic supplementary Table 2). 
 
 
4 Discussion 
 
There is considerable interest in translating targeted NGS of 
AML into clinical laboratories for routine detection of 
therapeutically actionable disease mutations [10, 11, 13, 14]. 
In this report, we have evaluated the inter- and intra-labo- 
ratory reproducibility and robustness of a commercial 19-
gene AML panel in three separate clinical centres in the UK 
and Ireland. Performance of the panel was assessed using six 
AML patient samples run on the Ion PGMTM platform 
across all centres. A high level of concordance was observed, 
with 15/16 mutations detected. Centre 2 did not report a 
PTPN11 c.215C[A p.Ala72Asp mutation that was excluded 
as the number of reads generated for the sample was low 
(150,312) and the subsequent read depth at the target site did 
not achieve 500X. As a depth of coverage of 500X is nec- 
essary for confidence in calling low-level mutations (25 
mutated reads are required for a 5 % burden), it is therefore 
essential to ensure appropriate coverage of all relevant 
amplicons to enable appropriate interrogation and interpre- 
tation of data produced. Improving efficiencies during the 
preanalytic stages could help achieve this and would reduce 
the variability in reads generated between samples and 
between centres. Optimisation of library equalisation or 
implementation of automated template preparation and chip 
loading (Ion ChefTM) could increase reads generated and 
improve preanalytical consistency. Reduction of sample 
number per chip or repeat testing and combination of results 
for samples that prove difficult to sequence would help 
deliver sufficient read depth for further analysis. 
Nevertheless, given the variation in reads generated per 
sample by each centre, the high concordance in the 
K. Haslam et al. 
 
 
 
 
 
Fig. 1 Allelic frequency of mutations detected in quality-control 
samples. Mutation 1: DNMT3A p.Leu344Gln; Mutation 2: NPM1 
p.Trp288fs; Mutation 3: NRAS p.Gly12Asp; Mutation 4: NRAS 
p.Gly12Ser; Mutation 5: TET2 pArg1216Ter; Mutation 6: RUNX1 
p.Arg204Gln; Mutation 7: PTPN11 p.Ala72Asp; Mutation 8: ASXL1 
p.Leu890fs; Mutation 9: DNMT3A p.Arg882His; Mutation 10: IDH1 
p.Arg132Cys; Mutation 11: ASXL1 p.Arg693Ter; Mutation 12: ASXL1 
p.Gly966del; Mutation 13: DNMT3A p.Arg882Cys; Mutation 14: 
DNMT3A p.Arg792His; Mutation 15: IDH2, p.Arg172Lys; Mutation 
16: ASXL1 p.Ser798fs 
 
identification and coverage depth of somatic mutations in 
the samples tested proves the capacity of the Ion 
AmpliseqTM AML Research Panel and Ion Torrent as a 
robust platform for generating reproducible results in a 
clinical diagnostic setting. Incorporation of this gene panel 
would complement and enhance the armoury of tools 
available for identification of relevant diagnostic and 
prognostic somatic mutations in AML patients. 
A limitation of this study was the limited number of 
genes available for analysis. Expansion of the panel to 
incorporate a greater number of relevant genes mutated in 
AML (e.g. splicing factors) would further improve its 
applicability. 
 
 
5 Conclusions 
 
The use of targeted panels in AML has the potential to 
overcome the limitations of standard Sanger sequencing in 
terms of time, the potential to sequence multiple gene targets 
at once, and the ability to quantify variant allelic 
frequencies. In a clinical diagnostic setting, these benefits 
translate into additional clinically relevant information and 
justify the application of limited resources to generate 
relevant information for clinical decision making. The 
implementation of common platforms and workflows to 
interrogate the mutational profile of AML patients will 
enable standardisation of results and further collaborative 
efforts between centres. 
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Abstract 
Introduction: For patients diagnosed with high-risk myeloid neoplasms the prognosis is poor 
with allogeneic stem cell transplantation offering the only potential cure. Preclusion of 
patients from standard conditioning on the basis of age or refractory disease has led to 
development of regimen combining cytoreduction and transplant conditioning, for example 
fludarabine, cytosine, arabinoside, amsacrine, cyclophosphamide, and busulfan (FLAMSA). 
The relevance of somatic mutations in the FLAMSA transplantation scenario remains to be 
fully elucidated. The profile of somatic mutations in twenty one patients uniformly treated 
with a FLAMSA transplant is reported. Methods: Targeted next generation sequencing was 
performed using a panel covering nineteen genes. Results: Thirty three somatic driver 
mutations were detected with a median of two mutations per patient. TET2 mutations were 
most common at 41.2%, followed by RUNX1 and DNMT3A at 23.5% each. Grouping mutations 
by disease classification revealed predominant associations of RUNX1 and TP53 within the 
myelodysplastic syndrome group, ASXL1 and TET2 within the chronic myelomonocytic 
leuekmia group (CMML), TET2 and DNMT3A within the acute myeloid leukemia group. The 
FLAMSA regimen was well tolerated with a non-relapse mortality below that predicted by 
Hematopoietic Cell Transplantation-Comorbidity Index scoring (9.5% versus 41%), however 
the outcome for CMML patients and those with therapy related myeloid neoplasms was 
inferior indicating a need for alternative therapeutic approaches. Conclusion: Profiling of 
somatic mutations enhances clinical insight in patients with high-risk myeloid malignancies 
prior to transplantation. 
Keywords: FLAMSA, next generation sequencing, transplantation, molecular diagnostics 
 
 
 
 
 
 
Introduction 
 
For patients with high-risk refractory or relapsed myeloid neoplasms the prognosis is poor 
and outcome after standard chemotherapy alone rarely results in cure. Although allogeneic 
stem cell transplantation (ASCT) offers a potential cure, relapse rates are high and patients 
can be precluded from standard protocols on the basis of older age, refractory or relapsed 
disease, and presence of co-morbidities.  
Whereas reduced intensity conditioning (RIC) transplantation regimens offer lower rates of 
non-relapse mortality (NRM) in aggressive disease this may not be sufficient to control 
disease until a graft versus leukaemia (GvL) effect occurs. In an attempt to overcome this, 
intermediate sequential conditioning regimen incorporating a short course of chemotherapy 
combining fludarabine, cytosine, arabinoside, amsacrine, cyclophosphamide, and either total 
body irradiation or busulfan (FLAMSA) to reduce disease burden prior to reduced intensity 
conditioning have been designed and implemented in high-risk myeloid neoplasms [1-3].  
Using next generation sequencing technologies, a range of somatic mutations have been 
associated with adverse outcome in myeloid malignancies including mutations affecting 
ASXL1, FLT3, TP53, RUNX1, EZH2, [4-6] with subsequent studies indicating an association 
between somatic mutations and response to therapy [7,8]. For high-risk myelodysplastic 
syndrome (MDS) patients who undergo ASCT, the use of pre-defined mutations can enable 
prediction of relapse risk [9], with somatic mutation in ASXL1, RUNX1, TET2, DNMT3A and 
TP53 associated with shorter survival in MDS and MDS/acute myeloid leukaemia (AML) 
patients [10,11]. Moreover, detection of somatic mutations prior to transplantation have 
shown potential as molecular targets of residual disease in the post-transplant setting [9, 12, 
13]. 
To further characterise the mutational profile in this context, a retrospective analysis of 
patients with high-risk myeloid malignancies treated with FLAMSA-Bu conditioned ASCT was 
conducted.  
 
Methods 
 
Patients 
Twenty-one patients (10 male, 11 female; median age 55 years; range 36-64 years) were 
included.  Patients were identified as having poor risk disease on the basis of AML with 
primary induction failure (n=5), MDS with high or very high-risk Revised International 
Prognostic Scoring System (R-IPSS) scores (n=8: 4 of whom had therapy-related MDS), 
therapy-related AML with MLL rearrangement (n=1), intermediate-2 or high-risk  CMML-
specific prognostic scoring system (CPSS) chronic myelomonocytic leukaemia (CMML) (n=4), 
blast crisis of chronic myeloid leukaemia (n=1), primary myelofibrosis (PMF) with > 10% 
myeloblasts on bone marrow (n=1), and mixed phenotype acute leukaemia (T/myeloid) with 
complex karyotype (n=1).  
Karyotype was available on 20/21 patient samples with a complex/monosomal karyotype 
detected in 10/21 (47.6%) patients, an intermediate risk karyotype in 6/21 (28.6%), and a 
normal karyotype in 4/21 (19%). The median Hematopoietic Cell Transplantation-Comorbidity 
Index (HCT-CI) score for patients was 4 (range 0-10). Patient details and previous induction 
chemotherapy are outlined in Table 1. 
 
Transplant conditioning 
All 21 patients underwent ASCT with FLAMSA-Bu conditioning. This consisted of cytoreductive 
treatment with fludarabine 30mg/m2, cytarabine 2g/m2 and amsacrine 100mg/m2 from days 
-12 to -9 followed by two days of rest before a reduced intensity conditioning (RIC) protocol 
consisting of fludarabine 30mg/m2, busulphan 8mg/kg intravenously, and rabbit anti-
thymocyte globulin 10-20mg/kg from days -6 to -1 before transplantation with peripheral 
blood stem cells (PBSC) with a CD34+ count of >2.5X106/kg.  Graft versus host disease (GvHD) 
prophylaxis was initiated on day 0 and composed of mycophenolate mofetil 1g tds up to day 
+35 in the absence of GvHD and cyclosporin 1.5mg/kg/bd, adjusted based on drug levels and 
tapered from day +60 to +90. Patients in complete remission (CR) without evidence of GvHD 
at day +120 and day +150 received escalating doses of donor lymphocyte infusions (DLI) at 1 
or 5x106 CD34+ cells/kg.  
 
Mutation profiling 
Tumour genomic DNA was available on 17/21 patient samples (peripheral blood (n=4), bone 
marrow (n=13) prior to conditioning. Internal tandem duplications (ITD) in FLT3 were 
identified as previously described [14]. For next generation sequencing, 10ng of DNA was 
used to generate amplicon libraries using a targeted sequencing approach with 264 amplicons 
generated covering 19 genes commonly mutated in myeloid disorders. Amplicons covered 
the entire coding region of DNMT3A, CEBPA, GATA2, TET2, TP53 and mutational hot spot 
regions of ASXL1, BRAF, CBL, FLT3 (tyrosine kinase domain mutations), IDH1, IDH2, JAK2, KIT, 
KRAS, NPM1, NRAS, PTPN11, RUNX1 and WT1. Sequencing was carried out on the Ion Torrent 
Personalised Genome Machine (PGMTM) (Thermo Fisher Scientific, Paisley, UK). 
Quality control for the methodology including the bioinformatics pipeline and capacity of the 
platform and panel to generate reproducible results of sufficient quality in AML samples was 
assessed. Briefly, samples that achieved >200X depth of coverage on >97% of amplicons were 
considered for further analysis and subjected to a bioinformatics algorithm that excluded 
non-exonic variants such those detected in the intronic or 3’untranslated regions of genes on 
the panel and excluded synonymous or silent mutations that result in no effect on the amino 
acid profile of the associated protein.  Remaining potential somatic mutations were then 
cross-checked using an array of on-line databases such as dbSNP, ClinVar, PubMed, COSMIC, 
Sift and Polyphen to exclude germ-line SNPs, mutations of known benign impact and to assess 
the impact of amino acid substitution on protein function. Insertions or deletions were 
manually reviewed using the Broad Institutes Integrated Genomics Viewer as previously 
described [15,16-21]. 
 
 
 
Statistics 
Estimates of overall survival (OS) and progression free survival (PFS) were calculated using 
GraphPad Prism® 7 (GraphPad Software, California, USA) and expressed as Kaplan-Meier 
curves. OS and PFS were calculated from time of transplantation to event, which was defined 
as death and progression or death for OS and PFS respectively. Non-relapse mortality (NRM), 
was defined as death from any cause other than refractory disease or relapse. Cumulative 
incidence was calculated using a competing risk model. Circos plots were generated from 
tabular data using Circos online software [22]. 
 
Results 
 
Somatic mutations 
Tumour genomic DNA was available on 17/21 patient samples at the time of diagnosis for 
mutational profiling. A FLT3-ITD mutation was detected in one patient sample (patient 9). All 
17 patient samples were sequenced by NGS at a sufficient depth and quality to permit 
bioinformatics analysis. A total of 423 variants were initially detected in 14/17 (82.4%) patient 
samples sequenced. Exclusion of non-exonic and synonymous variants reduced the number 
of variants to 124, before bioinformatic analysis of the remaining variants further reduced the 
field to a final number of 33 somatic driver mutations. Missense mutations predominated 
(n=22), followed by frame-shift (n=6) and nonsense (n=5).  
A median of 2 mutations (range 0-5) was detected, with 5/6 MDS, 4/5 AML, 3/3 CMML, and 
2/3 other, harbouring mutations detectable by the panel. TET2 mutations were the most 
common lesion, detected in 7/17 (41.2%) cases, followed by RUNX1 and DNMT3A mutations 
in 4/17 (23.5%) patients each. Allelic frequencies of the 33 mutations detected ranged from 
3%-87%, with samples harbouring multiple mutations displaying variable allelic frequencies. 
Details of somatic mutations detected by NGS are given in Table 2. 
Ordering mutations by disease group revealed predominant associations of RUNX1 and TP53 
within the MDS group, ASXL1 and TET2 within the CMML group, TET2 and DNMT3A within 
the AML group, and KRAS within the other grouping (Figure  1). Analysis of gene-gene co-
mutation within samples revealed the underlying heterogeneity within samples with TET2 as 
the gene with the highest number of associated mutations (n=12), followed by DNMT3A 
(n=9). Two de novo AML samples detected possessed an IDH2 R172 mutation with co-
mutated DNMT3A (patients 8 and 14, Table 2).  
 
Mutations versus outcome  
Assessment of age and number of mutations detected showed no significance, with patients 
<49 years versus those >50 years with a PFS/OS p-value of 0.8384 and 0.9166 respectively. 
Both groups had a median of two mutations (range 0-4) (p 0.7414). Analysis of the impact of 
individual genes on outcome was precluded by the limited patient cohort. 
 
Clinical outcome 
Twelve (57.1%) patients received stem cells from fully HLA matched unrelated donors. All 
patients achieved neutrophil engraftment, occurring at a median of 24 days (range 11-124 
days) and platelet engraftment at a median of 26 days (range 10-221 days) post-ASCT. Ten 
(47.6%) patients received planned donor lymphocyte infusions and seven (33.3%) patients 
developed acute GvHD. Two treatment-related deaths occurred; one from sepsis in the 
context of steroid-refractory GvHD and another from toxoplasmosis infection. Ten (47.6%) 
patients remain alive and disease-free after a median of 513 days follow-up. Nine (42.9%) 
patients have relapsed post ASCT, three of whom remain alive following salvage therapy. The 
median time to relapse is 109 days (62-751), with median progression free survival (PFS) at 
841 days and median overall survival (OS) has not yet been reached. The impact of donor 
source (related versus unrelated donor) did not impact on PFS (p=0.2568) or OS (p=0.7389). 
Of note, all four CMML patients relapsed at a median of 694 days post FLAMSA-Bu ASCT. The 
median PFS for de novo AML and MDS has not been reached (Figure 2). Overall non relapse 
mortality (NRM) was 9.5%, with a median predicted two year NRM of 41% using the HCT-CI 
Score. 
Discussion 
 
The potential to integrate somatically acquired mutation status into clinical decision making 
has been greatly enhanced by adoption of NGS technologies which allow for simultaneous 
detection of multiple mutations. Whereas the mutational landscape of myeloid diseases has 
been delineated in recent years [4, 5, 23, 24] the mutational profile in specific clinical 
scenarios such as ASCT has yet to be fully explored, with variation in mutational impact 
observed [25].  Data is presented on mutational status and clinical outcome in a cohort of 
high-risk myeloid malignancy patients uniformly treated with FLAMSA-Bu conditioning and 
ASCT. Using a gene panel covering 19 myeloid relevant genes, 14/17 (82.4%) patients had 
somatic mutations detected, with a median of 2 mutations per patient. The frequency of 
mutations in this cohort is consistent with that observed in myeloid disorders reported 
elsewhere [23, 24, 25] with variable allelic burdens observed in patients harbouring multiple 
mutations indicating the presence of subclones and a complex clonal architecture. Of note, 
two AML patient samples displayed an IDH2 R172 mutation, which has recently been 
proposed as a distinct AML genomic entity with a prevalence of approximately 1% based on 
mutual exclusivity with NPM1 or other class defining lesions and a gene-expression and DNA 
methylation profile that differs from other IDH mutations leading to more severe aberrations 
in metabolic activity [26]. 
Further analysis by disease group reflected the high-risk status of the patients with mutations 
associated with poor outcome such as RUNX1 and TP53 predominant within the MDS group 
and ASXL1 within the CMML group. Clear gene-gene co-mutation associations were not found 
likely reflecting the underlying heterogeneity of the patients and the limited number of 
patients studied. 
An association between patient age and number of mutations was not detected, nor between 
individual mutated genes and patient outcome, again probably due to the low patient 
number. A recent large scale landmark study matching mutation and clinical data in MDS has 
reinforced the poor risk of TP53 mutation regardless of conditioning intensity prior to 
transplant, questioning the benefit of conventional myeloablative conditioning over reduced 
intensity approaches in patients with TP53-mutated MDS [27]. It is therefore interesting to 
speculate on a growing role for FLAMSA-Bu based conditioning in these patients in the future, 
however further larger scale studies are needed to determine the true effect of conditioning 
on TP53-mutated patients.   
In the cohort tested, the FLAMSA-Bu regimen was clinically well tolerated with a NRM below 
that predicted by HCT-CI scoring (9.5% versus 41%). However, the outcome for CMML 
patients and those with therapy related myeloid neoplasms was poor indicating a need for 
alternative therapeutic approaches. 
 
Conclusion 
Notwithstanding the limitations of a small patient cohort and a limited gene panel, mutational 
profiling of patients prior to ASCT aids clinical understanding of patient genotype. Knowledge 
of the clonal/subclonal architecture provides potential markers for disease monitoring post 
ASCT in this cohort of patients at high risk of relapse. 
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Table Legends: 
Table 1: Patient Characteristics. 
Table 2: Mutation profile of patient cohort. 
 
Figure Legends: 
Figure 1: Circos plot connecting disease groups and mutated genes. 
Figure 2: Progression free survival of patient cohort by WHO 2008 category. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: 
Number  of Patients 21 
Median age in years (range) 55 years (36-64 years) 
Gender (male: female) 10 male: 11 female 
  
WHO 2008 Diagnosis   
Acute myeloid leukaemia 5 (23.8%) 
Therapy-related myeloid neoplasm 5 (23.8%) 
Chronic myelomonocytic leukaemia 4 (19%) 
Myelodysplasia 4 (19%) 
Chronic myeloid leukaemia; blast crisis 1 (4.8%) 
Primary myelofibrosis 1 (4.8%) 
Mixed phenotype acute leukaemia, T/myeloid, NOS 1 (4.8%) 
  
Cytogenetics   
Normal karyotype 4 
Complex karyotype 8 
Monosomal karyotype as a sole abnormality 2 
Other karyotype abnormality 6 
Not available 1 
  
Initial pre-transplant chemotherapy  
Azacytidine 3/21 
DAT 3+10 induction 11/21 
FLAG-IDA induction 3/21 
Other pre-transplant treatment 5/21 
  
  
Bone marrow blasts prior to ASCT  
<5% 11/21 
5-10% 7/21 
>10% 3/21 
  
Transplant characteristics  
Donor type 9 Sibling donors 
12 Matched unrelated donors 
Patient/donor CMV serostatus 4 Positive/Positive  
2 Positive/Negative  
1 Negative/Positive  
13 Negative/Negative 
1 Unknown 
Post-transplant immunosuppression 19 Ciclosporin/Mycophenolate 
2 Tacrolimus/Mycophenolate 
  
Graft versus Host Disease  
Acute 7/21 
Chronic 5/17 
  
Outcome  
Treatment related mortality 2/21 
Death from relapsed disease prior to 100 days 2/21 
Survival at 100 days  17/21 
Median Progression Free Survival 841 days 
Median Overall Survival  Not reached 
 
 
Table 2:          
          
Pati
ent Locus  Gene 
Ex
on 
Cove
rage  
Alellic 
Frequency  Coding Protein  Type 
1 
chr4:10615
5920 TET2 3 1993 53 
c.822_822del
C p.Asn275fs 
frameshiftDele
tion 
chr4:10615
6432 TET2 3 1995 27 
c.1334_1334d
elT p.Leu446fs 
frameshiftDele
tion 
chr20:3102
4371 ASXL1 12 2000 47 c.3856C>T 
p.Gln1286Te
r nonsense 
chr21:3623
1782 RUNX1 6 1990 42 c.602G>A p.Arg201Gln missense 
2 
chr1:11525
6528 NRAS 3 1996 25 c.183A>T p.Gln61His missense 
chr4:10616
4898 TET2 6 1253 51 c.3766G>C 
p.Gly1256Ar
g missense 
chr20:3102
4274 ASXL1 12 1556 16 
c.3759T>A|c.3
759T>C 
p.Ser1253Ar
g|p.(=) 
missense|syno
nymous 
chr12:1129
26888 PTPN11 13 821 4 c.1508G>T p.Gly503Val missense 
3 
chr4:10615
8490 TET2 3 1701 3 c.3391C>A 
p.Pro1131Th
r missense 
4 
chr20:3102
2981 ASXL1 12 1990 47 
c.2467_2467d
elT p.Leu823fs 
frameshiftDele
tion 
5 
chr4:10615
5755 TET2 3 737 87 
c.657_658del
AC p.His222fs 
frameshiftDele
tion 
chr5:17083
7543 NPM1 11 233 43 
c.859_860insT
CTG p.Trp288fs 
frameshiftInse
rtion 
chr2:25470
554 DNMT3A 8 1191 45 c.920C>T p.Pro307Leu missense 
6 
chr2:25457
243 DNMT3A 23 1629 30 c.2644C>T p.Arg882Cys missense 
chr12:2539
8281 KRAS 2 799 21 c.38G>A p.Gly13Asp missense 
chr12:2539
8284 KRAS 2 798 6 c.35G>T p.Gly12Val missense 
7 
chr11:1191
48919 CBL 8 915 4 c.1139T>C p.Leu380Pro missense 
8 
chr2:25464
535 DNMT3A 17 1891 70 c.1978T>C p.Tyr660His missense 
chr15:9063
1838 IDH2 4 1636 32 c.515G>A p.Arg172Lys missense 
9 
chr4:10615
8490 TET2 3 1999 3 c.3391C>A 
p.Pro1131Th
r missense 
chr21:3623
1783 RUNX1 6 1997 38 c.601C>T p.Arg201Ter nonsense 
10 
chr4:10615
8228 TET2 3 1084 45 
c.3129_3130i
nsAA p.Ala1045fs 
frameshiftInse
rtion 
chr11:1191
48877 CBL 8 1596 22 c.1097A>G p.Glu366Gly missense 
chr17:7578
212 TP53 6 1996 14 c.637C>T p.Arg213Ter nonsense 
11 
chr17:7578
461 TP53 5 678 8 c.469G>T p.Val157Phe missense 
chr3:12820
0073 GATA2 6 355 49 c.1232C>T p.Ala411Val missense 
12 
chr21:3623
1783 RUNX1 6 1103 24 c.601C>T p.Arg201Ter nonsense 
chr21:3625
2866 RUNX1 5 665 5 c.496C>T p.Arg166Ter nonsense 
13 
chr12:2539
8285 KRAS 2 750 35 c.34G>A p.Gly12Ser missense 
chr17:7578
190 TP53 6 212 78 c.659A>G p.Tyr220Cys missense 
14 
chr15:9063
1838 IDH2 4 387 12 c.515G>A p.Arg172Lys missense 
chr11:3241
7832 WT1 7 366 7 c.1220A>G p.His407Arg missense 
chr2:25457
249 DNMT3A 23 816 43 c.2638A>G p.Met880Val missense 
15   No pathogenic mutations detected         
16 
 
No pathogenic 
mutations detected       
17 
  
No pathogenic 
mutations detected             
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Targeted next-generation sequencing of familial platelet 
disorder with predisposition to acute myeloid leukaemia 
 
 
 
 
Familial platelet disorder with propensity to acute myeloid 
leukaemia (FPD-AML) is a rare, autosomal dominant disor- der 
characterized by quantitative and qualitative platelet 
abnormalities with a propensity to develop a myelodysplastic 
syndrome (MDS) or AML. FPD-AML kindred are defined by 
germ-line mutations of RUNX1 (Song et al, 1999), which 
encodes a transcription factor essential for definitive haema- 
topoiesis and myeloid cell differentiation, commonly dysreg- 
ulated by translocations, mutations or amplification in  de  novo 
and secondary MDS and acute leukaemias. Most germ line 
RUNX1 mutations are unique to the individual  FPD-  AML 
pedigree with variability observed in the MDS or AML 
phenotype and the incidence of leukaemic transformation of 
affected individuals (Nickels et al, 2013). The spectrum of 
somatic genetic events associated with progression to MDS   or 
AML have not been fully appreciated but acquisition of 
cytogenetic abnormalities, single gene defects that occur in de 
novo MDS and AML, and bi-allelic RUNX1 mutations have  all  
been  demonstrated  (Minelli  et al,  2004;   Preudhomme et al, 
2009; Shiba et al, 2012). More recently, mutations of CDC25C 
have been identified in approximately half of affected FPD-
AML patients. CDC25C mutations appear to disrupt a critical 
cell cycle check point in pre-leukaemic clones, allowing 
subsequent acquisition of further sub-clonal mutations 
(Yoshimi et al, 2014). Emerging next-generation sequencing 
(NGS) technologies, platforms and disease- targeted panels 
allow the simultaneous identification of numerous mutational 
events. Such a targeted NGS approach was applied to a known 
RUNX1 mutated  FPD-AML kindred to identify additional 
molecular events that co-operate with  the germ line RUNX1 
mutation in driving leukaemic transformation. 
A 56-year-old male and a 45-year-old female sibling both 
presented with AML with myelodysplastic features  (Fig  1, I–
3  and  I–7  respectively).  At  diagnosis,  I-3  had  trisomy 8 
and I-7 had monosomy 7. The eldest son of patient I-7 (II-1, Fig 
1) has thrombocytopenia. The history of familial throm- 
bocytopenia coupled with development of AML suggested a 
diagnosis of FPD-AML, which was confirmed by Sanger 
sequencing identification of a heterozygous RUNX1 p.Arg166X 
mutation in the leukaemic blasts and constitu- tional buccal 
scrapes of both affected patients. Patient I-3 underwent a 
reduced intensity conditioning allogeneic stem cell transplant 
(ASCT) from RUNX1 wild type sibling donor I-5. Patient I-7 
underwent a myeloblative ASCT  from  RUNX1 wild type 
sibling donor I-6. Both patients achieved 100% donor 
chimerism by day-100 post-ASCT. 
For NGS, amplicon libraries were generated from AML 
diagnostic bone marrow DNA of I-3 and I-7 using the Ion 
AmpliseqTM AML Panel (Thermo Fisher Scientific, Life Tech- 
nologies, Paisley, UK), a four primer-pool panel that gener- ates 
237 amplicons to allow interrogation of 19 commonly mutated 
genes implicated in AML. Amplicons cover the  entire coding 
region of DNMT3A, CEBPA, GATA2, TET2, TP53 and 
mutational hot spot regions  of  ASXL1,  BRAF,  CBL, FLT3, 
IDH1, IDH2, JAK2, KIT, KRAS, NPM1, NRAS, 
PTPN11, RUNX1 and WT1. Sequencing  was  performed  on an 
Ion PGMTM with data analysed and reviewed using Tor- rent 
Browser and Ion Reporter 4·2 software (Thermo Fisher 
Scientific, Life Technologies). Criteria to allow confident call- 
ing of somatic mutations were a minimum target coverage of 
500X, the presence of a mutation at >5% and a predicted change 
in amino acid sequence. Sanger sequencing was also performed 
of exon 8 of CDC25C, encompassing the muta-  tion hotspot 
previously described (Yoshimi et al, 2014). 
In addition to confirmation of the heterozygous RUNX1 
p.Arg166X mutation, targeted NGS demonstrated  the presence 
of further mutations in the genes known to disrupt epigenetic 
(ASXL1, IDH1, TET2) and transcription factor (CEBPA, 
RUNX1) function in AML (Table I). Although 
 
 
 
I 
 
Fig 1. Pedigree of the familial platelet disorder 
with propensity to acute myeloid leukaemia 
(FPD-AML) kindred. The index cases (I-3, I-7) 
are indicated as black symbols. II-1 (grey sym- 
bol) suffered from thrombocytopenia 
II 1 2 3 
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Table I. Mutations identified by targeted next-generation sequencing in the two affected siblings. 
 
Patient Mutated gene Nucleotide change Amino acid change Variant effect % Mutant allele COSMIC (Disease association) 
I-3 RUNX1 c.496C>T p.Arg166X nonsense 53% COSM24769 (AML, ETP-ALL) 
 ASXL1 c.2083C>T p.Gln695X nonsense 26% COSM1738037 (MDS) 
 IDH1 c.394C>T p.Arg132Cys missense 14% COSM28747 (AML, Glioma) 
 RUNX1 c.608C>G p.Pro203Arg missense 6% – 
I-7 RUNX1 c.496C>T p.Arg166X nonsense 50% COSM24769 (AML, ETP-ALL) 
 TET2 c.5162T>G p.Leu1721Trp missense 50% – 
 RUNX1 c.497G>A p.Arg166Gln missense 11% COSM36055 (AML) 
 CEBPA c.898C>T p.Arg300Cys missense 5% – 
COSMIC, Catalogue of somatic mutations in cancer (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/); AML, acute myeloid leukaemia; 
ETP-ALL, early T cell precursor-acute lymphoblastic leukaemia; MDS, myelodysplastic syndrome. 
matched germ line material was not studied  by  NGS,  the  fact 
that several of these mutations have been previously described 
in haematological malignancies (Table I) and that they are 
present at allele frequencies less than 50% implies they are 
somatic and not heterozygous germ  line  in nature. No 
mutations of CDC25C exon 8 were detected in either patient. 
Proof of principle feasibility and utility of a targeted NGS 
approach are demonstrated in a FPD-AML kindred with a 
known germ line RUNX1 mutation. A targeted  NGS  approach 
using more comprehensive MDS- and AML-asso- ciated gene 
panels or whole exome sequencing is likely to offer several 
advantages over standard sequencing method- ologies in 
familial AML: identification of the causative germ line 
mutation is possible where the phenotype may be unin- 
formative (Obata et al, 2015); the simultaneous detection of co-
operating mutations that may be clinically  actionable,  such as 
IDH and TET2 demonstrated in the FPD-AML kin- dred 
described herein (Falini et al, 2015); the ability to infer patterns 
of clonal evolution in patients with overt AML (Tawana et al, 
2015); and affords the opportunity to monitor identified 
thrombocytopenic individuals from FPD-AML kin- dred to 
identify progression to MDS or AML, thus allowing earlier 
clinical intervention. While no CDC25C mutations were 
detected in the two FPD-AML affected patients described, the 
role of these abnormalities requires clarifica- tion in other FPD-
AML kindred. If  NGS  technologies become integrated into 
routine practice, more cases of famil- ial leukaemia are likely 
to be resolved (Churpek et al, 2013) 
with this approach, possessing the potential to  enhance  
genetic testing and improve clinical management. 
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Nerve growth factor negatively regulates bone marrow 
granulopoiesis during small intestinal inflammation 
 
 
 
 
The regulation of haematopoiesis during inflammation is the 
subject of intense study with respect to anti-tumour immu-  nity 
and chronic disease. In particular, the generation of neu- trophils 
is crucial for host survival, yet the restoration of  steady state 
haematopoiesis is also essential for return to health. It is known 
that neutrophil homoeostasis is positively regulated by Toll-like 
receptor signalling and inflammatory cytokines (Wirths et al, 
2014), but the negative regulation of ‘emergency’ 
granulopoiesis is still poorly understood  (Manx & Boettcher, 
2014). 
Bone marrow stromal cells have been shown to both syn- 
thesize nerve growth factor (NGF) and express a functional 
p75NTR/TrkA receptor, suggesting that NGF is involved in the 
regulation of haematopoiesis (Tomellini et al,2014). Cur- rent 
literature presents conflicting evidence concerning the effect of 
NGF on myeloid progenitor colonies and their dif- ferentiation 
into mature cells. We hypothesized that NGF, a known survival 
factor for granulocytes, could also play a role in emergency 
granulopoiesis. Here we use a parasite infection model, 
Trichinella spiralis, to study an on-demand yet natu- rally 
resolving haematopoietic response during acute small intestinal 
inflammation (Pennock & Grencis, 2004). It has been shown 
previously that NGF is expressed by gut epithe- lium (Torrents 
et al, 2002) during T. spiralis infection. We were interested in 
the effect that systemic NGF may have on myelopoiesis in vivo 
during acute gut inflammation and, in particular, any effects on 
the generation of granulocytes, as these are thought to 
contribute to parasite survival and the control of inflammation. 
During  infection  we  found  that  there  was  no significant 
difference in either total monocytic (CD11b+Ly6G—CD115+) 
or granulocytic (Ly6G+) cell types in the bone marrow, 
although a trend towards reduced monocyte numbers could   be 
seen. However, gut homing neutrophils (CD11b+Ly6G+C- 
D115-a4b7+) were significantly increased in the bone marrow 
(P < 0·01) at day 1 post-infection and in the blood at day 7 post-
infection (P < 0·01, Fig 1A, B). This population was 
CD11blo/intLy6Gint, suggesting an immature phenotype similar 
to granulocytic myeloid-derived suppressor cells (Gr-MDSC) 
described previously (Van Ginderachter et al, 2010). Napthol 
AS-D chloroacetate staining of jejunum showed granulocytes 
were present the  small  intestine  at  day  7  post-infection  (Fig 
1C ii) correlating with the egress of gut homing  cells from the 
bone marrow. Interestingly, infection induced a reduction in the 
ability of myeloid-committed progenitor cells to respond to ex 
vivo growth factors in every colony type,  most significantly for 
granulocyte (CFU-G) and granulocyte/ macrophage colony-
forming units (CFU-GM)  (Fig 1D).  When incubated with 
whole bone marrow from uninfected NIH mice, serum from 
infected animals reproduced the observed in vivo inhibition of 
myelopoiesis (Fig 1E), confirm- ing the presence of systemic 
inhibitory factors and suggesting a dose response. These effects 
were inhibited by neutralizing anti-NGF antibody (Fig 1F) and 
could be replicated by co- culture of na€ıve bone marrow for 7 
days with exogenous recombinant NGF (1–500 ng/ml), causing 
a dose responsive inhibition of CFU-G (P < 0·001, data not 
shown). Of note, inhibition of serum NGF did not rescue CFU-
M, suggesting that NGF acted primarily on the granulocyte 
lineage. 
To test the role of NGF in granulopoiesis in vivo during 
immunological challenge, T. spiralis infected mice were treated 
with a neutralizing anti-NGF antibody. Treatment induced 
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Appendix 4: JAK2 V617F Negative MPN patients screened for CALR mutation 
status. PB; peripheral blood, BM; bone marrow. 
Suspected 
Diagnosis 
CALR mutation 
Status  
CALR 
Mutation Type 
Sex Age Sample Type 
? ET Not Detected 
   
PB 
? ET Not Detected 
   
PB 
? ET Not Detected 
   
PB 
? ET Not Detected 
   
PB 
? ET Not Detected 
   
PB 
? ET Not Detected 
   
PB 
? ET Not Detected 
   
PB 
? ET Not Detected 
   
PB 
? ET Not Detected 
   
PB 
? ET JAK2 
V617F- 
Not Detected 
   
PB 
? ET/PV Not Detected 
   
PB 
? MF Not Detected 
   
PB 
? MPN Not Detected 
   
PB 
? PMF Not Detected 
   
PB 
?ET Not Detected 
   
PB 
      
?ET Not Detected 
   
PB 
?ET  Not Detected 
   
PB 
?PMF Not Detected 
   
PB 
?PV/ET Not Detected 
   
PB 
AML vs PMF Not Detected 
   
PB 
BM fibrosis Not Detected 
   
BM 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
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ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected   
  
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
  
  PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
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ET Not Detected 
   
PB 
ET Not Detected 
   
PB 
ET Detected 2 M 61 PB 
ET Detected 1 F 58 PB 
ET Detected 2 M 49 PB 
ET Detected 1 M 58 PB 
ET Detected 2 M 56 PB 
ET Detected 2 M 62 PB 
ET Detected 1 F 49 PB 
ET Detected 1 F 63 PB 
ET Detected 2 M 51 PB 
ET Detected 1 F 25 PB 
ET Detected 1 F 52 PB 
ET Detected type 1-like F 60 PB 
ET Detected type 1-like M 55 PB 
ET Detected 1 F 60 PB 
ET Detected 2 M 59 PB 
ET Detected 2 M 56 PB 
ET Detected type 1 like F 54 PB 
ET Detected 1 F 52 PB 
ET Detected 2 M 57 PB 
ET Detected 1 M 49 PB 
ET Detected 1 M 54 PB 
ET Detected 1 F 60 PB 
ET Detected 1 M 32 PB 
ET Detected type 2-like F 50 PB 
ET Detected type 1-like F 59 PB 
ET Detected 1 F 56 PB 
ET Detected 1 F 55 PB 
ET Detected 2 F 62 PB 
ET Detected 2 M 51 PB 
ET Detected 1 F 58 PB 
ET Detected 1 F 52 PB 
ET Detected 2 F 44 PB 
ET Detected 12 bp del 
(48%) 52bpdel 
(25%) 
F 57 PB 
ET Detected 2 M 59 PB 
ET Detected 1 F 62 PB 
ET Detected 1 M 43 PB 
ET Detected 1 F 36 PB 
ET Detected 1 M 50 PB 
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ET Detected 1 F 59 PB 
ET Detected 1 M 58 PB 
ET Detected 1 M 61 PB 
ET Detected type 1-like F 55 PB 
ET Detected 1 M 62 PB 
ET/ALL Detected 1 M 61 BM 
ET/PMF Not Detected 
   
BM 
ET>MF Detected 1 M 57 BM 
ET>MF Detected 2 F 59 BM 
FMPN Not Detected 
   
PB 
FMPN Not Detected 
   
PB 
FMPN Not Detected 
   
PB 
FMPN Not Detected 
   
PB 
FMPN Not Detected 
   
PB 
FMPN Not Detected 
   
PB 
FMPN Not Detected 
   
PB 
FMPN Not Detected 
   
PB 
FMPN Not Detected 
   
PB 
FMPN Not Detected 
   
PB 
FMPN Not Detected 
   
PB 
FMPN Not Detected 
   
PB 
JAK2- 
erythrocytosis 
Not Detected 
   
PB 
JAK2- 
polycythaemia 
Not Detected 
   
PB 
JAK2- PV Not Detected 
   
PB 
JAK2- PV Not Detected 
   
PB 
JAK2- PV Not Detected 
   
PB 
JAK2- PV Not Detected 
   
PB 
JAK2- PV Not Detected 
   
PB 
JAK2- PV Not Detected 
   
PB 
JAK2- PV Not Detected 
   
PB 
Likely ET Not Detected 
   
PB 
Likely ET Not Detected 
   
PB 
Likely ET Not Detected 
   
PB 
Likely ET Not Detected 
   
PB 
Likely ET Not Detected 
   
PB 
Likely ET Not Detected 
   
PB 
Likely ET Not Detected 
   
PB 
Likely ET Not Detected 
   
PB 
Likely ET Not Detected 
   
PB 
Likely ET Not Detected 
   
PB 
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MDS/AA with 
thrombocytosi
s 
Not Detected 
   
BM 
MDS/MPN Not Detected 
   
BM 
MDS/MPN Detected 2 M 62 BM 
MGUS/ET Detected 1 M 55 PB 
MPN Not Detected 
   
PB 
MPN Not Detected 
   
PB 
MPN Not Detected 
   
PB 
MPN Not Detected 
   
PB 
Paed ? ET Not Detected 
   
PB 
Paed ? ET Not Detected 
   
PB 
Paed ? ET Not Detected 
   
PB 
Paed ? ET Not Detected 
   
PB 
Paed ? ET Not Detected 
   
PB 
PMF Not Detected 
   
PB 
PMF Not Detected 
   
PB 
PMF Not Detected 
   
PB 
PMF Not Detected 
   
BM 
PMF Not Detected 
   
PB 
PMF Not Detected 
   
PB 
PMF Not Detected 
   
PB 
PMF Not Detected 
   
BM 
PMF Not Detected 
   
PB 
PMF Detected 1 M 34 PB 
PMF Detected 2 F 68 PB 
PMF Detected 1 F 51 PB 
PMF Detected 1 F 86 BM 
PMF Detected 1 M 60 PB 
PMF Detected 2 M 58 PB 
PMF Detected 1 F 49 PB 
PMF Detected 1 M 61 PB 
PMF Detected 1 F 53 PB 
PMF Detected 1 F 68 PB 
PMF for 
ASCT 
Not Detected 
   
PB 
PMF pre-
ASCT 
Not Detected 
   
PB 
PMF vs MDS 
fibrosis 
Not Detected 
   
BM 
Polycythaemia Not Detected 
   
PB 
Polycythaemia Not Detected 
   
PB 
PV Not Detected 
   
PB 
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PV/ET Not Detected 
   
PB 
Thrombocytosis Not Detected 
   
PB 
Thrombocytosis Not Detected 
   
PB 
Thrombocytosis Not Detected 
   
PB 
Thrombocytosis Not Detected 
   
PB 
Thrombocytosis Not Detected 
   
PB 
Thrombocytosis Not Detected 
   
PB 
Thrombocytosis Not Detected 
   
PB 
Thrombosis Not Detected 
   
PB 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
273 
 
 
Appendix 5: Characteristics of SVT patients referred for molecular testing 
 
Patient 
No. 
Referral Reason Age at 
referral 
Gender JAK2 
V617F 
MPL 
W515L 
MPL 
W515K 
MPL 
S505N 
CALR 
1 Budd Chiari 
Syndrome 
39 Male Detected Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
2 Budd Chiari 
syndrome 
32 Female Detected Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
3 Budd Chiari 
syndrome 
60 Female Detected Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
4 Budd Chiari 
syndrome 
45 Female Detected Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
5 Budd Chiari 
syndrome 
23 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
6 Budd Chiari 
syndrome 
76 Female Not 
Detected 
Detected Not 
Detected 
Not 
Detected 
Not 
Detected 
7 Budd Chiari 
syndrome 
22 Female Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
8 Budd Chiari 
Syndrome 
72 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
9 Budd-Chiari 
syndrome 
21 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
10 superior mesenteric 
vein thrombosis 
31 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
11 superior mesenteric 
vein thrombosis 
42 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
12 superior mesenteric 
vein thrombosis 
48 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
13 superior mesenteric 
vein thrombosis 
37 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
14 superior mesenteric 
vein thrombosis 
46 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
15 superior mesenteric 
vein thrombosis 
45 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
16 superior mesenteric 
vein thrombosis 
54 Female Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
17 superior mesenteric 
vein,  
thrombocytosis 
35 Female Detected N/A N/A N/A Not 
Detected 
18 thrombocytopenia, 
neutropenia superior 
mesenteric vein 
thrombosis 
69 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
19 mesenteric ischaemia 42 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
20 mesenteric 
thrombosis & splenic 
infarcts 
63 Female Detected Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
21 mesenteric 
thrombosis, 
stroke, 
polycythaemia 
61 Female Detected N/A N/A N/A Not 
Detected 
22 mesenteric vein 
thrombosis 
65 Female Detected N/A N/A N/A Not 
Detected 
23 mesenteric vein 
thrombosis 
69 Female Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
24 mesenteric vein 
thrombosis 
58 Female Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
25 mesenteric vein 
thrombosis  
thrombocytosis 
41 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
26 mesenteric vein 
thrombosis 
63 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
27 mesenteric venous 
thrombosis 
60 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
28 mesenteric vein 
thrombosis 
38 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
29 polycythaemia portal 
vein thrombosis 
73 Female Detected N/A N/A N/A Not 
Detected 
274 
 
 
30 portal & splenic vein 
thrombosis 
55 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
31 portal vein 
thrombosis 
39 Male Detected Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
32 portal vein 
thrombosis 
48 Male Detected Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
33 portal vein 
thrombosis 
47 Male Detected Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
34 portal vein 
thrombosis 
19 Male Detected Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
35 portal vein 
thrombosis 
58 Female Detected Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
36 portal vein 
thrombosis 
54 Female Detected Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
37 portal vein 
thrombosis 
60 Male Detected N/A N/A N/A Not 
Detected 
38 portal vein 
thrombosis 
58 Male Detected N/A N/A N/A Not 
Detected 
39 portal vein 
thrombosis 
33 Male Detected N/A N/A N/A Not 
Detected 
40 portal vein 
thrombosis 
20 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
41 portal vein 
thrombosis 
52 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
42 portal vein 
thrombosis 
24 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
43 portal vein 
thrombosis 
40 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
44 portal vein 
thrombosis 
48 Female Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
45 portal vein 
thrombosis 
52 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
46 portal vein 
thrombosis 
76 Female Not 
Detected 
Detected Not 
Detected 
Not 
Detected 
Not 
Detected 
47 portal vein 
thrombosis 
66 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
48 portal vein 
thrombosis 
48 Female Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
49 portal vein 
thrombosis 
56 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
50 portal vein 
thrombosis 
39 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
51 portal vein 
thrombosis 
75 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
52 portal vein 
thrombosis 
71 Female Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
53 portal vein 
thrombosis 
48 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
54 portal vein 
thrombosis 
42 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
55 portal vein 
thrombosis 
49 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
56 portal vein 
thrombosis 
69 Female Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
57 portal vein 
thrombosis 
34 Female Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
58 portal vein 
thrombosis 
52 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
59 portal vein 
thrombosis 
66 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
60 portal vein 
thrombosis 
52 Female Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
61 portal vein 
thrombosis 
54 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
62 portal vein 
thrombosis 
58 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
63 portal vein 
thrombosis 
65 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
64 portal vein 
thrombosis 
55 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
65 portal vein 
thrombosis 
33 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
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66 portal vein 
thrombosis 
67 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
67 portal vein 
thrombosis 
31 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
68 portal vein 
thrombosis 
24 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
69 portal vein 
thrombosis 
74 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
70 portal vein 
thrombosis 
57 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
71 portal vein 
thrombosis 
51 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
72 portal vein 
thrombosis 
75 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
73 portal vein 
thrombosis 
68 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
74 portal vein 
thrombosis 
62 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
75 portal vein 
thrombosis 
30 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
76 portal vein 
thrombosis 
33 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
77 portal vein 
thrombosis 
44 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
78 portal vein 
thrombosis 
62 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
79 portal vein 
thrombosis 
74 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
80 portal vein 
thrombosis 
65 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
81 portal vein 
thrombosis 
83 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
82 portal vein 
thrombosis 
33 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
83 portal vein 
thrombosis 
45 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
84 portal vein 
thrombosis 
61 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
85 portal vein 
thrombosis 
51 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
86 portal vein 
thrombosis 
66 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
87 portal vein 
thrombosis 
32 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
88 portal vein 
thrombosis 
51 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
89 portal vein 
thrombosis 
69 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
90 portal vein 
thrombosis 
36 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
91 portal vein 
thrombosis 
38 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
92 portal vein 
thrombosis 
39 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
93 portal vein 
thrombosis 
47 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
94 portal vein 
thrombosis 
61 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
95 portal vein 
thrombosis 
59 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
96 portal vein 
thrombosis 
48 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
97 portal vein 
thrombosis 
28 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
98 portal vein 
thrombosis  
87 Female Detected N/A N/A N/A Not 
Detected 
99 portal vein 
thrombosis & 
intestinal infarction 
53 Male Detected Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
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100 portal vein 
thrombosis & 
pancreatitis 
26 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
101 portal vein 
thrombosis & 
recurrent deep vein 
thrombosis 
41 Female Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
102 portal vein 
thrombosis / 
splenomegaly 
60 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
103 portal vein 
thrombosis, anaemia 
51 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
104 portal vein 
thrombosis 
1 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
105 portal vein 
thrombosis 
60 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
106 portal vein 
thrombosis 
51 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
107 portal vein 
thrombosis 
54 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
108 portal vein 
thrombosis 
49 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
109 portal vein 
thrombosis 
57 Female Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
110 portal vein 
thrombosis 
64 Female Detected N/A N/A N/A Not 
Detected 
111 renal vein thrombosis 31 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
112 renal vein thrombosis 70 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
113 renal vein thrombosis 46 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
114 renal vein thrombosis 42 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
115 renal vein thrombosis 59 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
116 renal vein thrombosis 70 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
117 renal vein thrombosis 71 Female Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
118 splenic infarct 51 Male Detected Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
119 splenic infarct 72 Female Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
120 splenic infarct 72 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
121 splenic infarct 42 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
122 splenic infarction 71 Male Detected Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
123 splenic infarction 39 Female Detected Not 
Detected 
Not 
Detected 
 
Not 
Detected 
124 splenic infarction 81 Female Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
125 splenic infarction 37 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
126 splenic vein 
thrombosis 
28 Male Detected Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
127 splenic vein 
thrombosis 
66 Female Detected Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
128 splenic vein 
thrombosis 
76 Male Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
129 splenic vein 
thrombosis 
71 Female Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
130 hepatic vein 
thrombosis 
56 Male Detected Not 
Detected 
Not 
Detected 
Not 
Detected 
Not 
Detected 
131 hepatic vein 
thrombosis 
71 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
132 intra-abdominal  
thrombosis 
55 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
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133 intra-abdominal 
thrombosis 
39 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
134 ischaemic bowel 41 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
135 ischaemic bowel 35 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
136 ischaemic bowel 56 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
137 liver thrombosis 60 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
138 multiple abdominal 
organ infarcts 
59 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
139 pelvic thrombosis 27 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
140 splanchnic vein 
thrombosis 
52 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
141 Small bowel 
thrombosis 1998 
42 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
142 splanchnic vein 
thrombosis 
39 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
143 splanchnic vein 
thrombosis 
75 Female Not 
Detected 
N/A N/A N/A Not 
Detected 
144 thrombocytosis 
splenic/renal infarcts 
61 Male Not 
Detected 
N/A N/A N/A Not 
Detected 
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Appendix 6: Award 
 
Haematology Association of Ireland/Novartis Educational Fellowship Award 2016: 
(€10,000). 
Awarded for study entitled: “Utility of Targeted Next Generation Sequencing to 
Identify Clonal Somatic Mutations in Patients with Myelodysplastic Syndromes” .  
Findings presented at: 
Haematology Association for Ireland Annual Meeting, October 2016, Athlone, Ireland. 
American Society Haematology Annual Meeting, November 2016, San Diego, U.S.A. 
Citation: 
Haslam, K., Appleby, N., Armstrong, C., Flynn, C. M., Langabeer, S., & Conneally, E. 
(2016). Impact of Somatic Mutations on Clinical Outcomes Following Flamsa-Bu 
Conditioning and Allogenic Stem Cell Transplantation in Patients with Poor-Risk 
Myeloid Malignancies. Blood, 128(22), 2277. 
 
 
 
 
 
 
 
 
